# Catalogue 2017





For finding your local dealer visit www.zytovision.com

### DISCLAI<u>MER</u>

All information is supplied without liability. All product data are subject to changes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy.



ZytoVision GmbH · Fischkai 1 27572 Bremerhaven · Germany · www.zytovision.com



Dear Valued Customer,

ZytoVision GmbH is known to be an innovative German company focused on the development and production of high quality, state-of-the-art diagnostic products of prognostic, predictive and therapeutic value. We fulfill this claim by a continuous product development process in cooperation with many international clinical partners as well as strict and thorough quality controls during our production processes.

Throughout our 12-years history, ZytoVision has been first-to-market with dual color CISH for the simultaneous detection of ERBB2 and centromere 17 copy numbers as well as several uniquely designed probes as e.g. our ALK/EML4 TriCheck™ and ALK/ROS1 DistinguISH™ FISH probes for the detection of gene rearrangements in non-small cell lung cancer (NSCLC).

In order that treatments can be tailored with the utmost precision to the clinical profile of an individual patient, ZytoVision offers clinical trial service comprising the development of companion diagnostics.

We believe in a long-lasting relationship with our customers and support you via our worldwide network of highly qualified local distributors allowing us to respond to your needs immediately.

This catalogue presents our most current product portfolio of *in situ* Hybridization (ISH) probes and associated reagents, introducing many new products especially for the diagnosis of sarcomas and tumors of the hematopoietic and lymphoid tissues. Moreover, it includes now our two new product lines FlexISH® and VisionArray®. FlexISH® products are designed for a flexible FISH allowing to choose between a 1-day or a 2-day protocol. The VisionArray® products are designed for the qualitative detection of specific DNA sequences on a chip.

We hope to always fulfill your expectations and would like to thank existing customers for their partnership and would like to give a warm welcome to those of you, who are new customers.

Sincerely,

Your ZytoVision Team

## Table of Contents



ZytoLight® Products for FISH analysis	Page
Method Introduction - ZytoLight® Probes, human, sorted by Chromosome Index porcine, sorted by Chromosome Index human, sorted by Gene Index human, sorted by Indication Product Data Sheets Accessories ZytoVision FISH Reagents, Fluorochromes and Filter Recommendations	7 8 ff. 13 14 ff. 20 ff. 25 ff. 154 162 ff.
FlexISH® Products for flexible FISH	Page
Method Introduction - FlexISH® Probes, sorted by Chromosome Index sorted by Gene Index sorted by Indication Product Data Sheets Accessories ZytoVision FISH Reagents, Fluorochromes and Filter Recommendations	156 157 158 158 159 f. 161 162 ff.
ZytoDot® Products for CISH analysis	Page
Method Introduction - ZytoDot® - ZytoDot® 2C™  Probes, sorted by Chromosome Index sorted by Gene Index sorted by Indication  Product Data Sheets Accessories	166 167 168 ff. 172 f. 174 ff. 177 ff. 218 f.
ZytoFast® Products for CISH analysis	Page
Method Introduction - ZytoFast® - ZytoFast® PLUS  Probes, sorted by Virus Index sorted by mRNA Index sorted by Indication  Product Data Sheets Accessories	221 222 223 223 224 225 ff. 233 f.
VisionArray® Arrays for DNA analysis	Page
Method Introduction - Vision <i>Array</i> ® Product Data Sheets Accessories	236 237 f. 239 f.
	Page
Product Use Trademarks CE Marking & ISO Certificates Index	241 241 241 242 ff.


5



Zyt	oLight® Products for FISH analysis	Page
	Method Introduction - Zyto <i>Light</i> ®	7
-	Probes, human, sorted by Chromosome Index porcine, sorted by Chromosome Index human, sorted by Gene Index human, sorted by Indication	8 ff. 13 14 ff. 20 ff.
_	Product Data Sheets	25 ff.
	Accessories	154
_	ZytoVision FISH Reagents, Fluorochromes and Filter Recommendations	162 ff.




### Reliable Multi-Target Detection using Fluorescence in situ Hybridization!



### Introduction

ZytoLight® products are designed for the identification of genetic aberrations e.g. translocations, deletions, amplifications, and chromosomal aneuploidies by Fluorescence in situ Hybridization (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears, and metaphase chromosome spreads.



### **High Sensitivity and Specificity**

ZytoLight ® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. All ZytoLight® single copy (SPEC™) probes are processed by the unique ZytoLight ® Repeat Subtraction Technique resulting in advanced specificity and less background. No further blocking of repetitive sequences is needed! ZytoLight® CEN™ probes hybridize to highly repetitive human satellite DNA sequences of chromosomes producing sharp, bright signals specific for each individual chromosome.

### ZytoLight® Kits - Convenient Solutions

For making FISH analysis reliable and user-friendly, all ZytoLight® FISH probes can be combined with the ZytoLight® FISH-Tissue Implementation Kit (Z-2028-5/-20) or the ZytoLight ® FISH-Cytology Implementation Kit (Z-2099-20), for FISH analyses on cytology specimens. Both Implementation Kits include all necessary pretreatment solutions, wash buffers and DAPI/DuraTect<sup>TM</sup> -Solution and a detailed protocol to perform successful FISH experiments.

Additionally, for some major targets, complete kits including probes and all necessary reagents are available.

The ZytoLight® system uses direct labeled FISH probes (1), eliminating the need to detect the probes with fluorophore-coupled antibodies. The probes are detected by fluorescence microscopy using appropriate filter sets (2). Due to an exciter filter (3), full-spectrum light, emitted by the microscope lamp (4), is reduced to light of a defined wavelength that specifically excites the fluorophore of the probe. This light is reflected onto the specimen by a dichroic mirror (5). The fluorophore emits light of longer wavelengths that passes the mirror. Finally, a barrier filter (6) reduces the emitted light to a defined wavelength that can be detected.

#### **Protocol Overview**















Apply Probe



	Chr. Band	Product Name	Product No.	Quantity	Page
	1p36.3 1p36.1 1p12 1q21 1q23.1 1q25.2 1q25.3 1q32.1	Zyto Light SPEC 1p36/1q25 Dual Color Probe C € IVD  Zyto Light SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C € IVD  Zyto Light SPEC 1p12 Probe C € IVD  Zyto Light SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C € IVD  Zyto Light SPEC MCL1/1p12 Dual Color Probe C € IVD  Zyto Light SPEC NTRK1 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC ABL2 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC 1p36/1q25 Dual Color Probe C € IVD  Zyto Light SPEC MDM4/1p12 Dual Color Probe C € IVD	Z-2075-50/-200 Z-2019-50/-200 Z-2101-200 Z-2102-200 Z-2173-200 Z-2167-200 Z-2200-50 Z-2075-50/-200 Z-2080-200	50 µl/200 µl 50 µl/200 µl 200 µl 200 µl 200 µl 200 µl 50 µl 50 µl/200 µl 200 µl	25 112 150 ff. 39 27 28 29 25 30
2	2p24 2p23	Zyto Light SPEC MYCN/2q11 Dual Color Probe C € IVD  Zyto Light SPEC ALK/EML4 TriCheck™ Probe C € IVD  Zyto Light SPEC ALK Dual Color Break Apart Probe C € IVD  Zyto Light SPEC ALK/2q11 Dual Color Probe C € IVD	Z-2074-50/-200 Z-2117-50/-200 Z-2124-50/-200 Z-2161-200	50 μl/200 μl 50 μl/200 μl 50 μl/200 μl 200 μl	31 32 33 34
	2p21 2q11.2	ZytoLight SPEC EML4 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC ALK/EML4 TriCheck™ Probe C € IVD  ZytoLight SPEC 2q11 Probe  ZytoLight SPEC (CND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C € IVD	Z-2136-50 Z-2117-50/-200 Z-2049-200 Z-2118-200	50 μl 50 μl/200 μl 200 μl 200 μl	35 32 150 ff. 40
	2q13 2q34 2q36	Zyto Light SPEC MERTK/2q11 Dual Color Probe C € IVD  Zyto Light SPEC ERBB4/2q11 Dual Color Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 Dual Color Single Fusion Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 TriCheck™ Probe C € IVD NEW	Z-2155-200 Z-2057-200 Z-2018-50/-200 Z-2185-50	200 µl 200 µl 50 µl/200 µl 50 µl	36 37 110 111
3	3p25	Zyto Light SPEC VHL/CEN 3 Dual Color Probe C€ IVD  Zyto Light SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C€ IVD	Z-2084-200 Z-2102-200	200 µl 200 µl	38 39
	3p14.2 3p11.1-q11.1	Zyto Light SPEC FHIT/CEN 3 Dual Color Probe C € IVD  Zyto Light CEN 3 Probe  Zyto Light SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C € IVD	Z-2062-200 Z-2061-200 Z-2081-50/-200	200 μl 200 μl 200 μl 50 μl/200 μl	41 150 ff. 80
	3q12 3q25.1 3q26.3	Zyto Light SPEC TFG Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC WWTR1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC PIK3CA/CEN 3 Dual Color Probe C€ IVD  Zyto Light SPEC SOX2/CEN 3 Dual Color Probe C€ IVD	Z-2133-50 Z-2212-50 Z-2140-200 Z-2127-200	50 μl 50 μl 200 μl 200 μl	42 43 44 45
	3q27	Zyto Light SPEC BCL6 Dual Color Break Apart Probe C    IVD	Z-2177-50/-200	50 μl/200 μl	46
4	4p16.3	Zyto Light SPEC FGFR3 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C € IVD NEW  Zyto Light SPEC FGFR3/4p11 Dual Color Probe C € IVD	Z-2170-50/-200 Z-2186-200 Z-2082-200	50 μl/200 μl 200 μl 200 μl	47 48 49
	4p11 4q12	Zyto Light SPEC 4p11 Probe Zyto Light SPEC PDGFRA/FIP1L1 TriCheck™ Probe C € IVD NEW	Z-2083-200 Z-2209-50	200 μl 50 μl	150 ff. 50



		Chr. Band	Product Name	Product No.	Quantity	Page
5		5p15.3 5q31.2 5q32	Zyto Light SPEC TERT/5q31 Dual Color Probe C	Z-2091-50 Z-2107-50/-200 Z-2211-50 Z-2202-50 Z-2194-200 Z-2197-50	50 μl 50 μl/200 μl 50 μl 50 μl 200 μl 50 μl	51 52 53 54 69 55
6		6p25 6p24 6p21.1 6p11.1-q11	Zyto Light SPEC IRF4, DUSP22 Dual Color Break Apart Probe C € IVD NEW  Zyto Light SPEC RREB1/MYB/CEN 6 Triple Color Probe C € IVD  Zyto Light SPEC VEGFA/CEN 6 Dual Color Probe C € IVD  Zyto Light CEN 6 Probe	Z-2210-50 Z-2152-50/-200 Z-2195-200 Z-2002-200	50 µl 50 µl/200 µl 200 µl 200 µl	56 57 58 150 ff.
		6q22.1 6q23.3 6q25.1	Zyto Light SPEC (CND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C € IVD  Zyto Light SPEC ROS1 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC ROS1/CEN 6 Dual Color Probe C € IVD  Zyto Light SPEC MYB Dual Color Break Apart Probe C € IVD  Zyto Light SPEC RREB1/MYB/CEN 6 Triple Color Probe C € IVD  Zyto Light SPEC ESR1/CEN 6 Dual Color Probe C € IVD	Z-200Z-200 Z-2118-200 Z-2144-50/-200 Z-2162-200 Z-2143-200 Z-2152-50/-200 Z-2069-50/-200	200 µl 200 µl 50 µl/200 µl 200 µl 200 µl 50 µl/200 µl	40 59 60 61 57 62
7		7p21 7p15.2-p15.1 7p11.2 7q11.1	ZytoLight SPEC ETV1/CEN 7 Dual Color Probe C€ IVD  ZytoLight SPEC JAZF1 Dual Color Break Apart Probe C€ IVD  ZytoLight SPEC EGFR/CEN 7 Dual Color Probe C€ IVD  ZytoLight CEN 7 Probe  ZytoLight SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C€ IVD  ZytoLight SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C€ IVD	Z-2141-200 Z-2132-50 Z-2033-50/-200 Z-2003-200 Z-2081-50/-200 Z-2102-200	200 µl 50 µl 50 µl/200 µl 200 µl 50 µl/200 µl 200 µl	63 64 65 150 ff. 80
		7q31.2 7q34	Zyto Light SPEC MET/CEN 7 Dual Color Probe C€ IVD  Zyto Light SPEC BRAF/CEN 7 Dual Color Probe C€ IVD  Zyto Light SPEC BRAF/CEN 7 Dual Color Probe C€ IVD	Z-2087-200 Z-2189-200 Z-2191-200	200 μl 200 μl 200 μl	66 67 68
8		8p12 8p11.2 8p11.1-q11.1 8q21.3 8q24.21	Zyto Light SPEC NRG1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC NRG1/CD74 TriCheck™ Probe C€ IVD  Zyto Light SPEC FGFR1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C€ IVD  Zyto Light SPEC FGFR1/CEN 8 Dual Color Probe C€ IVD  Zyto Light SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC/CEN 8 Dual Color Probe C€ IVD  Zyto Light SPEC MYC/CEN 8 Dual Color Probe C€ IVD  Zyto Light SPEC MYC/CEN 8 Dual Color Probe C€ IVD	Z-2072-50/-200 Z-2004-50/-200 Z-2112-50 Z-2090-50/-200 Z-2092-50/-200	200 µl 200 µl 50 µl/200 µl 200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 200 µl 50 µl/200 µl	70 69 71 48 72 150 ff. 73 74 75



	Chr. Band	Product Name	Product No.	Quantity	Page
9	9p24 9p21 9q12 9q21.3 9q22.3-q31 9q34.1	ZytoLight SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe C€ IVD  ZytoLight SPEC CDKN2A/CEN 9 Dual Color Probe C€ IVD  ZytoLight SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C€ IVD  ZytoLight SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C€ IVD NEW  ZytoLight SPEC NTRK2 Dual Color Break Apart Probe C€ IVD NEW  ZytoLight SPEC NR4A3 Dual Color Break Apart Probe C€ IVD  ZytoLight SPEC ABL1 Dual Color Break Apart Probe C€ IVD  ZytoLight SPEC BCR/ABL1 Dual Color Dual Fusion Probe C€ IVD	Z-2179-50/-200 Z-2063-50/-200 Z-2081-50/-200 Z-2204-200 Z-2067-200 Z-2205-200 Z-2145-50 Z-2199-50 Z-2111-50/-200	50 μl/200 μl 50 μl/200 μl 50 μl/200 μl 200 μl 200 μl 200 μl 50 μl 50 μl	78 79 80 76 150 ff. 81 82 83
10	10p11.2 10p11.1-q11.1 10q11.2 10q23.3 10q26.1	Zyto Light SPEC KIF5B Dual Color Break Apart Probe C € IVD  Zyto Light CEN 10 Probe  Zyto Light SPEC RET Dual Color Break Apart Probe C € IVD  Zyto Light SPEC PTEN/CEN 10 Dual Color Probe C € IVD  Zyto Light SPEC FGFR2 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC FGFR2/CEN 10 Dual Color Probe C € IVD  Zyto Light SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C € IVD	Z-2131-50 Z-2079-200 Z-2148-50/-200 Z-2078-50/-200 Z-2169-200 Z-2122-200	50 μl 200 μl 50 μl/200 μl 50 μl/200 μl 200 μl 200 μl 200 μl	85 150 ff. 86 87 88 89 48
	- 11p15.4 - 11p13 - 11p11.11-q11 - 11q13.3 11q21 11q22.2 11q22.3 11q23.3 11q24.3	ZytoLight SPEC CARS Dual Color Break Apart Probe C € IVD  ZytoLight SPEC WT1 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC CCND1 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C € IVD  ZytoLight SPEC CCND1/CEN 11 Dual Color Probe C € IVD  ZytoLight SPEC CCND1/IGH Dual Color Dual Fusion Probe C € IVD  ZytoLight SPEC FGF3,4,19/CEN 11 Dual Color Probe C € IVD  ZytoLight SPEC MAML2 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C € IVD  ZytoLight SPEC TP53/ATM Dual Color Probe C € IVD  ZytoLight SPEC 11q gain/loss Triple Color Probe C € IVD  ZytoLight SPEC I1q gain/loss Triple Color Probe C € IVD  ZytoLight SPEC I1q gain/loss Triple Color Probe C € IVD NEW  ZytoLight SPEC EWSR1/FLI1 TriCheck™ Probe C € IVD NEW	Z-2137-50 Z-2142-50 Z-2005-200 Z-2108-50/-200 Z-2118-200 Z-2071-50/-200 Z-2125-50/-200 Z-2158-200 Z-2014-50/-200 Z-2146-50/-200 Z-216-50 Z-216-50 Z-2216-50 Z-2216-50 Z-2183-50	50 µl 50 µl 200 µl 50 µl/200 µl 50 µl/50 µl 50 µl	90 91 150 ff. 92 40 93 94 95 96 97 98 100 101 100 146
12	12p13.2 12p12.1 12p11.1-q11 12q13.2 12q13.3 12q14	ZytoLight SPEC ETV6 Dual Color Break Apart Probe C€ IVD  ZytoLight SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe C€ IVD  ZytoLight SPEC KRAS/CEN 12 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB3/CEN 12 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB3/CEN 12 Dual Color Probe C€ IVD  ZytoLight SPEC DDIT3 Dual Color Break Apart Probe C€ IVD  ZytoLight SPEC CDK4/CEN 12 Dual Color Probe C€ IVD	Z-2176-50/-200 Z-2157-50 Z-2115-200 Z-2050-200 Z-2056-200 Z-2100-50/-200 Z-2103-50/-200	50 μl/200 μl 50 μl 200 μl 200 μl 200 μl 50 μl/200 μl 50 μl/200 μl	102 103 104 150 ff. 105 106 107

Zyto Light SPEC MDM2/CEN 12 Dual Color Probe C€ IVD

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.

Z-2013-50/-200

108

10

50 µl/200 µl

12q15



		Chromosome mack, noman							
		Chr. Band	Product Name	Product No.	Quantity	Page			
13		13q12.1 13q14.1	Zyto Light SPEC 13q12 Probe C € IVD  Zyto Light SPEC 13/CEN 18/SPEC 21 Triple Color Probe C € IVD  Zyto Light SPEC 13/21 Dual Color Probe C € IVD  Zyto Light Aneusomy Probe Set C € IVD  Zyto Light SPEC FOXO1 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 Dual Color Single Fusion Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 TriCheck™ Probe C € IVD  Zyto Light SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C € IVD	Z-2085-200 Z-2095-50/-200 Z-2164-200 Z-2104-10/-40 Z-2139-50 Z-2018-50/-200 Z-2185-50 Z-2019-50/-200	200 µl 50 µl/200 µl 200 µl 2x 50 µl/2x 200 µl 50 µl 50 µl/200 µl 50 µl	150 ff. 150 ff. 150 ff. 150 ff. 109 110 111			
		13q14.2 13q34	Zyto Light SPEC D13S319/13q34/CEN 12 Triple Color Probe C € IVD  Zyto Light SPEC RB1/13q12 Dual Color Probe C € IVD  Zyto Light SPEC GAS6/13q12 Dual Color Probe C € IVD	Z-2160-50/-200 Z-2165-50/-200 Z-2156-200	50 µl/200 µl 50 µl/200 µl 200 µl	99 113 114			
14		14q11.2 14q32.3	Zyto Light SPEC BCL2L2/14q32 Dual Color Probe C € IVD  Zyto Light SPEC IGH Dual Color Break Apart Probe C € IVD  Zyto Light SPEC BCL2/IGH Dual Color Dual Fusion Probe C € IVD  Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C € IVD  Zyto Light SPEC MYC/IGH Dual Color Dual Fusion Probe C € IVD	Z-2172-200 Z-2110-50/-200 Z-2114-50/-200 Z-2125-50/-200 Z-2105-50/-200	200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl	115 116 137 94 77			
	O'								
15		15q14 15q24 15q25	Zyto <i>Light</i> SPEC NUTM1 Dual Color Break Apart Probe C€ IVD NEW Zyto <i>Light</i> SPEC PML/RARA Dual Color Dual Fusion Probe C€ IVD NEW Zyto <i>Light</i> SPEC NTRK3 Dual Color Break Apart Probe C€ IVD NEW	Z-2208-200 Z-2113-50/-200 Z-2206-200	200 μl 50 μl/200 μl 200 μl	117 118 119			
16		16p11.2 16q22	Zyto Light SPEC FUS Dual Color Break Apart Probe C € IVD NAW	Z-2130-50 Z-2207-50	50 µl 50 µl	120 121			
17		17p13	Zyto Light SPEC TP53/17q22 Dual Color Probe C€ IVD  Zyto Light SPEC TP53/ATM Dual Color Probe C€ IVD  Zyto Light SPEC TP53/CEN 17 Dual Color Probe C€ IVD  Zyto Light SPEC USP6 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC YWHAE Dual Color Break Apart Probe C€ IVD	Z-2198-50 Z-2159-50/-200 Z-2153-50/-200 Z-2151-50 Z-2175-50	50 μl 50 μl/200 μl 50 μl/200 μl 50 μl 50 μl	122 98 123 124 125			
		17p11.1-q11.1	Zyto Light CEN 17 Probe C € IVD  Zyto Light SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C € IVD  Zyto Light SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C € IVD  Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe C € IVD	Z-2006-200 Z-2081-50/-200 Z-2102-200 Z-2015-50/-200	200 µl 50 µl/200 µl 200 µl 50 µl/200 µl	150 ff. 80 39 126			
			Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe Kit C€ IVD  Zyto Light CEN 17/SPEC ERBB2 Dual Color Probe C€ IVD  Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C€ IVD	Z-2020-5/-20 Z-2077-50/-200 Z-2190-50 Z-2093-50/-200	5 Tests/20 Tests 50 μl/200 μl 50 μl 50 μl/200 μl	126 127 128 129			
	\\	17q21.2	Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C€   Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C€   Zyto Light SPEC BNN (ADAD D. L.G. L. D. L. G. L. D. L. D. L. G. L. D. L.	Z-2093-50/-200	200 µl 50 µl/200 µl	76 129			
		17q21.3	Zyto Light SPEC PML/RARA Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC COL1A1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C€ IVD	Z-2113-50/-200 Z-2121-200 Z-2116-50/-200	50 µl/200 µl 200 µl 50 µl/200 µl	118 130 131			



	Chr. Band	Product Name	Product No.	Quantity	Page
18	18p11.32 18p11.1-q11.1 18q11.2 18q21.3	Zyto Light SPEC TYMS/CEN 18 Dual Color Probe C € IVD  Zyto Light CEN 18 Probe  Zyto Light SPEC 13/CEN 18/SPEC 21 Triple Color Probe C € IVD  Zyto Light SPEC SS18 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC SS18/SSX1 TriCheck™ Probe C € IVD  Zyto Light SPEC 18/CEN X/Y Triple Color Probe C € IVD  Zyto Light SPEC BCL2 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC BCL2/CEN 18 Dual Color Probe C € IVD  Zyto Light SPEC BCL2/CEN 18 Dual Color Probe C € IVD  Zyto Light SPEC BCL2/IGH Dual Color Dual Fusion Probe C € IVD  Zyto Light SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C € IVD  Zyto Light SPEC MALT1 Dual Color Break Apart Probe C € IVD	Z-2098-200 Z-2007-200 Z-2095-50/-200 Z-2104-10/-40 Z-2097-50/-200 Z-2184-50 Z-2163-200 Z-2192-50/-200 Z-2174-50 Z-2114-50/-200 Z-2196-50/-200	200 µl 200 µl 50 µl/200 µl 2x 50 µl/2x 200 µl 50 µl/200 µl 50 µl 200 µl 50 µl/200 µl 50 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl	132 150 ff. 150 ff. 150 ff. 133 134 150 ff. 135 136 137 97 138
19	19p13.3 19q13.2 19q13.3	Zyto Light SPEC 19q13/19p13 Dual Color Probe C € IVD  Zyto Light SPEC AXL/19p13 Dual Color Probe C € IVD  Zyto Light SPEC 19q13/19p13 Dual Color Probe C € IVD	Z-2076-50/-200 Z-2154-200 Z-2076-50/-200	50 µl/200 µl 200 µl 50 µl/200 µl	26 139 26
20	20q11.2 20q12-13.1 20q13.2	Zyto Light SPEC BCL2L1/CEN 20 Dual Color Probe C € IVD  Zyto Light SPEC PTPRT/20q11 Dual Color Probe C € IVD NEW  Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C € IVD NEW	Z-2171-200 Z-2213-50 Z-2204-200	200 µl 50 µl 200 µl	140 141 76
21	21q22.1 21q22.1-q22.2 21q22.2 21q22.3	ZytoLight SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C	Z-2112-50 Z-2157-50 Z-2086-200 Z-2180-200 Z-2164-200 Z-2095-50/-200 Z-2104-10/-40 Z-2138-200 Z-2135-200 Z-2135-200	50 µl 50 µl 200 µl 200 µl 200 µl 200 µl 50 µl/200 µl 2x 50 µl/2x 200 µl 200 µl 200 µl	73 103 150 ff. 150 ff. 150 ff. 150 ff. 150 ff. 142 143
22	22q11.2 22q12.2 22q13.1	Zyto Light SPEC BCR/ABL1 Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC SMARCB1/22q12 Dual Color Probe C€ IVD  Zyto Light SPEC EWSR1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC EWSR1/FLI1 TriCheck™ Probe C€ IVD NEW  Zyto Light SPEC PDGFB Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C€ IVD	Z-2111-50/-200 Z-2178-50 Z-2096-50/-200 Z-2183-50 Z-2119-50/-200 Z-2116-50/-200	50 μl/200 μl 50 μl 50 μl/200 μl 50 μl/200 μl 50 μl/200 μl 50 μl/200 μl	84 144 145 146 147



	Chr. Band	Product Name	Product No.	Quantity	Page
	V 00 00	The Malestree Chirology Islands and Islands Is	7 0001 50	50 I	1.40
X	Xp22.33	Zyto Light SPEC CRLF2 Dual Color Break Apart Probe C€ ND	Z-2201-50	50 μl	148
	Xp11.23	Zyto Light SPEC SS18/SSX1 TriCheck™ Probe C € IVD NEW	Z-2184-50	50 µl	134
		Zyto <i>Light</i> SPEC TFE3 Dual Color Break Apart Probe C € IVD	Z-2109-50/-200	50 μl/200 μl	149
	Xp11.1-q11.1	Zyto <i>Light</i> CEN X Probe	Z-2008-200	200 µl	150 ff.
		Zyto <i>Light</i> CEN X/Yq12 Dual Color Probe C€ IVD	Z-2016-50/-200	50 μl/200 μl	150 ff.
		Zyto <i>Light</i> CEN X/Y Dual Color Probe C € IVD	Z-2120-200	200 µl	150 ff.
		Zyto Light SPEC 18/CEN X/Y Triple Color Probe C € IVD	Z-2163-200	200 µl	150 ff.
		Zyto Light SPEC 21/CEN X/Yq12 Triple Color Probe C € IVD	Z-2180-200	200 µl	150 ff.
		Zyto Light Aneusomy Probe Set C € IVD	Z-2104-10/-40	2x 50 µl/2x 200 µl	150 ff.
Y	Yp11.32	Zyto <i>Light</i> SPEC CRLF2 Dual Color Break Apart Probe C€ IVD	Z-2201-50	50 µl	148
	Yp11.1-q11.1	Zyto <i>Light</i> CEN Y (DYZ3) Probe C€ IVD	Z-2123-200	200 μΙ	150 ff.
		Zyto <i>Light</i> CEN X/Y Dual Color Probe C€ IVD	Z-2120-200	200 μΙ	150 ff.
		ZytoLight SPEC 18/CEN X/Y Triple Color Probe C € IVD	Z-2163-200	200 µl	150 ff.
	Yq12	Zyto <i>Light</i> CEN Yq12 Probe	Z-2010-200	200 µl	150 ff.
	•	Zyto <i>Light</i> CEN X/Yq12 Dual Color Probe C€ IVD	Z-2016-50/-200	50 μl/200 μl	150 ff.
		Lylulighi Cliv A/ 1412 Dudi Coloi 11006 CC Live	L 2010 30/ 200	30 pi/ 200 pi	130 11.
		Zyto Light SPEC 21/CEN X/Yq12 Triple Color Probe C IVD	Z-2180-200	200 μl	150 ff.

### **Chromosome Index, porcine**

	Chr. Band	Product Name	Product No.	Quantity	Page
X	Хр2.1-2.2	Zyto Light porcine X/Y Dual Color Probe	Z-2094-200	200 µl	153
Y	Yp1.2-1.3	Zyto Light porcine X/Y Dual Color Probe	Z-2094-200	200 µl	153



HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
ABL1	ABL	c-ABL	Zyto Light SPEC ABL1 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC BCR/ABL1 Dual Color Dual Fusion Probe C € IVD	Z-2199-50 Z-2111-50/-200	50 µl 50 µl/200 µl	83 84
ABL2		ARG	Zyto Light SPEC ABL2 Dual Color Break Apart Probe C€ IVD	Z-2200-50	50 µl	29
ALK		CD246	Zyto <i>Light</i> SPEC ALK/EML4 TriCheck™ Probe C € IVD  Zyto <i>Light</i> SPEC ALK Dual Color Break Apart Probe C € IVD  Zyto <i>Light</i> SPEC ALK/2q11 Dual Color Probe C € IVD	Z-2117-50/-200 Z-2124-50/-200 Z-2161-200	50 µl/200 µl 50 µl/200 µl 200 µl	32 33 34
ATM		AT1, TEL1	Zyto <i>Light</i> SPEC TP53/ATM Dual Color Probe C € IVD	Z-2159-50/-200	50 µl/200 µl	98
AXL		ARK, Tyro7	Zyto <i>Light</i> SPEC AXL/19p13 Dual Color Probe C € IVD	Z-2154-200	200 μΙ	139
BCL2		Bcl-2	Zyto <i>Light</i> SPEC BCL2 Dual Color Break Apart Probe C € IVD  Zyto <i>Light</i> SPEC BCL2/CEN 18 Dual Color Probe C € IVD  Zyto <i>Light</i> SPEC BCL2/IGH Dual Color Dual Fusion Probe C € IVD	Z-2192-50/-200 Z-2174-50 Z-2114-50/-200	50 µl/200 µl 50 µl 50 µl/200 µl	135 136 137
BCL2L1		BCLX	Zyto <i>Light</i> SPEC BCL2L1/CEN 20 Dual Color Probe C€ IVD	Z-2171-200	200 μΙ	140
BCL2L2		BCL-W	Zyto <i>Light</i> SPEC BCL2L2/14q32 Dual Color Probe C € IVD	Z-2172-200	200 μΙ	115
BCL6		BCL5, BCL6A	Zyto <i>Light</i> SPEC BCL6 Dual Color Break Apart Probe C€ IVD	Z-2177-50/-200	50 µl/200 µl	46
BCR		ALL, BCR1	Zyto <i>Light</i> SPEC BCR/ABL1 Dual Color Dual Fusion Probe C € IVD	Z-2111-50/-200	50 μl/200 μl	84
BIRC3		C-IAP, MALT2	Zyto <i>Light</i> SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C € IVD	Z-2146-50/-200	50 µl/200 µl	97
BRAF		BRAF1, NS7	Zyto Light SPEC BRAF Dual Color Break Apart Probe C € IVD  Zyto Light SPEC BRAF/CEN 7 Dual Color Probe C € IVD	Z-2189-200 Z-2191-200	200 μl 200 μl	67 68
CARS		CARS1	Zyto <i>Light</i> SPEC CARS Dual Color Break Apart Probe C € IVD	Z-2137-50	50 µl	90
CBFB		PEBP2B	Zyto <i>Light</i> SPEC CBFB Dual Color Break Apart Probe C€ IVD NEW	Z-2207-50	50 µl	121
CCND1		BCL1, U21B31	Zyto Light SPEC CCND1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C€ IVD  Zyto Light SPEC CCND1/CEN 11 Dual Color Probe C€ IVD  Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C€ IVD	Z-2108-50/-200 Z-2118-200 Z-2071-50/-200 Z-2125-50/-200	50 µl/200 µl 200 µl 50 µl/200 µl 50 µl/200 µl	92 40 93 94
CD274		PD-L1, PDL1	Zyto <i>Light</i> SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe C € IVD	Z-2179-50/-200	50 µl/200 µl	78
CD74		-	Zyto Light SPEC NRG1/CD74 TriCheck™ Probe C € IVD NBW	Z-2194-200	200 µl	69
CDK4		PSK-J3	Zyto <i>Light</i> SPEC CDK4/CEN 12 Dual Color Probe C € IVD	Z-2103-50/-200	50 µl/200 µl	107
CDKN2A	p16	ARF, INK4	Zyto Light SPEC CDKN2A/CEN 9 Dual Color Probe C€ IVD  Zyto Light SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C€ IVD  Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C€ IVD NEW	Z-2063-50/-200 Z-2081-50/-200 Z-2204-200	50 µl/200 µl 50 µl/200 µl 200 µl	79 80 76





IUGO Iame	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
OLIAI		014	Zyto Light SPEC COL1A1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C€ IVD	Z-2121-200 Z-2116-50/-200	200 µl 50 µl/200 µl	130 131
RLF2		CRL2, TSLPR	Zyto <i>Light</i> SPEC CRLF2 Dual Color Break Apart Probe C € IVD	Z-2201-50	50 µl	148
SF1R		FMS	Zyto Light SPEC CSF1R Dual Color Break Apart Probe C € IVD	Z-2202-50	50 µl	54
DIT3	СНОР	CHOP10, GADD153	Zyto <i>Light</i> SPEC DDIT3 Dual Color Break Apart Probe C € IVD	Z-2100-50/-200	50 µl/200 µl	106
LEU1		BCMS1, LEU1	Zyto Light SPEC D13S319/13q34/CEN 12 Triple Color Probe C € IVD	Z-2160-50/-200	50 µl/200 µl	99
USP22		JKAP	Zyto Light SPEC IRF4, DUSP22 Dual Color Break Apart Probe C € IVD NEW	Z-2210-50	50 µl	56
GFR		HER1, ERBB1	Zyto Light SPEC EGFR/CEN 7 Dual Color Probe C€ IVD	Z-2033-50/-200	50 µl/200 µl	65
GR1		KROX-24	Zyto Light SPEC EGR1/5p15 Dual Color Probe C € IVD  Zyto Light SPEC EGR1/D5S23,D5S721 Dual Color Probe C € IVD NAW	Z-2107-50/-200 Z-2211-50	50 µl/200 µl 50 µl	52 53
VIL4		ROPP120	Zyto <i>Light</i> SPEC EML4 Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC ALK/EML4 TriCheck™ Probe C€ IVD	Z-2136-50 Z-2117-50/-200	50 µl 50 µl/200 µl	35 32
RBB2	HER2	HER-2, NEU	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe C € IVD  Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe Kit C € IVD  Zyto Light CEN 17/SPEC ERBB2 Dual Color Probe C € IVD  Zyto Light SPEC ERBB2/D17S122 Dual Color Probe C € IVD  Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C € IVD  Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C € IVD	Z-2015-50/-200 Z-2020-5/-20 Z-2077-50/-200 Z-2190-50 Z-2093-50/-200 Z-2204-200	50 μl/200 μl 5 Tests/20 Tests 50 μl/200 μl 50 μl 50 μl/200 μl 200 μl	126 126 127 128 129 76
RBB3	HER3	HER3	Zyto Light SPEC ERBB3/CEN 12 Dual Color Probe C€ IVD	Z-2056-200	200 µl	105
RBB4	HER4	ALS19	Zyto Light SPEC ERBB4/2q11 Dual Color Probe C € □VD	Z-2057-200	200 µl	37
RG		erg-3, p55	Zyto <i>Light</i> SPEC ERG Dual Color Break Apart Probe C € IVD  Zyto <i>Light</i> SPEC ERG/TMPRSS2 TriCheck™ Probe C € IVD	Z-2138-200 Z-2135-200	200 µl 200 µl	142 143
SR 1		Era, NR3A1	Zyto Light SPEC ESR1/CEN 6 Dual Color Probe C € IVD	Z-2069-50/-200	50 µl/200 µl	62
ΙVΊ		ER81	Zyto Light SPEC ETV1/CEN 7 Dual Color Probe C € IVD	Z-2141-200	200 µl	63
TV6		TEL	Zyto Light SPEC ETV6 Dual Color Break Apart Probe C    Zyto Light SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe C    IVD	Z-2176-50/-200 Z-2157-50	50 μl/200 μl 50 μl	102 103
WSR1		EWS	Zyto Light SPEC EWSR1 Dual Color Break Apart Probe $C \in \overline{VVD}$ Zyto Light SPEC EWSR1/FLI1 TriCheck <sup>TM</sup> Probe $C \in \overline{VVD}$ NEW	Z-2096-50/-200 Z-2183-50	50 µl/200 µl 50 µl	145 146
GF3		HBGF-3	Zyto Light SPEC FGF3,4,19/CEN 11 Dual Color Probe C€ IVD	Z-2158-200	200 µl	95
GF4		HBGF-4, HST	Zyto Light SPEC FGF3,4,19/CEN 11 Dual Color Probe C € IVD	Z-2158-200	200 µl	95





HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
FGF19		-	Zyto <i>Light</i> SPEC FGF3,4,19/CEN 11 Dual Color Probe C € IVD	Z-2158-200	200 µl	95
FGFR1		FLT2, BFGFR	Zyto <i>Light</i> SPEC FGFR1 Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC FGFR1/CEN 8 Dual Color Probe C€ IVD  Zyto <i>Light</i> SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C€ IVD INAVI	Z-2168-50/-200 Z-2072-50/-200 Z-2186-200	50 μl/200 μl 50 μl/200 μl 200 μl	71 72 48
FGFR2		BEK, CD332	Zyto <i>Light</i> SPEC FGFR2 Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC FGFR2/CEN 10 Dual Color Probe C€ IVD  Zyto <i>Light</i> SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C€ IVD NEW	Z-2169-200 Z-2122-200 Z-2186-200	200 μl 200 μl 200 μl	88 89 48
FGFR3		CD333, JTK4	Zyto <i>Light</i> SPEC FGFR3 Dual Color Break Apart Probe C € IVD  Zyto <i>Light</i> SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C € IVD N3W  Zyto <i>Light</i> SPEC FGFR3/4p11 Dual Color Probe C € IVD	Z-2170-50/-200 Z-2186-200 Z-2082-200	50 µl/200 µl 200 µl 200 µl	47 48 49
FHIT		FRA3B	Zyto <i>Light</i> SPEC FHIT/CEN 3 Dual Color Probe C € IVD	Z-2062-200	200 µl	41
FIP1L1		FIP1	Zyto Light SPEC PDGFRA/FIP1L1 TriCheck™ Probe C € IVD NEW	Z-2209-50	50 µl	50
FLI1		EWSR2	Zyto <i>Light</i> SPEC EWSR1/FLI1 TriCheck™ Probe C € IVD NEW	Z-2183-50	50 µl	146
FOXO1		FKHR, FKH1	Zyto Light SPEC FOXO1 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 Dual Color Single Fusion Probe C € IVD  Zyto Light SPEC FOXO1/PAX3 TriCheck™ Probe C € IVD NAW  Zyto Light SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C € IVD	Z-2139-50 Z-2018-50/-200 Z-2185-50 Z-2019-50/-200	50 μl 50 μl/200 μl 50 μl 50 μl/200 μl	109 110 111 112
FUS		FUS1	Zyto <i>Light</i> SPEC FUS Dual Color Break Apart Probe C€ IVD	Z-2130-50	50 µl	120
GAS6		AXSF, AXLLG	Zyto <i>Light</i> SPEC GAS6/13q12 Dual Color Probe C € IVD	Z-2156-200	200 µl	114
IGH		IGH@	Zyto Light SPEC IGH Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC BCL2/IGH Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC MYC/IGH Dual Color Dual Fusion Probe C€ IVD	Z-2110-50/-200 Z-2114-50/-200 Z-2125-50/-200 Z-2105-50/-200	50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl	116 137 94 77
IRF4		MUM1	Zyto <i>Light</i> SPEC IRF4, DUSP22 Dual Color Break Apart Probe C € IVD NEW	Z-2210-50	50 µl	56
JAZF1		TIP27, ZNF802	Zyto <i>Light</i> SPEC JAZF1 Dual Color Break Apart Probe C€ IVD	Z-2132-50	50 µl	64
KIF5B		KNS	Zyto <i>Light</i> SPEC KIF5B Dual Color Break Apart Probe C€ IVD	Z-2131-50	50 µl	85
KMT2A		MLL	Zyto <i>Light</i> SPEC KMT2A Dual Color Break Apart Probe C € IVD	Z-2193-50	50 µl	101
KRAS		KRAS1	Zyto <i>Light</i> SPEC KRAS/CEN 12 Dual Color Probe C € IVD	Z-2115-200	200 µl	104
MALTI		MLT	Zyto <i>Light</i> SPEC MALT1 Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C€ IVD	Z-2196-50/-200 Z-2146-50/-200	50 µl/200 µl 50 µl/200 µl	138 97
MAML2		MAM3	Zyto <i>Light</i> SPEC MAML2 Dual Color Break Apart Probe C€ <b>IVD</b>	Z-2014-50/-200	50 μl/200 μl	96





	G IIIUGA								
HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page			
MCL1		BCL2L3	Zyto Light SPEC MCL1/1p12 Dual Color Probe C€ IVD	Z-2173-200	200 μΙ	27			
MDM2		HDM2	Zyto Light SPEC MDM2/CEN 12 Dual Color Probe C € IVD	Z-2013-50/-200	50 µl/200 µl	108			
MDM4		MDMX	Zyto Light SPEC MDM4/1p12 Dual Color Probe C € IVD	Z-2080-200	200 µl	30			
MERTK		MER, c-Eyk	Zyto Light SPEC MERTK/2q11 Dual Color Probe C € IVD	Z-2155-200	200 µl	36			
MET		HGFR, RCCP2	Zyto Light SPEC MET/CEN 7 Dual Color Probe C € IVD	Z-2087-200	200 µl	66			
МҮВ		c-myb	Zyto <i>Light</i> SPEC MYB Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC RREB1/MYB/CEN 6 Triple Color Probe C€ IVD	Z-2143-200 Z-2152-50/-200	200 µl 50 µl/200 µl	61 57			
MYC	СМҮС	bHLHe39, c-Myc	Zyto Light SPEC MYC Dual Color Break Apart Probe C € IVD  Zyto Light SPEC MYC/CEN 8 Dual Color Probe C € IVD  Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C € IVD NEW  Zyto Light SPEC MYC/IGH Dual Color Dual Fusion Probe C € IVD	Z-2090-50/-200 Z-2092-50/-200 Z-2204-200 Z-2105-50/-200	50 μl/200 μl 50 μl/200 μl 200 μl 50 μl/200 μl	74 75 76 77			
MYCN	NMYC	N-myc	Zyto Light SPEC MYCN/2q11 Dual Color Probe C € IVD	Z-2074-50/-200	50 μl/200 μl	31			
NR4A3		CHN, CSMF	Zyto <i>Light</i> SPEC NR4A3 Dual Color Break Apart Probe C€ IVD	Z-2145-50	50 µl	82			
NRG1		HGL, GGF	Zyto Light SPEC NRG1 Dual Color Break Apart Probe $C \in IVD$ Zyto Light SPEC NRG1/CD74 TriCheck <sup>TM</sup> Probe $C \in IVD$	Z-2181-200 Z-2194-200	200 µl 200 µl	70 69			
NTRK1		MTC, TRK	Zyto <i>Light</i> SPEC NTRK1 Dual Color Break Apart Probe C€ IVD	Z-2167-200	200 μΙ	28			
NTRK2		TRKB	Zyto <i>Light</i> SPEC NTRK2 Dual Color Break Apart Probe C€ IVD NEW	Z-2205-200	200 μΙ	81			
NTRK3		TRKC	Zyto Light SPEC NTRK3 Dual Color Break Apart Probe C€ IVD NEW	Z-2206-200	200 μΙ	119			
NUTM1		NUT	Zyto Light SPEC NUTM1 Dual Color Break Apart Probe C€ IVD NW	Z-2208-200	200 µl	117			
PAX3		HUP2	Zyto <i>Light</i> SPEC FOXO1/PAX3 Dual Color Single Fusion Probe C € IVD Zyto <i>Light</i> SPEC FOXO1/PAX3 TriCheck™ Probe C € IVD NEW	Z-2018-50/-200 Z-2185-50	50 µl/200 µl 50 µl	110 111			
PAX7		HUP1	Zyto Light SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C€ IVD	Z-2019-50/-200	50 µl/200 µl	112			
PDCD1LG2		PD-L2, PDL2	Zyto Light SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe C € IVD	Z-2179-50/-200	50 µl/200 µl	78			
PDGFB		SIS, SSV	Zyto <i>Light</i> SPEC PDGFB Dual Color Break Apart Probe C€ IVD  Zyto <i>Light</i> SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C€ IVD	Z-2119-50/-200 Z-2116-50/-200	50 µl/200 µl 50 µl/200 µl	147 131			
PDGFRA		GAS9	Zyto Light SPEC PDGFRA/FIP1L1 TriCheck™ Probe C € IVD NEW	Z-2209-50	50 µl	50			
PDGFRB		JTK12, PDGFR1	Zyto Light SPEC PDGFRB Dual Color Break Apart Probe C€ IVD	Z-2197-50	50 µl	55			
PIK3CA		PI3K	Zyto Light SPEC PIK3CA/CEN 3 Dual Color Probe C€ IVD	Z-2140-200	200 µl	44			





IUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
ML		MYL, RNF71	Zyto Light SPEC PML/RARA Dual Color Dual Fusion Probe C€ IVD	Z-2113-50/-200	50 μl/200 μl	118
PTEN		MMAC1, TEP1	Zyto Light SPEC PTEN/CEN 10 Dual Color Probe C€   IVD	Z-2078-50/-200	50 µl/200 µl	87
PTPRT		KIAA0283	Zyto Light SPEC PTPRT/20q11 Dual Color Probe C € IVD NEW	Z-2213-50	50 µl	141
RARA		NR1B1, RAR	Zyto Light SPEC PML/RARA Dual Color Dual Fusion Probe C€ IVD	Z-2113-50/-200	50 µl/200 µl	118
RB1		PPP1R130	Zyto Light SPEC RB1/13q12 Dual Color Probe C€ IVD	Z-2165-50/-200	50 µl/200 µl	113
RET		HSCR1, CDHF12	Zyto Light SPEC RET Dual Color Break Apart Probe C€ IVD	Z-2148-50/-200	50 µl/200 µl	86
ROS1		MCF3, ROS	Zyto Light SPEC ROS1 Dual Color Break Apart Probe C€ IVD Zyto Light SPEC ROS1/CEN 6 Dual Color Probe C€ IVD	Z-2144-50/-200 Z-2162-200	50 µl/200 µl 200 µl	59 60
REB1		HNT	Zyto Light SPEC RREB1/MYB/CEN 6 Triple Color Probe C€ IVD	Z-2152-50/-200	50 µl/200 µl	57
RUNX1	AML1	AMLCR1	Zyto Light SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C € IVD  Zyto Light SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe C € IVD	Z-2112-50 Z-2157-50	50 µl 50 µl	73 103
RUNX1T1	ETO	CDR, MTG8	Zyto Light SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C € IVD	Z-2112-50	50 µl	73
SMARCB1		BAF47	Zyto Light SPEC SMARCB1/22q12 Dual Color Probe C€ IVD	Z-2178-50	50 µl	144
60X2		ANOP3	Zyto Light SPEC SOX2/CEN 3 Dual Color Probe C € IVD	Z-2127-200	200 µl	45
SS18	SYT	SSXT	Zyto Light SPEC SS18 Dual Color Break Apart Probe C € IVD Zyto Light SPEC SS18/SSX1 TriCheck™ Probe C € IVD NW	Z-2097-50/-200 Z-2184-50	50 µl/200 µl 50 µl	133 134
SX1			Zyto Light SPEC SS18/SSX1 TriCheck™ Probe C€ IVD NW	Z-2184-50	50 µl	134
ERT		EST2, TCS1	Zyto Light SPEC TERT/5q31 Dual Color Probe C€ IVD	Z-2091-50	50 µl	51
FE3		TFEA	Zyto <i>Light</i> SPEC TFE3 Dual Color Break Apart Probe C€	Z-2109-50/-200	50 µl/200 µl	149
FG		TF6	Zyto Light SPEC TFG Dual Color Break Apart Probe C€ IVD	Z-2133-50	50 µl	42
MPRSS2		PRSS10	Zyto Light SPEC ERG/TMPRSS2 TriCheck™ Probe C€ IVD	Z-2135-200	200 µl	143
OP2A		TOP2	Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C€ IVD	Z-2093-50/-200	50 μl/200 μl	129
ГР53		LSF1, TRP53	Zyto Light SPEC TP53/17q22 Dual Color Probe C € IVD  Zyto Light SPEC TP53/ATM Dual Color Probe C € IVD  Zyto Light SPEC TP53/CEN 17 Dual Color Probe C € IVD	Z-2198-50 Z-2159-50/-200 Z-2153-50/-200	50 μl 50 μl/200 μl 50 μl/200 μl	122 98 123
TYMS		HsT422, TMS	Zyto Light SPEC TYMS/CEN 18 Dual Color Probe C € IVD	Z-2098-200	200 µl	132
JSP6		Tre-2	Zyto Light SPEC USP6 Dual Color Break Apart Probe C€ IVD	Z-2151-50	50 µl	124





HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
VEGFA		VEGF, VPF	Zyto Light SPEC VEGFA/CEN 6 Dual Color Probe C € IVD	Z-2195-200	200 µl	58
VHL		VHL1	Zyto Light SPEC VHL/CEN 3 Dual Color Probe C € IVD  Zyto Light SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C € IVD	Z-2084-200 Z-2102-200	200 µl 200 µl	38 39
WTI		AWT1	Zyto Light SPEC WT1 Dual Color Break Apart Probe C€ IVD	Z-2142-50	50 µl	91
WWTR1		TAZ	Zyto Light SPEC WWTR1 Dual Color Break Apart Probe C€ IVD NEW	Z-2212-50	50 µl	43
YWHAE		14-3-3 epsilon	Zyto Light SPEC YWHAE Dual Color Break Apart Probe C€ IVD	Z-2175-50	50 µl	125
ZNF217		ZABC1	Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C€ NWD NWW	Z-2204-200	200 µl	76

The Gene Index list includes only those probes directed against DNA sequences assigned to known genes. It does not contain probes directed against other genomic sequences as e.g. repetitive satellite DNA sequences. For a complete overview of all ZytoLight® probes, please refer to the Chromosome Index.

For cross referencing of previous ZytoVision probe names and new HUGO gene names - please visit the HUGO gene nomenclature committee website at www.genenames.org.



Indication	Product Name	Product No.	Quantity	Pag
Solid Tumors Brain and Neural Tumors	ZytoLight SPEC 1p36/1q25 Dual Color Probe C € IVD  ZytoLight SPEC 19q13/19p13 Dual Color Probe C € IVD  ZytoLight SPEC CDKN2A/CEN 9 Dual Color Probe C € IVD  ZytoLight SPEC GFR/CEN 7 Dual Color Probe C € IVD  ZytoLight SPEC MET/CEN 7 Dual Color Probe C € IVD  ZytoLight SPEC MYCN/2q11 Dual Color Probe C € IVD  ZytoLight SPEC NTRK2 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC TP53/17q22 Dual Color Probe C € IVD  ZytoLight SPEC TP53/17q22 Dual Color Probe C € IVD  ZytoLight SPEC TP53/17q22 Dual Color Probe C € IVD	Z-2075-50/-200 Z-2076-50/-200 Z-2063-50/-200 Z-2033-50/-200 Z-2087-200 Z-2074-50/-200 Z-205-200 Z-205-200 Z-2198-50 Z-2153-50/-200	50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 200 µl 50 µl/200 µl 200 µl 50 µl/200 µl 50 µl/200 µl 50 µl	25 26 79 65 66 31 81 87 122 123
Breast Cancer	ZytoLight SPEC CCND1/CEN 11 Dual Color Probe C€ IVD  ZytoLight SPEC EGFR/CEN 7 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe Kit C€ IVD  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB2/D17S122 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C€ IVD  ZytoLight SPEC ERBB3/CEN 12 Dual Color Probe C€ IVD  ZytoLight SPEC ERBB4/2q11 Dual Color Probe C€ IVD  ZytoLight SPEC ESR1/CEN 6 Dual Color Probe C€ IVD  ZytoLight SPEC FGFR1/CEN 8 Dual Color Probe C€ IVD  ZytoLight SPEC FGFR2/CEN 10 Dual Color Probe C€ IVD  ZytoLight SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C€ IVD  ZytoLight SPEC MYC/CEN 8 Dual Color Probe C€ IVD  ZytoLight SPEC MYC/CEN 8 Dual Color Probe C€ IVD  ZytoLight SPEC MYC/CEN 8 Dual Color Probe C€ IVD  ZytoLight SPEC MYC/CEN 8 Dual Color Probe C€ IVD	Z-2071-50/-200 Z-2033-50/-200 Z-2015-50/-200 Z-2020-5/-20 Z-2077-50/-200 Z-2190-50 Z-2093-50/-200 Z-2056-200 Z-2057-200 Z-2069-50/-200 Z-2072-50/-200 Z-2122-200 Z-2186-200 Z-2092-50/-200 Z-2195-200	50 μl/200 μl 50 μl/200 μl 50 μl/200 μl 5 Tests/20 Tests 50 μl/200 μl 50 μl/200 μl 200 μl 200 μl 50 μl/200 μl 50 μl/200 μl 200 μl 200 μl 200 μl 200 μl 200 μl	93 65 126 126 127 128 129 105 37 62 72 89 48 75 58
Cervical Cancer	Zyto Light SPEC MYC/CEN 8 Dual Color Probe C € IVD  Zyto Light SPEC TERT/5q31 Dual Color Probe C € IVD	Z-2092-50/-200 Z-2091-50	50 µl/200 µl 50 µl	75 51
Lung Cancer	ZytoLight SPEC ALK/EML4 TriCheck™ Probe C € IVD  ZytoLight SPEC ALK Dual Color Break Apart Probe C € IVD  ZytoLight SPEC ALK/2q11 Dual Color Probe C € IVD  ZytoLight SPEC BRAF/CEN 7 Dual Color Probe C € IVD  ZytoLight SPEC CARS Dual Color Break Apart Probe C € IVD  ZytoLight SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe C € IVD  ZytoLight SPEC EGFR/CEN 7 Dual Color Probe C € IVD  ZytoLight SPEC EML4 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe C € IVD  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe C € IVD  ZytoLight CEN 17/SPEC ERBB2 Dual Color Probe C € IVD  ZytoLight SPEC ERBB2/D17S122 Dual Color Probe C € IVD  ZytoLight SPEC FGFR1/CEN 8 Dual Color Probe C € IVD  ZytoLight SPEC FGFR2 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC FGFR3 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC FGFR3 Dual Color Break Apart Probe C € IVD  ZytoLight SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C € IVD  ZytoLight SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C € IVD	Z-2117-50/-200 Z-2124-50/-200 Z-2161-200 Z-2191-200 Z-2137-50 Z-2179-50/-200 Z-2033-50/-200 Z-2015-50/-200 Z-2015-50/-200 Z-2077-50/-200 Z-2190-50 Z-2072-50/-200 Z-2169-200 Z-2170-50/-200 Z-2170-50/-200 Z-2186-200 Z-2082-200	50 µl/200 µl 50 µl/200 µl 200 µl 50 µl 50 µl/200 µl 50 µl 200 µl 200 µl 200 µl 200 µl 200 µl 200 µl	32 33 34 68 90 78 65 126 127 128 72 88 89 47 48 49





ndication	Product Name	Product No.	Quantity	Paç
ung Cancer	Zyto Light SPEC KRAS/CEN 12 Dual Color Probe C € IVD	Z-2115-200	200 µl	104
	ZytoLight SPEC MET/CEN 7 Dual Color Probe C € IVD	Z-2087-200	200 μl	66
	Zyto Light SPEC NRG1 Dual Color Break Apart Probe C€ IVD	Z-2181-200	200 μl	70
	Zyto Light SPEC NRG1/CD74 TriCheck™ Probe C € IVD	Z-2194-200	200 μl	69
	Zyto <i>Light</i> SPEC NTRK1 Dual Color Break Apart Probe C€ IVD	Z-2167-200	200 μl	28
	Zyto <i>Light</i> SPEC NTRK2 Dual Color Break Apart Probe C€ IVD NEW	Z-2205-200	200 μl	81
	Zyto Light SPEC NTRK3 Dual Color Break Apart Probe CE IVD NEW	Z-2206-200	200 μl	11
	Zyto Light SPEC RET Dual Color Break Apart Probe C TVD	Z-2148-50/-200	50 µl/200 µl	86
	Zyto Light SPEC ROS1 Dual Color Break Apart Probe C€ IVD	Z-2144-50/-200	50 μl/200 μl	59
	Zyto Light SPEC SOX2/CEN 3 Dual Color Probe C € IVD	Z-2127-200	200 µl	45
	Zyto Light SPEC TFG Dual Color Break Apart Probe C C IVD	Z-2133-50	50 µl	42
ner Solid Tumors	Zyto <i>Light</i> CEN 8 Probe C € IVD	Z-2004-50/-200	50 µl/200 µl	15
	Zyto <i>Light</i> SPEC 13/CEN 18/SPEC 21 Triple Color Probe C€ IVD	Z-2095-50/-200	50 μl/200 μl	15
	Zyto Light SPEC ALK/EML4 TriCheck™ Probe C € IVD	Z-2117-50/-200	50 μl/200 μl	32
	Zyto Light SPEC ALK Dual Color Break Apart Probe C C IVD	Z-2124-50/-200	50 μl/200 μl	33
	Zyto Light SPEC ALK/2q11 Dual Color Probe C € IVD	Z-2161-200	200 μl	34
	Zyto Light SPEC AXL/19p13 Dual Color Probe C © IVD	Z-2154-200	200 μl	13
	Zyto Light SPEC BCL2L1/CEN 20 Dual Color Probe C C IVD	Z-2171-200	200 μl	14
	Zyto Light SPEC BCL2L2/14q32 Dual Color Probe C € IVD	Z-2172-200	200 μl	11
	Zyto Light SPEC BRAF Dual Color Break Apart Probe CE IVD	Z-2189-200	200 μl	67
	Zyto Light SPEC BRAF/CEN 7 Dual Color Probe C © IVD	Z-2191-200	200 µl	68
	Zyto Light SPEC CCND1/CEN 11 Dual Color Probe C C IVD	Z-2071-50/-200	50 µl/200 µl	93
	Zyto Light SPEC CDKN2A/CEN 9 Dual Color Probe C C IVD	Z-2063-50/-200	50 μl/200 μl	79
	Zyto Light SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C E IVD	Z-2081-50/-200	50 μl/200 μl	80
	Zyto Light SPEC EGFR/CEN 7 Dual Color Probe C TVD	Z-2033-50/-200	50 μl/200 μl	65
	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe C C IVD	Z-2015-50/-200	50 μl/200 μl	12
	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe Kit C E IVD	Z-2020-5/-20	5 Tests/20 Tests	
	Zyto Light CEN 17/SPEC ERBB2 Dual Color Probe C TVD	Z-2077-50/-200	50 µl/200 µl	12
	Zyto Light SPEC ETV1/CEN 7 Dual Color Probe C C IVD	Z-2141-200	200 μl	63
	Zyto Light SPEC ETV6 Dual Color Break Apart Probe C    IVD	Z-2176-50/-200	50 μl/200 μl	10
	Zyto Light SPEC FGF3,4,19/CEN 11 Dual Color Probe CE IVD	Z-2178-307-200 Z-2158-200	200 μl	95
	Zyto Light SPEC FGFR2 Dual Color Break Apart Probe C TVD	Z-2169-200	200 μl	88
	Zyto Light SPEC FGFR3/4p11 Dual Color Probe CE IVD	Z-2082-200	200 μl	49
	Zyto Light SPEC FHIT/CEN 3 Dual Color Probe C€ IVD	Z-2062-200 Z-2062-200	200 μl	41
	Zyto Light SPEC GAS6/13q12 Dual Color Probe CE IVD	Z-200Z-200 Z-2156-200	200 μl	11
	Zyto Light SPEC KRAS/CEN 12 Dual Color Probe C€ [VD]	Z-2136-200 Z-2115-200	200 μl	10
	Zyto Light SPEC MAML2 Dual Color Break Apart Probe CE IVD	Z-2113-200 Z-2014-50/-200	200 μι 50 μl/200 μl	96
	Zyto Light SPEC MCL1/1p12 Dual Color Probe C C TVD	Z-2014-307-200 Z-2173-200	30 μl/ 200 μl	27
	Zyto Light SPEC MDM4/1p12 Dual Color Probe C E IVD	Z-2173-200 Z-2080-200	200 μl	30
		Z-2000-200 Z-2155-200	200 μl	36
	Zyto Light SPEC MERTK/2q11 Dual Color Probe C€ IVD  Zyto Light SPEC MET/CEN 7 Dual Color Probe C€ IVD	Z-2133-200 Z-2087-200	200 μl	66
	. •	Z-2067-200 Z-2143-200	200 μl	61
	Zyto Light SPEC MYB Dual Color Break Apart Probe C € IVD  Zyto Light SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C € IV		200 μl	76
				31
	Zyto Light SPEC MYCN/2q11 Dual Color Probe C € IVD	Z-2074-50/-200	50 µl/200 µl	
	Zyto Light SPEC NTRK1 Dual Color Break Apart Probe CE IVD	Z-2167-200	200 µl	28
	Zyto Light SPEC NUTM1 Dual Color Break Apart Probe C ( IVD NEW)	Z-2208-200	200 µl	11
	ZytoLight SPEC PIK3CA/CEN 3 Dual Color Probe C € ND	Z-2140-200	200 µl	44
	Zyto <i>Light</i> SPEC RB1/13q12 Dual Color Probe C € IVD	Z-2165-50/-200	50 µl/200 µl	11





Indication	Product Name	Product No.	Quantity	Page
Other Solid Tumors	Zyto Light SPEC TFE3 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC TP53/CEN 17 Dual Color Probe C€ IVD  Zyto Light SPEC TYMS/CEN 18 Dual Color Probe C€ IVD  Zyto Light SPEC VEGFA/CEN 6 Dual Color Probe C€ IVD	Z-2109-50/-200 Z-2153-50/-200 Z-2098-200 Z-2195-200	50 μl/200 μl 50 μl/200 μl 200 μl 200 μl	149 123 132 58
Prostate Cancer	Zyto Light SPEC ERG Dual Color Break Apart Probe C € IVD  Zyto Light SPEC ERG/TMPRSS2 TriCheck™ Probe C € IVD  Zyto Light SPEC PTEN/CEN 10 Dual Color Probe C € IVD	Z-2138-200 Z-2135-200 Z-2078-50/-200	200 µl 200 µl 50 µl/200 µl	142 143 87
Renal Cell Carcinoma	Zyto Light SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C € IVD  Zyto Light SPEC FHIT/CEN 3 Dual Color Probe C € IVD  Zyto Light SPEC TFE3 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C € IVD  Zyto Light SPEC VHL/CEN 3 Dual Color Probe C € IVD	Z-2118-200 Z-2062-200 Z-2109-50/-200 Z-2102-200 Z-2084-200	200 µl 200 µl 50 µl/200 µl 200 µl 200 µl	40 41 149 39 38
Sarcomas	ZytoLight SPEC ALK Dual Color Break Apart Probe C	7-2124-50/-200 7-2103-50/-200 7-2116-50/-200 7-2116-50/-200 7-2176-50/-200 7-2176-50/-200 7-2183-50 7-2139-50 7-2185-50 7-2018-50/-200 7-2185-50 7-2132-50 7-2132-50 7-2080-200 7-2080-200 7-2145-50 7-2206-200 7-2178-50 7-2178-50 7-2195-50/-200 7-2184-50 7-2195-50/-200 7-2184-50 7-2195-50/-200 7-2184-50 7-2195-50/-200 7-2151-50 7-2175-50 7-2175-50	50 µl/200 µl 50 µl	33 107 130 131 106 102 145 146 109 110 111 112 120 64 108 30 75 82 119 147 144 133 134 149 124 58 91 43 125



Indication	Product Name	Product No.	Quantity	Page
Hematology Specific Probes Acute Lymphoblastic Leukemia (ALL)	Zyto Light SPEC ABL1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC ABL2 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CDKN2A/CEN 9 Dual Color Probe C€ IVD  Zyto Light SPEC CRLF2 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CSF1R Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC ETV6 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC KMT2A Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYB Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC NTRK3 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC PDGFRA/FIP1L1 TriCheck™ Probe C€ IVD NEW	Z-2199-50 Z-2200-50 Z-2063-50/-200 Z-2201-50 Z-2202-50 Z-2176-50/-200 Z-2157-50 Z-2193-50 Z-2143-200 Z-2206-200 Z-2209-50	50 µl 50 µl 50 µl/200 µl 50 µl 50 µl 50 µl/200 µl 50 µl 50 µl 200 µl 200 µl	83 29 79 148 54 102 103 101 61 119
Acute Myelogenous Leukemia (AML)	Zyto Light CEN 8 Probe C€ IVD  Zyto Light SPEC ABL2 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CBFB Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC EGR1/5p15 Dual Color Probe C€ IVD  Zyto Light SPEC EGR1/D5S23,D5S721 Dual Color Probe C€ IVD  Zyto Light SPEC FGFR1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC KMT2A Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC PDGFRA/FIP1L1 TriCheck™ Probe C€ IVD  Zyto Light SPEC PDGFRB Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC PML/RARA Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC PTPRT/20q11 Dual Color Probe C€ IVD  Zyto Light SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C€ IVD	Z-2004-50/-200 Z-2207-50 Z-2107-50/-200 Z-2211-50 Z-2168-50/-200 Z-2193-50 Z-2197-50 Z-2113-50/-200 Z-2213-50 Z-2112-50	50 µl/200 µl 50 µl	150 f 29 121 52 53 71 101 50 55 118 141 73
Chronic Lymphocytic Leukemia (CLL)	Zyto Light SPEC BCL2 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CCND1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CCND1/CEN 11 Dual Color Probe C€ IVD  Zyto Light SPEC D13S319/13q34/CEN 12 Triple Color Probe C€ IVD  Zyto Light SPEC MYC/CEN 8 Dual Color Probe C€ IVD  Zyto Light SPEC RB1/13q12 Dual Color Probe C€ IVD  Zyto Light SPEC TP53/ATM Dual Color Probe C€ IVD  Zyto Light SPEC TP53/CEN 17 Dual Color Probe C€ IVD	Z-2192-50/-200 Z-2108-50/-200 Z-2071-50/-200 Z-2160-50/-200 Z-2092-50/-200 Z-2165-50/-200 Z-2159-50/-200 Z-2153-50/-200	50 µl/200 µl	135 92 93 99 75 113 98 123
Chronic Myelogenous Leukemia (CML)	Zyto Light CEN 8 Probe C€ IVD  Zyto Light SPEC ABL1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC BCR/ABL1 Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC TP53/17q22 Dual Color Probe C€ IVD	Z-2004-50/-200 Z-2199-50 Z-2111-50/-200 Z-2197-50 Z-2198-50	50 µl/200 µl 50 µl 50 µl/200 µl 50 µl 50 µl	150 f 83 84 55 122
Multiple Myeloma	Zyto Light SPEC CCND1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CCND1/CEN 11 Dual Color Probe C€ IVD  Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC FGFR3 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC IGH Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC RB1/13q12 Dual Color Probe C€ IVD  Zyto Light SPEC TP53/CEN 17 Dual Color Probe C€ IVD	Z-2108-50/-200 Z-2071-50/-200 Z-2125-50/-200 Z-2170-50/-200 Z-2110-50/-200 Z-2165-50/-200 Z-2153-50/-200	50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl 50 µl/200 µl	92 93 94 47 116 113 123





Indication	Product Name	Product No.	Quantity	Page
Myelodysplastic Syndrome (MDS)	Zyto Light CEN 8 Probe C € IVD  Zyto Light SPEC EGR1/5p15 Dual Color Probe C € IVD  Zyto Light SPEC EGR1/D5S23,D5S721 Dual Color Probe C € IVD  Zyto Light SPEC ETV6 Dual Color Break Apart Probe C € IVD  Zyto Light SPEC PDGFRB Dual Color Break Apart Probe C € IVD  Zyto Light SPEC PTPRT/20q11 Dual Color Probe C € IVD  Zyto Light SPEC TERT/5q31 Dual Color Probe C € IVD	Z-2004-50/-200 Z-2107-50/-200 Z-2211-50 Z-2176-50/-200 Z-2197-50 Z-2213-50 Z-2091-50	50 μl/200 μl 50 μl/200 μl 50 μl 50 μl/200 μl 50 μl 50 μl	150 ff 52 53 102 55 141 51
Non-Hodgkin Lymphoma, other	Zyto Light SPEC 11q gain/loss Triple Color Probe C€ IVD  Zyto Light SPEC ALK Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC BCL2 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC BCL2/CEN 18 Dual Color Probe C€ IVD  Zyto Light SPEC BCL2/IGH Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC BCL6 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC CCND1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC CCND1/IGH Dual Color Probe C€ IVD  Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C€ IVD  Zyto Light SPEC IGH Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC IGH Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC IRF4, DUSP22 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MALT1 Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD  Zyto Light SPEC MYC Dual Color Break Apart Probe C€ IVD	Z-2216-50 Z-2124-50/-200 Z-2172-50/-200 Z-2174-50 Z-2114-50/-200 Z-2146-50/-200 Z-2146-50/-200 Z-2108-50/-200 Z-2125-50/-200 Z-2170-50/-200 Z-2110-50/-200 Z-2196-50/-200 Z-2196-50/-200 Z-2196-50/-200 Z-2105-50/-200 Z-2105-50/-200	50 µl 50 µl/200 µl	100 33 135 136 137 46 97 92 93 94 47 116 56 138 74
Genetics Sex Mismatched Bone-Marrow Transplantant Management	Zyto Light CEN X Probe  Zyto Light CEN X/Y Dual Color Probe C € IVD  Zyto Light CEN X/Yq12 Dual Color Probe C € IVD  Zyto Light CEN Yq12 Probe C € IVD  Zyto Light CEN Yq12 Probe	Z-2008-200 Z-2120-200 Z-2016-50/-200 Z-2123-200 Z-2010-200	200 µl 200 µl 50 µl/200 µl 200 µl	150 ff 150 ff 150 ff 150 ff 150 ff
Prenatal, Postnatal, and Preimplantation Genetics	Zyto Light Aneusomy Probe Set C€ IVD  Zyto Light SPEC 13/12 Probe C€ IVD  Zyto Light SPEC 13/21 Dual Color Probe C€ IVD  Zyto Light SPEC 13/21 Dual Color Probe C€ IVD  Zyto Light SPEC 18/CEN X/Y Triple Color Probe C€ IVD  Zyto Light SPEC 21/22 Probe C€ IVD  Zyto Light SPEC 21/CEN X/Yq12 Triple Color Probe C€ IVD  Zyto Light CEN X Probe  Zyto Light CEN X/Y Dual Color Probe C€ IVD  Zyto Light CEN X/Yq12 Dual Color Probe C€ IVD  Zyto Light CEN Y/q12 Dual Color Probe C€ IVD  Zyto Light CEN Y (DYZ3) Probe C€ IVD  Zyto Light CEN Yq12 Probe	Z-2104-10/-40 Z-2085-200 Z-2095-50/-200 Z-2164-200 Z-2007-200 Z-2163-200 Z-2086-200 Z-2180-200 Z-2008-200 Z-2120-200 Z-2016-50/-200 Z-2010-200	2x 50 µl/2x 200 µl 200 µl 50 µl/200 µl 200 µl	150 ff 150 ff 150 ff 150 ff 150 ff 150 ff 150 ff 150 ff 150 ff





## Zyto Light ® SPEC 1p36/1q25 Dual Color Probe



### **Background**

The ZytoLight® SPEC 1p36/1q25 Dual Color Probe is designed for the detection of 1p deletions.

Deletions affecting the short arm of chromosome 1 (1p) are frequently found in human gliomas and neuroblastomas, but also in breast, lung, endometrial, ovarian, and colorectal carcinomas. Loss of 1p is a strong prognostic factor in patients with neuroblastoma. Since loss of 1p reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable, more aggressive therapy may be considered in these patients.


Deletions affecting the long arm of chromosome 19 (19g) are frequently found in human malignant gliomas as well as in neuroblastomas and epithelial ovarian cancers.

Several studies showed correlation of combined allelic losses at 1p36 and 19q13 with oligodendroglioma histology and association with both chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Hence, determination of 1p and 19q status may aid in therapeutic decisions and predict outcome in patients with anaplastic oligodendrogliomas.


Derivation of the control of the con Caron H, et al. (1996) N Engl J Med 334: 225-30. Elsir T, et al. (2011) Br J Cancer 11: 1747-54. Hoeller S, et al. (2012) Hum Pathol 43: 405-12. Ragnarsson G, et al. (1999) Br J Cancer 79: 1468-74. Rosenberg JE, et al. (1996) Oncogene 13: 2483-5. Smith JS, et al. (1999) Oncogene 18: 4144-52. Smith JS, et al. (2000) Genes Chromosomes Cancer 29: 16-25. Smits A, et al. (2012) PLoS One 7: e37041. White PS, et al. (2005) Oncogene 24: 2684-94.

### **Probe Description**

The SPEC 1p36/1g25 Dual Color Probe is a mixture of an orange fluorochrome direct labeled 1p36 probe specific for the smallest region of consistent deletion (SRD) of chromosome 1 defined in neuroblastoma at 1p36.31 and a green fluorochrome direct labeled 1q25 probe specific for 1q25.3.




Ideogram of chromosome 1 indicating the hybridization locations.



#### Results

Using the SPEC 1p36/1a25 Dual Color Probe in a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the 1p36 locus, one or no copy of the orange signal will be observed.



SPEC 1p36/1q25 Dual Color Probe hybridized to a glioma tissue section with 1p36 deletion as indicated by one orange signal in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2075-50	Zyto <i>Light</i> SPEC 1p36/1q25 Dual Color Probe CE IVD	<b>●/●</b>	5 (50 µl)		
Z-2075-200	Zyto <i>Light</i> SPEC 1p36/1q25 Dual Color Probe CE IVD	<b>●/●</b>	20 (200 µl)		
Related Products					
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



### Zyto Light ® SPEC 19q13/19p13 Dual Color Probe



### **Background**

The ZytoLight ® SPEC 19q13/19p13 Dual Color Probe is designed for the detection of 19q deletions.

Deletions affecting the long arm of chromosome 19 (19q) are frequently found in human malignant gliomas as well as in neuroblastomas and epithelial ovarian


Deletions affecting the short arm of chromosome 1 (1p) are frequently found in human gliomas and neuroblastomas, but also in breast, lung, endometrial, ovarian, and colorectal carcinomas. Loss of 1p is a strong prognostic factor in patients with neuroblastoma. Since loss of 1p reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable, more aggressive therapy may be considered in these patients.

Several studies showed correlation of combined allelic losses at 1p36 and 19q13 with oligodendroglioma histology and association with both chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Hence, determination of 1p and 19q status may aid in therapeutic decisions and predict outcome in patients with anaplastic oligodendrogliomas.

References
Barbashina V, et al. (2005) Clin Cancer Res 11: 1119-28.
Cairncross JG, et al. (1998) J Natl Cancer Inst 90: 1473-9.
Capper D, et al. (2010) Acta Neuropathol 121: 241-52.
Caron H, et al. (1996) N Engl J Med 334: 225-30.
Elsir T, et al. (2011) Br J Cancer 11: 1747-54.
Hoeller S, et al. (2012) Hum Pathol 43: 405-12.
Ragnarsson G, et al. (1999) Br J Cancer 79: 1468-74. Kagnarsson G, et al. (1999) Br J Cancer /9: 1408-74. Rosenberg JE, et al. (1996) Oncogene 13: 2483-5. Smith JS, et al. (1999) Oncogene 18: 4144-52. Smith JS, et al. (2001) Genes Chromosomes Cancer 29: 16-25. Smits A, et al. (2012) PLoS One 7: e37041. White PS, et al. (2005) Oncogene 24: 2684-94.

### **Probe Description**


The SPEC 19q13/19p13 Dual Color Probe is a mixture of an orange fluorochrome direct labeled 19q13 probe specific for the region of common deletion in gliomas at 19q13.32-q13.33 and a green fluorochrome direct labeled 19p13 probe specific for 19p13.3.



Ideogram of chromosome 19 indicating the hybridization locations.




SPEC 19p13 Probe map (not to scale).



SPEC 19q13 Probe map (not to scale).

#### Results

Using the SPEC 19q13/19p13 Dual Color Probe in a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the 19q13 locus, one or no copy of the orange signal will be observed.



SPEC 19q13/19p13 Dual Color Probe hybridized to a glioma tissue section with 19q13 deletion as indicated by one orange signal in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2076-50	Zyto <i>Light</i> SPEC 19q13/19p13 Dual Color Probe C € IVD	<b> </b>	5 (50 µl)		
Z-2076-200	Zyto <i>Light</i> SPEC 19q13/19p13 Dual Color Probe C € IVD	<b>●/●</b>	20 (200 µl)		
Related Products					
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    INCL Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC MCL1/1p12 Dual Color Probe



#### **Background**

The ZytoLight ® SPEC MCL1/1p12 Dual Color Probe is designed for the detection of MCL1 gene amplifications.

The MCL1 (myeloid cell leukemia 1, a.k.a. BCL2L3) gene is located in the chromosomal region 1q21.3 and encodes for an anti-apoptotic protein that belongs to the BCL2 family. These genes are involved in a wide variety of cellular activities including lymphocyte development and hematopoiesis.

MCL1 amplifications have been reported in several human cancers including bladder, gastric, ovarian, lung, breast, melanoma, and hematologic malignancies. Overexpression of MCL1 reduces MYC-induced apoptosis in immortalized bronchial epithelial cells.


Furthermore, MCL1 amplifications are found in many tumor cell lines with resistance to chemotherapeutic agents. However, many MCL1 amplified cell lines are sensitive to treatment with the cyclindependent kinase (CDK) inhibitor dinaciclib. Targeting the BCL2 family proteins with small non-peptidic compounds, so called BH3-mimetics, is currently investigated in clinical trials.

Hence, the identification of MCL1 amplifications by Fluorescence in situ Hybridization and the inhibition of MCL1 signaling may be of therapeutic significance in various types of tumors.


References Beroukhim R, et al. (2010) Nature 463: 899-905. Booher RN, et al. (2014) PloS One 9: e108371 Sochalska M, et al. (2015) FEBS J 282: 834-49 Yasui K, et al. (2004) Cancer Res 64: 1403-10.

#### **Probe Description**


The SPEC MCL1/1p12 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC MCL1 probe hybridizing to the MCL1 gene in the chromosomal region 1q21.3 and an orange fluorochrome direct labeled SPEC 1p12 probe specific for the chromosomal region 1p12. Due to cross-hybridizations of chromosome 1 alpha satellites to other centromeric regions, probes specific for 1p12 are frequently used for chromosome 1 copy number detection.



Ideogram of chromosome 1 indicating the hybridization locations.




SPEC MCL1 Probe map (not to scale).



SPEC 1p12 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MCL1 gene locus, multiple copies of the green signal or green signal clusters will be observed.



H2110 cell line with interphase cells showing amplification of the MCL1 gene locus as indicated by multiple green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)				
Z-2173-200	Zyto <i>Light</i> SPEC MCL1/1p12 Dual Color Probe CE IVD	•/•	20 (200 µl)				
Related Produ	Related Products						
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20				
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml						

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



### Zyto Light ® SPEC NTRK1 Dual Color Break Apart Probe




### **Background**

The ZytoLight ® SPEC NTRK1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 1q23.1 harboring the NTRK1 (neurotrophic tyrosine kinase receptor type 1, a.k.a. TRKA or TRK) gene. NTRK1 encodes a tyrosine kinase (TK) receptor for the nerve growth factor (NGF). The NTRK1 gene was found to be rearranged in about 12% of papillary thyroid carcinoma (PTC) cases. PTC accounts for about 80% of all thyroid cancers. NTRK1 rearrangements result in the fusion of the 3' end of the NTRK1 gene with the 5' end of different activating genes (TPM3, TPR, or TFG). All these fusion genes encode hybrid proteins comprising the TK domain of NTRK1 and the N-terminus of the partner proteins carrying coiled-coil domains. NTRK1 rearrangements were shown to be involved in thyroid carcinogenesis. Several studies showed that NTRK1 rearrangements may be associated with a worse clinical course when compared with NRTK1 rearrangement-negative PTCs. Recently, NTRK1 rearrangements were also found in lung adenocarcinomas. Various inhibitors targeting the NTRK1-derived fusion proteins were shown in vitro to inhibit proliferation of cells expressing the fusion genes. This indicates that these fusion genes are potential therapeutic targets. Hence, detection of NTRK1 rearrangements by Fluorescence in situ Hybridization represents a useful tool for studying thyroid carcinogenesis and may be of prognostic and therapeutic significance.


Reterences
Alberti I, et al. (2003) J Cell Physiol 195: 168-86.
Bongarzone I, et al. (1998) Clin Cancer Res 4: 223-8.
Doebele RC, et al. (2013) J Clin Oncol 31 Suppl: Abstr. 8023.
Greco A, et al. (2010) Mol Cell Endocrinol 321: 44-9.
Mushalt TJ (2000) Surgery 128: 984-93.
Russell JP, et al. (2000) Oncogene 19: 5729-35.

### **Probe Description**

The SPEC NTRK1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 1q22-q23.1 band. The green fluorochrome direct labeled probe hybridizes proximal and the orange fluorochrome direct labeled probe hybridizes distal to the NTRK1 gene.




Ideogram of chromosome 1 indicating the hybridization locations.




SPEC NTRK1 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 1q22-q23.1 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 1q22-q23.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 1q22-q23.1 locus and one 1q22-q23.1 locus affected by a translocation.



SPEC NTRK1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Lung cancer tissue section with translocation of the NTRK1 gene as indicated by one non-rearranged orange/green fusion signal, one orange and one separate green signal indicating the translocation.

Image kindly provided by Prof. Büttner, Cologne, Germany

Prod. No.	Product	Label	Tests* (Volume)	
Z-2167-200	Zyto Light SPEC NTRK1 Dual Color Break Apart Probe CE IVD	•/•	20 (200 μl)	
Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C€ IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



### Zyto Light ® SPEC ABL2 Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC ABL2 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 1q25.2 harboring the ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase, a.k.a. ARG) gene. The ABL2 gene encodes for a non-receptor tyrosine kinase (TK) with high homology to ABL1. ABL1 and ABL2 proteins belong to the Abelson family and link diverse extracellular stimuli to signaling pathways controlling cell growth, survival, invasion, and migration.


The translocation t(1;12)(q25.2;p13.2)involving ABL2 was shown to result in a chimeric protein consisting of the helixloop-helix (HLH) domain of ETV6 and the TK domain of ABL2. The HLH domain of ETV6 is known to confer oncogenic activity to chimeric tyrosine kinase proteins by forming ligand-independent oligomers. The ETV6-ABL2 fusion gene has been detected in a patient with AML-M3 and in a T-cell ALL cell line.

Further ABL2 fusion partners have been identified in patients with Philadelphia chromosome-like ALL, including PAG1, RCSD1, and ZC3HAV1. Cell lines expressing ABL2 fusions were shown to respond to tyrosine kinase inhibitors. Moreover, a patient with B-ALL positive for RCSD1-ABL2 fusion was reported to respond to treatment with the ABL1 inhibitor imatinib. Hence, detection of ABL2 rearrangements by FISH may help in selecting patients eligible for therapy with TK inhibitors.


Cazzaniga G, et al. (1999) Blood 94: 4370-3. De Braekeleer E, et al. (2012) Leuk Res 36: 945-61. Greuber EK, et al. (2013) Nat Rev Cancer 13: 559-71. Roberts KG, et al. (2014) N Engl J Med 371: 1005-15.

#### **Probe Description**

The SPEC ABL2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 1q25.2 band. The orange fluorochrome direct labeled probe hybridizes proximal to the ABL2 gene at 1q25.2, the green fluorochrome direct labeled probe hybridizes distal to the ABL2 gene at 1a25.2




Ideogram of chromosome 1 indicating the hybridization locations.



SPEC ABL2 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 1q25.2 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 1q25.2 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 1q25.2 locus and one 1q25.2 locus affected by a translocation.



SPEC ABL2 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus and to metaphase chromosomes of a normal cell.

Prod. No.	Product	Label	Tests* (Volume)
Z-2200-50	Zyto <i>Light</i> SPEC ABL2 Dual Color Break Apart Probe C € IVD	•/•	5 (50 µl)
Related Produ	cts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Ind. Heat Pretreatment Solution (Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	ZytoLight FISH-Cytology Implementation Kit C € IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPL/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC MDM4/1p12 Dual Color Probe



### **Background**

The ZytoLight ® SPEC MDM4/1p12 Dual Color Probe is designed for the detection of MDM4 gene amplifications found in 10-20% of various tumors such as lung, colon, stomach, and breast cancers, as well as in 65% of retinoblastomas. The MDM4 (mouse double minute 4 homolog) gene (a.k.a. HDMX or MDMX) is located in the chromosomal region 1q32.1 and encodes a 490-amino acid protein which shows significant structural similarity to the p53-binding protein MDM2. Like MDM2, the oncogene MDM4 can bind to p53 thereby inactivating the function of p53 as a transcriptional activator. In addition, MDM4 has been shown to

Antitumor strategies employing combined inhibitors of the two oncogenic proteins MDM2 and MDM4 may lead to an effective activation of the tumor suppressor p53.


bind to MDM2 resulting in inhibition of

MDM2 degradation.

Duhamel LA, et al. (2012) Histopathology 60: 357-9. Dollaties DA, et al. (2012) Histophinology 90: 337-9. Laurie NA, et al. (2006) Nature 444: 61-6. Shvarts A, et al. (1996) EMBO J 15: 5349-57. Shvarts A, et al. (1997) Genomics 43: 34-42. Tanimura S et al. (1999) FEBS Lett 447: 5-9. Toledo F & Wahl GM (2006) Nat Rev Cancer 6: 909-23. Toledo F & Wahl GM (2007) Int J Biochem Cell Biol 39:1476-82.

### **Probe Description**


The SPEC MDM4/1p12 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC MDM4 probe hybridizing distal and proximal to the human MDM4 gene in the chromosomal region 1q32.1 and an orange fluorochrome direct labeled SPEC 1p12 probe hybridizing in close proximity to the centromere of chromosome 1 at the chromosomal region 1p12. Due to cross-hybridizations of chromosome 1 alpha satellites to other centromeric regions, probes specific for 1p12 are frequently used for chromosome 1 copy number detection.



Ideogram of chromosome 1 indicating the hybridization locations.




SPEC 1p12 Probe map (not to scale).



SPEC MDM4 Probe map (not to scale).

#### Results

In a normal interphase nucleus two orange and two green signals are expected. Nuclei with amplification of the MDM4 gene locus or aneuploidy of chromosome 1 will show multiple copies of the green signal or large green signal clusters.



SPEC MDM4/1p12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2080-200	Zyto <i>Light</i> SPEC MDM4/1p12 Dual Color Probe C € IVD	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C€ IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAP1/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informa



### Zyto Light ® SPEC MYCN/2q11 Dual Color Probe

Previously: Zyto Light SPEC NMYC/2q11 Dual Color Probe



#### **Background**

The ZytoLight ® SPEC MYCN/2q11 Dual Color Probe is designed for the detection of MYCN amplification which represents the most powerful unfavorable prognostic factor for neuroblastoma. Less frequently amplifications are found in retinoblastoma, small cell lung cancer, astrocytoma and other tumors derived from the neuroectoderm.


The MYCN (v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived, a.k.a. NMYC) gene is located in the chromosomal region 2p24.3 and encodes a 62-64 kDa transcription factor mainly expressed in the developing nervous system.

Amplification of the MYCN gene is found in about 25% of primary neuroblastomas and is strongly associated with rapid tumor progression, advanced stages of the disease, and poor prognosis. Hence, amplification status is increasingly being used for stratification of patients to different treatment protocols.


References
Gessi M, et al. (2014) Neuro Oncol 16: 924-32. Gessi M, et al. (2014) Neuro Oricoi 10: 24-32. Kaneko M, et al. (1984) Nature 309: 458-60. Slamon DJ, et al. (1986) Science 232: 768-72. Suita S, et al. (2007) J Pediatr Surg 42: 489-93.

### **Probe Description**

The SPEC MYCN/2q11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC MYCN probe hybridizing to the human MYCN gene in the chromosomal region 2p24.3 and an orange fluorochrome direct labeled SPEC 2q11 probe specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2g11 are frequently used for chromosome 2 copy number detection.



Ideogram of chromosome 2 indicating the hybridization locations.




SPEC MYCN Probe map (not to scale).



SPEC 2q11 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MYCN gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC MYCN/2q11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2074-50	Zyto <i>Light</i> SPEC MYCN/2q11 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2074-200	Zyto <i>Light</i> SPEC MYCN/2q11 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



### Zyto Light ® SPEC ALK / EML4 TriCheck™ Probe



### **Background**

The ZytoLight ® SPEC ALK/EML4 TriCheck™ Probe is designed to detect inversions involving the chromosomal region 2p23.1p23.2 harboring the ALK gene and the chromosomal region 2p21 harboring the EML4 gene. Moreover, using this probe it is possible to discriminate between EML4-ALK inversions and translocations affecting ALK, but not EML4, such as ALK-TFG or ALK-KIF5B translocations.

Inversions in the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. A few reports also identified EML4-ALK fusion transcripts in breast, gastric, and colorectal cancers. Many different breakpoints affecting ALK and EML4 were identified in these respective inversions.

Thus, multiple EML4-ALK transcript variants have been identified, all of which involve the intracellular kinase domain of ALK. ALK kinase targeted therapies may represent a very effective therapeutic strategy in NSCLC patients carrying EML4-ALK rearrangements. For the detection of this subset of NSCLC patients, the specific detection of EML4-ALK rearrangements using Fluorescence in situ Hybridization is a helpful tool for diagnosis and for selecting treatment.

References
Inamura K, et al. (2009) Mod Pathol 22: 508-15.
Koivunen JP, et al. (2008) Clin Cancer Res 14: 4275-83.
Lawce HJ & Olson S (2013) J Assoc Genet Technol 39: 66-71.
Martelli MP, et al. (2009) Am J Pathol 174: 661-70. Martelli Mr, et al. (2009) Am J Pation 174: 061-70.

Prener S, et al. (2008) Neoplasia 10: 298-302.

Preusser M, et al. (2013) Lung Cancer 80: 278-83.

Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.

Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.


Schildgen V, et al. (2012) Per Med 9: 801-3.

Schildhaus HU, et al. (2013) Mod Pathol 26: 1468-77.


Schoppmann SF, et al. (2013) Eur J Cancer 49: 1876-81. Thunnissen E, et al. (2012) Virchows Arch 461: 245-57 Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.

### **Probe Description**


The SPEC ALK/EML4 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the short arm of chromosome 2. The orange fluorochrome direct labeled probe hybridizes distal to the ALK gene breakpoint region at 2p23.2, the green fluorochrome direct labeled probe hybridizes proximal to the ALK gene breakpoint region at 2p23.1-p23.2, and the blue fluorochrome direct labeled probe hybridizes to the EML4 gene region at 2p21.



Ideogram of chromosome 2 indicating the hybridization locations.



SPEC ALK Probe map (not to scale).



SPEC EML4 Probe map (not to scale).


#### Results

In an interphase nucleus without rearrangement of the EML4-ALK locus, two orange/green fusion signals and two blue signals are expected.


An EML4-ALK inversion is indicated by one separate green signal, one separate orange signal, and an additional blue signal.

An ALK translocation is indicated by separated orange and green signals without an additional blue signal.

EML4-ALK inversion with deletion of 5'-ALK sequences is indicated by loss of one green signal and co-localization of the isolated orange signal with a blue signal.



SPEC ALK/EML4 TriCheck™ Probe on normal interphase cells with non-rearranged ALK loci (two orange/green fusion signals), and nonrearranged EML4 loci (two blue signals).



NSCLC tissue section with an EML4-ALK inversion as indicated by one green, one separated orange, and one additional blue signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2117-50	Zyto <i>Light</i> SPEC ALK/EML4 TriCheck Probe C	<b>•</b> /•/•	5 (50 µl)
Z-2117-200	Zyto <i>Light</i> SPEC ALK/EML4 TriCheck Probe C	•/•/•	20 (200 µl)
Related Produ	ıcts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPL/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>n



### Zyto Light ® SPEC ALK Dual Color Break Apart Probe




### **Background**

The ZytoLight ® SPEC ALK Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 2p23.1-p23.2 harboring the ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246) gene. ALK encodes a transmembrane receptor tyrosine kinase. This gene exerts characteristic oncogenic activities through fusion to several gene partners or mutations both in hemato-poietic and non-hematopoietic solid tumors.


Translocations affecting the ALK gene locus are frequently found in anaplastic large cell lymphoma (ALCL), an aggressive non-Hodgkin lymphoma arising from Tcells. The most frequent translocation t(2;5) results in a fusion with the NPM1 (nucleophosmin a.k.a. nucleolar phosphoprotein B23, numatrin) gene located on chromosome 5q35. This rearrangement results in a NPM1/ALK fusion protein, which is constitutively activated through autophosphorylation, and that in turn mediates malignant cell transformation by activating downstream effectors like e.g. STAT3. Additionally, inversions affecting the ALK gene located on the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. ALK kinase targeted therapies may represent a very effective therapeutic strategy in NSCLC patients carrying EML4-ALK

### **Probe Description**

The SPEC ALK Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 2p23.1-p23.2 band. The orange fluorochrome direct labeled probe hybridizes distal to the ALK gene breakpoint region at 2p23.2, the green fluorochrome direct labeled probe hybridizes proximal to the ALK gene breakpoint region at 2p23.1-p23.2.



Ideogram of chromosome 2 indicating the hybridization locations.



SPEC ALK Probe map (not to scale).


References Inamura K, et al. (2009) Mod Pathol 22: 508-15. Koivunen JP, et al. (2008) Clin Cancer Res 14: 4275-83. Martelli MP, et al. (2009) Am J Pathol 174: 661-70. Palmer RH, et al. (2009) Biochem J 420: 345-61.

Perner S, et al. (2008) Neoplasia 10: 298-302. Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23. Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.


#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 2p23.1-p23.2 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 2p23.1p23.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 2p23.1-p23.2 locus and one 2p23.1-p23.2 locus affected by a translocation or inversion.

EML4-ALK inversion with deletion of 5'-ALK sequences is indicated by one or multiple isolated orange signals.



SPEC ALK Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Lung carcinoma tissue section with translocation affecting the 2p23 locus as indicated by one orange/green fusion (non-rearranged) signal, one orange signal, and one separate green signal indicating the translocation.

	Von Laffert M, et al. (2013) Lung Cancer 81: 200-6. Zhang Q, et al. (2007) Nat Med 11:1341-8.	one separate green signal indic	
Prod. No.	Product	Label	Tests* (Volume)
Z-2124-50	Zyto <i>Light</i> SPEC ALK Dual Color Break Apart Probe C	•/•	5 (50 µl)
Z-2124-200	Zyto <i>Light</i> SPEC ALK Dual Color Break Apart Probe C    IVD	•/•	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C F IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml	l	20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

rearrangements.



## Zyto Light ® SPEC ALK/2q11 Dual Color Probe



### **Background**

The ZytoLight ® SPEC ALK/2q11 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the ALK gene.

The ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246) gene is located on chromosome 2p23.1-p23.2 and encodes a transmembrane receptor tyrosine kinase. ALK was originally identified as a fusion partner of NPM1. This gene fusion is frequently found in anaplastic large cell lymphoma (ALCL), an aggressive non-Hodgkin lymphoma. Rearrangements affecting the ALK gene locus have also been found to play a role in carcinogenesis of a variety of hematopoietic and non-hematopoietic solid tumors, including non-small cell lung cancer (NSCLC). Moreover, ALK amplifications and copy number gains have been reported to occur in a variety of tumors including NSCLC and alveolar rhabdomyosarcoma (ARMS). In colorectal cancer, ALK amplification was correlated with nodal status suggesting that ALK amplified tumors have a more aggressive phenotype. ALK copy number gains and amplifications are also a frequent genetic event in the tumorigenesis of neuroblastomas and were found to result in high ALK expression correlating with an unfavorable neuroblastoma


Hence, the identification of ALK gene copy number changes by in situ Hybridization might be of prognostic and therapeutic relevance.

#### References

Carén H, et al. (2008) Biochem J 416: 153-9. Corao DA, et al. (2009) Pediatr Dev Pathol 12: 275-83. Koivunen JP, et al. (2008) Clin Cancer Res 14: 4275-83. Montagut C, et al. (2010) J Clin Oncol 28: Suppl 10537. Pelosi G, et al. (2011) J Clin Oncol 28: Suppl 10537. Salido M, et al. (2011) J Thorac Oncol 6: 21-7. Subramaniam MM, et al. (2009) Hum Pathol 40: 1638-42.

#### **Probe Description**


The SPEC ALK/2g11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC ALK probe hybridizing to the human ALK gene in the chromosomal region 2p23.1-p23.2 and an orange fluorochrome direct labeled SPEC 2q11 probe. The SPEC 2q11 probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to crosshybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.



Ideogram of chromosome 2 indicating the hybridization locations.




SPEC ALK Probe map (not to scale).




SPEC 2q11 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ALK gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC ALK/2q11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Neuroblastoma tissue section with tetrasomy of chromosome 2 as indicated by four orange (2q11) and four green (ALK) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2161-200	Zyto Light SPEC ALK/2q11 Dual Color Probe CE IVD	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC EML4 Dual Color Break Apart Probe




### **Background**

The ZytoLight® SPEC EML4 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 2p21 harboring the EML4 (echinoderm microtubule-associated protein-like 4, a.k.a. ROPP120) gene. Inversions in the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. A few reports also identified these fusion transcripts in breast, gastric, and colorectal cancers. The fusion genes comprise variably truncated N-terminal portions of the EML4 gene and the intracellular signaling domain of the receptor tyrosine kinase ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246). It was found that EML4 mediates ligand-independent dimerization of ALK, resulting in constitutive kinase activity. EML4-ALK was shown to possess transforming activity in vitro and in vivo. The EML4-ALK fusion transcript is found in about 5% of NSCLC, predominantly adenocarcinomas, and is considered to be mutually exclusive to EGFR or KRAS mutations. The detection of the inversion by Fluorescence in situ Hybridization might represent a valuable tool to identify a subpopulation of NSCLC likely to respond to ALK kinase targeting therapies. The SPEC EML4 Dual Color Break Apart Probe can be used to subsequently confirm EML4-ALK inversion if an ALK Break Apart Probe has been used for initial diagnosis.


References
Choi YL, et al. (2008) Cancer Res 69: 4971-6.
Inamura K, et al. (2009) Mod Pathol 22: 508-15.
Lin E, et al. (2009) Mol Cancer Res 7: 1466-76.
Perner S, et al. (2008) Neoplasia 10: 298-302.
Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.
Soda M, et al. (2007) Nature 448: 561-6.
Shaw AT, et al. (2009) J Clin Oncol 27: 4247-53.

#### **Probe Description**

The SPEC EML4 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 2p21 band. The orange fluorochrome direct labeled probe hybridizes proximal, the green fluorochrome direct labeled probe hybridizes distal to the EML4 gene breakpoint region at 2p21.




Ideogram of chromosome 2 indicating the hybridization locations.




SPEC EML4 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking an inversion involving the 2p21 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 2p21 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 2p21 locus and one 2p21 locus affected by an inversion or translocation.



SPEC EML4 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



NSCLC tissue section with inversion affecting the EML4 locus at 2p21 as indicated by one orange/green fusion (non-rearranged) signal, one green signal, and one separate orange signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2136-50	Zyto <i>Light</i> SPEC EML4 Dual Color Break Apart Probe C	•/•	5 (50 µl)
Related Prod	lucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



### Zyto Light ® SPEC MERTK/2q11 Dual Color Probe



### **Background**

The ZytoLight ® SPEC MERTK/2q11 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the MERTK gene.

The MERTK (MER proto-oncogene, tyrosine kinase, a.k.a. MER, c-Eyk) gene is located on chromosome 2q13 and encodes a receptor tyrosine kinase which is a member of the TAM (TYRO3/AXL/MERTK) family. Binding of the ligands Protein S or growth arrest-specific 6 (GAS6) to MERTK activates the downstream MAPK and PI3K/Akt antiapoptotic pathways, thereby promoting proliferation and survival of normal and cancer cells. Additional downstream pathways lead to enhanced migration and invasion of tumor cells.

Ectopic expression or overexpression of MERTK has been demonstrated in many human cancers, e.g. ALL, AML, astrocytoma, breast cancer, gastric cancer, mantle cell lymphoma, melanoma, and NSCLC. In NSCLC, MERTK inhibition was shown to increase apoptosis and to decrease tumor formation in a mouse model.


In melanomas, MERTK expression was shown to correlate with disease progression, with the highest expression in metastatic melanomas. In addition, MERTK inhibition diminished tumor size by 60% in a human melanoma xenograft model. In gastric cancer patients, MERTK expression is associated with a shorter overall survival.

Hence, the identification of MERTK gene copy number changes by Fluorescence in situ Hybridization and targeted MERTK signaling inhibition may be of therapeutic significance in various types of tumors.


References Graham DK, et al. (1994) Cell Growth Differ 5: 647-57. Knubel KH, et al. (2014) Oncotarget 5: 1338-51. Linger RM, et al. (2013) Oncogene 32: 3420-31. Rogers AE, et al. (2012) Oncogene 31: 4171-81. Schlegel J, et al. (2013) J Clin Invest 123: 2257-67. Verma A, et al. (2011) Mol Cancer Ther 10: 1763-73 Yi JH, et al. (2015) Oncotarget [Epub ahead of print].

### **Probe Description**

The SPEC MERTK/2q11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC MERTK probe hybridizing to the MERTK gene in the chromosomal region 2q13 and an orange fluorochrome direct labeled SPEC 2q11 probe. The SPEC 2q11 probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.




Ideogram of chromosome 2 indicating the hybridization locations.



2a11.2 SPEC 2q11 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MERTK gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC MERTK/2q11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2155-200	Zyto <i>Light</i> SPEC MERTK∕2q11 Dual Color Probe C € IVD	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



# Zyto Light ® SPEC ERBB4/2q11 Dual Color Probe

Previously: Zyto Light SPEC HER4/2q11 Dual Color Probe



## **Background**

The ZytoLight ® SPEC ERBB4/2q11 Dual Color Probe is designed for the detection of amplifications of the chromosomal regions harboring the ERBB4 gene.

The ERBB4 (a.k.a. HER4) gene encodes a transmembrane glycoprotein acting as a cellular growth factor receptor. It belongs to the epidermal growth factor receptor subgroup of the receptor tyrosine kinase superfamily also including ERBB1 (EGFR), ERBB2, which is known to be affected by gene amplifications in a number of malignant tumors, and ERBB3.

Although EGFR and ERBB2 have been shown to represent good predictive markers and appropriate targets for therapeutic approaches, relatively less is known of comparable significance for ERBB3 and ERBB4. However, there is growing evidence that cooperation of all four members of the ERBB gene family contributes to a more aggressive tumor phenotype and influences therapeutic response.


Accordingly, it is assumed that the assessment of the combined amplification status of ERBB1 to ERBB4 may improve the diagnostic value significantly.

Recently it was shown in a retrospective study that responsiveness to Herceptin™ turned out to be more efficient if tumour cells show ERBB4 gene amplification.


Alimandi M, et al. (1995) Oncogene 10: 1813-21. Begnami MD, et al. (2011) J Clin Oncol 29: 3030-6. Brockhoff G, et al. (2011) Acta Derm Venereol 91: 488-90. Brunner K, et al. (2010) Ánal Quant Cytol Histol 32: 78-89. Plowman GD, et al. (1993) Proc Natl Ácad Sci USA 90: 1746-50. Sassen A, et al. (2008) Breast Cancer Res 10: R2. Sassen A, et al. (2009) Breast Cancer Res 11: R50. Zaczek A, et al. (2005) Histol Histopathol 20: 1005-15 Zimonjic DB, et al. (1995) Oncogene 10: 1235-7.

### **Probe Description**

The SPEC ERBB4/2q11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC ERBB4 probe hybridizing to intronic sequences of the human ERBB4 gene in the chromosomal region 2q34 and an orange fluorochrome direct labeled SPEC 2q11 probe. The SPEC 2q11 probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.



Ideogram of chromosome 2 indicating the hybridization locations.




SPEC ERBB4 Probe map (not to scale).




SPEC 2q11 Probe map (not to scale).

### Results

Using the SPEC ERBB4/2q11 Dual Color Probe in a normal interphase nucleus, two green and two orange signals are expected. In a cell with amplification of the ERBB4 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC ERBB4/2q11 Dual Color Probe hybridized to normal interphase cells as indicated by two green and two orange signals in each nucleus



Breast cancer tissue section with amplification of the ERBB4 gene (green), SPEC 2q1 1 (orange).

Image kindly provided by Prof. Brockhoff, Regensburg, Germany.

Prod. No.	Product	Label	Tests* (Volume)
Z-2057-200	Zyto <i>Light</i> SPEC ERBB4/2q11 Dual Color Probe C€ IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informatic



# Zyto Light ® SPEC VHL/CEN 3 Dual Color Probe



## **Background**

The ZytoLight ® SPEC VHL/CEN 3 Dual Color Probe is designed for the detection of deletions affecting the VHL gene. The tumor suppressor gene VHL (von Hippel-Lindau) is located on 3p25.3 and encodes a 30 kDa protein with ubiquitin ligase E3 activity. The protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a critical role in the regulation of gene expression by oxygen.


Loss of heterozygosity (LOH) at chromosome 3p and inactivation of the VHL gene by deletion or mutation is the most frequent genetic change in sporadic as well as VHL disease-associated conventional renal cell carcinomas (RCC) whereas alterations of this region are rarely seen in papillary and chromophobe RCC. Recent studies suggest that the determination of the VHL status by FISH can significantly improve the accuracy of kidney tumor biopsy evaluation, providing prognostic information that can guide management decisions.

### References


Barocas DA, et al. (2006) BJU Int 99: 290-5. Barocas DA, et al. (2006) BJU Int 99: 290-5.
Proom BJ, et al. (2012) Clin Genitourin Cancer 10: 202-6.
Dagher J, et al. (2013) Hum Pathol 44: 2106-15.
Hosoe S, et al. (1990) Genomics 8: 634-40.
Latif F, et al. (1993) Science 260: 1317-20.
Sükösd F, et al. (2003) Cancer Res 63: 455-7.

### **Probe Description**

The SPEC VHL/CEN 3 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 3 probe specific for the alpha satellite centromeric region of chromosome 3 (D3Z1) and a green fluorochrome direct labeled SPEC VHL probe spanning the VHL gene at 3p25.3.




Ideogram of chromosome 3 indicating the hybridization locations




## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the VHL gene, one or no copy of the green signal will be observed.



SPEC VHL/CEN 3 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus



Trisomy of chromosome 3 as indicated by three orange (CEN 3) and three green (VHL) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2084-200	Zyto <i>Light</i> SPEC VHL∕CEN 3 Dual Color Probe C€ IVD	•/•	20 (200 µl)
<b>Related Prod</b>	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light ® SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe




## **Background**


The ZytoLight ® SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe is designed for an accurate identification of renal cell carcinoma (RCC) subtypes by the simultaneous detection of VHL gene status and enumeration of chromosomes 1, 7, and 17 in tumor cells. Clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC) and renal oncocytomas (ROs) are the most frequent renal cell tumor subtypes. Patients with ccRCC have a poorer prognosis than patients with pRCC and chRCC. RO is considered to be a benign neoplasm. The differentiation between RCC types may sometimes be difficult on histopathological features alone. However, the different subtypes of kidney tumors are characterized by distinct genetic patterns. Chromosome 3p deletion, including deletion of the tumor suppressor gene VHL (von Hippel-Lindau) in 3p25.3, is the most typical genetic abnormality in ccRCC. pRCC is characterized by trisomy/polysomy of chromosomes 7 and 17. Combined losses of chromosomes 1, 2, 6, 10, 13, 17, and 21 (with 1, 2, 6, and 17 being affected most frequently) are the most common changes in chRCC, whereas ROs often show rearrangements involving 11a13.3 harboring the CCND1 gene or losses of chromosomes 1, 14, and sex chromosomes. Consequently, the ZytoLight ® SPEC VHL/1p12/ CEN 7/17 Quadruple Color Probe is designed to differentiate between ccRCC, pRCC, and some chRCC tumors and should be used in combination with the ZytoLight® SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe which helps to especially differentiate between chRCC and ROs.

References
Brunelli M, et al. (2005) Modern Pathology 18: 161-9.
Igbal MA, et al. (2000) Diagn Cytopathol 22: 3-6.
Jhang JS, et al. (2004) Cancer Genet Cytogenet 149: 114-9.
Mertz KD, et al. (2006) Urologe 45: 316-22.
Moch H (2013) Semin Cancer Biol 23: 3-9.
Sanjmyatav J, et al. (2013) Eur Urol 64: 689-91.
Sukov WR, et al. (2009) Hum Pathol 40: 1296-303.

### **Probe Description**

The SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe is a mixture of a green fluorochrome direct labeled SPEC VHL probe spanning the VHL gene at 3p25.3, a gold fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1), a blue fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1), and a red fluorochrome direct labeled SPEC 1p12 hybridizing in close proximity to the centromere of chromosome 1 at the chromosomal region 1p12. Due to cross-hybridizations of chromosome 1 alpha satellites to other centromeric regions, probes specific for 1p12 are frequently used for chromosome 1 copy number detection.







SPEC 1p12 Probe map (not to scale).

### Results


In a normal interphase nucleus, two green, two red, two gold, and two blue signals are expected. In a cell with deletion affecting the VHL gene, a reduced number of green signals will be observed. In cells with aneusomy of chromosome 1, 7, or 17, more or less signals of the respective color will be visible.



Renal cell carcinoma tissue section with deletion of the VHL gene as indicated by one green signal in each nucleus.



Renal cell carcinoma tissue section with polysomy of the chromosome 7 and 17 as indicated by multiple gold and/or blue signals in each nucleus.



Ideograms of chromosomes 3, 1, 7, and 17 indicating the hybridization locations.

Prod. No.	Product	Label	Tests* (Volume)
Z-2102-200	Zyto <i>Light</i> SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe C€ IVD	•/•/·/•	20 (200 µl)
Related Produ	ıcts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple **Color Probe**



## **Background**


The ZytoLight® SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe is designed for an accurate identification of renal cell carcinoma (RCC) subtypes by the simultaneous detection of rearrangements affecting the CCND1 (cyclin D1, a.k.a. PRAD1) gene in 11q13.3 and enumeration of chromosomes 2 and 6 in tumor cells.

Clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC), and renal oncocytomas (ROs) are the most frequent renal cell tumor subtypes. Patients with ccRCC have a poorer prognosis than patients with pRCC and chRCC. RO is considered to be a benign neoplasm. The differentiation between RCC types may sometimes be difficult on histopathological features alone. However, the different subtypes of kidney tumors are characterized by distinct genetic patterns. Chromosome 3p deletion, including deletion of the tumor suppressor gene VHL (von Hippel-Lindau) in 3p25.3, is the most typical genetic abnormality in ccRCC. pRCC is characterized by trisomy/polysomy of chromosomes 7 and 17. Combined losses of chromosomes 1, 2, 6, 10, 13, 17, and 21 (with 1, 2, 6, and 17 being affected most frequently) are the most common changes in chRCC, whereas ROs often show rearrangements involving 11q13.3 or losses of chromosomes 1, 14, and sex chromosomes.

Consequently, the ZytoLight ® SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe is designed to especially differentiate between chRCC and ROs and should be used in combination with the ZytoLight ® SPEC VHL/1p12/ CEN 7/17 Quadruple Color Probe which is designed for the differentiation between ccRCC, pRCC, and some chRCC tumors.

### **Probe Description**


The SPEC CCND1 Break Apart/2q11/ CEN 6 Quadruple Color Probe is a mixture of a green and a red fluorochrome direct labeled probe hybridizing proximal and distal to the breakpoint on 11q13.3, respectively, a gold fluorochrome direct labeled CEN 6 probe specific for the alpha satellite centromeric region of chromosome 6 (D6Z1), and a blue fluorochrome direct labeled SPEC 2q11 probe. The SPEC 2g11 probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.



SPEC CCND1 Probe map (not to scale).




SPEC 2q11 Probe map (not to scale).




Ideograms of chromosomes 11, 2, and 6 indicating the hybridization locations.

### Results

In a normal interphase nucleus, two red/ green fusion signals, two blue, and two gold signals are expected. In a cell with translocation of the CCND1 gene locus, a signal pattern consisting of one red/ green fusion signal, one red, and a separate green signal indicates one normal CCND1 locus and one CCND1 locus affected by an 11q13.3 translocation. In cells with aneusomy of chromosome 2 or 6, more or less signals of the respective color will be visible.



Renal cell carcinoma tissue section with translocation affecting the 11q13.3 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.



Renal cell carcinoma tissue section with monosomy of chromosome 2 and 6 as indicated by one blue and one gold signal in each nucleus.

Retretines

Brunelli M, et al. (2005) Modern Pathology 18: 161-9.

Iqbal MA, et al. (2000) Diagn Cytopathol 22: 3-6.

Jhang JS, et al. (2004) Cancer Genet Cytogenet 149: 114-9. Mertz KD, et al. (2006) Urologe 45: 316-22. Moch H (2013) Semin Cancer Biol 23: 3-9. Sanjmyatav J, et al. (2013) Eur Urol 64: 689-91. Sukov WR, et al. (2009) Hum Pathol 40: 1296-303.

Pro	d. No.	Product	Label	Tests* (Volume)
Z-21	118-200	Zyto <i>Light</i> SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe C E IVD	•/•/•/ <u>•</u>	20 (200 µl)
Rel	ated Produ	ucts		
Z-20	028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20
		Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmation</u>.



# Zyto Light ® SPEC FHIT/CEN 3 Dual Color Probe



## **Background**

The ZytoLight® SPEC FHIT/CEN 3 Dual Color Probe is designed for the detection of FHIT gene deletions frequently observed in most of the common epithelial neoplasms.

The FHIT (fragile histidine triad) gene is located in the chromosomal region 3p14.2 and encodes a 16.8 kDa member of the HIT superfamily of nucleoside monophosphate hydrolases and transferases.

The 1.6 Mb FHIT gene encompasses the most carcinogen-sensitive common fragile region FRA3B and the t(3;8) translocation breakpoint associated with hereditary renal carcinoma.


The tumor suppressor gene FHIT is inactivated by deletions in a variety of human tumors e.g. lung, kidney, gastric, breast, pancreatic, and cervical tumors. Since loss of the FHIT locus occurs in a number of preneoplastic lesions, FHIT may represent a potential marker for the detection of tumor precursor cells.

### References

Broom RJ, et al. (2012) Clin Genitourin Cancer 10: 202-6. Cirombella R, et al. (2010) Cancer Lett 291:230-6. Huebner K, et al. (1998) Annu Rev Genet 32: 7-31. Ishii H, et al. (2003) J Exp Ther Oncol 3: 291-6. Ohta M, et al. (1996) Cell 84: 587-97. Onia m, et al. (1976) Ceii 64: 367-97. Pekarsky Y, et al. (2002) Lancet Oncol 3: 748-54. Schwarz S, et al. (2008) Cytometry A 73: 305-11. Vieira J, et al. (2010) Genes Chromosomes Cancer 49: 935-47.

### **Probe Description**

The SPEC FHIT/CEN 3 Dual Color probe is a mixture of an orange fluorochrome direct labeled CEN 3 probe specific for the alpha satellite centromeric region of chromosome 3 (D3Z1) and a green fluorochrome direct labeled SPEC FHIT probe hybridizing to sequences of introns 4 and 5 of the human FHIT gene at 3p14.2.




Ideogram of chromosome 3 indicating the hybridization locations.



SPEC FHIT Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletion of the FHIT gene locus, a reduced number of green signals will be observed. Deletions affecting only parts of introns 4 and/or 5 of the FHIT gene might result in a normal signal pattern with green signals of reduced size.



SPEC FHIT/CEN 3 Dual Color Probe hybridized to interphase cells each showing three orange and two green signals

Prod. No.	Product	Label	Tests* (Volume)
Z-2062-200	ZytoLight SPEC FHIT/CEN 3 Dual Color Probe C	•/•	20 (200 µl)
Related Produ	ıcts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



# Zyto Light® SPEC TFG Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC TFG Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 3q12.2 harboring the TFG (TRKfused gene; a.k.a. TRCK fusion gene)

Initially, TFG was identified as a fusion partner of the protein kinases NTRK1 in papillary thyroid carcinoma and NR4A3 (a.k.a. NOR1) in extraskeletal myxoid chondrosarcoma generating the oncogenes TRK-T3 and TFG-NR4A3, respectively. The TFG gene has been found to be a fusion partner of the ALK gene, first identified in anaplastic large cell lymphomas (ALCL). However, the TFG-ALK fusion transcript was also found in non-small cell lung cancer (NSCLC). TFG is a ubiquitously expressed regulator of protein secretion. The translocation t(2;3)(p23;q12) results in the fusion of the first domains of TFG including the coiled-coil domain to the tyrosine kinase domain of ALK. It was shown that the aberrant TFG-ALK fusion transcript has transforming activity.


Fluorescence in situ Hybridization could be used to determine the specific translocation partners of the ALK gene e.g. in NSCLC.

### References


Greco A, et al. (1995) Mol Cell Biol 15: 6118-27. Hernández L, et al. (2002) Am J Pathol 160: 1487-94. Hisaoka M, et al. (2004) Genes Chromosomes Cancer 40: 325-8. Rikova K, et al. (2007) Cell 131: 1190-203. Witte K, et al. (2011) Nat Cell Biol 13: 550-8

### **Probe Description**

The SPEC TFG Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 3q12.1-q12.3 band. The orange fluorochrome direct labeled probe hybridizes at 3q12.1-q12.2 proximal to the TFG gene and the green fluorochrome direct labeled probe hybridizes at 3q12.2-q12.3 distal to that gene.




Ideogram of chromosome 3 indicating the hybridization locations.



SPEC TFG Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 3q12.1-q12.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 3q12.1-q12.3 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 3q12.1-q12.3 locus and one 3q12.1-q12.3 locus affected by a translocation.



SPEC TFG Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2133-50	Zyto <i>Light</i> SPEC TFG Dual Color Break Apart Probe C	•/•	5 (50 µl)		
Related Products					
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD		5		
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml				

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



# Zyto Light ® SPEC WWTR1 Dual Color Break Apart Probe



## **Background**


The ZytoLight ® SPEC WWTR1 Dual Color Break Apart Probe is designed for the detection of translocations involving the chromosomal region 3q25.1 harboring the WWTR1 (WW domain containing transcription regulator 1, a.k.a. TAZ) gene. Epithelioid vascular tumors encompass a spectrum of diseases that includes epithelioid hemangioma (EH), a benign neoplasm, epithelioid hemangioendothelioma (EHE), a low to intermediate grade malignancy, and epithelioid angiosarcoma (EAS), a high grade malignancy. Although certain morphologic features allow to distinguish EHE from EH and EAS, the diagnosis can be challenging due to considerable morphologic overlap, particularly on small biopsies or when EAS lacks vasoformative properties. Clinical behavior and, consequently, treatment and prognosis vary significantly among vascular tumors. Therefore, it is paramount to effectively distinguish them from each other.

The recurrent translocation t(1;3) (p36.3;q25.1) was identified in approximately 90% of EHE cases, but not in other vascular tumors. t(1;3) results in the WWTR1-CAMTA1 fusion gene which encodes a putative chimeric transcription factor which is under the transcriptional control of the WWTR1 promoter. A recurrent YAP1-TFE3 gene fusion has been identified in WWTR1-CAMTA1 negative EHEs. Thus, FISH analysis for the presence of WWTR1 translocation may serve as a useful molecular tool in the differential diagnosis of challenging cases.


Kererences
Anderson T, et al. (2015) Am J Surg Pathol 39: 132-9.
Errani C, et al. (2011) Genes Chromosomes Cancer 50:
Mendlick MR, et al. (2001) Am J Surg Pathol 25: 684-7.
Puls F, et al. (2015) Virchows Arch 466: 473-8.
Tanas MR, et al. (2011) Sci Transl Med 3: 98ra82.

### **Probe Description**

The SPEC WWTR1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 3q24-3q25.1 band. The green fluorochrome direct labeled probe hybridizes in 3q24-3q25.1 proximal and the orange fluorochrome direct labeled probe hybridizes in 3q25.1 distal to the WWTR1 gene.




Ideogram of chromosome 3 indicating the hybridization locations.



SPEC WWTR1 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 3q24-3q25.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 3q24-3q25.1 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 3q24-3q25.1 locus and one 3q24-3q25.1 locus affected by a translocation.



SPEC WWTR1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2212-50	Zyto <i>Light</i> SPEC WWTR1 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Related Produ	ıcts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC PIK3CA/CEN 3 Dual Color Probe



## **Background**

The ZytoLight ® SPEC PIK3CA/CEN 3 Dual Color Probe is designed for the detection of PIK3CA gene amplifications frequently found in a variety of human cancers.

The PIK3CA (a.k.a. PI3K-alpha) gene is located on chromosome 3q26.32 and encodes the 110 kDa catalytic subunit of the phosphatidylinositol 3-kinase (PI3K). Amplifications of PIK3CA were found e.g. in cervical, ovarian, endometrial, breast, gastric, and lung cancer.

In ovarian cancer as well as cervical cancer cells increased copy numbers were shown to be associated with increased expression of the gene product and PI3K activity. Furthermore, treatment with a PI3K inhibitor leads to decreased proliferation and increased apoptosis. It was concluded that PIK3CA is an important oncogene in these tumors.

Likewise in endometrial carcinomas detection of PIK3CA amplification is associated with tumor grade and stage.


A significant correlation between PIK3CA amplification and poor survival was found for gastric cancer patients.

PIK3CA amplification was also frequently found in non-small cell lung cancer (NSCLC) and was shown to be associated with certain clinicopathologic features. PIK3CA amplification seems to promote tumorigenesis through aberrant activation of the PI3K/Akt signaling pathway. Hence, this pathway might represent an effective therapeutic target in several cancer types.


Name of the state of the state

### **Probe Description**

The SPEC PIK3CA/CEN 3 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 3 probe specific for the alpha satellite centromeric region of chromosome 3 (D3Z1) and a green fluorochrome direct labeled SPEC PIK3CA probe specific for the chromosomal region 3q26.32-q26.33 harboring the PIK3CA gene.




Ideogram of chromosome 3 indicating the hybridization locations.




SPEC PIK3CA Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. Nuclei with amplification of the PIK3CA gene locus 3q26.32-q26.33 or aneuploidy of chromosome 3 will show multiple copies of the green signal or large green signal clusters.



SPEC PIK3CA/CEN 3 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Human breast cancer cell line with amplification of the PIK3CA gene as indicated by multiple green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2140-200	Zyto Light SPEC PIK3CA/CEN 3 Dual Color Probe CE IVD	•/•	20 (200 µl)		
<b>Related Prod</b>	Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20		
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml				

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light ® SPEC SOX2/CEN 3 Dual Color Probe



## **Background**

The ZytoLight ® SPEC SOX2/CEN 3 Dual Color Probe is designed for the detection of SOX2 gene amplifications frequently observed in squamous cell carcinoma (SCC) of the lung, the esophagus, the oral cavity, and further organ sites. In addition, amplifications and/or overexpression were found in glioma, breast cancer, and other tumor types.


The SOX2 (sex determining region Y-box 2, a.k.a. ANOP3) gene is located on chromosome 3q26.33 and encodes a High Mobility Group domain transcription factor that is a regulator of normal stem cell function in embryonic and neural stem cells. Amplification of the SOX2 gene was found in about 20% of lung SSC and 15% of esophageal SCC and results in oncogenic SOX2 overexpression. In a large series of lung SSC it was shown that amplification of SOX2 was associated with lower tumor grade and hence with favorable prognosis.

However, in glioma and glioma cell lines SOX2 expression seems to show a positive correlation with malignancy grade.


References
Alonso MM, et al. (2011) PLoS One 6: e26740.
Annovazzi I, et al. (2011) Cancer Genomics Proteomics 8: 139-47.
Bass AJ, et al. (2009) Nat Genet 41: 1238-42.
Hussenet T, et al. (2010) PLoS One 5: e8969.
Kokalj Vokac N, et al. (2014) Mol Cytogenet 7: 5.
Maier S, et al. (2011) Hum Pathol 42: 1078-88.
Wilbertz T, et al. (2011) Mod Pathol 24: 944-53.

### **Probe Description**

The SPEC SOX2/CEN 3 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 3 probe specific for the alpha satellite centromeric region of chromosome 3 (D3Z1) and a green fluorochrome direct labeled SPEC SOX2 probe specific for the SOX2 gene at 3q26.33.




Ideogram of chromosome 3 indicating the hybridization locations.




## Results

In a normal interphase nucleus, two orange and two green signals are expected. Nuclei with amplification of the SOX2 gene locus 3q26.33 or aneuploidy of chromosome 3 will show multiple copies of the green signal or large green signal clusters.



SPEC SOX2/CEN 3 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Lung cancer tissue section with amplification of the SOX2 gene (green) and trisomy of chromosome 3 (orange).

Prod. No.	Product	Label	Tests* (Volume)
Z-2127-200	Zyto Light SPEC SOX2/CEN 3 Dual Color Probe C € IVD	•/•	20 (200 µl)
<b>Related Prod</b>	ucts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



# Zyto Light ® SPEC BCL6 Dual Color Break Apart Probe




## **Background**

The ZytoLight ® SPEC BCL6 Dual Color Break Apart Probe is designed for the detection of translocations involving the chromosomal region 3q27.3 harboring the BCL6 (B-cell CLL/lymphoma 6, a.k.a. ZNF51, LAZ3) gene.


The BCL6 protein acts as a transcriptional repressor that is involved in the regulation of lymphoid development and function. Chromosomal rearrangements of the BCL6 gene region were found to occur in different types of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The most common BCL6 translocation t(3;14)(q27;q32.3) results in the IGH-BCL6 gene fusion. In addition, more than 20 partner loci have been identified including immunoglobulin (Ig) genes but also a number of non-lg genes. As a result of these translocations, the rearranged BCL6 gene comes under the control of the promoter of the partner gene leading to deregulated expression of BCL6. In DLBCL, the most common histologic subtype of NHL, BCL6 translocations represent one of the most frequent cytogenetic abnormality, occurring in 20% to 40% of the cases. Several studies reported a correlation of BCL6 translocation with an inferior overall survival. Moreover, DLBCL which are positive for both BCL6 and MYC rearrangements have been shown to have an extremely poor prognosis. Hence, the detection of BCL6 rearrangements by Fluorescence in situ Hybridization may help in predicting the clinical outcome in patients with NHL.

### **Probe Description**

The SPEC BCL6 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 3q27.3-q28 band. The green fluorochrome direct labeled probe hybridizes at 3q27.3 proximal to the BCL6 gene, and the orange fluorochrome direct labeled probe hybridizes at 3q27.3-q28 distal to the BCL6 gene.




Ideogram of chromosome 3 indicating the hybridization locations.




SPEC BCL6 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 3q27.3-q28 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 3q27.3-q28 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 3q27.3-q28 locus and one 3q27.3-q28 locus affected by a translocation.



SPEC BCL6 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



DLBCL tissue section with translocation of the BCL6 gene as indicated by one non-rearranged orange/ green fusion signal, one orange, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2177-50	Zyto <i>Light</i> SPEC BCL6 Dual Color Break Apart Probe C	•/•	5 (50 µl)
Z-2177-200	Zyto <i>Light</i> SPEC BCL6 Dual Color Break Apart Probe C	•/•	20 (200 µl)
<b>Related Prod</b>	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD		5
	Incl. Heat Pretreatment Solution Citric 150 ml: Pensin Solution 1 ml: Wash Buffer SSC 150 ml: 25x Wash Buffer A 50 ml: DAPI/DuraTect-Solution 0.2 ml		

Akyurek N, et al. (2012) Cancer 118: 4173-83. Cady FM, et al. (2008) J Clin Oncol 26: 4814-9. Ohno H (2004) Histol Histopathol 19: 637-50.

Ohno H (2006) J Clin Exp Hematop 46: 43-53

Zyto Light FISH-Tissue Implementation Kit C € IVD

20

Z-2028-20

Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml \* Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC FGFR3 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC FGFR3 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 4p16.3 harboring the FGFR3 (fibroblast growth factor receptor 3, a.k.a.

Rearrangements affecting the FGFR3 gene are frequently found in carcinomas of various types including multiple myeloma (MM), bladder cancer, glioblastoma, peripheral T-cell lymphoma, and lung squamous cell carcinoma.


FGFR3 encodes for a transmembrane receptor tyrosine kinase which dimerizes after ligand binding leading to activation of downstream signaling cascades. This gene develops characteristic oncogenic activities after fusion to several gene partners which often leads to ligand-independent activation of the tyrosine kinase of the FGFR3 fusion protein.

Several in vivo and in vitro studies have demonstrated the therapeutic potential of FGFR inhibitors in cell lines and animal models harboring FGFR3 fusion genes. Hence, the detection of FGFR3 translocations by Fluorescence in situ Hybridization may be a useful predictive biomarker in the selection of patients for FGFR-targeted therapy.


References
Cheng T, et al. (2013) PLoS One 8: e57284 Fonseca R, et al. (2009) Leukemia 23: 2210-21. Kang S, et al. (2009) Mol Cell Biol 29: 2105-17 Knowles MA (2007) World J Urol 25: 581-93. Parker BC, et al. (2014) J Pathol 232: 4-15.
Williams SV, et al. (2012) Hum Mol Genet 22: 795-803.

### **Probe Description**

The SPEC FGFR3 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 4p16.3 band. The orange fluorochrome direct labeled probe hybridizes proximal, the green fluorochrome direct labeled probe hybridizes distal to the FGFR3 gene at 4p16.3.




Ideogram of chromosome 4 indicating the hybridization locations.




SPEC FGFR3 Probe map (not to scale).

### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 4p16.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 4p16.3 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 4p16.3 locus and one 4p16.3 locus affected by a translocation.



SPEC FGFR3 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Breast cancer tissue section with translocation affecting the FGFR3 gene as indicated by one non-rearranged orange/green fusion signal, one orange, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2170-50	Zyto <i>Light</i> SPEC FGFR3 Dual Color Break Apart Probe C€	•/•	5 (50 µl)
Z-2170-200	Zyto <i>Light</i> SPEC FGFR3 Dual Color Break Apart Probe C€	•/•	20 (200 µl)
Related Pro	ducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C    Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x Mgd <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light ® SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe (

## **Background**

The ZytoLight ® SPEC FGFR3 Break Apart/ FGFR2/FGFR1 Quadruple Color Probe is designed for the simultaneous detection of FGFR3 gene rearrangements, and of the FGFR2 and FGFR1 gene copy number

Fibroblast growth-factor receptors (FGFRs) are involved in the regulation of organ development, cell proliferation and migration, and other processes. FGFR-activating genetic changes, including amplifications and translocations, were shown to be associated with the development and progression of tumors.

Rearrangements affecting the FGFR3 gene are frequently found in carcinomas of various types, including multiple myeloma (MM), bladder cancer, glioblastoma, and lung squamous cell carcinoma.

FGFR2 amplifications were found to occur in some gastric and breast tumors. FGFR1 is amplified in 21% of lung adenocarcinomas but also in other solid tumors, including oral squamous cell carcinoma, breast, ovarian, and bladder cancer.


Various types of FGFR inhibitors are available, some of which have entered anti-tumor clinical trials and have shown promising clinical effects and application prospects.

Thus, detection of FGFR aberrations may help in selecting patients eligible for an FGFR-targeted therapy.


Adnane J, et al. (1991) Oncogene 6: 659-63. Chesi M, et al. (1997) Nat Genet 16: 260-4. Liang G, et al. (2013) Cytokine Growth Factor Rev 24: 467-75. Parker BC, et al. (2014) J Pathol 232: 4-15.

### **Probe Description**

The SPEC FGFR3 Break Apart/FGFR2/ FGFR1 Quadruple Color Probe is a mixture of a green and a red fluorochrome direct labeled probe hybridizing distal and proximal to the FGFR3 gene at 4p16.3, respectively, a blue fluorochrome direct labeled probe specific for the FGFR2 gene at 10q26.12-q26.13, and a gold fluorochrome direct labeled probe specific for the chromosomal region 8p11.22-p11.23 harboring the FGFR1 gene.



SPEC FGFR3 Probe map (not to scale).




SPEC FGFR2 Probe map (not to scale).




SPEC FGFR1 Probe map (not to scale).

### Results

In a normal interphase nucleus, two red/ green fusion signals, representing two normal (non-rearranged) 4p16.3 loci, two blue (FGFR2), and two gold (FGFR1) signals are expected. One separate red signal and a separate green signal indicate a 4p16.3 locus affected by a translocation. In cells with amplification of the FGFR2, or FGFR1 gene locus, multiple signals of the respective color will be visible.



SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe hybridized to normal interphase cells as indicated by two red/green fusion signals (FGFR3), two blue (FGFR2), and two gold (FGFR1) signals.



Ideogram of chromosome 4, 10, and 8 indicating the hybridization locations.

Prod. No.	Product	Label	Tests* (Volume)
Z-2186-200	Zyto Light SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe C    IVD	•/•/•/ <u>•</u>	20 (200 µl)
Related Products			
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C€ IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC FGFR3/4p11 Dual Color Probe

Previously: Zyto Light SPEC FGFR3/CEN 4 Dual Color Probe



## **Background**

The ZytoLight® SPEC FGFR3/4p11 Dual Color Probe is designed for the detection of FGFR3 gene amplifications.


The FGFR3 (fibroblast growth factor receptor 3) gene is located in the chromosomal region 4p16.3 and encodes a receptor tyrosine kinase.

FGFR family members differ from one another in their ligand affinities and tissue distribution. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The FGFR3 protein binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Activating mutations are associated with multiple myeloma, cervical carcinoma, and carcinoma of the bladder. Additionally, it was found that copy number gains at 4p16.3 occurred significantly more frequently in recurred/metastasized salivary gland adenoid cystic carcinoma (ACC) compared with indolent ACC.


Keegan K, et al. (1991) PNAS 88: 1095-9. L'Hôte CG & Knowles MA (2005) Exp Cell Res 304: 417-31. Thompson LM, et al. (1991) Genomics 11: 1133-42. Vékony H, et al. (2007) Clin Cancer Res 13: 3133-9.

### **Probe Description**


The SPEC FGFR3/4p11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC FGFR3 probe hybridizing to the FGFR3 gene in the chromosomal region 4p16.3 and an orange fluorochrome direct labeled SPEC 4p11 probe specific for the ZAR1 (zygote arrest 1) gene region in 4p11. For an unambiguous enumeration of chromosome 4 the SPEC 4p11 is found to be more suitable.



Ideogram of chromosome 4 indicating the hybridization locations.




SPEC FGFR3 Probe map (not to scale).




SPEC 4p11 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the FGFR3 gene locus, multiple copies of the green signal or large green signal clusters will be observed.



SPEC FGFR3/4p11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bladder cancer tissue section with interphase cells showing polysomy of chromosome 4 as indicated by multiple green and orange signals in the nuclei.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2082-200	Zyto <i>Light</i> SPEC FGFR3/4p11 Dual Color Probe C € IVD	•/•	20 (200 µl)	
Related Pr	Related Products			
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € □VD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC PDGFRA/FIP1L1 TriCheck™ Probe



## **Background**


The ZytoLight ® SPEC PDGFRA/FIP1L1 TriCheck™ Probe is designed to detect rearrangements involving the chromosomal region 4q12 harboring the PDGFRA gene. The PDGFRA (platelet-derived growth factor receptor alpha) gene encodes a transmembrane glycoprotein that belongs to the type III receptor tyrosine kinase family and has a key role in a variety of cellular processes. PDGFRA gene rearrangements are rarely genetic events detected in myeloid and lymphoid neoplasms. These rearrangements most frequently occur in chronic eosinophilic leukemia (CEL), but can be also detected in acute myeloid leukemia (AML), and T-lymphoblastic leukemia/lymphoma (T-ALL). The most common gene fusion partner for PDGFRA is the FIP1-like 1 (FIP1L1) gene caused by an 800 kb interstitial deletion on chromosome 4q12. The result of this deletion is the loss of the CHIC2 gene and the fusion of the 5' end of the FIP1L1 gene with the 3' end of the PDGFRA gene.

Although FIP1L1 is the most common fusion partner of PDGFRA, five other partner genes have been identified, including BCR, ETV6, KIF5B, STRN, and CDK5RAP2. Identification of patients harboring a PDGFRA rearrangement is important as these patients respond very well to a targeted therapy with imatinib.


In CEL patients harboring a PDGFRA-FIP1L1 fusion a good response to other tyrosine kinase inhibitors like dastinib, nilotinib, sorafenib, and midostaurin could be demonstrated. Hence, detection of PDGFRA rearrangements by Fluorescence in situ Hybridization (FISH) may be of diagnostic and predictive relevance.

### **Probe Description**

The SPEC PDGFRA/FIP1L1 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the 4q12 band. The green fluorochrome direct labeled probe hybridizes proximal to the FIP1L1 gene, the orange fluorochrome direct labeled probe hybridizes distal to the FIP1L1 gene and proximal to the PDGFRA gene, and the blue fluorochrome direct labeled probe hybridizes distal to the PDGFRA gene.



Ideogram of chromosome 4 indicating the hybridization locations.




SPEC PDGFRA/FIP1L1 Probe map (not to scale).

### Results

In an interphase nucleus lacking a deletion or translocation involving the 4q12 band, two tricolor orange/green/blue fusion signals are expected representing two normal 4q12 loci.

A PDGFRA-FIP1L1 fusion resulting from an interstitial DNA deletion is indicated by the loss of the orange signal leading to a separate green signal co-localizing with a blue signal.

A PDGFRA translocation without involvement of FIP1L1 is indicated by one orange/ green fusion signal and one separate blue



SPEC PDGFRA/FIP1L1 TriCheck™ Probe hybridized to normal interphase cells as indicated by two tricolor orange/green/blue fusion signals per nucleus.

References
Bain BJ (2010) Haematologica 95: 696-8.
Cools J (2003) N Engl J Med 248: 1201-1214.
Curtis CE (2007) Br J Haematol 138: 77-81.
Golfib J (2004) Blood 103: 2879-2891. Savage N, et al. (2013) Int J Lab Hematol 35: 491-500. Vega F, et al. (2015) Am J Clin Pathol 144: 377-392.

Prod. No.	Product	Label	Tests* (Volume)
Z-2209-50	Zyto Light SPEC PDGFRA/FIP1L1 TriCheck Probe CE IVD	•/•/•	5 (50 µl)
<b>Related Prod</b>	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit CE IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC TERT/5q31 Dual Color Probe



## **Background**

The ZytoLight® SPEC TERT/5q31 Dual Color Probe is designed for the detection of TERT gene amplifications and chromosomal gains found in a variety of human tumors.


The TERT (telomerase reverse transcriptase) gene is located in the chromosomal region 5p15.33 and encodes the reverse transcriptase component of the human telomerase. Telomerase, the ribonucleoprotein enzyme complex necessary to maintain the ends of chromosomes, is absent from the majority of somatic cells but is present and active in the majority of immortal cell lines and human cancers.

Chromosomal gain or amplification of the TERT gene was found in various human tumors such as lung, cervical, bladder, breast, hepatocellular and colorectal carcinomas as well as in neuroblastoma and melanoma. It was shown that TERT amplification is a poor prognostic factor in non-small cell lung cancer (NSCLC) and is associated with poorly differentiated histopathology of hepatocellular carcinomas. Thus, detection of TERT amplification may have useful applications in cancer diagnosis and prognosis.


Bryce LA, et al. (2000) Neoplasia 2: 197-201. Cao Y, et al. (2008) Cancer Sci 99: 1092-9. Morin GB (1989) Nature 353: 454-6.
Takuma Y, et al. (2004) J Gastroenterol Hepatol 19: 1300-4.
Zhu C-Q, et al. (2006) Br J Cancer 94: 1452-9.

## **Probe Description**


The SPEC TERT/5q31 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC TERT probe hybridizing to the TERT gene in the chromosomal region 5p15.33 and an orange fluorochrome direct labeled SPEC 5q31 probe specific for the chromosomal region 5q31.2 harboring the EGR1 gene. Since chromosomes 1, 5, and 19 share the same repetitive sequences, probes specific for 5q31.2 are commonly used for chromosome 5 copy number detection.



Ideogram of chromosome 5 indicating the hybridization locations.




SPEC 5p15 Probe map (not to scale)



SPEC 5q31 Probe map (not to scale).

## Results

In a normal interphase nucleus two orange and two green signals are expected. In a cell with amplification of the TERT gene locus or aneuploidy of chromosome 5, multiple copies of the green signal or green signal clusters will be observed.



SPEC TERT/5q31 Dual Color Probe hybridized to melanoma tissue section showing normal cell as indicated by two green and two orange signals in each nucleus and cells with TERT gene amplification as indicated by multiple green signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2091-50	Zyto <i>Light</i> SPEC TERT/5q31 Dual Color Probe C	•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C FIVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC EGR1/5p15 Dual Color Probe



## **Background**

The ZytoLight ® SPEC EGR1/5p15 Dual Color Probe is designed for the detection of EGR1 gene deletions.

The EGR1 (early growth response 1) gene is located in the chromosomal region 5q31.2. Deletions spanning the region 5q31.2 are among the most common reoccurring abnormalities detectable in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

The EGR1 protein belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator.


Deletion of EGR1 in estrogen receptor negative (ER-) breast carcinomas is correlated with a higher tumor grade, suggesting that loss of the EGR1 gene (and thereby loss of functioning EGR1 protein) may contribute to the pathogenesis of ER- breast carcinomas.

In patients with therapy-related MDS and AML, dicentric chromosomes have often been observed. In such conditions, many patients show a complex karyotype with several marker chromosomes unidentifiable by conventional cytogenetics. Fluorescence in situ Hybridization (FISH) has now made the characterization of these rearrangements much easier.


Graubert TA, et al. (2009) PLoS One 4: e4583. Ronski K, et al. (2007) Cancer Genet Cytogenet 175: 125-31.
Ronski K, et al. (2005) Cancer 104: 925-30.
Sun Y & Cook JR (2010) Leuk Res 34: 340-3.

### **Probe Description**


The SPEC EGR1/5p15 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC EGR1 probe hybridizing to the EGR1 gene in the chromosomal region 5q31.2 and an orange fluorochrome direct labeled SPEC 5p15 probe specific for the chromosomal region 5p15.33.



Ideogram of chromosome 5 indicating the hybridization locations.




SPEC EGR1 Probe map (not to scale).




SPEC 5p15 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the EGR1 gene locus, one or no copy of the green signal will be observed.



SPEC EGR1/5p15 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



SPEC EGR1/5p15 Dual Color Probe hybridized to bone marrow biopsy section with deletion of the EGR1 gene as indicated by one green signal and two orange signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2107-50	Zyto <i>Light</i> SPEC EGR1/5p15 Dual Color Probe C € IVD	•/•	5 (50 µl)
Z-2107-200	Zyto <i>Light</i> SPEC EGR1/5p15 Dual Color Probe C € IVD	•/•	(الم 200) 20
Related Proc	Related Products		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C (IVD) Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € 🔯 only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# Zyto Light ® SPEC EGR1/D5S23, D5S721 Dual Color Probe



## **Background**

The ZytoLight ® SPEC EGR1/D5S23, D5S721 Dual Color Probe is designed for the detection of EGR1 gene deletions. The EGR1 (early growth response 1) gene is located in the chromosomal region 5q31.2 and encodes a zinc finger transcription factor which is associated with cell proliferation, differentiation, and transformation.

Deletions spanning the region 5q31.2 are among the most common reoccurring abnormalities detectable in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In therapy-related MDS or AML, 40% of the patients exhibit a 5q deletion. Deletion of EGR1 in estrogen receptor negative (ER negative) breast carcinomas is correlated with a higher tumor grade, suggesting that loss of the EGR1 gene may contribute to the pathogenesis of ER-breast carcinomas.

Transfusion-dependent, lower-risk MDS patients with 5q deletion are treated with the thalidomide analog lenalidomide which is approved by the FDA.

In patients with de novo or therapy-related MDS and AML, dicentric chromosomes, involving chromosome 5, have often been observed. These patients frequently show a complex karyotype. In such conditions the characterization of rearrangement is nearly not feasible by conventional cytogenetics. Hence, Fluorescence in situ Hybridization (FISH) may be a helpful tool for diagnosis and therapy decisions.


References
Boultwood J, et al. (2010) Blood 116: 5803-11. Coleman JF, et al. (2011) Am J Clin Pathol 135: 915-20. Herry A, et al. (2007) Cancer Genet Cytogenet 175: 125-31. Horrigan SK, et al. (2000) Blood 95: 2372-7. Sukhatme V, et al. (1988) Cell 53: 37-43. Sun Y & Cook JR (2010) Leuk Res 34: 340-3 Tian J, et al. (2016) Intractable Rare Dis Res 5: 76-82. Wei S, et al. (2009) Proc Natl Acad Sci U S A 106: 12974-9. Zhao N, et al. (1997) Proc Natl Acad Sci U S A 94: 6948-53

### **Probe Description**

The SPEC EGR1/D5S23,D5S721 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC EGR1 probe hybridizing to the EGR1 gene in the chromosomal region 5q31.2 and an orange fluorochrome direct labeled SPEC D5S23,D5S721 probe specific for the chromosomal region 5p15.2-p15.31. Since in diverse solid tumors the chromosomal region 5p15.33 is affected by amplifications, probes targeting the D5S23,D5S721 region are more suitable for the enumeration of chromosome 5.




Ideogram of chromosome 5 indicating the hybridization locations.



SPEC D5S23,D5S721 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletion of the EGR1 gene locus, one or no copy of the green signal will be observed.



SPEC EGR1/D5S23,D5S721 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2211-50	ZytoLight SPEC EGR1/D5S23,D5S721 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Related Produ	cts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		
Z-2099-20	Zyto <i>Light</i> FISH-Cytology Implementation Kit C € IVD		20
	Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml;		
	Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC CSF1R Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC CSF1R Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 5q32 harboring the CSF1R (colony stimulating factor 1 receptor, a.k.a. FMS) gene.

The CSF1 receptor is activated by dimerization upon binding of its ligand CSF1 and is involved in macrophage development.

Rearrangement of the CSF1R gene was first detected in an acute megakaryoblastic leukemia (AMKL) cell line generating the RBM6-CSF1R fusion gene. A MEF2D-CSF1R fusion gene was described in a patient with primary pre-B cell acute lymphoblastic leukemia (pre-B ALL). Both fusion proteins contain the intact kinase domain of CSF1R.


Philadelphia chromosome-like ALL (Ph-like ALL) is a subgroup of B-cell precursor ALL and is associated with a high risk of treatment failure. SSBP2-CSF1R fusions were detected in some patients with Ph-like ALL. They result from either the balanced translocation t(5;5)(q14;q32) or the duplication dup(5)(q14q32). Expression of this fusion gene results in cytokine-independent growth and enhanced STAT5 activation which are inhibited by dasatinib in vitro. CSF1R signaling was also shown to be suppressed by the ABL1 kinase inhibitor imatinib.

Hence, the detection of CSF1R rearrangements by FISH may help in selecting ALL patients eligible for treatment with CSF1R inhibitors.


References
Dewar AL, et al. (2005) Blood 105: 3127-32.
Gu TL, et al. (2007) Blood 110: 323-33.
Lilljebjörn H, et al. (2014) Leukemia 28: 977-9.
Roberts KG, et al. (2014) N Engl J Med 371: 1005-15.
Schwab C, et al. (2014) Blood 124: 3773.

### **Probe Description**

The SPEC CSF1R Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 5q32-q33.1 band. The orange fluorochrome direct labeled probe hybridizes proximal to the CSF1R gene at 5q32, the green fluorochrome direct labeled probe hybridizes distal to the CSF1R gene at 5q32-q33.1.




Ideogram of chromosome 5 indicating the hybridization locations.



SPEC CSF1R Probe map (not to scale).

### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 5g32q33.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 5q32-q33.1 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 5q32-q33.1 locus and one 5q32q33.1 locus affected by a translocation. Duplication of the 5q32 locus will result in additional orange signals.



SPEC CSF1R Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2202-50	Zyto <i>Light</i> SPEC CSF1R Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IVD  Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit CE IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>y</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



# Zyto Light ® SPEC PDGFRB Dual Color Break Apart Probe



## **Background**


The ZytoLight® SPEC PDGFRB Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 5q32 harboring the PDGFRB gene. The PDGFRB (platelet-derived growth factor receptor-B) gene encodes a transmembrane glycoprotein that belongs to the type III receptor tyrosine kinase family and has a key role in a variety of cellular processes.

Translocations involving the PDGFRB gene are rare genetic disorders and are identified in myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), chronic myeloproliferative disorders (CMPD), acute myeloid leukemia (AML), and also in atypical (BCR-ABL1-negative) chronic myeloid leukemia/chronic myelomonocytic leukemia (CML/CMML)-like diseases, often with eosinophilia and splenomegaly. The most common translocation involving PDGFRB is the t(5;12)(q32;p13.2). Result of this translocation is the fusion protein ETV6-PDGFRB, in which the pointed domain of ETV6 is juxtaposed next to the transmembrane and entire tyrosine kinase domain of PDGFRB. As a result, the tyrosine kinase is constitutively activated leading to hematopoietic cell proliferation. Patients with PDGFRB translocations respond well to imatinib therapy with excellent hematopoietic and molecular responses. Recent studies revealed that sorafenib is a further potential inhibitor of patients with ETV6-PDGFRB translocation.


Bain BJ (2010) Haematologica 95: 696-8. Cross NC and Reiter A (2008) Acta Haematol 119: 199-206. Jones AV and Cross NC (2004) Cell Mol Life Sci 61: 2912-23. Keene P, et al. (1987) Br J Haematol 67: 25-31. Lierman E, et al. (2007) Haematologica 92: 27-34. Savage N, et al. (2013) Int J Lab Hematol 35: 491-500 Steer EJ and Cross NC (2002) Acta Haematol 107: 113-22. Vega F, et al. (2015) Am J Clin Pathol 144: 377-92.

### **Probe Description**

The SPEC PDGFRB Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 5q32q33.1 band. The green fluorochrome direct labeled probe hybridizes distal to the PDGFRB gene, and the orange fluorochrome direct labeled probe hybridizes proximal to the PDGFRB locus.




Ideogram of chromosome 5 indicating the hybridization locations.



SPEC PDGFRB Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 5q32-q33.1 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 5q32-q33.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 5q32-q33.1 locus and one 5q32-q33.1 locus affected by a translocation.



SPEC PDGFRB Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

P	rod. No.	Product	Label	Tests* (Volume)
Z-	-2197-50	Zyto Light SPEC PDGFRB Dual Color Break Apart Probe C    IVD	•/•	5 (50 µl)
R	Related Products			
Z-		Zyto Light FISH-Tissue Implementation Kit C FivD  Ind. Heat Pretreatment Solution, Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-		Zyto Light FISH-Cytology Implementation Kit C € IVD  Ind. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light® SPEC IRF4, DUSP22 Dual Color Break Apart Probe




## **Background**

The ZytoLight® SPEC IRF4, DUSP22 Dual Color Break Apart Probe is designed for the detection of translocations involving the chromosomal region 6p25.3 harboring the DUSP22 (dual specificity phosphatase 22, a.k.a. JKAP) and IRF4 (interferon regulatory factor 4, a.k.a. MUM1) genes. IRF4 is normally expressed in plasma cells, melanocytes, some B-cells, and in activated T-cells. The IRF4 protein is required at several stages of B-cell development, and is also critical for T-cell differentiation. Rearrangements of the IRF4/DUSP22 chromosomal region have been detected in various B-cell and T-cell lymphomas. Large B-cell lymphoma (LBCL) with IRF4 rearrangement, which occurs most commonly in children and young adults, is considered a distinct new provisional entity. These lymphomas most typically occur in Waldeyer ring and/or cervical lymph nodes. Most cases have IG/IRF4 fusions and have a favorable prognosis. Rearrangements of IRF4 and/or DUSP22 have also been described in peripheral T-cell lymphomas and in cutaneous anaplastic large cell lymphoma (ALCL). ALCL is difficult to distinguish from other CD30-positive T-cell lymphoproliferative disorders. IRF4 translocation has a high specificity for cutaneous ALCL supporting the clinical utility of FISH for IRF4 in the differential diagnosis of T-cell lymphoproliferative disorders.


Moreover, DUSP22 rearrangement in ALK-negative ALCL is associated with a favorable outcome indicating the usefulness of DUSP22 as a predictive biomarker.

### **Probe Description**

The SPEC IRF4, DUSP22 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 6p25.3 band. The green fluorochrome direct labeled probe hybridizes proximal and the orange fluorochrome direct labeled probe hybridizes distal to the IRF4 and DUSP22 genes.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC IRF4, DUSP22 map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 6p25.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 6p25.3 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 6p25.3 locus and one 6p25.3 locus affected by a translocation.



SPEC IRF4, DUSP22 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



T-cell lymphoma tissue section with translocation affecting the 6p25.3 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

# References lide S, et al. (1997) Nat Genet 17: 226-30. Parrilla Castellar ER, et al. (2014) Blood 124: 1473-80. Pham-Ledard A, et al. (2010) J Invest Dermatol 130: 816-25. Salaverria I, et al. (2011) Blood 118: 139-47. Swerdlow SH, et al. (2016) Blood 127: 2375-90. Wada DA, et al. (2011) Mod Pathol 24: 596-605.

Prod. No.	Product	Label	Tests* (Volume)
Z-2210-50	Zyto <i>Light</i> SPEC IRF4,DUSP22 Dual Color Break Apart Probe C € IVD	•/•	5 (50 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   IvD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C   IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC RREB1/MYB/CEN 6 Triple Color Probe



## **Background**

The ZytoLight® SPEC RREB1/MYB/CEN 6 Triple Color Probe is designed for the detection of copy number changes of the chromosomal regions harboring the RREB1 and the MYB gene, respectively. The RREB1 (ras responsive element binding protein 1, a.k.a. HNT) gene is located in 6p24.3 and encodes a zinc finger transcription factor. The MYB (v-myb avian myeloblastosis viral oncogene homolog, a.k.a. c-myb) gene is located in 6g23.3 and encodes a transcription factor that is implicated in proliferation, survival, and differentiation of hematopoietic progenitor

Overexpression of the RREB1 protein was detected in prostate cancer and in a medullary thyroid cancer cell line. RREB1 is suggested to play a role in Ras and Raf signal transduction in medullary thyroid cancer.


MYB has been found to be amplified in a variety of human cancers. In pancreatic cancer, MYB amplification was mainly found in advanced and metastatic tumors. In breast tumors from BRCA1 germ-line mutation carriers, MYB amplification was observed in 29% of the cases and resulted in overexpression of the MYB protein. Moreover, duplication of the MYB gene occurs in 8.4% of individuals with T-cell acute lymphoblastic leukemia (T-ALL).

cells.


Kauraniemi P, et al. (2000) Cancer Res 60: 5323-8. Lahortiga I, et al. (2007) Nat Genet 39: 593-5. Thiogalingam A, et al. (1996) Mol Cell Biol 16: 5335-45. Wallrapp C, et al. (1997) Cancer Res 57: 3135-9. Zou J, et al. (2011) Prostate 71: 1518-24.


### **Probe Description**

The SPEC RREB1/MYB/CEN 6 Triple Color Probe is a mixture of a green fluorochrome direct labeled SPEC RREB1 probe hybridizing to the RREB1 locus at 6p24.3p25.1, an orange fluorochrome direct labeled SPEC MYB probe hybridizing to the MYB locus at 6q23.2-q23.3, and a blue fluorochrome direct labeled CEN 6 probe specific for the alpha satellite centromeric region of chromosome 6 (D6Z1).



Ideogram of chromosome 6 indicating the hybridization locations.






SPEC MYB Probe map (not to scale).

### Results

In a normal interphase nucleus, two green, two orange, and two blue signals are expected. In a cell with amplification of the RREB1 or the MYB gene locus, multiple copies of the green or orange signal will be observed, respectively. In a cell with deletion of the RREB1 or the MYB gene locus, a reduced number of green or orange signals will be observed, respectively.



SPEC RREB1/MYB/CEN 6 Triple Color Probe hybridized to normal interphase cells as indicated by two green, two orange, and two blue signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2152-50	ZytoLight SPEC RREB1/MYB/CEN 6 Triple Color Probe C    IVD	<b>•</b> /•/•	5 (50 µl)
Z-2152-200	ZytoLight SPEC RREB1/MYB/CEN 6 Triple Color Probe C€ IVD	•/•/•	20 (200 µl)
Related Produ	cts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   IVD  Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD  Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC VEGFA/CEN 6 Dual Color Probe



## **Background**

The ZytoLight® SPEC VEGFA/CEN 6 Dual Color Probe is designed for the detection of amplifications involving the chromosomal region 6p21.1 harboring the VEGFA gene (vascular endothelial growth factor A, a.k.a. VEGF, VPF).

The VEGFA protein is involved in vascular permeability, angiogenesis, cell migration, and inhibition of apoptosis. In addition, binding of VEGFA to its receptors activates the RAS/MEK/MAPK pathway, thus, leading to mitotic activation. Amplification of the VEGFA gene locus was found in several types of malignancy, such as osteosarcoma, hepatocellular carcinoma (HCC), and colorectal cancers. In patients with osteosarcoma, VEGFA gene amplification results in elevated expression of VEGFA and is associated with adverse tumor-free survival.

VEGFA amplifications occur in 3-6 % of colorectal cancers and result in a highly aggressive disease.


HCC patients with VEGFA gain responded better to sorafenib, a multi-kinase inhibitor that blocks, i.a., receptors of the VEGFA protein, resulting in improved survival of the patients. This suggests that VEGFA is a potential biomarker for response to sorafenib therapy in HCC.

Hence, detection of VEGFA amplifications by Fluorescence in situ Hybridization may help in selecting patients eligible for an anti-VEGFA therapy.


orwitz E, et al. (2014) Cancer Discov 4: 730-43. Vlajnic T, et al. (2011) Mod Pathol 24: 1404-12. Yang J, et al. (2011) Cancer 117: 4925-38.

### **Probe Description**

The SPEC VEGFA/CEN 6 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC VEGFA probe specific for the VEGFA gene at 6p21.1 and an orange fluorochrome direct labeled CEN 6 probe specific for the alpha satellite centromeric region of chromosome 6 (D6Z1).




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC VEGFA Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the VEGFA gene locus, multiple copies of the green signal or large green signal clusters will be observed.



SPEC VEGFA/CEN 6 Dual Color Probe hybridized to normal interphase calls as indicated by two orange and two green signals in each nucleus.



HCC tissue section with interphase cells showing a polysomy of chromosome 6 as indicated by multiple green (VEGFA) and orange (CÉN 6) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2195-200	Zyto <i>Light</i> SPEC VEGFA/CEN 6 Dual Color Probe CE IVD	•/•	20 (200 µl)	
Related Pro	Related Products			
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC ROS1 Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC ROS1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 6q22.1 harboring the c-ros oncogene 1 (ROS1, a.k.a. MCF3) gene. The ROS1 gene is located on 6q22.1 and encodes a receptor tyrosine kinase. Translocations affecting ROS1 have been detected in glioblastoma, cholangiocarcinoma, and non-small cell lung cancer (NSCLC).


In NSCLC several ROS1 translocation partners have been detected all of which result in the fusion of variably truncated forms of e.g. TPM3, SDC4, SLC34A2, CD74, EZR, or LRIG3 to the kinase domain of ROS1. GOPC has also been found to be fused to ROS1 in NSCLC. GOPC-ROS1 fusions result from interstitial deletion of approx. 240 kb on 6q22.1. ROS1 rearrangements are thought to define a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK rearranged NSCLC.

First evidence suggests that administration of ROS1 kinase inhibitors may represent a very effective therapeutic strategy in NSCLC patients harboring activating ROS1 rearrangements. Accordingly, detection of ROS1 rearrangements using Fluorescence in situ Hybridization might be a helpful tool for the identification of patients likely to respond to ROS1 kinase targeting therapies.


Bergethon K, et al. (2012) J Clin Oncol 30: 863-70. Birchmaier C, et al. (1987) Proc Natl Acad Sci 84: 9270-74.
Bos M, et al. (2013) Lung Cancer 81: 142-3.
Lee SE, et al. (2015) Mod Pathol 28: 468-79. Lee Sc, et al. (2017) Mod rainol 25: 40679. Rikova K, et al. (2007) Cell 131: 1190-203. Rimkunas VM, et al. (2012) Clin Cancer Res 18: 4449-57. Suehara Y, et al. (2012) Clin Cancer Res 18: 6599-608. Takeuchi K, et al. (2012) Nat Med 18: 378-81.

### **Probe Description**

The SPEC ROS1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 6q22.1 band. The orange fluorochrome direct labeled probe hybridizes distal, the green fluorochrome direct labeled probe hybridizes proximal to the ROS1 breakpoint region at 6q22.1.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC ROS1 Probe map (not to scale).

### Results

In an interphase nucleus lacking an aberration involving the 6q22.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 6q22.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 6a22.1 locus and one 6q22.1 locus affected by a translocation. Isolated green signals are the result of deletions distal to the ROS1 breakpoint region or are due to unbalanced translocations affecting this chromosomal region.



SPEC ROS1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Section of paraffin embedded NSCLC cell line with translocation affecting the 6q22.1 locus harboring ROS1 as indicated by one orange/green fusion signal (non-rearranged), one orange signal, and one separate green signal indicating the translocation

		separate green signar matcan	ng me nansiocanon.
Prod. No.	Product	Label	Tests* (Volume)
Z-2144-50	Zyto <i>Light</i> SPEC ROS1 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2144-200	Zyto <i>Light</i> SPEC ROS1 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Products			
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IND  Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light ® SPEC ROS1/CEN 6 Dual Color Probe



## **Background**

The ZytoLight ® SPEC ROS1/CEN 6 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the ROS1 gene. The ROS1 (c-ros oncogene 1, a.k.a. MCF3) gene is located on 6q22.1 and encodes a receptor tyrosine kinase of the insulin receptor family. ROS1 has been found to undergo genetic rearrangements in a variety of human cancers including glioblastoma, cholangiocarcinoma, and non-small cell lung cancer (NSCLC). ROS1 rearrangements, detected in adenocarcinoma of the lung, are thought to define a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK rearranged NSCLC. Targeting ROS1 fusion proteins with the kinase inhibitor crizotinib was shown to be a promising and effective therapy in NSCLC patients whose tumors are positive for this genetic aberration.


Recently, copy number gain of the ROS1 gene was reported to occur in NSCLC patients and to be associated with poor prognosis.

Hence, detection of ROS1 amplification by FISH could help to identify patients who might be selected for further clinical examinations with regard to potential ROS1 targeting treatments.


Bergethon K, et al. (2012) J Clin Oncol 30: 863-70. Bos M, et al. (2013) Lung Cancer 81: 142-3. Jin Y, et al. (2015) Virchows Arch 466: 45-52. Mazières J, et al. (2015) J Clin Oncol 33: 992-9 Takeuchi K, et al. (2012) Nat Med 18: 378-81.

### **Probe Description**

The SPEC ROS1/CEN 6 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 6 probe specific for the alpha satellite centromeric region of chromosome 6 (D6Z1) and a green fluorochrome direct labeled SPEC ROS1 probe specific for the ROS1 gene at 6q22.1.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC ROS1 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ROS1 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC ROS1/CEN 6 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Lung cancer tissue section with interphase cells showing a polysomy of chromosome 6 as indicated by multiple orange (CEN 6) and green (ROS1) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2162-200	Zyto Light SPEC ROS1/CEN 6 Dual Color Probe C€ IVD	•/•	20 (200 µl)
Related Products			
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



# Zyto Light ® SPEC MYB Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC MYB Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 6q23.3 harboring the MYB (v-myb avian myeloblastosis viral oncogene homolog, a.k.a. c-Myb) gene.


The MYB gene is expressed predominantly in immature progenitor cells of all hematopoietic lineages and is highly expressed in most leukemias and in some solid tumors. Translocations affecting MYB have been detected in T-cell acute lymphoblastic leukemia (T-ALL) and adenoid cystic carcinoma (ACC).

Recent studies have identified a subgroup of T-ALL with reciprocal translocation t(6;7) (q23.3;q34) that juxtaposes MYB and TCRB (T-cell receptor beta) leading to the activation of MYB expression. Since the translocation breakpoints in 6q23 map to two clusters located 5 kb and more than 50 kb telomeric of MYB, no true MYB fusion gene is generated. It is assumed that the abnormal MYB expression could confer oncogenic properties and that MYB might represent a potential target for therapeutic intervention in T-ALL. In ACC a recurrent translocation t(6;9) (q22-23;p23-24) is found in about one third of karyotypically abnormal cases. The translocation results in the fusion of the two transcription factor genes MYB and NFIB (nuclear factor I/B) which leads to enhanced expression of the MYB-NFIB fusion protein. The detection of MYB rearrangements using FISH might represent a powerful adjunctive diagnostic tool useful in the differential diagnosis of ACC.


References Clappier E, et al. (2007) Blood 110: 1251-61. Persson M, et al. (2009) Pro Natl Acad Sci USA 106: 18740-4. Stenman G, et al. (2010) Cell Cycle 9: 2986-95.

## **Probe Description**

The SPEC MYB Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 6q23.2-q23.3 band. The orange fluorochrome direct labeled probe hybridizes distal and the green fluorochrome direct labeled probe hybridizes proximal to the MYB breakpoint cluster region.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC MYB Probe map (not to scale).

### **Results**

In an interphase nucleus lacking a translocation involving the 6q23.2-q23.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 6q23.2-q23.3 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 6q23.2-q23.3 locus and one 6q23.2-q23.3 locus affected by a translocation.



SPEC MYB Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Adenoid cystic carcinoma tissue section with translocation affecting the 6q23.3 locus as indicated by one orange/green fusion (non-rearranged) signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2143-200	Zyto <i>Light</i> SPEC MYB Dual Color Break Apart Probe C	•/•	20 (200 µl)
Related Proc	lucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC ESR1/CEN 6 Dual Color Probe



## **Background**

The ZytoLight ® SPEC ESR1/CEN 6 Dual Color Probe is designed for the detection of ESR1 gene amplification frequently observed in breast cancer.


The ESR1 (estrogen receptor 1) gene is located in the chromosomal region 6q25.1 and encodes estrogen receptor alpha (ER). ER expression is one of the most important known factors in the development of breast cancer, and assessing its status by immunohistochemistry is important for determining the use of anti-estrogen receptor therapies.

ESR1 gene amplification has been found frequently in ER-positive breast tumors. Additionally, it has been shown very recently for breast cancer patients receiving adjuvant tamoxifen monotherapy that survival is significantly longer in cases of ESR1 gene amplification as determined by FISH compared to immunohistochemically ER-positive cases without gene amplification. Additionally, it has been shown that response to tamoxifen is dependent on the absolute ESR1 copy number. Thus, determination of ESR1 amplification may identify a subgroup of breast cancer patients particularly likely to respond to anti-estrogen therapy.


References Burkhardt L, et al. (2010) Breast Cancer Res Treat 123: 757-65. Holst F, et al. (2007) Nature Genet 39: 655-60. Lacroix M (2006) Endocr Relat Cancer 13: 1033-67. Moelans CB, et al. (2010) Anal Cell Pathol 33: 13-8. Nembrot M, et al. (1990) Biochem Biophys Res Comm 166: 601-7. Nessling M, et al. (2005) Cancer Res 65: 439-47. Pentheroudakis G, et al. (2013) PLoS One 8: e70634. Rahman MT, et al. (2013) Anticancer Res 33: 3775-81 Sassen A, et al. (2009) Breast Cancer Res 11: R50. Tomita S, et al. (2009) Cancer Sci 100: 1012-7

### **Probe Description**

The SPEC ESR1/CEN 6 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 6 probe specific for the alpha satellite centromeric region of chromosome 6 (D6Z1) and a green fluorochrome direct labeled SPEC ESR1 probe hybridizing to the ESR1 locus at 6q25.1.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC ESR1 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ESR1 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC ESR1/CEN 6 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



ESR1 gene amplification as indicated by mutiple green ESR1 specific signals in each nucleus.

	Prod. No.	Product	Label	Tests* (Volume)
	Z-2069-50	Zyto <i>Light</i> SPEC ESR1/CEN 6 Dual Color Probe C	•/•	5 (50 µl)
	Z-2069-200	Zyto <i>Light</i> SPEC ESR1/CEN 6 Dual Color Probe C	•/•	20 (200 µl)
Related Products				
	Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C (IVD) Incl. Hear Pretreatment Solution (Gtric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
	Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC ETV1/CEN 7 Dual Color Probe



## **Background**


The ZytoLight ® SPEC ETV1/CEN 7 Dual Color Probe is designed for the detection of ETV1 gene amplifications observed e.g. in melanoma.

The ETV1 (ETS translocation variant 1, a.k.a. ER81) gene is located on chromosome 7p21.2 and encodes an ETS (E26 transformation-specific) transcription factor. The gene was first identified as a fusion partner of the EWS gene in Ewing's sarcoma. Moreover, it was frequently found to be fused to TMPRSS2 (transmembrane protease, serine 2) in prostate cancer. ETV1 amplification or copy number gain of chromosome 7p was detected in melanoma, lung adenocarcinoma of never smokers, and pleomorphic liposarcoma. In melanoma, more than 40% of the cases show amplification or copy number gain of the ETV1 locus. As ectopic ETV1 overexpression in the context of aberrant MAP kinase pathway activation was found to transform immortalized human melanocytes, it was suggested that ETV1 acts as a melanoma oncogene.


Name-Valbuena J, et al. (2010) Cancer Res 70: 2075-84. Jeon IS, et al. (1995) Oncogene 10: 1229-34. Job B, et al. (2010) PLoS One 5: e15145. Taylor BS, et al. (2008) PLoS One 3: e3179.

### **Probe Description**

The SPEC ETV1/CEN 7 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC ETV1 probe specific for the chromosomal region 7p21.2-p21.3 harboring the ETV1 gene and an orange fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1).




Ideogram of chromosome 7 indicating the hybridization locations.




## Results

In a normal interphase nucleus, two orange and two green signals are expected. Nuclei with amplification of the ETV1 gene locus 7p21.2 or polysomy of chromosome 7 will show multiple copies of the green signal or large green signal clusters.



SPEC ETV1/CEN 7 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Lung cancer tissue section with interphase cells showing polysomy of chromosome 7 as indicated by multiple green and orange signals in the nuclei.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2141-200	Zyto <i>Light</i> SPEC ETV1/CEN 7 Dual Color Probe C	•/•	20 (200 µl)	
Related Pro	Related Products			
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



# Zyto Light® SPEC JAZF1 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC JAZF1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 7p15.1-p15.2 harboring the JAZF1 (Juxtaposed with Another Zinc Finger) gene.

Translocations involving the region 7p15.1-p15.2 are frequently found in endometrial stromal sarcoma (ESS). The most common cytogenetic abnormality detected in 33-80% of ESS is t(7:17) (p15.1-p15.2;q11.2) which results in the fusion of the JAZF1 gene at 7p15.1-p15.2 to the JJAZ1 (Joined to JAZF1; a.k.a. SUZ12) gene at 17q11.2. Both genes involved contain zinc finger domains characteristic for DNA binding proteins. It was shown that the fusion protein JAZF1-JJAZ1 can promote cell proliferation when the wild-type JJAZ1 is silenced as it is in ESS harboring the t(7;17).


In 25-30% of ESS the JAZF1 gene is disrupted by another translocation t(6;7) where the first zinc finger domain of JAZF1 is fused to both zinc finger domains of the PHF1 (PHD finger protein 1) gene at 6p21.32. As a result the entire coding region of PHF1 is regulated by the JAZF1 promoter.

Since the diagnosis of ESS is often difficult in cases showing diverse histological differentiation or in undifferentiated endometrial sarcoma (UES), the detection of the JAZF1 translocations can serve as a diagnostic tool to confirm the diagnosis of ESS.


References Hrzenjak A, et al. (2005) J Mol Diagn 7: 388-95. Koontz JI, et al. (2001) PNAS 98: 6348-53. Li H, et al. (2007) PNAS 104: 20001-6. Micci F, et al. (2003) Cancer Genet Cytogenet 144: 119-24.

### **Probe Description**

The SPEC JAZF1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 7p15.1-p15.2 band. The orange fluorochrome direct labeled probe hybridizes proximal, the green fluorochrome direct labeled probe hybridizes distal to the JAZF1 breakpoint region.




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC JAZF1 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 7p15.1-p15.2 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 7p15.1-p15.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 7p15.1-p15.2 locus and one 7p15.1p15.2 locus affected by a translocation.



SPEC JAZF1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Endometrial stromal sarcoma with translocation affecting JAZF1 at 7p15.1-p15.2 as well as monosomy of chromosome 7 as indicated by one orange and one separate green signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2132-50	Zyto <i>Light</i> SPEC JAZF1 Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Pro	lucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light® SPEC EGFR/CEN 7 Dual Color Probe



## **Background**

The ZytoLight ® SPEC EGFR/CEN 7 Dual Color Probe is designed for the detection of EGFR gene amplification frequently observed in solid neoplasms including non-small-cell lung cancer (NSCLC) and alioblastoma.


The EGFR gene (a.k.a. ERBB1 and HER1) is located in the chromosomal region 7p11.2 and encodes a transmembrane glycoprotein acting as a cellular growth factor receptor. The protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including ERBB2 (ERBB2), ERBB3 (HER3), and ERBB4 (HER4).

Overexpression of EGFR has been shown in a number of tumor entities and is associated with poor prognosis. EGFR copy number identified by FISH is thought to be a molecular predictor in neoplasms.


References
Ach T, et al. (2013) Virchows Arch 462: 65-72.
Balla P, et al. (2011) Histopathology 59: 376-89.
Bernardes VM, et al. (2013) BMJ Open 3: e002077.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Cappuzzo F, et al. (2005) J Natl Cancer Inst 97: 643-55.
Ettl T, et al. (2012) Br J Cancer 106: 719-26.
Ettl T, et al. (2014) Head Neck 36: 517-23. Ettl T, et al. (2014) Head Neck 36: 517-23. Gogas H, et al. (2010) Clin Breast Cancer 10: 230-7. Gonçalves A, et al. (2008) BMC Cancer 8: 169ff. Gonçalves A, et al. (2008) BMC Cancer 8: 169ff.
Kondo I & Shimizu N (1983) Cytogenet Cell Genet 35: 9-14.
Lauand C, et al. (2013) Cancer Cell Int 13: 38.
Libermann TA, et al. (1985) J Cell Sci Suppl 3: 161-72.
Merlino GT, et al. (1985) J Clin Invest 75: 1077-9.
Murray S, et al. (2012) J Exp Clin Cancer Res 31: 77.
Projetti F, et al. (2013) Human Pathology 44: 2116-25.
Sassen A, et al. (2008) Breast Cancer Res 10: R2.
Sassen A, et al. (2009) Breast Cancer Res 11: R50.
Tower SM et al. (2004) Report Cancer Res 1. Tovey SM, et al. (2004) Breast Cancer Res 6: 246-51

### **Probe Description**

The SPEC EGFR/CEN 7 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1) and a green fluorochrome direct labeled SPEC EGFR probe specific for the EGFR gene at 7p11.2




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC EGFR Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the EGFR gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC EGFR/CEN 7 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Cancer cells with multiple copies of chromosome 7 and extra EGFR signals (green) in sputum sample from an NSCLC patient.

Prod. No.	Product	Label	Tests* (Volume)
Z-2033-50	Zyto Light SPEC EGFR/CEN 7 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2033-200	Zyto Light SPEC EGFR/CEN 7 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreament Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC MET/CEN 7 Dual Color Probe



## **Background**


The ZytoLight ® SPEC MET/CEN 7 Dual Color Probe is designed for the detection of MET gene amplifications found in a variety of human tumors.

The MET gene (a.k.a. c-Met) is located in the chromosomal region 7q31.2 and encodes a transmembrane tyrosine kinase receptor for the hepathocyte growth factor (HGF). HGF and MET play an important role in angiogenesis and tumor growth. Activation or upregulation of MET was found in a number of carcinomas including lung, breast, colorectal, prostate, and gastric carcinomas as well as in gliomas, melanomas and some sarcomas. MET overexpression is known as a negative prognostic indicator in patients with various carcinomas, multiple myeloma, or glioma. Therefore, several inhibitors of the HGF/MET signaling pathway are being studied and developed as potent therapies to inhibit angiogenesis and tumor growth. Recently, it was shown that MET amplification leads to resistance to gefitinib or erlotinib in lung cancer by driving ERBB3dependent activation of the PI3K pathway.


Ketrernes Ach T, et al. (2013) Virchows Arch 462: 65-72. Cooper CS, et al. (1984) Nature 311: 29-32. Engelman JA, et al. (2007) Science 316: 1039-43. Ettl T, et al. (2014) Head Neck 36: 517-23. Garcia S, et al. (2007) Int J Oncol 31: 49-58. Hara T, et al. (1998) Lab Invest 78: 1143-53. Lacroix I, et al. (2014) PLoS One 1: e84319. Lee D, et al. (2015) Cancer Res Treat 47: 120-5. Preusser M, et al. (2014) Histopathology 65: 684-92. Schildhaus HU, et al. (2015) Clin Cancer Res 21: 907-15.

### **Probe Description**

The SPEC MET/CEN 7 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1) and a green fluorochrome direct labeled SPEC MET probe specific for the MET gene located at 7q31.2.




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC MET Probe map (not to scale).

### **Results**

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MET gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC MET/CEN 7 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Lung cancer cells with polysomy of chromosome 2 as indicated by four orange (CEN 7) and four green (MET) signals in the nuclei.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2087-200	Zyto <i>Light</i> SPEC MET/CEN 7 Dual Color Probe C€ IVD	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC BRAF Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC BRAF Dual Color Break Apart Probe is designed for the detection of rearrangements involving the chromosomal region 7q34 harboring the BRAF (B-Raf proto-oncogene, serine/threonine kinase, a.k.a. BRAF1, NS7) gene. The BRAF gene encodes a protein-serine/ threonine kinase that participates in the MAPK cascade, which regulates a large variety of cell processes.

Various BRAF translocations were observed in melanocytic nevi, pilocytic astrocytomas, malignant melanoma, prostate and gastric cancer. The AKAP9-BRAF fusion resulting from paracentric inversion of chromosome 7g was found in radiationinduced papillary thyroid carcinomas. The fusion proteins contain the protein kinase domain but lack the autoinhibitory N-terminal portion of BRAF resulting in constitutive kinase activity.

In addition, in pilocytic astrocytoma the FAM131B-BRAF fusion has been described resulting from interstitial deletion which removes the BRAF N-terminal inhibitory domain. Moreover, pancreatic acinar cell carcinoma - a rare subtype of pancreatic cancer with poor prognosis - shows a recurrent SND1-BRAF rearrangement. SND1-BRAF-transformed cells were shown to be sensitive to treatment with a MEK


Hence, the detection of BRAF rearrangements by Fluorescence in situ Hybridization may represent a novel therapeutic target in various diseases.

## References


References
Chmielecki J, et al. (2014) Cancer Discov 4: 1398-405.
Ciampi R, et al. (2005) J Clin Invest 115: 94-101.
Cin H, et al. (2011) Acta Neuropathol 121: 763-74.
Dessars B, et al. (2007) J Invest Dermatol 127: 1468-70.
Dougherty MJ, et al. (2010) Neuro Oncol 12: 621-30.
Hutchinson KE, et al. (2013) Clin Cancer Res 19: 6696-702.
Jones DT, et al. (2013) Nat Genet 45: 927-32. Miller VA, et al. (2014) J Clin Oncol 32 Suppl: Abstr. 11029. Palanisamy N, et al. (2010) Nat Med 16: 793-8.

### **Probe Description**

The SPEC BRAF Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 7q34 band. The orange fluorochrome direct labeled probe hybridizes proximal, and the green fluorochrome direct labeled probe hybridizes distal to the BRAF gene breakpoint region.




Ideogram of chromosome 7 indicating the hybridization locations.



SPEC BRAF Probe map (not to scale).

### Results

In an interphase nucleus lacking a rearrangement involving the 7q34 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 7q34 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 7q34 locus and one 7q34 locus affected by a translocation or inversion. Isolated orange signals are the result of deletions distal to the BRAF breakpoint region.



SPEC BRAF Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2189-200	Zyto <i>Light</i> SPEC BRAF Dual Color Break Apart Probe C	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# Zyto Light ® SPEC BRAF/CEN 7 Dual Color Probe



## **Background**

The ZytoLight ® SPEC BRAF/CEN 7 Dual Color Probe is designed for the detection of amplifications involving the chromosomal region 7q34 harboring the BRAF gene (B-Raf proto-oncogene, serine/ threonine kinase). The BRAF gene encodes a protein-serine/threonine kinase that participates in the MAPK cascade, which regulates a large variety of cell processes. Activating mutations in BRAF are found in many tumor types, including malignant melanoma, thyroid, colorectal, and ovarian carcinomas, lung adenocarcinoma, as well as in some sarcomas and gliomas. These mutations lead to constitutive activation of BRAF thereby promoting tumorigenesis.

Copy number gains of mutated and non-mutated BRAF have been identified in malignant melanoma (MM), follicular thyroid tumors, astrocytoma, colorectal, and prostate cancer due to amplification of the gene or polysomy of chromosome 7. These amplifications lead to an overexpression of BRAF and to constitutive activation of the MAPK signaling pathway. Follicular carcinomas with BRAF copy number gain were observed to be more often invasive. Colorectal carcinoma or melanoma patients with BRAF V600E mutation were found to acquire resistance to MEK and BRAF inhibitors through amplification of the mutated BRAF gene.

Hence, detection of BRAF amplifications by Fluorescence in situ Hybridization may be of therapeutic relevance for these cancer patients.

References
Ciampi R, et al. (2005) Endocr Pathol 16: 99-105. Clampi R, et al. (2005) Endocr Pathol 16: 99-103.

Corcoran RB, et al. (2010) Sci Signal 3: ra84.

Dougherty MJ, et al. (2010) Neuro Oncol 12: 621-30.


Little AS, et al. (2011) Sci Signal 4: ra17.

Pfister S, et al. (2008) J Clin Invest 118: 1739-49.

Ren G, et al. (2012) Genes Chromosomes Cancer 51: 1014-23. Ren G, et al. (2012) Genes Chromosomies Carcer 31: 1014-25. Roskoski R Jr. (2010) Biochem Biophys Res Commun 399: 313-7. Spittle C, et al. (2007) J Mol Diagn 9: 464-71. Tanami H, et al. (2004) Oncogene 23: 8796-804. Villanueva J, et al. (2013) Cell Rep 4: 1090-9. Willmore-Payne C, et al. (2006) Hum Pathol 37: 520-7.

### **Probe Description**

The SPEC BRAF/CEN 7 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC BRAF probe specific for the BRAF gene at 7q34 and an orange fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1).




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC BRAF Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the BRAF gene locus or polysomy of chromosome 7, multiple copies of the green signal or large green signal clusters will be observed.



Normal interphase cells, BRAF (green), CEN 7 (orange).



NSCLC tissue section with amplification of the BRAF gene (green).

Willinder dyne C, et al. (2000) Fruiti Fathol 37 : 3207 :				
	Prod. No.	Product	Label	Tests* (Volume)
	Z-2191-200	Zyto Light SPEC BRAF/CEN 7 Dual Color Probe C    IVD	•/•	20 (200 µl)
	<b>Related Prod</b>	ucts		
	Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
		Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC NRG1/CD74 TriCheck™ Probe



## **Background**

The ZytoLight® SPEC NRG1/CD74 TriCheck™ Probe is designed to detect translocations involving the chromosomal region 8p12 harboring the NRG1 (neuregulin 1, a.k.a. HGL or GGF) gene and the chromosomal region 5q32 harboring the CD74 gene.

Using this probe it is possible to discriminate between CD74-NRG1 fusions and translocations affecting NRG1, but not CD74, such as SLC3A2-NRG1 or VAMP2-NRG1 fusions.

NRG1 encodes a variety of growth factors that are ligands for tyrosine kinase receptors of the ERBB family. Rearrangements of the NRG1 gene have been detected in various tumors, including breast cancer, lung cancer, and ovarian adenocarcinoma.

NRG1 translocation-positive breast tumors show a more advanced pathological stage compared with translocation-negative tumors.


NRG1 rearrangements in lung adenocarcinoma of never smokers were found to result in, e.g., the fusion of CD74 to the EGF-like domain of NRG1 and to be associated with a shorter overall and diseasefree survival. Due to the involvement of NRG1 fusion proteins in oncogenesis and their association with ERBB receptors, NRG1 constitutes a good candidate for potential therapeutic applications, e.g., in relation to lung tumor subtypes with so far no effective treatment.

Hence, detection of NRG1 rearrangements and CD74-NRG1 fusions by FISH may be of prognostic and therapeutic significance.


Adélaïde J, et al. (2003) Genes Chromosomes Cancer 37: 333-45. Fernandez-Cuesta L, et al. (2014) Cancer Discov 4: 415-22. Han JY, et al. (2015) Cancer Res 75: 614. Huang HE, et al. (2004) Cancer Res 64: 6840-4. Jung Y, et al. (2015) J Thorac Oncol 10: 1107-11 Pole JC, et al. (2006) Oncogene 25: 5693-706.

### **Probe Description**


The SPEC NRG1/CD74 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the 8p12 and 5q32-q33.1 bands. The green fluorochrome direct labeled probe hybridizes distal and the orange fluorochrome direct labeled probe hybridizes proximal to the NRG1 breakpoint region at 8p12. The blue fluorochrome direct labeled probe hybridizes to the CD74 gene region at 5q32-q33.1.




Ideogram of chromosome 8 indicating the hybridization locations



Ideogram of chromosome 5 indicating the hybridization locations






SPEC CD74 Probe map (not to scale).

## Results

In an interphase nucleus lacking a rearrangement involving the 8p12 and 5q32q33.1 bands, two orange/green fusion signals and two blue signals are expected. A CD74-NRG1 fusion is indicated by one separate green signal, one separate orange signal, and an additional blue signal which colocalizes with the separated orange signal. An NRG1 rearrangement not involving CD74 is indicated by separated orange and green signals without an additional blue signal.



SPEC NRG1/CD74 TriCheck™ Probe hybridized to normal interphase cells as indicated by two orange/ green fusion signals and two blue signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2194-200	Zyto <i>Light</i> SPEC NRG1/CD74 TriCheck Probe C	<b>•/•/•</b>	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



# Zyto Light ® SPEC NRG1 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC NRG1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 8p12 harboring the NRG1 (neuregulin 1, a.k.a. HGL or GGF) gene. NRG1 encodes a variety of growth factors that are ligands for tyrosine kinase receptors of the ERBB family. Rearrangements of the NRG1 gene have been detected in various tumors, including breast cancer, lung cancer, and ovarian adenocarcinoma. NRG1 translocation-positive breast tumors show a more advanced pathological stage compared with translocationnegative tumors.


NRG1 rearrangements in lung adenocarcinomas of never smokers were found to result in the fusion of CD74 to the EGF-like domain of NRG1. Several in vitro studies indicate that NRG1 fusion proteins lead to an increased activation of ERBB receptors and are hence involved in tumor development.

Due to the involvement of NRG1 isoforms in oncogenesis and their association with ERBB receptors, NRG1 constitutes a good candidate for potential therapeutic applications, e.g., in relation to lung tumor subtypes with so far no effective treatment. Hence, detection of NRG1 rearrangements by Fluorescence in situ Hybridization represents a useful tool for studying carcinogenesis of various solid tumors and may be of prognostic and therapeutic significance.


Adélaïde J, et al. (2003) Genes Chromosomes Cancer 37: 333-45. Fernandez-Cuesta L, et al. (2014) Cancer Discov 4: 415-22. Huang HE, et al. (2004) Cancer Res 64: 6840-4. Pole JC, et al. (2006) Oncogene 25: 5693-706.

### **Probe Description**

The SPEC NRG1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 8p12 band. The green fluorochrome direct labeled probe hybridizes distal and the orange fluorochrome direct labeled probe hybridizes proximal to the NRG1 breakpoint region.




Ideogram of chromosome 8 indicating the hybridization locations.




SPEC NRG1 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 8p12 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 8p12 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal in lung adenocarcinoma specimens indicates one normal 8p12 locus and one 8p12 locus affected by a translocation.



SPEC NRG1 Dual Color Break Apart Probe hybridized on normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Lung cancer tissue section with rearrangement of the NRG1 gene as indicated by extra orange signals.

Image kindly provided by Mc Leer A, Duruisseaux M, Wislez M and colleagues, Grenoble and Paris, France

Prod. No.	Product	Label	Tests* (Volume)
Z-2181-200	Zyto <i>Light</i> SPEC NRG1 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Prod			
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.

70



# Zyto Light ® SPEC FGFR1 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC FGFR1 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 8p11.23-p11.22 harboring the FGFR1 (fibroblast growth factor receptor 1, a.k.a. FLT2 and FLG) gene. Translocations affecting FGFR1 are hallmarks of the 8p11 myeloproliferative syndrome (EMS), also known as stem cell leukemia/lymphoma syndrome, an aggressive stem cell myeloproliferative neoplasm that is associated with eosinophilia, poor prognosis, T-cell lymphoma, and frequent progression to acute myeloid leukemia.


The most common translocation detected in EMS is t(8;13)(p11.2;q12.1) fusing FGFR1 to ZMYM2 (a.k.a. ZNF198). Several other rearrangements affecting the FGFR1 locus are also common in EMS, all of which result in fusion proteins comprising the tyrosine kinase domain of FGFR1 and a dimerization domain of a partner protein. Due to dimerization these fusion proteins show constitutive kinase activity. Currently, bone marrow or stem cell transplantation is the only curative treatment for patients with EMS. In vitro studies suggest that certain receptor tyrosine kinase inhibitors may provide a new therapeutic option.

Detection of FGFR1 rearrangements using FISH may assist in the diagnosis of patients with this aggressive stem cell disorder.


Reterences
Chase A, et al. (2007) Blood 110: 3729-34.
Chase A, et al. (2013) Haematologica 98: 103-6.
Jackson CC, et al. (2010) Hum Pathol 41: 461-76.
Sohal J, et al. (2001) Genes Chromosomes Cancer 32: 155-63.

### **Probe Description**

The SPEC FGFR1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 8p11.23p11.22 band. The orange fluorochrome direct labeled probe hybridizes distal, the green fluorochrome direct labeled probe hybridizes proximal to the FGFR1 gene breakpoint region at 8p11.23-p11.22.




Ideogram of chromosome 8 indicating the hybridization locations.




SPEC FGFR1 Probe map (not to scale).

### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 8p11.23-p11.22 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 8p11.23-p11.22 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 8p11.23-p11.22 locus and one 8p11.23p11.22 locus affected by a translocation.



SPEC FGFR1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



8p11 myeloproliferative syndrome (EMS) tissue section with translocation of the FGFR1 gene as indicated by one non-rearranged orange/green fusion signal, one orange, and one separate green signal indicating the translocation.

-, , , -			
Prod. No.	Product	Label	Tests* (Volume)
Z-2168-50	Zyto Light SPEC FGFR1 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2168-200	Zyto Light SPEC FGFR1 Dual Color Break Apart Probe CE IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C FIVD  Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C (IVD) Ind. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC FGFR1/CEN 8 Dual Color Probe



## **Background**

The ZytoLight ® SPEC FGFR1/CEN 8 Dual Color Probe is designed for the detection of FGFR1 gene amplification frequently observed in malignant tumors e.g. breast and prostate cancer and oral squamous cell carcinoma (OSCC).


The FGFR1 (fibroblast growth factor receptor 1) gene is located in the chromosomal region 8p11.23-p11.22 and encodes a transmembrane receptor tyrosine kinase. Amplification of the FGFR1 gene, observed in approximately 10% of all breast cancer samples, has revealed to be an independent prognostic factor for overall survival. FGFR1 is believed to emerge as a potential therapeutic target for lobular breast carcinomas.

In prostate cancer, FGFR1 gene amplification seems to be an important step during the transmission to hormone resistance. In OSCC, FGFR1 gene amplification, observed in nearly 20% of all cases, is indicated to contribute to oral carcinogenesis at an early stage of development.


Balko JM, et al. (2012) Mol Cancer Ther 11: 2301-5. Broom RI, et al. (2012) Clin Genitourin Cancer 10: 202-6. Cihoric N, et al. (2014) Br J Cancer 110: 2914-22. Edwards J, et al. (2003) Clin Cancer Res 9: 5271-81 Elbauomy Elsheikh S, et al. (2007) Breast Cancer Res 9: R23. Fernanda Amary M, et al. (2014) Cancer Med 3: 980-7. Freier K, et al. (2007) Oral Oncology 43: 60-6. Kohler I.H, et al. (2012) Virchows Arch 461: 49-57 Lacroix-Triki M, et al. (2010) J Pathol 222: 282-98. Lantuejoul S, et al. (2012) Oncologie 14: 530-7. Lee PL, et al. (1989) Science 245: 57-60. Lehnen NC, et al. (2013) Histopathology 63: 157-66. Pfeiffer M, et al. (2012) Nat Genet 44: 1104-10. Preusser M, et al. (2014) Lung Cancer 83: 83-9. Reis-Filho JS, et al. (2006) Clin Cancer Res 12: 6652-62. Schildhaus HU, et al. (2012) Mod Pathol 25: 1473-80. Schultheis AM, et al. (2014) Mod Pathol 27: 214-21. Seo AN, et al. (2014) Virchows Arch 465: 547-58. Turner N, et al. (2010) Cancer Res 70: 2085-94. Wetterskog D, et al. (2012) J Pathol 226: 84-96

### **Probe Description**

The SPEC FGFR1/CEN 8 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 8 probe specific for the alpha satellite centromeric region of chromosome 8 (D8Z2) and a green fluorochrome direct labeled SPEC FGFR1 probe specific for the FGFR1 gene at 8p11.23p11.22.




Ideogram of chromosome 8 indicating the hybridization locations.




### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the FGFR1 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC FGFR 1/CEN 8 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Lung carcinoma tissue section with interphase cells showing amplification of the FGFR1 gene (green) and partly polysomy 8 (orange).

Prod. No.	Product	Label	Tests* (Volume)
Z-2072-50	Zyto Light SPEC FGFR1/CEN 8 Dual Color Probe C € IVD	•/•	5 (50 µl)
Z-2072-200	Zyto Light SPEC FGFR1/CEN 8 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

72



## Zyto Light ® SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe

Previously: Zyto Light SPEC AML1/ETO Dual Color Dual Fusion Probe



### **Background**

The ZytoLight ® SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe is designed to detect the specific translocation involving the chromosomal region 21q22.12 harboring the RUNX1 (a.k.a. AML1) gene and the chromosomal region 8q21.3 harboring the RUNX1T1 (a.k.a. ETO, CBF2T1) gene.

The balanced chromosomal translocation t(8;21) is found in about 90% of acute myeloid leukemia (AML) patients. AML is a heterogeneous clonal disorder of hematopoietic progenitor cells and one of the most common malignant myeloid disorders in adults.

The runt-related transcription factor 1 gene (RUNX1) and the runt-related transcription factor 1; translocated to, 1 (RUNX1T1) gene are both involved in the transcriptional regulation of genes during normal hematopoiesis.


The non-random translocation t(8;21) (q21.3;q22.1) is strongly associated with the French-American-British (FAB) phenotype M2 (AML-M2) and produces a chimeric gene consisting of the 5'-region of the RUNX1 gene fused to the 3'-region of the RUNX1T1 gene. The chimeric protein is thought to be associated with the nuclear corepressor/ histone deacetylase complex to block hematopoietic differentiation.

Fluorescence in situ Hybridization (FISH) can provide important information for the management of patients with hematologic disorders.


References
Dayyani F, et al. (2008) Blood 111: 4338-47.
Estey E & Döhner H (2006) Lancet 368: 1894-907.
Gmidène A, et al. (2010) Med Oncol: 28 Suppl 1: 509-12.
Licht D (2001) Oncogene 20: 5560-79. Vangala RK, et al. (2003) Blood 101: 270-7.

#### **Probe Description**


The SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe is a mixture of a green fluorochrome direct labeled RUNX1 probe covering the breakpoint region of the RUNX1 gene and an orange fluorochrome direct labeled RUNX1T1 probe covering the breakpoint region of the RUNX1T1 gene.



Ideograms of chromosomes 21 (above) and 8 (below) indicating the hybridization locations.




SPEC RUNX1T1 Probe map (not to scale).




SPEC RUNX1 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange and green signal, respectively.



SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bone marrow biopsy section with translocation affecting the RUNX1/RUNX1T1 locus as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2112-50	Zyto <i>Light</i> SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe C € IVD	•/•	5 (50 µl)
Related Pro	ducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit CE IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC MYC Dual Color Break Apart Probe

Previously: Zyto Light SPEC CMYC Dual Color Break Apart Probe




### **Background**

The ZytoLight® SPEC MYC Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 8q24.21 harboring the MYC gene. The MYC proto-oncogene (v-myc avian myelocytomatosis viral oncogene homolog, a.k.a. CMYC) encodes a transcription factor essential for cell growth and proliferation and is broadly implicated in tumorigenesis. Translocations involving the MYC gene are considered to be cytogenetic hallmarks for Burkitt Lymphoma but are also found in other types of lymphomas. The most frequent translocation involving the MYC gene region is t(8;14) (q24.21;q32.3) juxtaposing the MYC gene in 8q24.21 next to the IgH (immunoglobulin heavy chain) locus in 14q32.33. Further translocations affecting the MYC gene are t(8;22)(q24.21;q11.2) and t(2;8)(p11.2;q24.21), both of which involve one of the two immunoglobulin light chain loci. All three translocations bring the MYC gene under the control of a regulatory element from one of the immunoglobulin loci resulting in constitutive overexpression of MYC.


Boerma EG, et al. (2009) Leukemia 23: 225-34. Dalla-Favera R, et al. (1982) PNAS 79: 6497-501. Haralambieva E, et al. (2004) Genes Chromosomes Cancer 40: 10-8. Veronese ML, et al. (1995) Blood 85: 2132-8.

#### **Probe Description**

The SPEC MYC Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 8q24.21 band. The orange fluorochrome direct labeled probe hybridizes proximal to the MYC gene, the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 8 indicating the hybridization locations.




SPEC MYC Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 8q24.21 band two orange/green fusion signals are expected representing two normal (non-rearranged) 8q24.21 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 8q24.21 locus and one 8q24.21 locus affected by an 8q24.21 translocation. Alternative break points particularly observed in variant MYC translocations t(8;22) and t(2;8) might result in different signal patterns.



SPEC MYC Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Burkitt Lymphoma tissue section with translocation affecting the 8q24.21 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2090-50	Zyto Light SPEC MYC Dual Color Break Apart Probe C E IVD	•/•	5 (50 µl)
Z-2090-200	Zyto Light SPEC MYC Dual Color Break Apart Probe C E IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C ( IVD Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC MYC/CEN 8 Dual Color Probe

Previously: Zyto Light SPEC CMYC/CEN 8 Dual Color Probe



### **Background**


The ZytoLight ® SPEC MYC/CEN 8 Dual Color Probe is designed for the detection of MYC gene amplifications found in a variety of human tumors.

The MYC proto-oncogene (v-myc avian myelocytomatosis viral oncogene homolog, a.k.a. CMYC) is located in the chromosomal region 8q24.21 and encodes a transcription factor that can activate and repress transcription thereby regulating expression of numerous target genes that are essential for cell growth and proliferation. Deregulation of MYC is a common denominator in cancer. MYC amplification was found e.g. in breast, colon, kidney, lung, ovary, bladder, head and neck, and endometrial cancer. Several studies showed a correlation between gene amplification and disease progression or recurrence in breast cancer and other malignancies. Malignant cutaneous angiosarcomas, for example, but not benign and atypical vascular lesions occurring after radiotherapy of breast cancer are characterized by amplification of the MYC gene. The presence of MYC amplification is thus of considerable diagnostic importance for the distinction of malignant from atypical postradiation vascular neoplasms of the skin.

Since inactivation of MYC appears to be effective in the treatment of neoplasia MYC targeting therapies have been developed some of which have entered clinical trials.

#### **Probe Description**

The SPEC MYC/CEN 8 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 8 probe specific for the alpha satellite centromeric region of chromosome 8 (D8Z2) and a green fluorochrome direct labeled SPEC MYC probe specific for the MYC gene at 8q24.21.




Ideogram of chromosome 8 indicating the hybridization locations.




SPEC MYC Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MYC gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC MYC/CEN 8 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus



Breast cancer tissue section with interphase cells showing partly polysomy 8 and partly amplification of the MYC gene locus.

Dalla-Favera R, et al. (1982) PNAS 79: 6497-501. Fromont G, et al. (2013) Hum Pathol 44: 1617-23. Mannuci S, et al. (2012) Adv Hematol 2012: 149780. Mannucl 3, et al. (2012) AdV relation 2012: 1497 of Mentzel T, et al. (2012) Mod Pathol 25: 75-95. Nesbit CE, et al. (1999) Oncogene 18: 3004-16. Schroml P, et al. (1999) Clin Cancer Res 5: 1966-75. Taub R, et al. (1982) PNAS 79: 7837-41.

Prod. No.	Product	Label	Tests* (Volume)
Z-2092-50	Zyto <i>Light</i> SPEC MYC/CEN 8 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2092-200	Zyto <i>Light</i> SPEC MYC/CEN 8 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C    IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe ( E

#### **Background**

The ZytoLight ® SPEC MYC/CDKN2A/ ERBB2/ZNF217 Quadruple Color Probe is designed for the simultaneous detection of the MYC (a.k.a. CMYC), CDKN2A (a.k.a. p16), ERBB2 (a.k.a. HER2), and ZNF217 gene copy number status. Barrett's esophagus (BE), a preneoplastic condition in which the squamous epithelium of the distal esophagus undergoes transformation to intestinal metaplasia, is considered a precursor for the development of adenocarcinoma. The evolution of cancer from BE includes the following stages: metaplasia, low-grade dysplasia, high-grade dysplasia (HGD), and esophageal adenocarcinoma (EA). EA has a poor prognosis unless detected and treated at its earliest stages. It is believed that the progression of normal squamous epithelium to EA in patients with BE results from the accumulation of genetic alterations including, e.g., CDKN2A loss or gain of the MYC, ERBB2, or ZNF217 gene locus. Hence, detection of these aberrations may provide useful information on disease progression. Moreover, allelic loss of CDKN2A was shown to result in decreased response to photodynamic therapy in patients with HGD and EA. In addition, detection of ERBB2 amplifications may help in selecting patients eligible for an ERBB2 targeted therapy such as trastuzumab.

Noterences


Brankley SM, et al. (2012) Hum Pathol 43: 172-9.

Dahlberg PS, et al. (2004) Ann Thorac Surg 78: 1790-800.


Fritcher EG, et al. (2008) Hum Pathol 39: 1128-35. Prasad GA, et al. (2008) Gastroenterology 135: 370-9 Riegman PH, et al. (2001) Cancer Res 61: 3164-70.

#### **Probe Description**


The SPEC MYC/CDKN2A/ERBB2/ ZNF217 Quadruple Color Probe is a mixture of a blue fluorochrome direct labeled SPEC MYC probe specific for the MYC gene at 8q24.21, a red fluorochrome direct labeled SPEC CDKN2A probe specific for the CDKN2A gene at 9p21.3, a green fluorochrome direct labeled SPEC ERBB2 probe specific for the chromosomal region 17q12-q21.1 harboring the ERBB2 gene, and a gold fluorochrome direct labeled SPEC ZNF217 probe specific for the ZNF217 gene at 20q13.2.



SPEC MYC Probe map (not to scale).




SPEC CDKN2A Probe map (not to scale)




SPEC ERBB2 Probe map (not to scale).

#### Results


In a normal interphase nucleus, two blue, two red, two green, and two gold signals are expected. In a cell with deletion of the CDKN2A gene locus, a reduced number of red signals will be observed. In cells with amplification of the MYC, ERBB2, or ZNF217 gene locus, more signals of the respective color will be visible.



SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe hybridized to normal interphase cells as indicated by two blue (MYC), two red (CDKN2A), two green (ERBB2), and two gold (ZNF217) signals.



SPEC ZNF217 Probe map (not to scale).



Ideograms of chromosomes 8, 9, 17, and 20 indicating the hybridization locations.

Prod. No.	Product	Label	Tests* (Volume)
Z-2204-200	Zyto <i>Light</i> SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe C	•/•/•/ <u> </u>	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light® SPEC MYC/IGH Dual Color Dual Fusion Probe

Previously: ZytoLight SPEC CMYC/IGH Dual Color Dual Fusion Probe



### **Background**

The ZytoLight ® SPEC MYC/IGH Dual Color Dual Fusion Probe is designed to detect the translocation t(8;14)(q24;q32) affecting the MYC gene in the chromosomal region 8q24.21 and the IGH locus in 14q32.33. The MYC proto-oncogene (v-myc avian myelocytomatosis viral oncogene homolog, a.k.a. CMYC) encodes a transcription factor essential for cell growth and proliferation and is broadly implicated in tumorigenesis. Translocations involving the MYC gene are considered to be cytogenetic hallmarks for Burkitt Lymphoma (BL) but are also found in other types of lymphomas.


The most frequent translocation involving the MYC gene region t(8;14) (q24.21;q32.3) can be found in approx. 80% of the BL cases and juxtaposes the MYC gene next to the IgH (immunoglobulin heavy chain) locus. Further translocations affecting the MYC gene are t(8;22)(q24.21;q11.2) and t(2;8) (p11.2;q24.21), both of which involve one of the two immunoglobulin light chain loci. All three translocations bring the MYC gene under the control of a regulatory element from one of the immunoglobulin loci resulting in constitutive overexpression of MYC.

The identification of MYC specific rearrangements is a critical part of the diagnostic work-up and management of patients, identifying those who will benefit from the intensive therapeutic regimens used to treat BL. Fluorescence in situ Hybridization (FISH) which allows the correlation with immunochemistry can be critical to patient management and is an approach commonly used.


#### **Probe Description**

The SPEC MYC/IGH Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled MYC probe spanning the known MYC breakpoints, and a green fluorochrome direct labeled IGH probe spanning the known breakpoints of IGH.





Ideograms of chromosomes 8 (above) and 14 (below) indicating the hybridization locations.




SPEC MYC Probe map (not to scale).




SPEC IGH Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange respectively green signal.



SPEC MYC/IGH Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus



Burkitt Lymphoma tissue section with t(8;14) as indicated by one separate orange signal, one separate green signal and two orange/green fusion signals indicating the MYC/IGH translocation.

May P, et al. (2010) Cancer Genet Cytogenet 198: 71-5.
Perkins A & Friedberg J (2008) Hematology Am Soc Hematol Educ Program 2008: 341-8.
Veronese ML, et al. (1995) Blood 85: 2132-8.

Prod. No.	Product	Label	Tests* (Volume)
Z-2105-50	Zyto Light SPEC MYC/IGH Dual Color Dual Fusion Probe CE IVD	<b>●/●</b>	5 (50 µl)
Z-2105-200	Zyto <i>Light</i> SPEC MYC/IGH Dual Color Dual Fusion Probe C€ IVD	<b>●/●</b>	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more inform



## Zyto Light ® SPEC CD274, PDCD1LG2/CEN 9 Dual Color Probe



### **Background**

The ZytoLight ® SPEC CD274,PDCD1LG2/ CEN 9 Dual Color Probe is designed for the detection of CD274,PDCD1LG2 gene cluster amplifications observed in various carcinomas, e.g. classical non-Hodgkin lymphoma and mediastinal large B-cell lymphoma.

The CD274 (cluster of differentiation 274, a.k.a. PDCD1LG1, PDL1) and PDCD1LG2 (programmed cell death 1 ligand 2, a.k.a. PDL2, CD273) genes, which are separated by 42 kilobases, are located on chromosome 9p24.1.


The genes encode ligands for the PD-1 receptor of T-cells. CD274 is expressed by cancer cells of various tumor types, including melanoma, non-small cell lung cancer (NSCLC), breast cancer, and renal cell carcinomas. It is believed that interactions between the T-cell PD-1 receptor and its ligands CD274 or PDCD1LG2 expressed by tumor cells prevent the immune system from attacking the tumor cells.

The blockade of the PD-1/CD274, PDCD1LG2 pathway has yielded promising results in clinical trials conducted on tumors that express the PD-1 receptor. In early phase clinical trials compounds blocking PD-1 and CD274 have shown to be especially effective in advanced-stage NS-CLC patients positive for CD274. Hence, targeting PD-1 or CD274,PDCD1LG2 represents a promising new treatment for this cancer entity.


Consequently, the identification of CD274,PDCD1LG2 gene copy number detected by Fluorescence in situ Hybridization might be of prognostic and predictive relevance in diverse cancers.

#### **Probe Description**

The SPEC CD274, PDCD1LG2/CEN 9 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC CD274, PDCD1LG2 probe specific for the CD274 and PDCD1LG2 genes at 9p24.1 and an orange fluorochrome direct labeled CEN 9 probe specific for the classical satellite III region of chromosome 9 (D9Z3) at 9q12.




Ideogram of chromosome 9 indicating the hybridization locations.



SPEC CD274, PDCD1LG2 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the CD274,PDCD1LG2 gene cluster, multiple copies of the green signal or large green signal clusters will be observed.



Primary mediastinal large B-cell lymphoma tissue section with amplification of the CD274,PDCD1LG2 gene region as indicated by green signal clusters in each nucleus.

Green MR, et al. (2012) Clin Cancer Res 18: 1611-8 Hao Y, et al. (2014) Clin Cancer Res 20: 2674-83. Mamalis A, et al. (2014) Arch Dermatol Res 306: 511-9. Schalper KA, at al. (2014) Clin Cancer Res 20: 2773-82. Velcheti V, et al. (2014) Lab Invest 94: 107-16.

Prod. No.	Product	Label	Tests* (Volume)
Z-2179-50	Zyto Light SPEC CD274, PDCD1LG2/CEN 9 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2179-200	Zyto Light SPEC CD274, PDCD1LG2/CEN 9 Dual Color Probe C€ IVD	•/•	20 (200 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPL/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC CDKN2A/CEN 9 Dual Color Probe

Previously: Zyto Light SPEC p16/CEN 9 Dual Color Probe




### **Background**

The ZytoLight ® SPEC CDKN2A/CEN 9 Dual Color Probe is designed for the detection of CDKN2A deletions frequently observed in most tumor cell lines as well as in primary human malignancies. The CDKN2A gene, often referred to as p16 or INK4a/ARF, is located in the chromosomal region 9p21.3. Using alternative first exons and an alternative reading frame, the gene encodes for two distinct tumor suppressor proteins p16INK4a and p14ARF, both involved in cell cycle regulation. CDKN2A has been identified as a major susceptibility gene for melanoma. The tumor suppressor gene CDKN2A is inactivated by homozygous deletions with high frequency in a variety of human primary tumors e.g. bladder and renal cell carcinoma, prostate and ovarian adenocarcinoma, non-small cell lung cancer, sarcoma, glioma, mesothelioma, and melanoma. Furthermore, deletion of the CDKN2A gene is found in up to 80% of T-cell acute lymphoblastic leukemia cases and is associated with poor prognosis and relapse of the disease.


Reterences Cowan JM et al. (1988) J Natl Cancer Inst 80: 1159-64. Holley T, et al. (2012) PLoS One 7: e50586. Hussussian CJ, et al. (1994) Nat Genet 8: 15-21. Kamb A, et al. (1994) Science 264: 436-40. Nobori T, et al. (1994) Nature 368: 753-6. Nobor 1, et al. (1994) Nature 308: 733-6. Quelle DE, et al. (1995) Cell 83: 993-1000. Rocco JW & Sidransky D (2001) Exp Cell Res 264: 42-55. Schoppmeyer K, et al. (1999) Neoplosia 1: 128-37. Schwarz S, et al. (2008) Cytometry A 73: 305-11. Sharpless NE (2005) Mutat Res 576: 22-38.

#### **Probe Description**

The SPEC CDKN2A/CEN 9 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 9 probe specific for the classical satellite III region of chromosome 9 (D9Z3) at 9q12 and a green fluorochrome direct labeled SPEC CDKN2A probe specific for the CDKN2A gene at 9p21.3.




Ideogram of chromosome 9 indicating the hybridization locations.



SPEC CDKN2A Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletion of the CDKN2A gene locus, a reduced number of green signals will be observed. Deletions affecting only parts of the CDKN2A gene might result in a normal signal pattern with green signals of reduced size.



SPEC CDKN2A/CEN 9 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2063-50	Zyto Light SPEC CDKN2A/CEN 9 Dual Color Probe C € IVD	•/•	5 (50 µl)
Z-2063-200	Zyto Light SPEC CDKN2A/CEN 9 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C E IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe

Previously: Zyto Light SPEC p16/CEN 3/7/17 Quadruple Color Probe




### **Background**

The ZytoLight ® SPEC CDKN2A/ CEN 3/7/17 Quadruple Color Probe is designed for the simultaneous detection of CDKN2A gene status and enumeration of chromosomes 3, 7, and 17 in tumor cells. The tumor suppressor gene CDKN2A (a.k.a. p16 or p16INK4a) is located in the chromosomal region 9p21.3 and is inactivated by homozygous deletions with high frequency in a variety of human primary tumors e.g. renal cell carcinoma, prostate and ovarian adenocarcinoma, non-small cell lung cancer, sarcoma, glioma, mesothelioma, and melanoma. Additionally, non-random numerical chromosome aberrations are frequently observed in a variety of solid tumors.

Hence, detection of these specific chromosome aberrations in tumor cells can serve as a valuable diagnostic aid in tumor classification and staging. For example, in papillary renal cell carcinoma trisomy 7 or 17 is frequently found, while chromophobic RCC is characterized by widespread chromosomal losses.

#### **Probe Description**


The SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe is a mixture of a gold fluorochrome direct labeled SPEC CDKN2A probe specific for the CDKN2A gene at 9p21.3, a red fluorochrome direct labeled CEN 3 probe specific for the alpha satellite centromeric region of chromosome 3 (D3Z1), a green fluorochrome direct labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1), and a blue fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1).




SPEC CDKN2A Probe map (not to scale).

#### Results

In a normal interphase nucleus, two gold, two red, two green, and two blue signals are expected. In a cell with deletion of the CDKN2A gene locus, a reduced number of gold signals will be observed. In cells with aneusomy of chromosomes 3, 7, or 17 more or less signals of the respective color will be visible.



Normal cytological specimen hybridized with SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe as indicated by two gold (CDKN2A), two red (CEN 3), two green (CEN 7), and two blue (CEN 17) signals.



SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe hybridized to tumor cells showing a trisomy 9 as indicated by three CDKN2A signals (gold) in each nucleus.


References

Barocas DA, et al. (2006) BJU Int 99: 290-5.

Gallucci M, et al. (2005) J Clin Pathol 58: 367-71.

Kamb A, et al. (1994) Science 264: 436-40.

Sharpless NE (2005) Mutat Res 576: 22-38.



Ideograms of chromosomes 9, 3, 7, and 17 indicating the hybridization locations.

Prod. No.	Product	Label	Tests* (Volume)
Z-2081-50	Zyto <i>Light</i> SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C€ IVD	<u> </u>	5 (50 µl)
Z-2081-200	Zyto Light SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe C€ IVD	<u> </u>	20 (200 µl)

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC NTRK2 Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC NTRK2 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 9q21.33 harboring the NTRK2 (neurotrophic receptor tyrosine kinase 2, a.k.a. TRKB) gene.


NTRK2 is a receptor tyrosine kinase (TK) that upon brain-derived growth factor (BDGF) and neurotrophin 4/5 (NT-4/5) binding phosphorylates itself and members of the MAPK pathway. It plays a key role in central and peripheral nervous system development as well as in cell survival. Translocations affecting the NTRK2 gene have been reported in several cancer types, including glioblastomas, pilocytic astrocytomas, head and neck squamous cell carcinoma, and lung adenocarcinoma. NTRK2 rearrangements result in the fusion of the 3' end of the NTRK2 gene with the 5' end of different activating genes (AGBL4, PAN3, or AFAP1). All these fusion genes encode hybrid proteins comprising the TK domain of NTRK2 and the N-terminus of the partner proteins encoding dimerization domains which results in ligand-independent TK activity.

Currently, there are several ongoing clinical trials involving drugs with known inhibitory activity of NTRK-related kinases. Entrectinib and LOXO-101 represent two of these TRK inhibitors which have shown promising activity and good tolerability in patients with advanced solid tumors or NSCLC harboring NTRK1, 2, and 3 rearrangements. Hence, detection of NTRK2 translocations by Fluorescence in situ Hybridization (FISH) may be of diagnostic and therapeutic relevance.


References
Amatu A, et al. (2016) ESMO Open 1: e000023.
Jones DTW, et al. (2013) Nat Genet 45: 927-32.
Raez LE & Rolfo C (2016) Lung Cancer Manag 5: 1-4.
Stransky N, et al. (2014) Nat Commun 5: 4846.
Wu G, et al. (2014) Nat Genet 46: 444-50.

#### **Probe Description**

The SPEC NTRK2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 9q21.32q21.33 band. The green fluorochrome direct labeled probe hybridizes proximal to the NTRK2 breakpoint region at 9q21.32q21.33, the orange fluorochrome direct labeled probe hybridizes distal to the NTRK2 breakpoint region at 9q21.33.




Ideogram of chromosome 9 indicating the hybridization locations.



#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 9q21.32-q21.33 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 9q21.32-q21.33 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 9q21.32-q21.33 locus and one 9q21.32q21.33 locus affected by a translocation.



SPEC NTRK2 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2205-200	Zyto <i>Light</i> SPEC NTRK2 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Produ	cts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC NR4A3 Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC NR4A3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 9q22.33-q31.1 harboring the nuclear receptor subfamily 4, group A, member 3 (NR4A3; a.k.a. TEC, NOR1, CHN) gene. Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft-tissue sarcoma of chondroblastic origin that occurs primarily in adults. The tumor is characterized by recurrent chromosomal translocations resulting in fusions of the NR4A3 gene to various N-terminal partners including EWSR1, RBP56, TCF12, and TFG. NR4A3 is a member of the steroid/thyroid receptor superfamily and acts as a transcriptional activator. The resulting chimeric proteins contain N-terminal parts of the various partners fused to the entire coding sequence of NR4A3. The most frequent reciprocal translocation is t(9;22) (q22.3-q31;q12.2) found in about 70% of EMC generating a EWSR1-NR4A3 fusion gene in which the 3'-terminal part of EWSR1 is replaced by the entire NR4A3 gene.

EMC is histologically characterized by a mixture of cellular and myxoid stromal components, making it difficult to distinguish it from other benign or malignant mesenchymal tumors. Since chromosomal translocations of EWSR1 are found in several different neoplasias while NR4A3 rearrangements have been exclusively detected in EMC, assessment of NR4A3 rearrangements by Fluorescence in situ Hybridization might represent a helpful tool for the differential diagnosis of EMC.


Benini S, et al. (2014) J Mol Diagn 16: 314-23. Labelle Y, et al. (1995) Hum Mol Genet 4: 2219-26. Nogushi H, et al. (2010) Hum Pathol 41: 336-42.

Ohkura N, et al. (1994) Biochem Biophys Res Commun 205: 1959-65.


Panagopoulos I, et al. (2002) Genes Chromosomes Cancer 35: 340-52.

#### **Probe Description**

The SPEC NR4A3 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 9q22.33-q31.1 band. The orange fluorochrome direct labeled probe hybridizes distal to the NR4A3 gene and the green fluorochrome direct labeled probe hybridizes proximal to that gene.




Ideogram of chromosome 9 indicating the hybridization locations.




SPEC NR4A3 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 9q22.33-q31.1 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 9q22.33-q31.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 9q22.33-q31.1 locus and one 9q22.33q31.1 locus affected by a translocation.



SPEC NR3A3 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signal per nucleus.



Extraskeletal myxoid chondrosarcoma tissue section with translocation affecting the 9q22.33-q31.1 locus as indicated by one orange/green fusion (non-rearranged) signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2145-50	Zyto <i>Light</i> SPEC NR4A3 Dual Color Break Apart Probe C	•/•	5 (50 µl)
<b>Related Prod</b>	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C€ IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

ZytoLight  $^{\circ}$  FISH probes are direct labeled using the unique ZytoLight  $^{\circ}$  Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision  $^{\circ}$  Repeat Subtraction Technique.

82



## Zyto Light ® SPEC ABL1 Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC ABL1 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 9q34.12 harboring the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase, a.k.a. ABL) gene. Chromosomal rearrangements involving ABL1 occur in various hematological malignancies leading to fusions of the ABL1 gene to different fusion partners. The translocation t(9;22)(a34.1;a11.2)results in BCR/ABL1 fusion and is observed in approx. 90% of patients with chronic myeloid leukemia (CML) and in approx. 25% of adults with acute lymphoblastic leukemia (ALL). The rearrangements

are cytogenetically characterized by the

presence of the Philadelphia (Ph) chromo-


Other ABL1 fusion partners include, e.g., ETV6 and NUP214. The kinase domain of ABL1 is retained in all chimeric proteins. The NUP214-ABL1 is the second most prevalent ABL1 fusion gene in malignant hemopathies, with a frequency of 5% in T-cell ALL. NUP214-ABL1 fusion genes are often found amplified on episomes. Tyrosine kinase inhibitors, such as imatinib, suppress the constitutive kinase activity of ABL1 fusion proteins. Therefore, these drugs may have potential in the treatment of patients with ABL1 fusions.

some.


References
De Braekeleer E, et al. (2011) Eur J Haematol 86: 361-71. De Klein A, et al. (1982) Nature 300: 765-7. Graux C, et al. (2009) Leukemia 23: 125-33. Lim TH, et al. (2005) Ann Acad Med Singapore 34: 533-8. Lim In, et al. (2003) Anin Acad wee Singapore 34: . Primo D, et al. (2003) Leukemia 17: 1124-9. Rieder H, et al. (1998) Leukemia 12: 1473-81. Sessarego M, et al. (2000) Haematologica 85: 35-9. Zheng X, et al. (2009) PLoS One 4: e7661.

### **Probe Description**

The SPEC ABL1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 9q34.11q34.13 band. The green fluorochrome direct labeled probe hybridizes proximal to the ABL1 gene at 9q34.11-q34.12, the orange fluorochrome direct labeled probe hybridizes distal to the ABL1 gene at 9q34.12-q34.13.




Ideogram of chromosome 9 indicating the hybridization locations.




SPEC ABL1 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 9q34.11-q34.13 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 9q34.11-q34.13 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 9q34.11-q34.13 locus and one 9q34.11q34.13 locus affected by a translocation. Amplifications of the NUP214-ABL1 fusion genes will result in multiple orange signals or orange signal clusters.



SPEC ABL1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Bone marrow biopsy section with translocation affecting the 9q34.11-q34.13 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2199-50	Zyto <i>Light</i> SPEC ABL1 Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Produ	cts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		••
Z-2099-20	Zyto <i>Light</i> FISH-Cytology Implementation Kit C€ IVD		20
	Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml;		
	Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Light ® SPEC BCR/ABL1 Dual Color Dual Fusion Probe

Previously: Zyto Light SPEC BCR/ABL Dual Color Dual Fusion Probe



### **Background**

The ZytoLight ® SPEC BCR/ABL1 Dual Color Dual Fusion Probe is designed for the detection of the specific translocations involving the chromosomal region 9q34.12 harboring the ABL1 (a.k.a ABL) gene, and the chromosomal region 22q11.23, harboring the BCR (a.k.a. BCR1) gene. Rearrangements involving t(9;22) (q34.1;q11.2) are observed in approx. 90% of patients with chronic myeloid leukemia (CML) and in approx. 25% of adults with acute lymphoblastic leukemia (ALL). The rearrangements are cytogenetically characterized by the presence of the Philadelphia (Ph) chromosome.

The translocation frequently results in the formation of a chimeric BCR/ABL1 fusion gene on the derivative chromosome 22. The gene product is a BCR/ABL1 protein with abnormal tyrosine kinase activity. In normal cells, ABL1 kinase activity is finely regulated in response to growth factors and other stimuli. The BCR/ABL1 fusion protein leads to constitutive activation of down-stream signaling pathways, including Ras, Jak/Stat and PI-3 kinase. In rare cases the BCR/ABL1 fusion gene is located on chromosomal sites other than the Ph chromosome.


Fluorescence in situ Hybridization (FISH) allows for the identification of rearrangements that could otherwise not be detected by conventional karyotyping.

References
Hehne S, et al. (2012) Pathol Res Pract 208: 510-7.
Lim TH, et al. (2005) Ann Acad Med Singapore 34: 533-8.
Primo D, et al. (2003) Leukemia 17: 1124-9.
Rieder H, et al. (1998) Leukemia 12: 1473-81.
Sessargeo M, et al. (2000) Haematologica 85: 35-9.
Zheng X, et al. (2009) PLoS One 4: e7661.


#### **Probe Description**

The SPEC BCR/ABL1 Dual Color Dual Fusion Probe is a mixture of a green fluorochrome direct labeled BCR probe spanning the minor and major breakpoint cluster of the BCR gene and an orange fluorochrome direct labeled ABL1 probe spanning the breakpoint region of the ABL1 gene.






Ideograms of chromosomes 22 (above) and 9 (below) indicating the hybridization locations.




SPEC ABL1 Probe map (not to scale).




SPEC BCR Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange respectively green signal.



SPEC BCR/ABL1 Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bone marrow biopsy tissue section with translocation affecting the BCR/ABL1 loci as indicated by one separate orange signal, one separate green signal and two orange/green fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2111-50	Zyto Light SPEC BCR∕ABL1 Dual Color Dual Fusion Probe C€ IVD	•/•	5 (50 µl)
Z-2111-200	Zyto Light SPEC BCR∕ABL1 Dual Color Dual Fusion Probe C€ IVD	•/•	20 (200 µl)
<b>Related Prod</b>	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light® SPEC KIF5B Dual Color Break Apart Probe




### **Background**

The ZytoLight ® SPEC KIF5B Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 10p11.22 harboring the KIF5B (kinesin family member 5B) gene. About 5% of all non-small cell lung cancer cases are positive for the ALK-EML4 fusion as a result of an inversion in chromosome 2. However, not in all cases showing an aberration of the ALK gene the EML4-ALK fusion transcript could be detected. KIF5B was identified as a novel fusion partner for ALK in ALK-positive lung cancer. KIF5B is a ubiquitously expressed microtubulebased motor protein involved in organelle transport. The translocation t(2;10) (p23;p11.2) results in the fusion of the first domains of KIF5B including the motor domain and the coiled-coil domain with the tyrosine kinase domain of ALK. Overexpression of the aberrant KIF5B/ALK fusion transcript can lead to enhanced cell proliferation, migration, and invasion. A further aberration affecting the KIF5B gene is inv(10)(p11.2q11.2). This inversion was detected in adenocarcinomas of the lung and results in the fusion of KIF5B with the ret proto-oncogene (RET). The fusion transcript again comprises the coiledcoil domain of KIF5B and the tyrosine kinase domain of RET. In accordance with the EML4-ALK fusion the development of specific agents targeting KIF5B-RET might provide a new therapeutic strategy for lung adenocarcinomas.


Gautschi O, et al. (2013) J Thorac Oncol 8: e43-4. Ju YS, et al. (2012) Genome Res 22: 436-45 Kohno T, et al. (2012) Nat Med 18: 375-7. Takeuchi K, et al. (2009) Clin Cancer Res 15: 3143-9. Takeuchi K, et al. (2012) Nat Med 18: 378-81. Wong DW, et al. (2011) Cancer 117: 2709-18

#### **Probe Description**

The SPEC KIF5B Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 10p11.22 band. The orange fluorochrome direct labeled probe hybridizes distal, the green fluorochrome direct labeled probe hybridizes proximal to the KIF5B gene.




Ideogram of chromosome 10 indicating the hybridization locations.




SPEC KIF5B Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 10p11.22 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 10p11.22 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 10p11.22 locus and one 10p11.22 locus affected by a translocation.



SPEC KIF5B Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



NSCLC tissue section with tetrasomy of chromosome 10 in some cells and an unbalanced translocation affecting KIF5B as indicated by one or two extra green signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2131-50	Zyto <i>Light</i> SPEC KIFSB Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC RET Dual Color Break Apart Probe



### **Background**

The ZytoLight ® SPEC RET Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 10q11.21 harboring the RET (rearranged during transfection proto-oncogene) gene. RET encodes a tyrosine kinase (TK) receptor. Translocations involving RET were first described in papillary thyroid carcinoma (PTC) where somatic rearrangements result in the fusion of its TK catalytic domain with an N-terminal dimerization domain encoded by various fusion partner genes. More recently, recurrent inversions [inv (10)(p11.2q11.2)] fusing the coiled-coil domains of the kinesin family member 5B (KIF5B) gene to the RET kinase domain have been detected in lung adenocarcinoma. The resulting KIF5B-RET fusion protein can form homodimers through the coiledcoil domains of KIF5B, causing an aberrant activation of the TK of RET, a mechanism known from KIF5B-ALK fusions which is also found in lung adenocarcinoma.

Since in vitro studies showed transforming activity of KIF5B-RET which could be suppressed by a TK inhibitor, it was assumed that the chimeric oncogene might be a promising molecular target for the treatment of lung cancer.


The same holds true for the very recently discovered BCR-RET and FGFR1OP-RET fusion genes in chronic myelomonocytic leukemia (CMML) generated by two balanced translocations t(10;22)(q11.2;q11.2) and t(6;10)(q27;q11.2), respectively.

#### References

Ballerini P. et al. (2012) Leukemia 26: 2384-9 Gautschi O, et al. (2012) Teurenini 22 2344-7. Ju YS, et al. (2012) Genome Res 22: 436-45. Kohno T, et al. (2012) Nat Med 18: 375-7. Lee SE, et al. (2015) Mod Pathol 28: 468-79. Nikiforov YE (2002) Endocr Pathol 13: 3-16. Takahashi M, et al. (1985) Cell 42: 581-8. Takeuchi K, et al. (2012) Nat Med 18: 378-81

#### **Probe Description**

The SPEC RET Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 10q11.21 band. The orange fluorochrome direct labeled probe hybridizes proximal to the RET gene, the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 10 indicating the hybridization locations.




SPEC RET Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 10q11.21 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 10q11.21 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 10q11.21 locus and one 10q11.21 locus affected by a translocation or inversion.



SPEC RET Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Human thyroid tumor cell line (TPC-1) with translocation affecting the 10q11.21 locus as indicated by one orange/green fusion (non-rearranged) signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2148-50	Zyto Light SPEC RET Dual Color Break Apart Probe C	•/•	5 (50 µl)
Z-2148-200	Zyto <i>Light</i> SPEC RET Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC PTEN/CEN 10 Dual Color Probe



### **Background**

The ZytoLight ® SPEC PTEN/CEN 10 Dual Color Probe is designed for the detection of PTEN deletions frequently observed in many tumor types, including renal, melanoma, endometrial, breast, prostate, lung, bladder, and thyroid cancer but also in hematological neoplasms.

The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome ten), often referred to as MMAC1 (mutated in multiple advanced cancers 1), is located on 10q23.31 and encodes a 47 kDa dual-specificity phosphatase that has both lipid and protein phosphatase activity. Its inactivation results in constitutive activation of the PI3K/AKT pathway and in subsequent increase in protein synthesis, cell cycle progression, migration, and survival.


Deletions affecting the long arm of chromosome 10 have been detected in 30 to 50% of early and advanced stage sporadic melanomas and about 40 to 70% of prostate cancers. In both tumor entities loss of PTEN has been associated with poor clinical outcome. Currently, several drugs targeting the PI3K/AKT pathway for the therapy of solid tumors have entered clinical trials.

#### References


Neterences Ach T, et al. (2013) Virchows Arch 462: 65-72. Dahia PLM, et al. (1999) Hum Mol Genet 8: 185-93. Ettl T, et al. (2012) Br J Cancer 106: 719-26. Ettl T, et al. (2014) Head Neck 36: 517-23. Healy E, et al. (1998) Oncogene 16: 2213-8. Li J, et al. (1997) Science 275: 1943-7. Swoboda A, et al. (2011) Genes Chromosomes Cancer 50: 680-8. Weng LP, et al. (2001) Hum Mol Genet 10: 599-604. Yoshimoto M, et al. (2006) Cancer Genet Cytogenet 'Yoshimoto M, et al. (2007) Br J Cancer 97: 678-85.

#### **Probe Description**

The SPEC PTEN/CEN 10 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 10 probe specific for the alpha satellite centromeric region of chromosome 10 (D10Z1) and a green fluorochrome direct labeled SPEC PTEN probe specific for the chromosomal region 10q23.2-q23.31 harboring the PTEN gene.




Ideogram of chromosome 10 indicating the hybridization locations.




SPEC PTEN Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions of the PTEN gene locus, a reduced number of green signals will be observed. Deletions affecting only parts of the PTEN gene might result in normal signal pattern with green signals of reduced size.



SPEC PTEN/CEN 10 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Melanoma tissue section with chromosome 10 monosomy as indicated by one orange and one green signal in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2078-50	Zyto <i>Light</i> SPEC PTEN/CEN 10 Dual Color Probe C	•/•	5 (50 µl)
Z-2078-200	Zyto <i>Light</i> SPEC PTEN/CEN 10 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Hearl Pretreatment Solution Gitric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC FGFR2 Dual Color Break Apart Probe



### **Background**

The ZytoLight ® SPEC FGFR2 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 10q26.13 harboring the FGFR2 (fibroblast growth factor receptor 2, a.k.a. BEK) gene.

Translocations and inversions affecting FGFR2 have been detected in several solid tumors, including e.g. breast cancer, lung cancer, and the intrahepatic subtype of cholangiocarcinoma.


Several partner genes have been described to be fused to FGFR2 after rearrangement. The resulting fusion genes are predicted to encode chimeric proteins carrying the kinase domain of FGFR2. Most of the currently known FGFR2 fusion products are likely to exhibit oligomerization capability resulting in kinase activation.

In prostate cancer FGFR2 was found to be fused to the promoter region of SLC45A3 predicted to result in signal activation by overexpression of the FGFR2 protein. Recent studies indicate the involvement of FGFR2 fusion proteins in tumorigenesis. Moreover, in vitro studies suggest that certain FGFR tyrosine kinase inhibitors may provide a new therapeutic option for patients showing FGFR2 rearrangement. Hence, detection of FGFR2 rearrangements using FISH may help to identify patients which might respond to FGFR2 kinase targeting therapies.


Neretences
Arai Y, et al. (2014) Hepatology 59: 1427-34.
Seo JS, et al. (2012) Genome Res 22: 2109-19.
Wu YM, et al. (2013) Cancer Discov 3: 636-47.

#### **Probe Description**

The SPEC FGFR2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 10q26.12q26.13 band. The orange fluorochrome direct labeled probe hybridizes distal to the FGFR2 gene at 10q26.13, the green fluorochrome direct labeled probe hybridizes proximal to the FGFR2 gene at 10q26.12-q26.13.




Ideogram of chromosome 10 indicating the hybridization locations.




SPEC FGFR2 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 10q26.13 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 10q26.13 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 10q26.13 locus and one 10q26.13 locus affected by a translocation.



SPEC FGFR2 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



section with translocation of the FGFR2 gene as indicated by one non-rearranged orange/green fusion signal, one orange, and one separate green signal indicating the translocation.

Kindly provided by Prof. Dr. Büttner, Cologne, Germany.

Prod. No.	Product	Label	Tests* (Volume)
Z-2169-200	Zyto Light SPEC FGFR2 Dual Color Break Apart Probe CE IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



## Zyto Light ® SPEC FGFR2/CEN 10 Dual Color Probe



### **Background**

The ZytoLight ® SPEC FGFR2/CEN 10 Dual Color Probe is designed for the detection of FGFR2 gene amplifications frequently observed in breast cancer as well as in gastric cancer.

The FGFR2 (fibroblast growth factor gene 2, a.k.a. BEK) gene is located on chromosome 10q26.13 and encodes splice variants of the receptor tyrosine kinases FGFR2b and FGFR2c.


Amplification of the FGFR2 gene leads to overexpression of the FGFR2 protein and subsequently to signal activation. Additionally, during the amplification process the C-terminal deletion of FGFR2 can occur due to exclusion of the last exon from the FGFR2 amplicon. Both, overexpression and deletion of the last exon result in FGFR2 signaling activation based on constitutive phosphorylation of the FRS2 adaptor molecule.

The process of ligand independent FGFR2 signaling leads to a more severe malignant phenotype of these tumors. Moreover, high FGFR2 expression is correlated with poor overall survival (OS) and poor disease-free survival (DFS) rates in breast cancer patients. Consequently, FGFR2 gene amplification detected by Fluorescence in situ Hybridization might be used as a prognostic marker e.g. in breast cancer.


Azuma K, et al. (2011) Biochem Biophys Res Commun 407: 219-24. Chang J, et al. (2015) Oncotarget 6: 2009-22. Katoh M (2010) Expert Rev Anticancer Ther 10: 1375-9. Katoh Y & Katoh M (2009) Int J Mol Med 23: 307-11. Moffa AB, et al. (2004) Mol Cancer Res 2: 643-52. Sun S, et al. (2012) J Surg Oncol 105: 773-9.

#### **Probe Description**

The SPEC FGFR2/CEN 10 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 10 probe specific for the alpha satellite centromeric region of chromosome 10 (D10Z1) and a green fluorochrome direct labeled SPEC FGFR2 probe specific for the chromosomal region 10q26.12-q26.13 harboring the FGFR2 gene.




Ideogram of chromosome 10 indicating the hybridization locations.




SPEC FGFR2 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. Nuclei with amplification of the FGFR2 gene locus 10q26.12-q26.13, or aneuploidy of chromosome 10 will show multiple copies of the green signal or large green signal clusters.



SPEC FGFR2/CEN 10 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus



Breast cancer tissue section with amplification of the FGFR2 gene as indicated by green signal cluster in each nucleus.

Pı	rod. No.	Product	Label	Tests* (Volume)
Z-	-2122-200	Zyto Light SPEC FGFR2/CEN 10 Dual Color Probe C    IVD	•/•	20 (200 µl)
R	Related Produ	ıcts		
Z-	-2028-20	Zyto Light FISH-Tissue Implementation Kit C€ IVD		20
		Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informa



## Zyto Light® SPEC CARS Dual Color Break Apart Probe



#### **Background**

The ZytoLight ® SPEC CARS Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 11p15.4 harboring the CARS (cysteinyl-tRNA-synthetase) gene detected in inflammatory myofibroblastic tumors (IMT).

IMT are neoplastic mesenchymal proliferations that occur predominantly in children and young adults. Cytogentic studies of IMT show various complex karyotypic abnormalities, frequently involving the short arm of chromosome 2 harboring the ALK gene locus in 2p23.1-p23.2. The ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246) gene encodes a receptor tyrosine kinase and was frequently identified as a fusion partner of various hybrid genes predominantly in anaplastic large cell lymphoma, and more recently, in non-small cell lung cancer. However, also in IMT several different ALK fusion genes have been identified including CARS-ALK.

CARS encodes a class 1 aminoacyl-tRNA synthetase and is ubiquitously expressed. The translocation results in the fusion of the active promoter as well as the first domains of CARS to the receptor tyrosine kinase domain of ALK. Thus, CARS is predicted to mediate homodimerization of the chimeric product resulting in constitutive ALK kinase activation.

The detection of translocations affecting CARS and ALK by Fluorescence in situ Hybridization might represent a valuable tool to identify a subpopulation of IMT likely to respond to ALK kinase targeting therapies.

Netrences Butrynski JE, et al. (2010) N Engl J Med 363: 1727-33.


Cools J, et al. (2002) Genes Chromosomes Cancer 34: 354-62.

Cruzen ME, et al. (1993) Genomics 15: 692-3.


Debelenko LV, et al. (2003) Lab Invest 83: 1255-65.

#### **Probe Description**

The SPEC CARS Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 11p15.4-p15.5 band. The orange fluorochrome direct labeled probe hybridizes proximal to the CARS gene and the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 11 indicating the hybridization locations.



SPEC CARS Probe map (not to scale).

#### **Results**

In an interphase nucleus lacking a translocation involving the 11p15.4-p15.5 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 11p15.4-p15.5 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 11p15.4-p15.5 locus and one 11p15.4p15.5 locus affected by a translocation.



SPEC CARS Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2137-50	Zyto <i>Light</i> SPEC CARS Dual Color Break Apart Probe C	•/•	5 (50 µl)
Related Produ	ıcts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light® SPEC WT1 Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC WT1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 11p13 harboring the WT1 (Wilms tumor 1) gene.

The WT1 gene is located on 11p13 and encodes a zinc finger DNA-binding protein that acts as a transcriptional activator or repressor depending on the cellular or chromosomal context. Inactivating mutations in the tumor suppressor gene WT1 have been identified in patients with Wilms' tumor and in a subset of sporadic cancers.


However, in desmoblastic small round cell tumors (DSRCT) recurrent translocations affecting the WT1 gene have been found. DSRCT is a highly aggressive mesenchymal tumor that primarily affects male adolescents and young adults. The translocation t(11;22)(p13;q12.2) is detectable in virtually all DSRCT tested and results in the fusion of the potent transcriptional activator domain of the EWSR1 gene and the DNA-binding zinc-finger domains of the WT1 gene. The EWSR1-WT1 chimeric protein acts as an oncogenic transcription factor as evidenced by its ability to transform cells in vitro.

While EWSR1 rearrangements are present in about 90% of DSRCT but are also frequently found in other small round blue cell neoplasms as e.g. Ewing sarcoma, WT1 translocations are exclusively found in DSRCT. Hence, detection of the t(11;22) by Fluorescence in situ Hybridization represents a valuable tool for the differential diagnosis of DSRCT.


References
Gerald WL, et al. (1995) Pro Natl Acad Sci USA 92: 1028-32.
Kim J, et al. (1998) Oncogene 16: 1973-9.
Ladanyi M & Gerald W (1994) Cancer Res 54: 2837-40.
Wang ZY, et al. (1993) J Biol Chem 268: 9172-5.

#### **Probe Description**

The SPEC WT1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 11p13 band. The orange fluorochrome direct labeled probe hybridizes distal and the green fluorochrome direct labeled probe hybridizes proximal to the WT1 gene.




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC WT1 Probe map (not to scale).

#### **Results**

In an interphase nucleus lacking a translocation involving the 11p13 band, two orange/ green fusion signals are expected representing two normal (non-rearranged) 11p13 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 11p13 locus and one 11p13 locus affected by a translocation.



SPEC WT1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Desmoblastic small round cell tumor tissue section with translocation affecting the 11p13 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2142-50	Zyto <i>Light</i> SPEC WT1 Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC CCND1 Dual Color Break Apart Probe



### **Background**


The ZytoLight ® SPEC CCND1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 11q13.3 harboring the CCND1 gene. The CCND1 gene (cyclin D1, a.k.a. PRAD1) encodes a regulatory subunit of cyclin-dependent kinases.

Translocations involving the chromosomal region t(11;14) (q13.3;q32.3) are considered to be characteristic for mantle cell lymphomas (MCL) but have also been identified in other lymphoproliferative disorders (LPDs), such as B-prolymphocytic leukemia, and, less frequently, in plasma cell myelomas, B-cell chronic lymphocytic leukemia, and in splenic lymphomas with villous lymphocytes (SLVL).


The t(11;14) rearrangement often leads to overexpression of the CCND1 protein. Determination of translocations involving the chromosomal region 11q13.3 can also help to distinguish MCL from other chronic lymphoproliferative disorders. Since the course of MCL is aggressive, and its response to chemotherapy is poor, differential diagnosis is clinically important. Additionally, it was also shown that a renal oncocytoma (RO) specific breakpoint is located in band 11q13.3, involving the CCND1 locus. The histologic features of RO may overlap with those of chromophobe renal cell carcinoma (ChRCC). Fluorescence in situ Hybridization (FISH) can be used as a diagnostic tool for differentiation of RO from ChRCC.

#### **Probe Description**

The SPEC CCND1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 11q13.2-q13.3 band. The orange fluorochrome direct labeled probe hybridizes distal to and covers the CCDN1 gene, while the green fluorochrome direct labeled probe hybridizes proximal to that gene.




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC CCND1 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 11q13.2-q13.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) CCND1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal CCND1 locus and one CCND1 locus affected by an 11q13.2-q13.3 trans-



SPEC CCND1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Bone marrow biopsy section with translocation affecting the 11q13.2-q13.3 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

# References Bentz JS, et al. (2004) Cancer 102: 124-31. Bosch F, et al. (1997) Cancer 82: 567-75. Sinke RJ, et al. (1997) Cancer Genet Cytogenet 96: 95-101. Sukov WR, et al. (2007) Hum Pathol 40: 1296-303. Tarsitano M, et al. (2009) Cancer Genet Cytogenet 195: 164-7. Vaandrager JW, et al. (1996) Blood 4: 1177-82.

Prod. No.	Product	Label	Tests* (Volume)
Z-2108-50	Zyto <i>Light</i> SPEC CCND1 Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Z-2108-200	Zyto <i>Light</i> SPEC CCND1 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C€ IVD Ind. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC CCND1/CEN 11 Dual Color Probe



### **Background**

The ZytoLight® SPEC CCND1/CEN 11 Dual Color Probe is designed for the detection of CCND1 gene amplification frequently observed in breast cancer and other human tumors.


The cyclin D1 gene (a.k.a. CCND1 or PRAD1) is located in the chromosomal region 11q13.3 and encodes a regulatory subunit of cyclin-dependent kinases that promote progression through the cell

The proto-oncogene CCND1 is amplified in a number of solid tumors including approx. 20% of all human breast cancer cases and about 30% of squamous cell carcinomas of the esophagus and the head and neck region. Amplification of chromosomal material from 11q13.3 harboring the CCND1 gene is discussed as a prognostic marker in terms of metastasis, tumor recurrence, and survival for several tumor entities. In gastrointestinal stromal tumors (GIST), CCND1 amplification was found in 16% of high-risk tumors and was absent in low- or intermediate-risk tumors indicating the prognostic relevance of this genetic alteration in GIST.


Al-Kuraya K, et al. (2004) Cancer Res 64: 8534-40. Courjal F, et al. (1997) Cancer Res 57: 4360-7. Motokura T, et al. (1991) Nature 350: 512-5. Ormandy CJ, et al. (2003) Breast Cancer Res Treat 78: 323-35. Schuuring E (1995) Gene 159: 83-96. Torrillo L, et al. (2005) Lob Invest 85: 921-31. Xiong Y, et al. (1991) Cell 65: 691-9.

### **Probe Description**

The SPEC CCND1/CEN 11 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 11 probe specific for the alpha satellite centromeric region of chromosome 11 (D11Z1) and a green fluorochrome direct labeled SPEC CCND1 probe specific for the CCND1 gene at 11q13.3.




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC CCND1 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the CCND1 gene locus, multiple copies of the green signal or large green signal clusters will be observed.



SPEC CCND1/CEN 11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Polysomy of chromosome 11 as indicated by three orange (CEN 11) and three green (CCND1) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2071-50	Zyto <i>Light</i> SPEC CCND1/CEN 11 Dual Color Probe C € IVD	•/•	5 (50 µl)
Z-2071-200	Zyto <i>Light</i> SPEC CCND1/CEN 11 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Pro	ducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit CE IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC CCND1/IGH Dual Color Dual Fusion Probe



### **Background**


The ZytoLight ® SPEC CCND1/IGH Dual Color Dual Fusion Probe is designed to detect translocation t(11;14)(q13.3;q32.3) frequently found in mantle cell lymphomas. The translocation juxtaposes the CCND1 gene (cyclin D1, a.k.a. PRAD1 and BCL1) next to the IGH (immunoglobulin heavy locus, a.k.a. IGH@) locus and results in constitutive overexpression of CCND1. The translocation t(11;14)(q13.3;q32.3)that involves the CCND1 and IGH gene regions is detected in up to 95% of patients with mantle cell lymphomas (MCL) and are considered to be the genetic hallmark of this subtype of low-grade peripheral B-cell neoplasms. However, the t(11;14) has also been identified in other lymphoproliferative disorders (LPDs), such as B-prolymphocytic leukemia (PLL), and, less frequently, in plasma cell myelomas, B-cell chronic lymphocytic leukemia, and in splenic lymphomas with villous lymphocytes (SLVL).


Since the course of MCL is aggressive, and its response to standard chemotherapy is poor, differential diagnosis from other chronic lymphoproliferative disorders via detection of the t(11;14) translocation might be of great clinical importance.

References Bentz JS, et al. (2004) Cancer 102: 12431. Li JY, et al. (1999) Am J Pathol 154: 1449-52. Siebert R, et al. (1998) Ann of Oncol 9: 519-26. Vaandrager JW, et al. (1996) Blood 88: 1177-82.


#### **Probe Description**

The SPEC CCND1/IGH Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled CCND1 probe spanning the major translocation cluster (MTC) region comprising about 120 kb upstream of CCND1 and a green fluorochrome direct labeled IGH probe spanning the breakpoint cluster region of IGH.





Ideograms of chromosomes 11 (above) and 14 (below) indicating the hybridization locations.




SPEC CCND1 Probe map (not to scale).




SPEC IGH Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal CCND1/IGH translocation leads to two orange/green fusion signals indicating both rearranged chromosomes. Additionally, the non-rearranged chromosomes are indicated by one orange signal and a separate green signal, respectively.



SPEC CCND1/IGH Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Section of an iliac crest biopsy with translocation affecting the CCND1/IGH loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2125-50	Zyto <i>Light</i> SPEC CCND1/IGH Dual Color Dual Fusion Probe C €	<b>●/●</b>	5 (50 µl)
Z-2125-200	Zyto Light SPEC CCND1/IGH Dual Color Dual Fusion Probe C € IVD	<b>o/o</b>	20 (200 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



### Zyto Light ® SPEC FGF3,4,19/CEN 11 Dual Color Probe



### **Background**

The ZytoLight ® SPEC FGF3,4,19/CEN 11 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the genes FGF3, FGF4, and FGF19.

The fibroblast growth factor encoding genes FGF3 (a.k.a. INT2), FGF4 (a.k.a. HSTF1, HST-1), and FGF19 are located in a cluster on 11q13.3, a locus that is amplified in multiple tumor types. Fibroblast growth factors and their receptors (FGFRs) regulate the growth, differentiation, and regeneration of a variety of tissues.

The genes FGF3, FGF4, and/or FGF19 were found to be amplified in some hepatocellular carcinoma (HCC). FGF3/FGF4 amplification is associated with HCC metastasis and recurrence as well as with sensitivity to treatment with sorafenib. Amplification of FGF19 in HCC results in an increased expression of this gene which is correlated with a worse prognosis. Moreover, in vitro studies have demonstrated that patients positive for 11q13.3 amplification are likely to respond to anti-FGF19 therapy.

Amplifications of the chromosomal region 11q13.3 have also been detected in nonsmall cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), and bladder cancer.


Hence, the detection of amplifications of the FGF3, FGF4, and FGF19 genes by Fluorescence in situ Hybridization may be of prognostic significance and may aid in therapeutic decision making in HCC.

#### References

Nation Test al. (2013) Hepatology 57: 1407-15. Chaffer CL, et al. (2007) Differentiation 75: 831-42. Hu L, et al. (2007) Cancer Lett 252: 36-42. Miura S, et al. (2012) BMC Cancer 12: 56. Sawey ET, et al. (2011) Cancer Cell 19: 347-58. Tai AL, et al. (2005) Cancer 106: 146-55. Vékony H, et al. (2007) Clin Cancer Res 13: 3133-9. Zaharieva BM, et al. (2003) J Pathol 201: 603-8.

#### **Probe Description**

The SPEC FGF3,4,19/CEN 11 Dual Color Probe is a mixture of an orange fluorochrome direct labeled SPEC FGF3,4,19 probe hybridizing to the human FGF3, FGF4, and FGF19 genes in the chromosomal region 11q13.3 and a green fluorochrome direct labeled CEN 11 probe specific for the alpha satellite centromeric region of chromosome 11 (D11Z1).




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC FGF3,4,19 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the FGF3, FGF4, and/or FGF19 gene locus, multiple copies of the orange signal or orange signal clusters will be observed.



SPEC FGF3,4,19/CEN 11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Breast cancer tissue section with interphase cells showing amplification of the FGF3, FGF4, and/or FGF19 gene locus as indicated by multiple orange signals in each nucleus.

Prod. No	. Product	Label	Tests* (Volume)	
Z-2158-20	O Zyto <i>Light</i> SPEC FGF3,4,19/CEN 11 Dual Color Probe C € IVD	<u>•/•</u>	20 (200 µl)	
Related	Related Products			
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20	
	Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			



## Zyto Light ® SPEC MAML2 Dual Color Break Apart Probe




### **Background**

The ZytoLight ® SPEC MAML2 Dual Color Break Apart Probe is designed to detect the translocation t(11;19)(q21;p13.1)specific for mucoepidermoid carcinomas. The mucoepidermoid carcinoma is the most common malignant tumor of the salivary gland. With about 30-50% of all cases, the translocation t(11;19) (q21;p13.1) is the most frequent chromosomal aberration in mucoepidermoid carcinomas. In some cases the t(11;19) is the sole chromosomal anomaly and in other cases the t(11;19) was found either as a more complex translocation involving other chromosomes or together with other abnormalities.


References
Bishop JA, et al. (2014) Head Neck Pathol 8: 287-90.
Camelo-Piragua SI, et al. (2009) Hum Pathol 40: 887-92.
Chiosea SI, et al. (2012) Laryngoscope 122: 1690-4.
ElNaggar A, et al. (1996) Cancer Genet Cytogenet 87: 29-33. EI-Naggar A, et al. (1996) Cancer Genet Cytogenet 87: Jee KJ, et al. (2013) Mod Pathol 26: 213-22. Lei Y & Chiosea SI (2012) Head Neck Pathol 6: 166-70. Noda H, et al. (2013) Cancer Sci 104: 85-92. Nordkvist A, et al. (1994) Cancer Genet Cytogenet 74: 7 Rotellini M, et al. (2012) J Oral Pathol Med 41: 615-20. Schwarz S, et al. (2011) Histopathology 58: 557-70.
Schwarz S, et al. (2011) Histopathology 58: 557-70.
Schwarz S, et al. (2011) Int J Clin Exp Pathol 4: 336-48.
Winnes M, et al. (2007) Genes Chromosomes Cancer 46: 559-63. Zhu F, et al. (2014) PLoS One 9: e94399

#### **Probe Description**

The SPEC MAML2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 11q21 band. The green fluorochrome direct labeled probe hybridizes distal to the MAML2 gene, the orange fluorochrome direct labeled probe hybridizes proximal to that gene.




Ideogram of chromosome 11 indicating the hybridization locations



SPEC MAML2 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 11q21 band two orange/green fusion signals are expected representing two normal (non-rearranged) 11q21 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 11g21 locus and one 11q21 locus affected by the translocation specific for mucoepidermoid carcinomas.



SPEC MAML2 Dual Color Break Apart Probe hybridized to abnormal nuclei containing two normal chromosomes 11 as indicated by two orange/green signal pairs and a derivative chromosome 11 with a translocation involving the 11q21 band as indicated by one orange and one separate green signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2014-50	Zyto Light SPEC MAML2 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2014-200	Zyto <i>Light</i> SPEC MAML2 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe



### **Background**

The ZytoLight ® SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe is designed to detect translocations involving the chromosomal region 11q22.2 harboring the BIRC3 (baculoviral IAP repeat containing 3, a.k.a. API2) gene and the chromosomal region 18q21.32 harboring the MALT1 (mucosa associated lymphoid tissue lymphoma translocation gene 1, a.k.a. MLT) gene.


The recurrent translocation t(11;18) (q22.2;q21.3) is frequently found in mucosa-associated lymphoid tissue (MALT) lymphoma which represents the most common extranodal B-cell tumor and accounts for 5-10% of all non-Hodgkin lymphoma. The translocation results in the expression of chimeric fusion transcripts comprising the N-terminal end of the apoptosis inhibitor BIRC3 which is highly expressed in adult lymphoid tissue and C-terminal parts of the MALT1 protease.


The BIRC3/MALT1 fusion protein was shown to induce proteolytic cleavage of NF-kappa-B-inducing kinase (NIK) ultimately resulting in constitutive non-canonical NF-kappa-B signaling, enhanced B-cell adhesion, and apoptosis resistance. It is assumed that disruption of the BIRC3-NIK interaction and/or blocking of MALT1 protease or NIK kinase activity could represent new treatment approaches for refractory t(11;18)-positive MALT lymphoma.

Dierlamm J, et al. (1999) Blood 93: 3601-9 Dierlamm J, et al. (2000) Blood 96: 2215-8. Morgan JA, et al. (1999) Cancer Res 59: 6205-13. Rosebeck S, et al. (2011) Science 331: 468-72.


#### **Probe Description**

The SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe is a mixture of a green direct labeled BIRC3 probe spanning the BIRC3 gene region at 11q22.1-q22.2 and an orange direct labeled MALT1 probe spanning the MALT1 gene region at 18q21.31q21.32.






Ideograms of chromosomes 11 (above) and 18 (below) indicating the hybridization locations.




SPEC BIRC3 Probe map (not to scale).




SPEC MALT 1 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange and green signal, respectively.



SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



MALT lymphoma tissue section with translocation affecting the BIRC3/MALT1 loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2146-50	Zyto <i>Light</i> SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C  IVD	•/•	5 (50 µl)
Z-2146-200	Zyto <i>Light</i> SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe C€ □VD	•/•	20 (200 µl)
Related P	oducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.

97



## Zyto Light ® SPEC TP53/ATM Dual Color Probe



### **Background**

The ZytoLight® SPEC TP53/ATM Dual Color Probe is designed for the detection of deletions affecting the genes TP53 and ATM.

CLL (chronic lymphocytic leukemia) is the most common form of leukemia in Western population.

TP53 (tumor protein 53, a.k.a. p53) gene deletions have been detected in patients with CLL, multiple myeloma (MM), and acute myeloid leukemia (AML). In CLL patients, allelic loss of the short arm of chromosome 17 is associated with treatment failure with alkylating agents and short survival times.

The ATM (ataxia telangiectasia mutated) gene is located on 11q22.3 and encodes a protein kinase which is involved in cell cycle regulation, including TP53 activation. CLL patients with 11q deletion exhibit rapid disease progression and inferior


Hence, in combination with further biological markers, morphology and clinical


FISH is a valuable tool to predict disease progression and overall survival in CLL patients.

Retrences
Pettitt AR, et al. (2001) Blood 98: 814-22.
Ripollés L, et al. (2006) Cancer Genet Cytogenet 171: 57-64.
Shanafelt TD, et al. (2006) Ann Intern Med 145: 435-47.
Stilgenbauer S, et al. (2002) Leukemia 16: 993-1007.


#### **Probe Description**

The SPEC TP53/ATM Dual Color Probe is a mixture of an orange fluorochrome direct labeled SPEC TP53 probe hybridizing to the TP53 gene in the chromosomal region 17p13.1 and a green fluorochrome direct labeled SPEC ATM probe specific for the ATM gene at 11q22.3.






Ideograms of chromosomes 17 (above) and 11 (below) indicating the hybridization locations.




SPEC TP53 Probe map (not to scale).




SPEC ATM Probe map (not to scale).

#### Results

Using the SPEC TP53/ATM Dual Color Probe in a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the TP53 gene locus, a reduced number of orange signals will be observed. Deletions affecting only parts of the TP53 locus might result in a normal signal pattern with orange signals of reduced size. In a cell with ATM gene deletions, a reduced number of green signals will be observed. Deletions affecting only parts of the ATM locus might result in a normal signal pattern with green signals of reduced size.



SPEC TP53/ATM Dual Color Probe hybridized to bone marrow biopsy section with deletions of the ATM and the TP53 genes as indicated by one green and one orange signal in each nucleus.



SPEC TP53/ATM Dual Color Probe hybridized to bone marrow biopsy section with deletion of the ATM gene as indicated by one green signal in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2159-50	Zyto <i>Light</i> SPEC TP53/ATM Dual Color Probe C € IVD	<b>●/●</b>	5 (50 µl)
Z-2159-200	Zyto Light SPEC TP53/ATM Dual Color Probe C € IVD	<b>_/</b> ●	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C€ IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD		20
	Ind. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml;		
(	Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC D13S319/13q34/CEN 12 Triple Color Probe



### **Background**

The ZytoLight ® SPEC D13S319/13q34/ CEN 12 Triple Color Probe is designed for the detection of D13S319 deletions as well as for the enumeration of chromosome 12. CLL (chronic lymphocytic leukemia) is the most common form of leukemia in Western population.

The most frequent aberration in CLL is the deletion of 13q14 which involves the D13S319 locus and which is associated with a favorable prognosis if occurring as the sole genetic aberration. Deletions of the long arm of chromosome 13 are also frequently detected in patients with aggressive non-Hodgkin lymphoma (NHL) and have been found to represent an adverse prognostic factor in MM.

Trisomy 12 represents another frequent chromosomal aberration in CLL, detected in about 20% of CLL cases. Trisomy 12 as single aberration is associated with an intermediate prognostic outcome.

Hence, in combination with further biological markers, morphology and clinical information FISH is a valuable tool to predict disease progression and overall survival in CLL patients.


Chang H, et al. (1999) Leukemia 13: 105-9. Dal Bo M, et al. (2011) Genes Chromosomes Cancer 50: 633-43. Dati Bo M, et al. (2011) Clin Cancer Res 21: 6778-90.

Ripollés L, et al. (2001) Clin Cancer Res 21: 6778-90.

Ripollés L, et al. (2006) Cancer Genet Cytogenet 171: 57-64.

Shanafelt TD, et al. (2006) Ann Intern Med 145: 435-47.


Stilgenbauer S, et al. (2002) Leukemia 16: 993-1007.




SPEC D13S319 Probe map (not to scale).

#### **Probe Description**

The SPEC D13S319/13q34/CEN 12 Triple Color Probe is a mixture of an orange fluorochrome direct labeled SPEC D13S319 probe specific for the D13S319 locus at 13q14.2, a blue fluorochrome direct labeled SPEC 13q34 probe specific for the chromosomal region 13q34 and a green fluorochrome direct labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3). The SPEC 13q34 probe is specific for the LAMP1 (lysosome-associated membrane protein 1) gene region in 13q34. Due to cross-hybridizations of chromosome 13 alpha satellites to other centromeric regions, probes specific for 13q34 are frequently used for chromosome 13 copy number detection.




Ideograms of chromosomes 13 (above) and 12 (below) indicating the hybridization locations.




SPEC 13a34 Probe map (not to scale)

#### Results

Using the SPEC D13S319/13q34/ CEN 12 Triple Color Probe in a normal interphase nucleus, two orange, two green, and two blue signals are expected. In a cell with deletions affecting the D13S319 locus, a reduced number of orange signals will be observed. Deletions affecting only parts of the D13S319 locus might result in a normal signal pattern with orange signals of reduced size. In a cell with trisomy or polysomy 12, three or more copies of the green signal will be observed, respectively.



SPEC D13S319/13q34/CEN 12 Triple Color Probe hybridized to bone marrow biopsy section with deletion of the D13S319 locus as indicated by one orange signal and two blue signals in each nucleus.



SPEC D13S319/13q34/CEN 12 Triple Color Probe hybridized to bone marrow biopsy section with trisomy of chromosome 12 as indicated by three green signals in each nucleus.

OI LC D 1000	or the map the to seale.		
Prod. No.	Product	Label	Tests* (Volume)
Z-2160-50	Zyto Light SPEC D13S319/13q34/CEN 12 Triple Color Probe C ( IVD)	<b>●/●/●</b>	5 (50 µl)
Z-2160-200	Zyto Light SPEC D13S319/13q34/CEN 12 Triple Color Probe C ( IVD)	<b>•/•/•</b>	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C C IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl., 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/Durglert-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmation</u>.



## Zyto Light ® SPEC 11q gain/loss Triple Color Probe



### **Background**

The ZytoLight ® SPEC 11a gain/loss Triple Color Probe is designed to detect 11q

A subset of lymphomas with gene expression and pathological characteristics of Burkitt lymphomas (BL) but absence of MYC translocation has been recently described which carries 11g proximal gains and telomeric losses. It is assumed that this aberration leads to co-deregulation of oncogenes and tumor suppressor genes which are located in the affected chromosomal regions. The current WHO classification introduced this new provisional entity as Burkitt-like lymphoma with 11q aberration. The minimal region of gain (MGR) and loss (MLR) was defined at 11q23.3 and at 11q24.1q25, respectively, based on the studies by Ferreiro et al. (2015) and Salaverria et al. (2014). Potential oncogenes located in the MGR are USP2 and PAFAH1B2. The candidate tumor suppressor genes in the MLR comprise, e.g., FLI1 and ETS1.


The 11q-gain/loss pattern in high-grade Bcell lymphoma is significantly more frequent in lymphoma occurring in the setting of transplantation and immunosuppression than in immunocompetent patients. This suggests that immunosuppression may favor its formation.

As identification of patients with the 11qgain/loss aberration is clinically important but cytogenetically challenging, FISH assay is a useful diagnostic tool to evaluate both post-transplant and immunocompetent Burkitt and Burkitt-like lymphoma patients.


Ferreiro JF, et al. (2015) Haematologica 100: e275-9. Salaverria I, et al. (2014) Blood 123: 1187-98. Swerdlow SH, et al. (2016) Blood 127: 2375-90.

#### **Probe Description**

The SPEC 11g gain/loss Triple Color Probe is a mixture of a green fluorochrome direct labeled probe hybridizing in the MGR at 11q23.3, an orange fluorochrome direct labeled probe hybridizing in the MLR at 11q24.3, and a blue fluorochrome direct labeled CEN 11 probe specific for the alpha satellite centromeric region of chromosome 11 (D11Z1).




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC 11q Probe map (not to scale).

#### Results

In a normal interphase nucleus, two green, two orange, and two blue signals are expected. In a cell with amplification at 11q23.3 and deletion at 11q24.3, multiple copies of the green signals and a reduced number of orange signals will be observed.



SPEC 11q gain/loss Triple Color Probe hybridized to normal interphase cells as indicated by two green, two orange, and two blue signals per nucleus and to metaphase chromosomes of a normal cell.



Burkitt-like lymphoma tissue section with 11q aberration as indicated by three green signals and one orange signal indicating the gain and loss at 11q, respectively.

Prod. No.	Product	Label	Tests* (Volume)
Z-2216-50	Zyto <i>Light</i> SPEC 11q gain/loss Triple Color Probe CE IVD	•/•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light® SPEC KMT2A Dual Color Break Apart Probe



#### **Background**


The ZytoLight ® SPEC KMT2A Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 11q23.3 harboring the KMT2A gene. The KMT2A (a.k.a. MLL: mixedlineage leukemia or myeloid-lymphoid leukemia) gene encodes a histone lysine N-methyltransferase and is involved in a variety of cellular processes, including hematopoiesis, DNA damage response, and cell cycle control.

Translocations involving the KMT2A gene are identified in 5-6% of all acute myeloid leukemias (AML) and 5-10% of all acute lymphoblastic leukemias (ALL). The frequency of translocations involving the KMT2A gene is significantly higher in infants with AML (50%) as well as with ALL (80%). More than 30 fusion partners are documented for KMT2A, the most common translocations are t(4;11) and t(11;19) in ALL, and t(6;11), t(9;11), and t(11;19) in AML patients.


Between 1-15% of cancer patients treated with DNA topoisomerase II inhibitor develop therapy-related leukemia (t-AML) associated with KMT2A translocations. Generally, the presence of KMT2A rearrangements in patients with acute leukemia indicates a less favorable prognosis. However, recent studies suggest that the specific KMT2A translocation partner may influence response to therapy and overall prognosis depending on the clinical context. Hence, detection of KMT2A translocations by Fluorescence in situ Hybridization may be of diagnostic and prognostic relevance.

#### **Probe Description**

The SPEC KMT2A Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 11q23.3 band. The green fluorochrome direct labeled probe hybridizes proximal to the KMT2A gene, and the orange fluorochrome direct labeled probe hybridizes distal to the KMT2A gene region.




Ideogram of chromosome 11 indicating the hybridization locations.




SPEC KMT2A Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 11q23.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 11q23.3 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 11q23.3 locus and one 11q23.3 locus affected by a translocation.



SPEC KMT2A Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Bone marrow smear with translocation of the KMT2A gene as indicated by one non-rearranged orange/ green fusion signal, one orange signal, and one separate green signal indicating the translocation.

### **References** Broeker PL, et al. (1996) Blood 87: 1912-22. Broeker PL, et al. (1996) Blood 87: 1912-22. De Braekeleer M, et al. (2005) Anticancer Res 25: 1931-44. Ford DJ & Dingwall AK (2015) Cancer Genet 208: 178-91. Gindin T, et al. (2015) Hematol Oncol 33: 239-46. Keefe JC, et al. (2010) J Mol Diagn 12: 441-52. Langer T, et al. (2003) Genes Chromosomes Cancer 36: 393-401. Wechsler DS, et al. (2003) Genes Chromosomes Cancer 36: 26-36.

Prod. No.	Product	Label	Tests* (Volume)
Z-2193-50	Zyto <i>Light</i> SPEC KMT2A Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C F IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>y</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



## **Zyto Light** ® SPEC ETV6 Dual Color Break Apart Probe



### **Background**


The ZytoLight® SPEC ETV6 Dual Color Break Apart Probe is designed for the detection of translocations involving the chromosomal region 12p13.2 harboring the ETV6 (ETS variant gene 6, a.k.a. TEL)

ETV6 is a member of the ETS family of transcription factors. More than 40 translocations with ETV6 involvement have been reported in diverse types of hematological and non-hematological malignancies. The balanced chromosomal translocation t(12;21)(p13.2;q22.1), which leads to ETV6-RUNX1 fusion, represents the most frequent genetic rearrangement (19-27%) in initial childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) and has been associated with good prognosis. The ETV6-NTRK3 gene fusion resulting from the t(12;15)(p13.2;q25) translocation was found to be characteristic for mammary analogue secretory carcinoma (MASC) of the salivary glands. Since MASC morphologically mimics other neoplasms, the detection of ETV6 rearrangements may be helpful for the differential diagnosis of MASC.


In a subgroup of myeloproliferative disorders, the t(5;12)(q32;p13.2) translocation is a recurrent chromosome abnormality resulting in the fusion of ETV6 to the receptor tyrosine kinase PDGFRB. Patients carrying the t(5;12) translocation can be successfully treated with tyrosine kinase inhibitors.

#### **Probe Description**

The SPEC ETV6 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 12p13.2 band. The green fluorochrome direct labeled probe hybridizes proximal and the orange fluorochrome direct labeled probe hybridizes distal to the ETV6 gene.




Ideogram of chromosome 12 indicating the hybridization locations.




SPEC ETV6 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 12p13.2 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 12p13.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 12p13.2 locus and one 12p13.2 locus affected by a translocation.



SPEC ETV6 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



MASC tissue section of the salivary glands with translocation of the ETV6 gene as indicated by one non-rearranged orange/green fusion signal, one orange and one separate green sianal indicatina the translocation

		signal malcaling me mansiocation.	
Prod. No.	Product	Label	Tests* (Volume)
Z-2176-50	Zyto <i>Light</i> SPEC ETV6 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2176-200	Zyto <i>Light</i> SPEC ETV6 Dual Color Break Apart Probe CE IVD	•/•	20 (200 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C FIVD  Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C FIVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	ZytoLight FISH-Cytology Implementation Kit C € IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

References
Bohlander SK (2005) Semin Cancer Biol 15: 162-74.

De Braekeleer E, et al. (2012) Leuk Res 36: 945-61.

Peter A, et al. (2009) Eur J Haematol 83: 420-32.

Pinto A, et al. (2014) Mod Pathol 27: 30-7.

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe



### **Background**

The ZytoLight ® SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe is designed for the detection of the specific translocation involving the chromosomal region 12p13.2 harboring the ETV6 (ETS variant gene 6, a.k.a. TEL) gene and the chromosomal region 21q22.12 harboring the RUNX1 (runt-related transcription factor 1, a.k.a. AML1) gene.


The balanced chromosomal translocation t(12;21)(p13.2;q22.1), which leads to ETV6/RUNX1 fusion, represents the most frequent genetic rearrangement in initial childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) (19-27%) and has been associated with good prognosis. The ETV6/RUNX1 fusion protein, comprising a putative repressor domain of ETV6, a member of the ETS family of transcription factors, fused to RUNX1, the DNA-binding subunit of the RUNX1/CBF beta transcription factor complex, acts as a trans-dominant repressor of RUNX1 regulated target genes involved in hema-

Three secondary aberrations in ETV6/ RUNX1 positive ALL have been found to negatively influence the clinical course: deletion of the second non-translocated ETV6 allele, gains of the RUNX1 gene, and duplication of the derivative chromo-

Detection of t(12;21) by Fluorescence in situ Hybridization enables the simultaneous identification of the most common secondary changes and thus provides additional information about the possible outcome of the disease in patients with ALL.


#### **Probe Description**

The SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled ETV6 probe spanning the known breakpoint region of the ETV6 gene and a green fluorochrome direct labeled RUNX1 probe covering the known breakpoint region of the RUNX1 gene.






Ideograms of chromosomes 12 (above) and 21 (below) indicating the hybridization locations.




SPEC ETV6 Probe map (not to scale).




SPEC RUNX1 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange and green signal, respectively.



SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bone marrow tissue section with translocation affecting the ETV6/RUNX1 loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Reterences Fenrick R, et al. (1999) Mol Cell Biol 19: 6566-74. Martínez-Ramírez A, et al. (2001) Haematologica 86: 1245-53. Morrow M, et al. (2007) Oncogene 26: 4404-14. Peter A, et al. (2009) Eur J Haematol 83: 420-32. Shurtleff SA, et al. (1995) Leukemia 9: 1985-9.

Prod. No.	Product	Label	Tests* (Volume)
Z-2157-50	ZytoLight SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe C    IVD	<b>o/o</b>	5 (50 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD  Incl. Cytology Pepsin Solution, 4 mt; 20x Wash Buffer TBS, 50 mt; 10x MgCl <sub>y</sub> , 50 mt; 10x PBS, 50 mt; Cytology Stringency Wash Buffer SSC, 500 mt; Cytology Wash Buffer SSC, 500 mt; DAPI/Duraïect-Solution, 0.8 mt		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Light ® SPEC KRAS/CEN 12 Dual Color Probe



### **Background**

The ZytoLight ® SPEC KRAS/CEN 12 Dual Color Probe is designed for the detection of KRAS gene amplifications found e.g. in lung cancer.

The KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene located on chromosome 12p12.1 is a member of the RAS gene family comprising HRAS, KRAS, and NRAS, all of which encode a 21 kDa protein. The wildtype proteins play a pivotal role in cell proliferation, differentiation, and senescence. Mutations of KRAS are frequently found in epithelial malignancies and lead to activation of the downstream mitogen-activated protein kinase (MAPK) resulting in unchecked cellular proliferation and tumor progression.


Amplifications of KRAS and the implications in tumorigenesis are not as well characterized as KRAS mutations. However, recent studies using different methods found amplification of KRAS or copy number gain of the 12p12.1 region including KRAS in various primary tumors, as e.g. in lung, colorectal, pancreatic, and gastric cancers.

For non-small cell lung cancer (NSCLC) patients KRAS amplification as assessed by Fluorescence in situ Hybridization (FISH) was detected in about 15% of the tumors. Amplification of KRAS was found to be correlated with poor prognosis and may act synergistically with KRAS mutations to promote tumor progression.


References Little AS, et al. (2011) Sci Signal 4: er2. Mita H, et al. (2009) BMC Cancer 9: 198. Sasaki H, et al. (2011) J Thorac Oncol 6: 15-20. Wagner PL, et al. (2011) Lung Cancer 74: 118-23.

#### **Probe Description**

The SPEC KRAS/CEN 12 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3) and a green fluorochrome direct labeled SPEC KRAS probe specific for the KRAS gene at 12p12.1.




ldeogram of chromosome 12 indicating the hybridization locations.




SPEC KRAS Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. Nuclei with amplification of the KRAS gene locus 12p12.1 or aneuploidy of chromosome 12 will show multiple copies of the green signal or large green signal clusters.



SPEC KRAS/CEN 12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus



Lung cancer tissue section with amplification of the KRAS gene (green).

Image kindly provided by Prof. Diebold, Lucerne, Switzerland.

Prod. No.	Product	Label	Tests* (Volume)
Z-2115-200	Zyto <i>Light</i> SPEC KRAS/CEN 12 Dual Color Probe C	•/•	20 (200 µl)
<b>Related Prod</b>	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



### Zyto Light ® SPEC ERBB3/CEN 12 Dual Color Probe

Previously: Zyto Light SPEC HER3/CEN 12 Dual Color Probe



### **Background**


The ZytoLight® SPEC ERBB3/CEN 12 Dual Color Probe is designed for the detection of amplifications of the chromosomal regions harboring the ERBB3 gene. The ERBB3 (a.k.a. HER3) gene encodes a transmembrane glycoprotein acting as a cellular growth factor receptor. It belongs to the epidermal growth factor receptor subgroup of the receptor tyrosine kinase superfamily also including ERBB1 (EGFR), ERBB2, which is known to be affected by gene amplifications in a number of malignant tumors, and ERBB4.

Although EGFR and ERBB2 have been shown to represent good predictive markers and appropriate targets for therapeutic approaches, relatively less is known of comparable significance for ERBB3 and ERBB4. However, there is growing evidence that cooperation of all four members of the ERBB gene family contributes to a more aggressive tumor phenotype and influences therapeutic response. Accordingly, it is assumed that the assessment of the combined amplification status of ERBB1 to ERBB4 may improve the diagnostic value significantly.


References
Alimandi M, et al. (1995) Oncogene 10: 1813-21. Allindar M, et al. (2011) J Clin Oncol 29: 3030-6. Berghoff AS, et al. (2014) Breast J 23: 637-43. Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89. Kraus MH, et al. (1989) Proc Natl Acad Sci USA 86: 9193-7. Lédel F, et al. (2014) Eur J Cancer 50: 656-62. Sassen A, et al. (2008) Breast Cancer Res 10: R2. Sassen A, et al. (2009) Breast Cancer Res 11: R50. Zaczek A, et al. (2005) Histol Histopathol 20: 1005-15. Zimonjic DB, et al. (1995) Oncogene 10: 1235-7

#### **Probe Description**

The SPEC ERBB3/CEN 12 Dual Color Probe is a mixture of a green fluorochrome direct labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3) and an orange fluorochrome direct labeled SPEC ERBB3 probe hybridizing distal and proximal to the human ERBB3 gene in the chromosomal region 12q13.2-q13.3.




Ideogram of chromosome 12 indicating the hybridization locations.



SPEC ERBB3 Probe map (not to scale).

#### Results

Using the SPEC ERBB3/CEN 12 Dual Color Probe in a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ERBB3 gene locus, multiple copies of the orange signal or orange signal clusters will be observed.



SPEC ERBB3/CEN 12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2056-200	Zyto <i>Light</i> SPEC ERBB3/CEN 12 Dual Color Probe C € IVD	<b>-/-</b>	20 (200 µl)
Related Produ	ıcts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati

ZytoLight  $^{\circ}$  FISH probes are direct labeled using the unique ZytoLight  $^{\circ}$  Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision  $^{\circ}$  Repeat Subtraction Technique.

105



### Zyto Light ® SPEC DDIT3 Dual Color Break Apart Probe

Previously: Zyto Light SPEC CHOP Dual Color Break Apart Probe



### **Background**

The ZytoLight® SPEC DDIT3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 12q13.3 harboring the DDIT3 (C/EBP-homologous protein) gene (a.k.a. CHOP, GADD153).


The DDIT3 gene encodes for a stressinduced dominant-negative inhibitor of the transcription factors C/EBP and LAP. DDIT3 is consistently rearranged in myxoid liposarcomas (MLS). The most frequent translocation involving the DDIT3 gene region is t(12;16)(q13.3;p11.2) and occurs in about 90% of patients with MLS. The rearrangement results in a fusion gene comprising the 5'part of the FUS (fused in sarcoma) gene, located in 16p11.2, and the complete coding region of the DDIT3 gene. The FUS-DDIT3 fusion protein acts as an abnormal transcription factor and development of myxoid liposarcomas is thus regarded as a consequence of deregulated FUS-DDIT3 target genes.

Differential diagnosis of liposarcomas and accurate classification, the latter being especially important with regard to appropriate treatment and prognosis, are often problematic. Therefore, detection of DDIT3 rearrangements via FISH analysis is a valuable tool to confirm the histopathological diagnosis of myxoid liposacrcoma.


References Aman P. et al. (1992) Genes Chromosomes Cancer 5: 278-85. Andersson M, et al. (2010) BMC Cancer 10: 249-58. Germano G, et al. (2010) Cancer Res 70: 2235-44. Meis-Kindblom JM, et al. (2001) Virchows Arch 439: 141-51. Panagopoulos I, et al. (1994) Cancer Res 54: 6500-3. Ron D & Habener JF (1992) Genes Dev 6: 439-53

#### **Probe Description**

The SPEC DDIT3 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 12q13.3-q14.1 band. The orange fluorochrome direct labeled probe hybridizes proximal to the DDIT3 gene and the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 12 indicating the hybridization locations.




SPEC DDIT3 Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 12q13.3-q14.1 band, two orange/green fusion signals are expected representing two normal (nonrearranged) 12q13.3-q14.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 12q13.3-q14.1 locus and one 12q13.3q14.1 locus affected by a 12q13.3-q14.1 translocation.



SPEC DDIT3 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



translocation affecting the 12q13.3-q14.1 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2100-50	Zyto Light SPEC DDIT3 Dual Color Break Apart Probe C    IVD	•/•	5 (50 µl)
Z-2100-200	Zyto Light SPEC DDIT3 Dual Color Break Apart Probe C    IVD	•/•	20 (200 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC CDK4/CEN 12 Dual Color Probe



### **Background**


The ZytoLight ® SPEC CDK4/CEN 12 Dual Color Probe is designed for the detection of CDK4 gene amplifications. The cyclin-dependent kinase 4 (CDK4) gene is located in the chromosomal region 12q14.1, ~10 Mb centromeric to the murine double minute (MDM2) gene and is frequently coamplified with MDM2 in different malignancies.

In a complex with cyclin D1 (CCND1), the CDK4 encoded serine/threonine kinase phosphorylates the retinoblastoma protein 1 (RB1) which in turn leads to the release of the EF2 transcription factor and subsequently to an upregulation of genes which are required for progression through the S-, G2-, and M-phases of the cell cycle. Due to amplification of the respective chromosomal region, CDK4 is overexpressed in many human tumors such as soft tissue sarcomas, osteosarcomas (OS), and gliomas. In glioblastomas, the lack of amplification of several genes like CDK4 was recognized to be associated with a longer survival time. In OS, coamplification of MDM2 and CDK4, located in two discontinuous regions, occurs frequently in parosteal OS and less often in classical high-grade OS.


Although MDM2/CDK4 coamplification is not restricted to atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLPS) and dedifferentiated liposarcomas (DDLPS), its detection is a strong criterion for distinguishing these tumor types from other undifferentiated sarcomas and even from carcinomas and lymphomas.

#### **Probe Description**

The SPEC CDK4/CEN 12 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3) and a green fluorochrome direct labeled SPEC CDK4 probe specific for the chromosomal region 12q13.3-q14.1 harboring the CDK4 gene.




Ideogram of chromosome 12 indicating the hybridization locations.




#### Results

In a normal interphase nucleus two orange and two green signals are expected. Nuclei with amplification of the CDK4 gene locus 12q13.3-q14.1, or polysomy of chromosome 12 will show multiple copies of the green signal or large green signal clusters.



SPEC CDK4/CEN 12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Liposarcoma tissue section, CDK4 signal cluster (green), CEN 12 (orange).

#### References

Binh MB, et al. (2005) Am J Surg Pathol 29: 1340-7. Fischer U, et al. (2010) Int J Cancer 126: 2594-602. Tactier 12, et al. (2001) Oral Oncol 37: 566-71.

Mejia-Guerrero S, et al. (2010) Genes Chromosomes Cancer 49: 518-25.

Sirvent N, et al. (2007) Am J Surg Pathol 31: 1476-89. Wunder JS, et al. (1999) Oncogene 18: 783-8

Prod. No.	Product	Label	Tests* (Volume)
Z-2103-50	Zyto <i>Light</i> SPEC CDK4/CEN 12 Dual Color Probe C € IVD	•/•	5 (50 µl)
Z-2103-200	Zyto <i>Light</i> SPEC CDK4/CEN 12 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

107



## Zyto Light ® SPEC MDM2/CEN 12 Dual Color Probe



### **Background**

The ZytoLight® SPEC MDM2/CEN 12 Dual Color Probe is designed for the detection of MDM2 gene amplifications found in more than 10% of human tumors. The MDM2 (mouse double minute 2) gene is located in the chromosomal region 12q15 and encodes for an E3 ubiquitin ligase which acts as a major negative regulator of the tumor suppressor p53. Due to amplification of the respective chromosomal region, MDM2 is overexpressed in many human tumors such as soft tissue sarcomas, osteosarcomas, gliomas, NSCLC, gastric and breast carcinomas. Well-differentiated liposarcomas (WDLPS), the most common soft tissue tumors in adults, are characterized by the amplification of 12q-derived chromosomal material, harboring the MDM2 oncogene while lipomas show balanced translocations involving 12q13-15. Accordingly, detection of the 12a14-15 amplification is regarded as a valuable tool for the differential diagnosis between WDLPS and lipomas. Furthermore, detection of MDM2 amplification might have prognostic relevance in gastrointestinal stromal tumors (GIST), the most common primary mesenchymal tumor of the gastrointestinal tract.

References
Brisson M, et al. (2013) Skeletal Radiol 42: 635-47.

Duhamel LA, et al. (2012) Histopathology 60: 357-9.
Flanagan AM, et al. (2010) Skeletal Radiol 39: 213-24.
Kashima T, et al. (2012) Mod Pathol 25: 1384-96.

Kikuchi K, et al. (2013) Sarcoma 2013: 520858.


Korcheva VB, et al. (2011) Appl Immunhistochem Mol Morphol 19: 119-25.

Larousserie F, et al. (2013) Eur J Radiol 82: 2149-53.

Lakka S, et al. (2014) BMC Clin Pathol 14: 36. Lakka S, et al. (2014) BMC Clin Pathol 14: 36. Luan SL, et al. (2010) I Pathol 222: 166-79. Momand J, et al. (1992) Cell 69: 1237-45. Oliner JD, et al. (1992) Nature 358: 80-3. Pedeutour F, et al. (1994) Genes Chromosomes Cancer 10: 85-94. Pedeutour F, et al. (2004) Genes Chromosomes Cancer 10: 85-94. Pedeutour F, et al. (2012) Virchows Arch 461: 67-78. Poaty H, et al. (2012) PLoS One 7: e29426. Toledo F & Wahl GM (2006) Nat Rev Cancer 6: 909-23. Topillo Let al. (2005) Lab Invest 85: 921-31. Tornillo L, et al. (2005) Lab Invest 85: 921-31 Vassilev LT (2007) Trends Mol Med 13: 23-31

#### **Probe Description**

The SPEC MDM2/CEN 12 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3) and a green fluorochrome direct labeled SPEC MDM2 probe specific for the MDM2 gene at 12q15.




Ideogram of chromosome 12 indicating the hybridization locations.




SPEC MDM2 Probe map (not to scale).

#### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the MDM2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Normal interphase cells, MDM2 (green), CEN 12 (orange).



Liposarcoma tissue section with amplification of the MDM2 gene (green), CEN 12 (orange).

Prod. No.	Product	Label	Tests* (Volume)
Z-2013-50	Zyto Light SPEC MDM2/CEN 12 Dual Color Probe C E IVD	•/•	5 (50 µl)
Z-2013-200	Zyto Light SPEC MDM2/CEN 12 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

108



## Zyto Light ® SPEC FOXO1 Dual Color Break Apart Probe

Previously: Zyto Light SPEC FKHR Dual Color Break Apart Probe



## **Background**


The ZytoLight® SPEC FOXO1 Dual Color Break Apart Probe is designed for the detection of specific translocations involving the chromosomal region 13q14.11 harboring the FOXO1 (forkhead box O1, a.k.a. FKHR) gene characteristic for alveolar rhabdomyosarcoma.

Among solid tumors of the childhood, rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma. RMS are classified in two main categories: embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). The alveolar histology is associated with a poorer prognosis. ARMS is characterized by two tumor-specific reciprocal translocations t(2;13)(q36;q14.1) and t(1;13)(p36.1;q14.1) detectable in more than 80% of all ARMS. These translocations fuse the FOXO1 locus on 13q14.11 to either PAX3 on chromosome 2 or to PAX7 on chromosome 1. The resulting fusion transcripts encode for the chimeric proteins PAX3-FOXO1 and PAX7-FOXO1 that combine transcriptional domains from the corresponding wild-type proteins and thereby acquire oncogenic activity. The translocations and their fusion genes represent highly specific genetic markers useful in the diagnosis of ARMS.


References
Dal Cin P, et al. (1991) Cancer Genet Cytogenet 55: 191-5.
Douglass EC, et al. (1991) Genes Chromosomes Cancer 3: 480-2.
Gunawan B, et al. (1999) Pathol Oncol Res 5: 211-3.
Seidal T, et al. (1982) Acta Pathol Microbiol Immunol Scand A 90: 345-54.
Sorensen PH, et al. (2002) J Clin Oncol 20: 2672-9.

## **Probe Description**

The SPEC FOXO1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 13q14.11 band. The orange fluorochrome direct labeled probe hybridizes distal, the green fluorochrome direct labeled probe hybridizes proximal to the breakpoint region of the FOXO1 gene.




Ideogram of chromosome 13 indicating the hybridization locations.




SPEC FOXO1 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 13q14.11 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 13q14.11 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 13q14.11 locus and one 13q14.11 locus affected by a translocation.



SPEC FOXO1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Rhabdomyosarcoma tissue section with translocation affecting the 13q14.11 locus harboring FOXO1 as indicated by one orange/green fusion signal (non-rearranged), one orange signal, and one separate green signal indicating the translocation.

	Prod. No.	Product	Label	Tests* (Volume)
	Z-2139-50	Zyto <i>Light</i> SPEC FOXO1 Dual Color Break Apart Probe C	<b>-/-</b>	5 (50 µl)
Related Products				
	Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
		Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC FOXO1/PAX3 Dual Color Single Fusion Probe

Previously: ZytoLight RMS | Probe SPEC t(2;13) Dual Color Fusion Probe



## **Background**

The ZytoLight ® SPEC FOXO1/PAX3 Dual Color Single Fusion Probe is designed to detect the translocation t(2;13) (q36;q14.1) in alveolar rhabdomyosarcomas.

Among solid tumors of the childhood, rhabdomyosarcoma is the most common soft tissue sarcoma. Rhabdomyosarcomas are classified in two main categories: embryonal and alveolar rhabdomyosarcoma. The alveolar histology is associated with a poorer prognosis.

Alveolar rhabdomyosarcoma is characterized by two tumor-specific translocations, i.e., t(2;13)(q36;q14.1) and t(1;13) (p36.1;q14.1) which are detectable in most cases of alveolar rhabdomyosarcomas.


The translocations and their fusion genes represent highly specific genetic markers useful in the diagnosis of alveolar rhabdomyosarcomas.

Correlations between the type of translocation and clinical features as e.g. longer disease-free survival have been identified.

References
Dal Cin P, et al. (1991) Cancer Genet Cytogenet 55: 191-5.
Douglass EC, et al. (1991) Genes Chromosomes Cancer 3: 480-2.
Gunawan B, et al. (1999) Pathol Oncol Res 5: 211-3.
Rekhi B, et al. (2014) Pathol Res Pract 210: 328-33. Seidal T, et al. (1982) Acta Pathol Microbiol Immunol Scand [A]: 345-54.


## **Probe Description**

The SPEC FOXO1/PAX3 Dual Color Single Fusion Probe is a mixture of two direct labeled probes hybridizing to the 2q36.1 and 13q14.11 band. The green fluorochrome direct labeled probe hybridizes distal to the PAX3 gene at 2q36.1, the orange fluorochrome direct labeled probe hybridizes proximal to the FOXO1 gene at 13q14.11.





Ideograms of chromosomes 2 (above) and 13 (below) indicating the hybridization locations.



SPEC PAX3 Probe map (not to scale).




SPEC FOXO1 Probe map (not to scale).

### Results

In an interphase nucleus lacking the t(2;13), two orange and two green signals

In a cell harboring the t(2;13), one orange signal, one green signal, and one orange/green fusion signal will be observed.



SPEC FOXO1/PAX3 Dual Color Single Fusion Probe hybridized to abnormal nuclei harboring a t(2;13)(q35;q14) as indicated by one orange, one green, and one orange/green fusion signal.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2018-50	Zyto <i>Light</i> SPEC FOX01/PAX3 Dual Color Single Fusion Probe C € IVD	<b>-/-</b>	5 (50 µl)	
Z-2018-200	Zyto <i>Light</i> SPEC FOX01/PAX3 Dual Color Single Fusion Probe C € IVD	<b>-/-</b>	20 (200 µl)	
Related Products				
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   Ind. Heat Pretreatment Solution (Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5	
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20	

<sup>\*</sup> Using 10 µl probe solution per test. C € 🔟 only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rma</u>



## Zyto Light ® SPEC FOXO1/PAX3 TriCheck™ Probe



## **Background**


The ZytoLight ® SPEC FOXO1/PAX3 TriCheck™ Probe is designed to detect translocations involving the chromosomal region 13q14.11 harboring the FOXO1 (forkhead box O1, a.k.a. FKHR) gene and the chromosomal region 2q36.1 harboring the PAX3 (paired box 3, a.k.a. HUP2) gene. Among solid tumors of the childhood, rhabdomyosarcoma is the most common soft tissue sarcoma. Rhabdomyosarcomas are classified in two main categories: embryonal and alveolar rhabdomyosarcoma. Generally, the alveolar histology is associated with a poorer prognosis.


Alveolar rhabdomyosarcoma (ARMS) is characterized by two tumor-specific translocations, i.e., t(2;13)(q36;q14.1) and t(1;13)(p36.1;q14.1) which are detectable in most cases of ARMS. The translocations involve the FOXO1 gene and either PAX7 on chromosome 1p36.13 or PAX3 on chromosome 2q36.1. PAX7-FOXO1 is less common but is associated with a better prognosis than PAX3-FOXO1 fusion. The translocations and their fusion genes represent highly specific genetic markers useful in the diagnosis and prognosis of ARMS.

Noterences
Dal Cin P, et al. (1991) Cancer Genet Cytogenet 55: 191-5.
Douglass EC, et al. (1991) Genes Chromosomes Cancer 3: 480-2.
Gunawan B, et al. (1999) Pathol Oncol Res 5: 211-3.
Jain S, et al. (2010) Int J Clin Exp Pathol 3: 416-28.
Seidal T, et al. (1982) Acta Pathol Microbiol Immunol Scand [A]: 345-54.

## **Probe Description**

The SPEC FOXO1/PAX3 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the 13q14.11 and 2q36.1 bands. The orange fluorochrome direct labeled probe hybridizes proximal and the green fluorochrome direct labeled probe hybridizes distal to the FOXO1 breakpoint region at 13q14.11. The blue fluorochrome direct labeled probe hybridizes distal to the PAX3 gene at 2q36.1.






Ideograms of chromosomes 13 (above) and 2 (below) indicating the hybridization locations.

## Results


In an interphase nucleus without PAX3-FOXO1 rearrangement, two green/orange fusion signals and two blue signals are expected.

A PAX3-FOXO1 fusion is indicated by one separate orange signal co-localizing with one blue signal and one separate green


A FOXO1 translocation without involvement of PAX3 is indicated by the split of one green/orange fusion signal without co-localization of the separated orange signal with one blue signal.




SPEC FOXO1/PAX3 TriCheck™ Probe hybridized to normal interphase cells as indicated by two orange/ green fusion signals and two blue signals per nucleus.



ARMS tissue section with PAX3-FOXO1 fusion as indicated by orange/blue fusion signals.



SPEC FOXO1 Probe map (not to scale).



SPEC PAX3 Probe map (not to scale).

D. J. M.	D., J., J	1.4.1	T * (V. l )	
Prod. No.	Product	Label	Tests* (Volume)	
Z-2185-50	Zyto <i>Light</i> SPEC FOXO1/PAX3 TriCheck Probe C	•/•/•	5 (50 µl)	
Related Products				
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IVD		5	
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC FOXO1/PAX7 Dual Color Single Fusion Probe

Previously: ZytoLight RMS II Probe SPEC t(1;13) Dual Color Fusion Probe



## **Background**

The ZytoLight ® SPEC FOXO1/PAX7 Dual Color Single Fusion Probe is designed to detect the translocation t(1;13) (p36.1;q14.1) in alveolar rhabdomyosarcomas.

Among solid tumors of the childhood, rhabdomyosarcoma is the most common soft tissue sarcoma. Rhabdomyosarcomas are classified in two main categories: embryonal and alveolar rhabdomyosarcoma. The alveolar histology is associated with a poorer prognosis.

Alveolar rhabdomyosarcoma is characterized by two tumor-specific translocations, i.e., t(2;13)(q36;q14.1) and t(1;13) (p36.1;q14.1) which are detectable in most cases of alveolar rhabdomyosarco-


The translocations and their fusion genes represent highly specific genetic markers useful in the diagnosis of alveolar rhabdomyosarcomas.


Correlations between the type of translocation and clinical features as e.g. longer disease-free survival have been identified.

National References
Dal Cin P, et al. (1991) Cancer Genet Cytogenet 55: 191-5.
Douglass EC, et al. (1991) Genes Chromosomes Cancer 3: 480-2.
Gunawan B, et al. (1999) Pathol Oncol Res 5: 211-3.
Rekhi B, et al. (2014) Path

## **Probe Description**

The SPEC FOXO1/PAX7 Dual Color Single Fusion Probe is a mixture of two direct labeled probes hybridizing to the 1p36.13 and 13q14.11 band. The green fluorochrome direct labeled probe hybridizes distal to the PAX7 gene at 1p36.13, the orange fluorochrome direct labeled probe hybridizes proximal to the FOXO1 gene at 13q14.11.






SHGC-142982

SPEC FOXO1 Probe map (not to scale).

### Results

In an interphase nucleus lacking the t(1;13), two orange and two green signals

In a cell harboring the t(1;13), one orange signal, one green signal, and one orange/green fusion signal will be observed.



SPEC FOXO1/PAX7 Dual Color Single Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2019-50	Zyto <i>Light</i> SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C€ IVD	<u> </u>	5 (50 µl)
Z-2019-200	Zyto <i>Light</i> SPEC FOXO1/PAX7 Dual Color Single Fusion Probe C € IVD	<b>-/-</b>	20 (200 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   IND Ind. Heat Pretreatment Solution (Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD Ind. Heat Pretreatment Solution (Itric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informat



# Zyto Light ® SPEC RB1/13q12 Dual Color Probe



## **Background**

The ZytoLight ® SPEC RB1/13q12 Dual Color Probe is designed for the detection of deletions affecting the RB1 gene. The RB1 (retinoblastoma 1, a.k.a. pRb) gene is located on 13q14.2 and encodes a protein which acts as a tumor suppressor playing a crucial role in cell cycle regulation and genome stability. Deletions of RB1 are frequently found in retinoblastoma.

However, either monoallelic or biallelic deletions of RB1 are also common in a wide variety of solid tumors and hematologic malignancies such as multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).


While 13q14 deletions exclusive of RB1 confer a more favorable prognosis in CLL patients, 13a14 deletions that encompass the RB1 locus (present in approx. 20% of all CLL cases) are associated with shortened survival.

Hence, Fluorescence in situ Hybridization is a valuable tool for the detection of RB1 gene deletions and can be used in combination with further biological markers, morphology and clinical information for the prediction of disease progression and overall survival.


References
Dal Bo M, et al. (2011) Genes Chromosomes Cancer 50: 633-43. Dal Bo M, et al. (2011) Genes Chromosomes Cancer 50: 63 Dao DD, et al. (1994) Leukemia 8: 1280-4. Di Fiore R, et al. (2013) J Cell Physiol 228: 1676-87. Juge-Morineau N, et al. (1997) Leuk Lymphoma 24: 229-37. Orlandi EM, et al. (2013) Hematol Oncol 31: 136-42. Ouillette P, et al. (2011) Clin Cancer Res 17: 6778-90.

## **Probe Description**

The SPEC RB1/13q12 Dual Color Probe is a mixture of an orange fluorochrome direct labeled SPEC RB1 probe specific for the RB1 gene in the chromosomal region 13q14.2 and a green fluorochrome direct labeled SPEC 13q12 probe specific for the chromosomal region 13q12.11. The SPEC 13q12 Probe is designed to hybridize in close proximity of centromere 13 at 13q12.11. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.



Ideogram of chromosome 13 indicating the hybridization locations.







SPEC 13q12 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the RB1 gene locus, one or no copy of the orange signal will be observed.



SPEC RB1/13q12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



SPEC RB1/13q12 Dual Color Probe hybridized to benign spindle cell lipoma tissue section with deletion of the RB1 gene as indicated by one orange signal and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2165-50	ZytoLight SPEC RB1/13q12 Dual Color Probe C    IVD	<b>●/●</b>	5 (50 µl)
Z-2165-200	Zyto <i>Light</i> SPEC RB1/13q12 Dual Color Probe C€ IVD	<b>●/●</b>	20 (200 µl)
Related Pr	oducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	ZytoLight FISH-Tissue Implementation Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	ZytoLight FISH-Cytology Implementation Kit C   Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light ® SPEC GAS6/13q12 Dual Color Probe



## **Background**

The ZytoLight® SPEC GAS6/13q12 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the GAS6 gene. The GAS6 (growth arrest-specific 6, a.k.a.

AXSF, AXLLG) gene is located on chromosome 13q34 and encodes a ligand for the receptor tyrosine kinase family TAM which includes the proteins TYRO3, AXL, and MERTK. GAS6 has the highest affinity for AXL, followed by TYRO3, and MERTK. Binding of GAS6 to TAM receptors has been shown to promote proliferation and survival of cancer cells in vitro.

GAS6 overexpression and its association with poorer prognosis has been reported in several human cancers including glioblastoma, pancreatic ductal adenocarcinoma, ovarian cancer, and cytogenetically normal acute myeloid leukemia. In patients with gastric cancer, high expression of GAS6 was shown to be associated with lymph node metastasis. GAS6 has been shown to be a target for overexpression and amplification in breast cancer positively correlating with a number of favorable prognostic markers

Hence, the identification of GAS6 gene copy number changes by Fluorescence in situ Hybridization may be of prognostic significance in various types of tumors. Moreover, interventions which inhibit GAS6 pathways could have therapeutic potential.


including smaller tumor size.

### References


Reterences
Abba MC, et al. (2007) Cancer Res 67: 4104-12.
Buehler M, et al. (2013) Biomed Res Int 2013: 238284.
Hutterer M, et al. (2008) Clin Cancer Res 14: 130-8.
Mc Cormack O, et al. (2008) Br J Cancer 98: 1141-6.
Nagata K, et al. (1996) J Biol Chem 271: 30022-7. Nagara K, et al. (2011) Cancer 117: 734-43. Verma A, et al. (2011) Mol Cancer Ther 10: 1763-73. Whitman SP, et al. (2014) Leukemia 28: 1252-8.

## **Probe Description**

The SPEC GAS6/13q12 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC GAS6 probe hybridizing to the human GAS6 gene in the chromosomal region 13q34 and an orange fluorochrome direct labeled SPEC 13q12 probe specific for 13q12.11. The SPEC 13q12 Probe is designed to hybridize in close proximity of centromere 13 at 13q12.11. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.



Ideogram of chromosome 13 indicating the hybridization locations.




SPEC GAS6 Probe map (not to scale).



SPEC 13q12 Probe map (not to scale).

## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the GAS6 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC GAS6/13q12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2156-200	Zyto <i>Light</i> SPEC GAS6/13q12 Dual Color Probe C € IVD	•/•	20 (200 µl)		
Related Products					
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20		
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml				

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# Zyto Light ® SPEC BCL2L2/14q32 Dual Color Probe



## **Background**


The ZytoLight ® SPEC BCL2L2/14q32 Dual Color Probe is designed for the detection of BCL2L2 gene amplifications. The BCL2L2 (BCL2-like 2, a.k.a. BCL-W) gene is located in the chromosomal region 14q11.2 and encodes for an anti-apoptotic protein that belongs to the BCL2 family. These genes are involved in a wide variety of cellular activities including lymphocyte development and hematopoiesis. BCL2L2 amplifications have been reported in several human cancers including lung, ovarian, breast, and hematologic malignancies.

BCL2L2 amplifications are found in many tumor cell lines with resistance to chemotherapeutic agents. Targeting the BCL2 family proteins with small non-peptidic compounds, so called BH3-mimetics, is currently investigated in clinical trials. Hence, the identification of BCL2L2 amplifications by Fluorescence in situ Hybridization and the inhibition of BCL2L2 signaling may be of therapeutic significance in various types of tumors.


References
Beroukhim R, et al. (2010) Nature 463: 899-905. Booher RN, et al. (2014) PloS One 9: e108371. Sochalska M, et al. (2015) FEBS J 282: 834-49. Yasui K, et al. (2004) Cancer Res 64: 1403-10.

## **Probe Description**


The SPEC BCL2L2/14q32 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC BCL2L2 probe hybridizing to the BCL2L2 gene in the chromosomal region 14q11.2 and an orange fluorochrome direct labeled SPEC 14q32 probe specific for the chromosomal region 14q32.33. Due to cross-hybridizations of chromosome 14 alpha satellites to other centromeric regions, probes specific for 14g32 are frequently used for chromosome 14 copy number detection.



Ideogram of chromosome 14 indicating the hybridization locations.




SPEC BCL2L2 Probe map (not to scale).



SPEC 14q32 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the BCL2L2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC BCL2L2/14q32 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2172-200	Zyto <i>Light</i> SPEC BCL2L2/14q32 Dual Color Probe C € IVD	•/•	20 (200 µl)	
Related Products				
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20	
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## Zyto Light ® SPEC IGH Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC IGH Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 14q32.33 harboring the IGH gene.

Rearrangements involving the IGH (immunoglobulin heavy locus, a.k.a. IGH@) gene are considered to be cytogenetic hallmarks for non-Hodgkin lymphoma (NHL). NHLs represent 50% of all hematological malignancies.


IGH gene rearrangements have been identified in about 50% of NHLs and are associated with specific subtypes of NHLs. Translocation t(11;14)(q13.3;q32.3) can be found in about in 95% of mantle cell lymphoma (MCL), t(14;18)(q32.3;q21.3) in 80% of follicular lymphoma (FL), t(3;14) (q27;q32.3) in diffuse large B-cell lymphoma (DLBCL), and t(8;14)(q24.21;q32.3) in Burkitt's lymphoma. In all of these translocations an oncogene located near the breakpoint of the translocation partner is activated by juxtaposing to IGH regulatory

Rearrangements involving 14q32.33 have unique biological characteristics and correlate with clinical, morphological, and immunophenotypic features. Fluorescence in situ Hybridization is a helpful tool for the diagnosis, selecting treatment, and giving prognostic information.


Retreences
Bernicot 1, et al. (2007) Cytogenet Genome Res 118: 345-52.
Hehne S, et al. (2012) Pathol Res Pract 208: 510-7.
Nishida K, et al. (1997) Blood 90: 526-34. Lu S, et al. (2004) Cancer Genet and Cytogenet 152: 141-5. Quintero-Rivera F, et al. (2009) Cancer Genet and Cytogenet 190: 33-9.

## **Probe Description**

The SPEC IGH Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 14q32.33 band. The orange fluorochrome direct labeled probe hybridizes proximal, and the green fluorochrome direct labeled probe hybridizes distal to the constant regions of the IGH locus.




Ideogram of chromosome 14 indicating the hybridization locations.




SPEC IGH Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 14q32.33 band two orange/green fusion signals are expected representing two normal (non-rearranged) 14q32.33 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 14q32.33 locus and one 14q32.33 locus affected by a translocation.



SPEC IGH Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Burkitt-Lymphoma tissue section with translocation affecting the 14q32.33 locus as indicated by one non-rearranged orange/areen fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2110-50	Zyto <i>Light</i> SPEC IGH Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Z-2110-200	Zyto Light SPEC IGH Dual Color Break Apart Probe CE IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit CE IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit CE IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC NUTM1 Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC NUTM1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 15q14 harboring the NUTM1 (NUT midline carcinoma family member 1, a.k.a.

NUT midline carcinoma (NMC) is a rare and aggressive form of squamous cell carcinoma that arises mainly in the head, neck, or mediastinum. NMC is genetically defined by the presence of chromosomal rearrangements involving the NUTM1 gene. Two-thirds of NMCs have t(15;19) (q14;p13.1) fusing the NUTM1 gene to the BRD4 gene. Less commonly, NMC harbors a NUTM1-variant fusion gene involving BRD3 or still-uncharacterized genes. NMCs may be indistinguishable from more common squamous cell carcinomas and are thus an underdiagnosed entity. Therefore, the diagnosis of NMC depends on the confirmation of NUTM1 rearrangement. BRD3 and BRD4 belong to the bromo and extra terminal (BET) family of bromodomain proteins. BRD-NUTM1 chimeric oncoproteins repress squamous differentiation, possibly by sequestering histone acetyltransferase activity. Accordingly, histone deacetylase inhibitors or BET inhibitors were shown to reverse the effects of BRD-NUTM1 fusion proteins by inducing terminal differentiation of NMC cells in vitro and in xenograft models.


Hence, detection of NUTM1 rearrangements by FISH represents a useful tool in the differential diagnosis of NMC and may be of therapeutic significance.

References French CA (2012) Annu Rev Pathol 7: 247-65. Kubonishi I, et al. (1991) Cancer Res 51: 3327-8.


Müller S & Knapp S (2014) Med Chem Commun 5: 288-96.

## **Probe Description**

The SPEC NUTM1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 15q14 band. The green fluorochrome direct labeled probe hybridizes proximal and the orange fluorochrome direct labeled probe hybridizes distal to the NUTM1 gene.




Ideogram of chromosome 15 indicating the hybridization locations.




SPEC NUTM1 Probe map (not to scale).

### **Results**

In an interphase nucleus lacking a translocation involving the 15q14 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 15q14 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 15q14 locus and one 15q14 locus affected by a translocation.



SPEC NUTM1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



NMC tissue section with translocation of the NUTM1 gene as indicated by one non-rearranged orange/ green fusion signal, one orange and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)		
Z-2208-200	Zyto <i>Light</i> SPEC NUTM1 Dual Color Break Apart Probe CE IVD	•/•	20 (200 µl)		
Related Pro	Related Products				
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20		
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml				

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>n



# Zyto Light® SPEC PML/RARA Dual Color Dual Fusion Probe



## **Background**

The ZytoLight® SPEC PML/RARA Dual Color Dual Fusion Probe is designed to detect the translocation t(15;17)(q24;q21.2)affecting the PML gene in the chromosomal region 15q24.1 and the RARA locus in 17q21.2.

Translocations involving the PML (promyelocytic leukemia, a.k.a. MYL) gene and the RARA (retinoic acid receptor alpha, a.k.a.  $RAR\alpha$ ) gene are considered to be characteristic for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia.


Various fusion partners of RARA have been identified, however, in 95% of all APL cases, rearrangements involving the PML gene are detectable. This translocation t(15;17)(q24;q21) leads to a gene fusion of the PML and the RARA gene. The fusion is supposed to play a fundamental role in induction, development, and progression of APL.


Since the PML/RARA fusion accounts for the response of these neoplasms to all-trans retinoic acid (ATRA) therapy and other conventional chemotherapy it is important to accurately distinguish between t(15;17) translocations and translocations involving other partners of RARA.

Ketrernces Abe S, et al. (2008) Cancer Genet and Cytogenet 184: 44-7. Brockmann SR, et al. (2003) Cancer Genet and Cytogenet 145: 144-51. Reiter A, et al. (2004) Acta Hematol 112: 55-67. Sanz MA, et al. (2009) Blood 113: 1875-91.


## **Probe Description**

The SPEC PML/RARA Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled PML probe spanning the known PML breakpoints, and a green fluorochrome direct labeled RARA probe spanning the known breakpoints of RARA.






Ideograms of chromosomes 15 (above) and 17 (below) indicating the hybridization locations.




SPEC PML Probe map (not to scale).




SPEC RARA Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal PML/RARA translocation leads to two orange/green fusion signals indicating both rearranged chromosomes. Additionally, the non-rearranged chromosomes are indicated by one orange signal and a separate green signal, respectively.



SPEC PML/RARA Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bone marrow biopsy section with translocation affecting the PML/RARA loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

	Prod. No.	Product	Label	Tests* (Volume)
	Z-2113-50	Zyto <i>Light</i> SPEC PML/RARA Dual Color Dual Fusion Probe C € IVD	<u> </u>	5 (50 µl)
	Z-2113-200	Zyto <i>Light</i> SPEC PML/RARA Dual Color Dual Fusion Probe C € IVD	<b>●/●</b>	20 (200 µl)
	Related Proc	lucts		
	Z-2028-5	ZytoLight FISH-Tissue Implementation Kit C FIVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
	Z-2028-20	ZytoLight FISH-Tissue Implementation Kit C FIVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
	Z-2099-20	ZytoLight FISH-Cytology Implementation Kit C € IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>r



## Zyto Light ® SPEC NTRK3 Dual Color Break Apart Probe



## **Background**


The ZytoLight ® SPEC NTRK3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 15q25.3 harboring the NTRK3 (neurotrophic receptor tyrosine kinase receptor type 3, a.k.a. TRKC) gene.

NTRK3 is a receptor tyrosine kinase (TK) for neurotrophin 3 (NT3) and plays a key role in central and peripheral nervous system development as well as in cell survival. Translocations affecting the NTRK3 gene have been reported in several cancer types, including glioblastomas, Philadelphia chromosome-like acute lymphoblastic leukemia, congenital fibrosarcomas, cellular mesoblastic nephromas, acute myeloid leukemia, radiation-associated thyroid cancer, secretory breast carcinoma, and mammary analog secretory carcinoma of the salivary gland. The most frequent rearrangement involving the NTRK3 gene is the t(12;15) (p13;q25) which results in a fusion between the 5' part of the ETV6 gene and the 3' part of the NTRK3 gene. This fusion gene encodes a hybrid protein comprising the TK domain of NTRK3 and the dimerization domain of ETV6 which leads to a ligandindependent TK activity.


Currently, there are several ongoing clinical trials involving drugs with known inhibitory activity of NTRK-related kinases. Entrectinib and LOXO-101 represent two of these TRK inhibitors which have shown promising activity and good tolerability in patients with advanced solid tumors and NSCLC harboring NTRK1, 2, and 3 rearrangements. Hence, detection of NTRK3 translocations by Fluorescence in situ Hybridization (FISH) may be of diagnostic and therapeutic relevance.

## **Probe Description**

The SPEC NTRK3 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 15q25.3-q26.1 band. The orange fluorochrome direct labeled probe hybridizes proximal to the NTRK3 breakpoint region at 15q25.3, the green fluorochrome direct labeled probe hybridizes distal to the NTRK3 breakpoint region at 15q25.3-q26.1.




Ideogram of chromosome 15 indicating the hybridization locations.




SPEC NTRK3 Probe map (not to scale)

## Results

In an interphase nucleus of a normal cell lacking a translocation involving the 15q25.3-q26.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 15q25.3q26.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 15q25.3-q26.1 locus and one 15q25.3-q26.1 locus affected by a translocation.



SPEC NTRK3 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Secretory breast carcinoma tissue section with translocation affecting the 15q25.3-q26.1 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation

References
Amotu A, et al. (2016) ESMO Open 1: e000023.
Arce C, et al. (2005) World J Surg Oncol 3: 35.
Knezevich SR, et al. (1998) Not Genet 18: 184-7.
Leeman-Neill RJ, et al. (2014) Cancer 120: 799-807.
Nagasubramanian R, et al. (2014) Pediatr Blood Cancer 63: 1468-70.
Roez LE & Rolfo C (2016) Lung Cancer Manag 5: 1-4.
Roberts KG, et al. (2014) N Engl J Med 371: 1005-15.
Skálová A, et al. (2010) Am J Surg Pathol 34: 599-608.
Tagnon C, et al. (2002) Cancer Cell 2: 367-76.
Wu G, et al. (2014) N Engl 46: 446-50. Wu G, et al. (2014) Nat Genet 46: 444-50.

Prod. No.	Product	Label	Tests* (Volume)
Z-2206-200	Zyto <i>Light</i> SPEC NTRK3 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C€ IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC FUS Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC FUS Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 16p11.2 harboring the FUS (fused in sarcoma) gene (a.k.a. TLS, FUS/TLS, hnRNP P2).

The FUS gene encodes an RNA-binding protein, the C-terminal end of which is involved in protein and RNA binding and which appears to be involved in transcriptional activation with its N-terminal end. It shares distinct characteristics with EWSR1 and TAF15 which together with FUS are frequently referred to as the FET family of proteins.


FUS gene rearrangements have been shown to be involved in both solid tumors and leukemias fusing the N-terminal end of FUS to various fusion partners. The most frequent translocation involving the FUS gene region is t(12;16)(q13.3;p11.2). Occurring in over 90% of myxoid liposarcomas, the FUS-DDIT3 fusion protein is regarded as being consequential for the development of myxoid liposarcomas by acting as an abnormal transcription factor and thus deregulating FUS-DDIT3 target genes.

Differential diagnosis of liposarcomas and accurate classification, the latter being especially important with regard to appropriate treatment and prognosis, are often problematic. Therefore, detection of FUS rearrangements via in situ Hybridization analysis is a valuable tool to confirm the histopathological diagnosis of myxoid liposarcoma.

References Andersson M, et al. (2010) BMC Cancer 10: 249-58. Antonescu C, et al. (2000) J Mol Diagn 2: 132-8. Germano G, et al. (2010) Cancer Res 70: 2235-44. Kuroda M, et al. (1995) Am J Pathol 147: 1221-7. Meis-Kindblom JM, et al. (2001) Virchows Arch 439: 141-51. Panagopoulos I, et al. (1994) Cancer Res 54: 6500-3. Panagopoulos I, et al. (1997) Oncogene 15: 1357-62

## **Probe Description**

The SPEC FUS Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 16p11.2 band. The orange fluorochrome direct labeled probe hybridizes proximal to the FUS gene, the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 16 indicating the hybridization locations.




SPEC FUS Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 16p11.2 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 16p11.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 16p11.2 locus and one 16p11.2 locus affected by a 16p11.2 translocation.



SPEC FUS Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Myxoid liposarcoma tissue section with translocation affecting the 16p11.2 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2130-50	Zyto <i>Light</i> SPEC FUS Dual Color Break Apart Probe C	•/•	5 (50 µl)	
Related Products				
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5	
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml			

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light® SPEC CBFB Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC CBFB Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 16q22.1 harboring the CBFB (core-binding factor beta, a.k.a. PEBP2B)


CBFB encodes the beta subunit of the CBFA/CBFB transcription factor complex involved in myeloid differentiation. The chromosomal aberrations inv(16) (p13.1a22.1) and the related translocation t(16;16)(p13.1;q22.1), which have been detected in about 10% of patients with AML (acute myeloblastic leukemia), lead to the fusion of the CBFB gene with the MYH11 (smooth muscle myosin heavy chain) gene on 16p13.1. The resulting CBFB-MYH11 fusion gene is involved in leukemic transformation. AML patients with these genetic rearrangements have a favorable prognosis. Inv(16) may sometimes be difficult to identify using conventional cytogenetic analysis.

Accordingly, Fluorescence in situ hybridization proved to be a reliable method overcoming this problem and might consequently be a helpful tool to predict the prognosis of AML patients.


Aventin A, et al. (2002) Cancer Genet Cytogenet 134: 142-4.
Dierlamm J, et al. (1998) Genes Chromosomes and Cancer 22: 87-94.
Krauter J, et al. (2001) Genes Chromosomes and Cancer 30: 342-8.
Le Beau MM, et al. (1983) N Engl J Med 309: 630-6. Li MM, et al. (2013) Curr Genet Med Rep 1: 99-112

## **Probe Description**

The SPEC CBFB Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 16q22.1 band. The orange fluorochrome direct labeled probe hybridizes proximal, the green fluorochrome direct labeled probe hybridizes distal to the CBFB gene breakpoint region at 16q22.1.




Ideogram of chromosome 16 indicating the hybridization locations.



SPEC CBFB Probe map (not to scale).

### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 16q22.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 16q22.1 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 16q22.1 locus and one 16q22.1 locus affected by a transloca-



SPEC CBFB Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2207-50	Zyto <i>Light</i> SPEC CBFB Dual Color Break Apart Probe C	•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C   IND  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC TP53/17q22 Dual Color Probe



## **Background**

The ZytoLight ® SPEC TP53/17q22 Dual Color Probe is designed for the detection of TP53 deletions as well as for the determination of copy number changes of the chromosomal region 17q22, harboring the MPO (myeloperoxidase) gene. TP53 loss in combination with signal gain of the 17q22 chromosomal region serve as a marker for the detection of isochromosomes often found in hematologic malignancies as well as in neuroblastoma.

The TP53 gene (tumor protein 53, a.k.a. p53, BCC7, LFS1, TRP53) is located in the chromosomal region 17p13.1 and encodes a 53 kDa transcription factor. TP53 gene deletions have been detected in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and acute myeloid leukemia (AML). In CLL patients, allelic loss of the short arm of chromosome 17 is associated with treatment failure with alkylating agents and short survival times.


Isochromosome 17q is a frequent cytogenetic abnormality seen in hematologic malignancies including blast phase of chronic myelogenous leukemia (CML), AML, Hodgkin and non-Hodgkin lymphomas. In neuroblastoma, gain of the 17q21-qter is associated with stronger tumor progression.

Thus, the combined detection of both targets by Fluorescence in situ Hybridization allows for a sensitive determination of isochromosomes and may be a helpful tool for diagnosis and selecting treatment.


Retreences
Becher R, et al. (1990) Blood 8: 1679-83.
Bown N, et al. (1999) N Engl J Med 340: 1954-61.
Fioretos T, et al. (1999) Blood 94: 225-32.
Petitit AR, et al. (2001) Blood 98: 814-22. Ripollés L, et al. (2006) Cancer Genet Cytogenet 171: 57-64. Shanafelt TD, et al. (2006) Ann Intern Med 145: 435-47.

## **Probe Description**


The SPEC TP53/17q22 Dual Color Probe is a mixture of an orange fluorochrome direct labeled SPEC TP53 probe hybridizing to the TP53 gene in the chromosomal region 17p13.1 and a green fluorochrome direct labeled SPEC 17q22 probe specific for the chromosomal region 17q22 harboring the MPO gene.



Ideogram of chromosome 17 indicating the hybridization locations.




SPEC TP53 Probe map (not to scale).




SPEC 17q22 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletion of the TP53 gene locus, one orange signal and two green signals can be detected. A gain of 17q involving the 17q22 region will result in three or more green signals and two orange signals. Isochromosome 17q is indicated by three green signals and one orange signal.



SPEC TP53/17q22 Dual Color Probe hybridized to bone marrow tissue section with deletion of the TP53 gene as indicated by one green signal and two orange signals in each nucleus.



SPEC TP53/17q22 Dual Color Probe hybridized to a bone marrow smear with isochromosome 17q as indicated by three green signals and one orange signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2198-50	Zyto <i>Light</i> SPEC TP53/17q22 Dual Color Probe C € IVD	<b>o/o</b>	5 (50 µl)
Related Pro	ducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC TP53/CEN 17 Dual Color Probe



## **Background**

The ZytoLight ® SPEC TP53/CEN 17 Dual Color Probe is designed for the detection of TP53 gene deletions observed e.g. in chronic lymphocytic leukemia (CLL). The TP53 gene (tumor protein 53, a.k.a. p53, BCC7, LFS1, TRP53) is located in the chromosomal region 17p13.1 and encodes a 53 kDa transcription factor which regulates cell proliferation, differentiation, and apoptosis and which functions as a tumor suppressor by activating the expression of genes that inhibit cell growth. Deletions affecting the short arm of chromosome 17 (17p), the site of the TP53 gene, are often accompanied by mutations in the remaining allele, and thus result in the loss of TP53 tumor suppressor activity.


TP53 gene deletions have been detected in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), and are also very frequent in primary solid tumors of different histological origin. The presence of TP53 deletion has been shown to correlate with more aggressive disease, shortened survival, and poor response to standard treatment. CLL patients with deletion of 17p are more likely to respond to treatment with the monoclonal anti-CD52 antibody alemtuzumab than to conventional chemotherapy. FISH is an effective method to screen for deletions affecting the TP53 gene locus in order to identify patients who are candidates for alternative treatment and to avoid administration of otherwise ineffective therapy.

## **Probe Description**

The SPEC TP53/CEN 17 Dual Color Probe is a mixture of a green fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1) and an orange fluorochrome direct labeled SPEC TP53 probe specific for the TP53 gene at 17p13.1.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC TP53 Probe map (not to scale).

## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the TP53 gene locus, one or no copy of the orange signal will be observed.



SPEC TP53/CEN 17 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



SPEC TP53/CEN 17 Dual Color Probe hybridized to bone marrow tissue section with deletion of the TP53 gene as indicated by one orange signal and two green signals in each nucleus.

Reterences
Amiel A, et al. (1997) Cancer Genet Cytogenet 97: 97-100.
Chang H, et al. (2005) Blood 105: 358-60.
Chang H, et al. (2010) Am J Clin Pathol 133: 70-4.
Herrera JC, et al. (2010) Biomedica 30: 390-400.
Lozanski G, et al. (2004) Blood 103: 3278-81.
Tavor S, et al. (2011) Leuk Lymphoma 52: 642-7.

Prod. No.	Product	Label	Tests* (Volume)
Z-2153-50	ZytoLight SPEC TP53/CEN 17 Dual Color Probe C    IVD	<b>o/o</b>	5 (50 µl)
Z-2153-200	Zyto <i>Light</i> SPEC TP53/CEN 17 Dual Color Probe C€	<b>o/o</b>	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD		20
	Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml;		
	Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC USP6 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC USP6 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 17p13.2 harboring the USP6 (Ubiquitin-specific peptidase 6, a.k.a. TRE2 or TRE17) gene.

Translocations affecting USP6 have been initially found in primary aneurysmal bone cysts (ABC), a benign, but locally aggressive bone lesion that occurs predominantly during the first two decades of life. USP6 rearrangements are restricted to spindle cells in primary ABC, indistinguishable from surrounding normal spindle cells. The resulting fusion genes detected are formed by juxtaposition of the USP6 coding sequences to the highly active promoter sequences of several partner genes, as e.g. CDH11, COL1A1, OMD, TRAP150, and ZNF9, leading to the transcriptional upregulation of USP6. No true fusion genes are formed.


More recently, nodular fasciitis (NF), another mesenchymal lesion, has been tested positive for USP6 rearrangements. NF is a subcutaneous pseudosarcomatous myofibroblastic proliferation of unknown pathogenesis that regresses spontaneously when not surgically resected. The translocation results in the fusion of the promoter region of MYH9 located on 22q12.3 to the entire coding sequence of USP6 and subsequently in upregulated USP6 expression. For both lesions it is assumed that the detection of USP6 rearrangements by Fluorescence in situ Hybridization might represent a valuable diagnostic tool.

## References


Erickson-Johnson MR, et al. (2011) Lab Invest 91: 1427-33 Nakamura T, et al. (1988) Oncogene Res 2: 357-7 Oliveira AM, et al. (2004) Cancer Res 64: 1920-3. Oliveira AM, et al. (2005) Oncogene 24: 3419-26.

## **Probe Description**

The SPEC USP6 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 17p13.2 band. The orange fluorochrome direct labeled probe hybridizes proximal to the USP6 gene and the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC USP6 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 17p13.2 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 17p13.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 17p13.2 locus and one 17p13.2 locus affected by a translocation.



SPEC USP6 Break Apart Probe hybridized to aneurysmal bone cyst tissue section with polysomy of chromosome 17 but without translocation affecting the 17p13.2 locus as indicated by multiple orange, green fusion signals per nucleus.



Aneurysmal bone cyst tissue section with translocation affecting the 17p13.2 locus as indicated by one orange/green fusion (non-rearranged) signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2151-50	Zyto <i>Light</i> SPEC USP6 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light® SPEC YWHAE Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC YWHAE Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 17p13.3 harboring the YWHAE (tyrosine 3-monooxygenase/ tryptophan 5-monooxygenase activation protein, epsilon a.k.a. 14-3-3 epsilon)

YWHAE encodes a protein of the 14-3-3 family which is involved in regulation of cellular proliferation, metabolism, and differentiation. However, altered expression of 14-3-3 family proteins is associated with development and progression of cancer.


The fusion between YWHAE and one of the FAM22 family members (FAM22A or FAM22B) caused by a t(10;17)(q22;p13) has been identified in the clinically aggressive, high-grade endometrial stromal sarcoma (ESS) as well as in clear cell sarcoma of the kidney (CCSK). In contrast to the classic low-grade form of ESS harboring JAZF1 gene fusions, YWHAE-FAM22 ESS display high-grade histologic features and an aggressive clinical course. Moreover, due to the lack of estrogen and progesterone receptor expression in YWHAE-FAM22 ESS, the hormonal therapy used to treat low-grade ESS is likely to be ineffective. Consequently, differentiation between YWHAE-FAM22 and JAZF1 ESS by FISH is clinically relevant to support the diagnosis and may aid in therapeutic decision making.

### References


Isphording A, et al. (2013) Hum Pathol 44: 837-43. Lee CH, et al. (2012) PNAS 109: 929-34. O'Meara E, et al. (2012) J Pathol 227: 72-80. Stewart JC, et al. (2014) Histopathology 65: 473-82.

## **Probe Description**

The SPEC YWHAE Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 17p13.3 band. The orange fluorochrome direct labeled probe hybridizes distal to the YWHAE gene breakpoint region at 17p13.3, the green fluorochrome direct labeled probe hybridizes proximal to the YWHAE gene breakpoint region at 17p13.3.




Ideogram of chromosome 17 indicating the hybridization locations.



SPEC YWHAE Probe map (not to scale).

## Results

In an interphase nucleus of a normal cell lacking a translocation involving the 17p13.3 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 17p13.3 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 17p13.3 locus and one 17p13.3 locus affected by a translocation.



Endometrial stromal sarcoma tissue section with translocation affecting the YWHAE gene as indicated by one non-rearranged orange/green fusion signal, one orange, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2175-50	Zyto <i>Light</i> SPEC YWHAE Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Related Prod	ucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## Zyto Light ® SPEC ERBB2/CEN 17 Dual Color Probe

Previously: Zyto Light SPEC HER2/CEN 17 Dual Color Probe



## **Background**

The ZytoLight ® SPEC ERBB2/CEN 17 Dual Color Probe is designed for the detection of ERBB2 gene amplification frequently observed in solid malignant neoplasms e.g. breast cancer samples. The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185-190 kDa transmembrane glycoprotein, p185, acting as a cellular growth factor receptor. The p185 protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including ERBB1 (HER1), ERBB3 (HER3), and ERBB4 (HER4). Amplification of the proto-oncogene ERBB2, observed in approximately 20%

of all breast cancer samples, has been correlated with a poor prognosis of the disease. Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland.


References
Baselga J, et al. (1999) Semin Oncol 26: 78-83.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Cochet A, et al. (2012) J Nucl Med 53: 512-20. Coussens L, et al. (1985) Science 230: 1132-9 Ettl T, et al. (2012) Hum Pathol 43: 921-31. Ettl T, et al. (2012) Br J Cancer 106: 719-26. Ettl T, et al. (2012) Br J Cancer 106: 719-26. Fasching P, et al. (2011) BMC Cancer 11: 486. Haas M, et al. (2011) Virchows Arch 458: 403-11. Hillig T, et al. (2012) APMIS 120: 1000-7. Humbert O, et al. (2012) Ann Oncol 23: 2572-7. Hwang CC, et al. (2011) Histopathology 59: 984-92. Hynes NE & Stern DF (1994) Biochim Biophys Acta 1198: 165-84. Jäger M, et al. (2009) Cancer Res 69: 4270-6. Lang D, et al. (2008) Diagn Pathol 3: 49ff. Lehmann-Che L, et al. (2011) Br J Cancer 104: 1739-46. IVM et al. (2012) Oncolays 83: 257-63. Lehmann-Che I, et al. (2011) Br J Cancer 104: 1739-46. ly M, et al. (2012) Oncology 83: 257-63. Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92. Oliveira-Costa JP, et al. (2011) Diagn Pathol 6: 73. Park JB, et al. (1989) Cancer Res 49: 6605-9. Parris TZ, et al. (2010) Clin Cancer Res 16: 3860-74. Perrone G, et al. (2014) Elim Catica New York Perrone G, et al. (2012) PLoS One 7: e43110. Popescu NC, et al. (1989) Genomics 4: 362-6. Sassen A, et al. (2008) Breast Cancer Res 10: R2 Sassen A, et al. (2009) Breast Cancer Res 11: R50.
Schindlbeck C, et al. (2010) J Cancer Res Clin Oncol 136: 1029-37.
Slamon DJ, et al. (1987) Science 235: 177-82.
Vollmann-Zwerenz A, et al. (2010) Cytometry Part A 77: 387-99.
Voutsas IF, et al. (2013) Int J Radiat Biol 89: 319-25.

## **Probe Description**

The SPEC ERBB2/CEN 17 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1) and a green fluorochrome direct labeled SPEC ERBB2 probe specific for the chromosomal region 17q12-q21.1 harboring the ERBB2 gene.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2 Probe map (not to scale).

## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ERBB2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Normal interphase cells, ERBB2 (green), CEN 17 (orange).



Breast carcinoma tissue section, ERBB2 gene cluster (green), CEN 17 (orange).

Prod. No.	Product	Label	Tests* (Volume)
Z-2015-50	Zyto <i>Light</i> SPEC ERBB2/CEN 17 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2015-200	Zyto <i>Light</i> SPEC ERBB2/CEN 17 Dual Color Probe C € IVD	•/•	20 (200 µl)
Z-2020-5	ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe Kit C    Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; Probe, 0.05 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml	•/•	5
Z-2020-20	ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe Kit C    Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; Probe, 0.2 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml	•/•	20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® CEN 17/SPEC ERBB2 Dual Color Probe



## **Background**

The ZytoLight ® CEN 17/SPEC ERBB2 Dual Color Probe is designed for the detection of ERBB2 gene amplification frequently observed in solid malignant neoplasms e.g. breast cancer samples. The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185-190 kDa transmembrane glycoprotein, p185, acting as a cellular growth factor receptor. The p185 protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including ERBB1 (HER1), ERBB3 (HER3), and ERBB4 (HER4). Amplification of the proto-oncogene


ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease.

Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland.


References
Baselga J, et al. (1999) Semin Oncol 26: 78-83.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Coussens I, et al. (1985) Science 230: 1132-9.
Ettl T, et al. (2012) Br J Cancer 106: 719-26.
Hwang CC, et al. (2011) Histopathology 59: 984-92.
Hynes NE & Stern DF (1994) Biochim Biophys Acta 1198: 165-84.
Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92.
Park JB, et al. (1989) Cancer Res 49: 6605-9.
Popescu NC, et al. (1989) Genomics 4: 362-6.
Sassen A, et al. (2008) Breast Cancer Res 10: R2.
Slamon DJ, et al. (1987) Science 235: 177-82.
Voutsas IF, et al. (2013) Int J Radiat Biol 89: 319-25.
Wolff AC, et al. (2013) I Clin Oncol 31: 3997-4013. Wolff AC, et al. (2013) J Clin Oncol 31: 3997-4013

## **Probe Description**

The CEN 17/SPEC ERBB2 Dual Color Probe is a mixture of a green fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1) and an orange fluorochrome direct labeled SPEC ERBB2 probe specific for the chromosomal region 17q12-q21.1 harboring the ERBB2 gene.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2 Probe map (not to scale).

## **Results**

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ERBB2 gene locus, multiple copies of the orange signal or orange signal clusters will be observed.



Normal interphase cells, ERBB2 (orange), CEN 17 (green).



Breast carcinoma tissue section ERBB2 gene cluster (orange), CEN 17 (green).

Prod. No.	Product	Label	Tests* (Volume)
Z-2077-50	ZytoLight CEN 17/SPEC ERBB2 Dual Color Probe CE IVD	•/•	5 (50 µl)
Z-2077-200	Zyto <i>Light</i> CEN 17/SPEC ERBB2 Dual Color Probe C€ IVD	•/•	20 (200 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C TVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## Zyto Light ® SPEC ERBB2/D17S122 Dual Color Probe



## **Background**

The ZytoLight ® SPEC ERBB2/D17S122 Dual Color Probe is designed for the detection of ERBB2 gene amplification frequently observed in solid malignant neoplasms e.g. breast cancer samples. The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185-190 kDa transmembrane glycoprotein, p185, acting as a cellular growth factor receptor. The p185 protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including ERBB1 (HER1), ERBB3 (HER3), and ERBB4 (HER4).


Amplification of the proto-oncogene ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease.

Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland. Fluorescence in situ Hybridization targeting the alpha satellite centromeric regions of chromosome 17 may be misleading in some cases due to possible gains or losses of this region. For these cases, judged as equivocal according to the ASCO guidelines, reflex testing is recommended using the SPEC ERBB2/D17S122 Dual Color Probe.

References
Baselga J, et al. (1999) Semin Oncol 26: 78-83.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Coussens L, et al. (1985) Science 230: 1132-9. Coussens I, et al. [1985] Science 230: 1132-9. Ettl T, et al. (2012) Br J Cancer 106: 719-26. Hwang CC, et al. (2011) Histopathology 59: 984-92. Hynes NE & Stern DF (1994) Biochim Biophys Acta 1198: 165-84. Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92. Park JB, et al. (1989) Cancer Res 49: 6605-9. Popescu NC, et al. (1989) Cancer Res 40: 6605-9. Sassen A, et al. (2008) Breast Cancer Res 10: R2. Slamon DJ, et al. (1987) Science 235: 177-82. Voutsas IF, et al. (2013) Int J Radiat Biol 89: 319-25. Wolff AC et al. (2013) Clin Oncol 31: 3997-4013 Wolff AC, et al. (2013) J Clin Oncol 31: 3997-4013

## **Probe Description**

The SPEC ERBB2/D17S122 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC ERBB2 probe specific for the chromosomal region 17q12q21.1 harboring the ERBB2 gene and an orange fluorochrome direct labeled SPEC D17S122 probe specific for the chromosomal region 17p12. The SPEC D17S122 probe is designed to be used for chromosome 17 copy number detection.



Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2 Probe map (not to scale).




SPEC D17S122 Probe map (not to scale).

## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the ERBB2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Normal interphase cells, ERBB2 (green), D17S122 (orange).



Breast carcinoma tissue section, ERBB2 gene cluster (green), D17S122 (orange).

Prod. No.	Product	Label	Tests* (Volume)
Z-2190-50	Zyto Light SPEC ERBB2/D17S122 Dual Color Probe C E IVD	•/•	5 (50 µl)
Related P	roducts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe

Previously: Zyto Light SPEC HER2/TOP2A/CEN 17 Triple Color Probe



## **Background**

The ZytoLight ® SPEC ERBB2/TOP2A/ CEN 17 Triple Color Probe is designed for the simultaneous detection of ERBB2 and TOP2A gene status.

The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185 kDa transmembrane glycoprotein. The TOP2A (topoisomerase II alpha) gene is located in the chromosomal region 17q21.2 and encodes a 170 kDa DNA topoisomerase.

The TOP2A gene is frequently either co-amplified or deleted in ERBB2 positive breast cancer cases. TOP2A functions as the target for several anticancer agents, e.g. anthracyclines. Recent data suggests that amplification and deletion of the TOP2A gene locus may account for relative chemosensitivity or resistance to TOP2A inhibitor therapy in ERBB2 positive breast cancer. Thus, determination of the ERBB2 and TOP2A status may help to predict benefit from adjuvant anthracyclines in breast cancer treatment.


References
Arriola E. et al. (2007) Breast Cancer Res Treat 106: 181-9. Arriola E, et al. (2007) Breast Cancer Res Ireat 106 Brunello E, et al. (2012) Histopathology 60: 482-8. Coussens L, et al. (1985) Science 230: 1132-9. Fountzilas G, et al. (2012) J Transl Med 10: 212. Fountzilas G, et al. (2012) PloS One 7: e37946. Fountzilas G, et al. (2013) BMC Cancer 13: 163. Tourization 5, etc. (2006) Curr Cancer Drug Targets 6: 579-602. Popescu NC, et al. (1989) Genomics 4: 362-6. Pritchard KI, et al. (2008) J Clin Oncol 26: 736-44. Razis E, et al. (2011) Breast Cancer Res Treat 128: 447-56. Tsai-Pflugfelder M, et al. (1988) Proc Nat Acad Sci 85: 7177-81.

## **Probe Description**

The SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe is a mixture of a green fluorochrome direct labeled SPEC ERBB2 probe specific for the chromosomal region 17q12-q21.1 harboring the ERBB2 gene, an orange fluorochrome direct labeled SPEC TOP2A probe specific for the TOP2A gene at 17q21.2, and a blue fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1).




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2/TOP2A Probe map (not to scale).

### Results

In a normal interphase nucleus, two green, two orange, and two blue signals are expected. In a cell with amplification of the ERBB2 gene locus, multiple copies of the green signal or large green signal clusters will be observed. Amplification of TOP2A will result in multiple copies of the orange signal or large orange signal clusters. Deletion of the TOP2A gene results in a reduced number of orange signals.



SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe hybridized to normal interphase cells as indicated by two green, two orange, and two blue signals per nucleus.



Breast cancer tissue section with two copies of chromosome 17 (blue) and TOP2A (orange) and ERBB2 gene clusters (green) in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2093-50	Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C € IVD	<b>•/•/•</b>	5 (50 µl)
Z-2093-200	Zyto Light SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe C € IVD	<b>•/•/•</b>	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C    INCL Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informatic

129



## Zyto Light ® SPEC COL1A1 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC COL1A1 Dual Color Break Apart Probe is designed for the detection of the specific translocations involving the chromosomal region 17q21.33 harboring the COL1A1 (a.k.a. OI4) gene. Reciprocal translocations involving t(17;22)(q21.3;q13.1) are characteristic for dermatofibrosarcoma protuberans (DFSP). DFSP is a highly recurrent, infiltrative skin tumor of intermediate malignancy. The rearrangements are cytogenetically characterized by the presence of supernumerary ring chromosomes containing low-level amplified sequences from chromosomes 17q21-qter and 22q10-q13.1, or unbalanced derivatives of the t(17;22) (q21.3;q13.1) translocation.


The rearrangement frequently results in formation of a COL1A1-PDGFB fusion protein which is post-transcriptionally processed to a functional platelet-derived growth factor beta chain (PDGFB) protein, and results in PDFGB-mediated autocrine and/or paracrine activation of the plateled-derived growth factor receptor-B (PDGFRB).

The accurate diagnosis of DFSP is important because of the intermediate malignant nature of the DFSP and can be facilitated by Fluorescence in situ Hybridization (FISH) analyses.


Labropoulos SV & Razis ED (2007) Biologics 4: 347-53 Patel KU, et al. (2008) Human Pathol 39: 184-93. Shimizu A, et al. (1999) Cancer Res 59: 3719-23. Simon MP, et al. (1997) Nat Genet 15: 95-8.

## **Probe Description**

The SPEC COL1A1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 17q21.33 band. The orange fluorochrome direct labeled probe hybridizes distal, and the green fluorochrome direct labeled probe hybridizes proximal to the COL1A1 gene.




Ideograms of chromosome 17 indicating the hybridization locations.




SPEC COL1A1 Probe map (not to scale).

## Results

In a normal interphase nucleus lacking a translocation involving the 17q21.33 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 17q21.33 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 17q21.33 locus and one 17q21.33 locus affected by a 17q21.33 translocation.



DFSP tissue section with translocation affecting the 17q21.33 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.



DFSP tissue section with amplification of the 17q21-gter and 22q10-q13.1 sequences probably due to a COL1A1-PDGFB fusion product on the ring chromosome

Image kindly provided by Dr. Schildhaus, Cologne, Germany.

Prod. No.	Product	Label	Tests* (Volume)
Z-2121-200	Zyto <i>Light</i> SPEC COL1A1 Dual Color Break Apart Probe C€ IVD	<u> </u>	20 (200 µl)
Related Produ	ucts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe



## **Background**

The ZytoLight ® SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe is designed for the detection of the specific translocations involving the chromosomal region 17q21.33 harboring the COL1A1 (a.k.a. OI4) gene, and the chromosomal region 22q13.1, harboring the PDGFB (a.k.a PDGF2,SIS) gene.

The reciprocal translocations involving t(17;22)(q21.3;q13.1) are characteristic for dermatofibrosarcoma protuberans (DFSP) patients. DFSP is a highly recurrent, infiltrative skin tumor of intermediate malignancy.

The rearrangements are cytogenetically characterized by the presence of supernumerary ring chromosomes containing low-level amplified sequences from chromosomes 17q21-gter and 22q10-q13.1, or unbalanced derivatives of the t(17;22) (q21.3;q13.1) translocation.


The rearrangement results in a COL1A1-PDGFB fusion protein which is posttranscriptionally processed to a functional platelet-derived growth factor beta chain (PDGFB) protein, and results in PDFGBmediated autocrine and /or paracrine activation of the plateled-derived growth factor receptor-β (PDGFRB).

The accurate diagnosis of DFSP is important because of the intermediate malignant nature of the DFSP and can be facilitated by Fluorescence in situ Hybridization (FISH) analyses.

Labropoulos SV & Razis ED (2007) Biologics 4: 347-53. Patel KU, et al. (2008) Human Pathol 39: 184-93. Shimizu A, et al. (1999) Cancer Res 59: 3719-23. Simon MP, et al. (1997) Nat Genet 15: 95-8. Walluks K, et al. (2013) Pathol Res Pract 209: 30-5.


## **Probe Description**

The SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled COL1A1 probe covering the breakpoint region of the COL1A1 gene and a green fluorochrome direct labeled PDGFB probe covering the breakpoint region of the PDGFB gene.






Ideograms of chromosomes 17 (above) and 22 (below) indicating the hybridization locations.




SPEC COL1A1 Probe map (not to scale)




SPEC PDGFB Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange and green signal, respectively.



SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



DFSP tissue section with translocation affecting the COL1A1/PDGFB loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Prod.	No.	Product	Label	Tests* (Volume)
Z-2116	6-50	Zyto <i>Light</i> SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C € IVD	<u> </u>	5 (50 µl)
Z-2116	6-200	Zyto <i>Light</i> SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe C € IVD	<b>-/-</b>	20 (200 µl)
Relate	ed Produ	cts		
Z-2028	8-5	Zyto Light FISH-Tissue Implementation Kit C F IVD Ind. Heat Pretreatment Solution (Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028	8-20	Zyto Light FISH-Tissue Implementation Kit C F IVD Ind. Heat Pretreatment Solution (Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light ® SPEC TYMS/CEN 18 Dual Color Probe



## **Background**

The ZytoLight® SPEC TYMS/CEN 18 Dual Color Probe is designed for the detection of TYMS gene amplifications found in gastrointestinal cancer.

The TYMS proto-oncogene (thymidylate synthetase) is located in the chromosomal region 18p11.32. The thymidylate synthetase (TS) in combination with a cofactor maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair.

Patients with low expression of TS are shown to be more sensitive to 5-Fluorouracil (5-FU), a drug commonly used for treatment of colorectal cancer. It is suggested that genetic amplification of the TYMS gene is a major mechanism of 5-FU resistance and has important implications for the management of colorectal cancer patients with recurrent disease.

Fluorescence in situ Hybridization combines the advantage of possible detection of gene specific copy numbers in morphologically identified tumor cell nuclei.


References Brody JR, et al. (2006) Cancer Res 66: 9369-73. Jensen SA, et al. (2008) Acta Oncol 47: 1054-61. Langer R, et al. (2007) Am J Clin Pathol 128: 191-7. Wang TL, et al. (2004) PNAS 101: 3089-94. Watson RG, et al. (2010) Eur J Cancer 46: 3358-64.

## **Probe Description**

The SPEC TYMS/CEN 18 Dual Color Probe is a mixture of an orange fluorochrome direct labeled CEN 18 probe specific for the alpha satellite centromeric region of chromosome 18 (D18Z1) and a green fluorochrome direct labeled SPEC TYMS probe specific for the TYMS gene at 18p11.32.




Ideogram of chromosome 18 indicating the hybridization locations




SPEC TYMS Probe map (not to scale)

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the TYMS gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC TYMS/CEN 8 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Myxoid liposarcoma tissue section with amplification of the TYMS gene as indicated by multiple green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2098-200	Zyto <i>Light</i> SPEC TYMS/CEN 18 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Produ	cts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC SS18 Dual Color Break Apart Probe

Previously: Zyto Light SPEC SYT Dual Color Break Apart Probe



## **Background**


The ZytoLight® SPEC SS18 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 18q11.2 harboring the SS18 (synovial sarcoma translocation, chromosome 18) gene (a.k.a. SYT).

Translocations involving the region 18q11.2 are found in over 90% of synovial sarcoma. Among soft tissue sarcomas, synovial sarcoma is one of the most common and classically occurs in the extremities of young adults with greater prevalence in males even though, the occurrence of synovial sarcoma has also been described in a wide variety of anatomical locations and in all ages. The most frequent translocation involving the SS18 gene region is t(X;18) (p11.23;q11.2) juxtaposing the SS18 gene in 18q11.2 either next to the SSX1 (synovial sarcoma, translocated to X chromosome) or the SSX2 gene, or very rarely to the SSX4 locus located in Xp11.23. Complex translocations involving other chromo-somes are observed in less than 10% of synovial sarcomas. In combination with histopathological diagnosis, detection of SS18 rearrangements via FISH analysis is a valuable tool to confirm the diagnosis of synovial sarcoma.


References
Amary MF, et al. (2007) Mod Pathol 20: 482-96.
Clark J, et al. (1994) Nat Genet 7: 502-8.
Ilmiawan MI, et al. (2012) Med J Indones 21: 196-202.
Kawai A, et al. (1998) N Engl J Med 338: 153-60. Surace C, et al. (2004) Lab Invest 84: 1185-92. Torres L, et al. (2008) Cancer Genet Cytogenet 187: 45-9.

## **Probe Description**

The SPEC SS18 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 18q11.2 band. The orange fluorochrome direct labeled probe hybridizes distal to the SS18 gene, the green fluorochrome direct labeled probe hybridizes proximal to that gene.




Ideogram of chromosome 18 indicating the hybridization locations.




SPEC SS18 Probe map (not to scale).

### Results

In an interphase nucleus lacking a translocation involving the 18q11.2 band two orange/green fusion signals are expected representing two normal (non-rearranged) 18q11.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 18q11.2 locus and one 18q11.2 locus affected by an 18q11.2 translocation.



SPEC SS18 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Synovial sarcoma tissue section with translocation affecting the 18q11.2 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
Z-2097-50	Zyto Light SPEC SS18 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2097-200	Zyto <i>Light</i> SPEC SS18 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Proc	ducts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



## Zyto Light ® SPEC SS18/SSX1 TriCheck™ Probe



## **Background**


The ZytoLight ® SPEC SS18/SSX1 TriCheck™ Probe is designed to detect translocations involving the chromosomal region 18q11.2 harboring the SS18 (synovial sarcoma translocation, chromosome 18, a.k.a. SYT) gene and the chromosomal region Xp11.23 harboring the SSX1 (synovial sarcoma, X breakpoint 1) gene. Synovial sarcoma is characterized by the t(X;18) found in more than 95% of these tumors and juxtaposing the SS18 gene in 18q11.2 either next to the SSX1 or the SSX2 gene, or very rarely to the SSX4 locus.

Synovial sarcoma is one of the most common soft tissue tumors that typically occurs in the extremities of young adults with greater prevalence in males, even though, the occurrence of synovial sarcoma has also been described in a wide variety of anatomical locations and in all ages. In combination with histopathological diagnosis, detection of SS18 rearrangements via FISH is a valuable tool to confirm the diagnosis of synovial sarcoma. Moreover, patients with SS18-SSX1 fusions were shown to have a higher risk of developing metastases compared to those with SS18-SSX2 fusions. Hence, detection of the SS18 fusion gene variant by FISH may also be of prognostic significance.


References
Amary MF, et al. (2007) Mod Pathol 20: 482-96. Clark J, et al. (1994) Nat Genet 7: 502-8. Kawai A, et al. (1998) N Engl J Med 338: 153-60. Panagopoulos I, et al. (2001) Genes Chromosomes Cancer 31: 362-72. Surace C, et al. (2004) Lab Invest 84: 1185-92.
Torres L, et al. (2008) Cancer Genet Cytogenet 187: 45-9.

## **Probe Description**

The SPEC SS18/SSX1 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the 18q11.2 and Xp11.23 bands. The green fluorochrome direct labeled probe hybridizes proximal and the orange fluorochrome direct labeled probe hybridizes distal to the SS18 breakpoint region at 18q11.2. The blue fluorochrome direct labeled probe hybridizes proximal to the SSX1 gene at Xp11.23.



Ideograms of chromosomes 18 (above) and X (below) indicating the hybridization locations.



SPEC SS18 Probe map (not to scale).



SPEC SSX1 Probe map (not to scale).


### Results

In an interphase nucleus of a normal female cell without SS18-SSX1 rearrangement, two green/orange fusion signals and two blue signals are expected.


In an interphase nucleus of a normal male cell without SS18-SSX1 rearrangement, two green/orange fusion signals and one blue signal are expected.

An SS18-SSX1 or an SS18-SSX4 fusion is indicated by one separate orange signal co-localizing with one blue signal and one separate green signal.

An SS18-SSX2 fusion is indicated by one separate green signal, one separate orange signal, and a blue signal in close proximity of the separated green signal. An SS18 translocation without involvement of SSX1, SSX2, or SSX4 is indicated by the split of one green/orange fusion signal without co-localization of the separated orange or green signal with one blue signal.



Male synovial sarcoma tissue section with SS18-SSX1 or SS18-SSX4 fusion as indicated by orange/blue fusion signals.



Female synovial sarcoma tissue section with SS18-SSX2 fusion as indicated by green/blue fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2184-50	ZytoLight SPEC SS18/SSX1 TriCheck Probe C€ IVD	<b>•</b> /•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC BCL2 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC BCL2 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 18q21.33 harboring the BCL2 gene. The BCL2 (B-cell CLL/lymphoma 2, a.k.a. PPP1R50) gene encodes a mitochondrial membrane protein that regulates apoptosis and is expressed in B-cells.


Translocations involving the BCL2 gene are commonly identified in B-cell lymphomas. In particular, the translocation t(14;18) (q32.3;q21.3) has been identified in about 80% of follicular lymphoma (FL), in 20% to 30% of diffuse large B-cell lymphoma (DLB-CL), and rarely in B-cell chronic lymphocytic leukemia (B-CLL).

In FL this translocation is considered to be a cytogenetic hallmark. As a result of this rearrangement, the BCL2 gene is juxtaposed to the IGH (Immunglobulin heavy chain) locus at 14q32.33 which leads to overexpression of the anti-apoptotic protein BCL2, and finally to progression to lymphoma. Alternative BCL2 translocations to immunoglobulin light chain genes as well as non-IG translocation events have been reported. In DLBCL, BCL2 gene overexpression has been implicated in conferring resistance to chemotherapy and has been associated with poor prognosis.

Hence, detection of BCL2 translocations by Fluorescence in situ Hybridization (FISH) may be of diagnostic and prognostic relevance.

## **Probe Description**

The SPEC BCL2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 18q21.33q22.1 band. The green fluorochrome direct labeled probe hybridizes proximal to the BCL2 gene, and the orange fluorochrome direct labeled probe hybridizes distal to the BCL2 locus.



Ideogram of chromosome 18 indicating the hybridization locations.



SPEC BCL2 Probe map (not to scale).


References
Da Cunha Santos G, et al. (2011) Cancer Cytopathol 119: 254-62.

Dar Cunna Santos G, et al. (2011) Cancer Cytopatriol 11 Dyer MJ, et al. (1994) Blood 83: 3682-8. Gu K, et al. (2008) Arch Pathol Lab Med 132: 1355-61. Hockenbery D, et al. (1990) Nature 348: 334-6. Impera L, et al. (2008) Oncogene 27: 6187-90. López-Guillermo A, et al. (1999) Blood 93: 3081-7. Nelson BP, et al. (2007) Am J Clin Pathol 128: 323-32.


Tibiletti MG, et al. (2009) Hum Pathol 40: 645-52. Tomita N, et al. (2009) Haematologica 94: 935-4: Weinberg OK, et al. (2007) J Mol Diagn 9: 530-7

## Results

In an interphase nucleus lacking a translocation involving the 18q21.33-q22.1 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 18q21.33-q22.1 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 18q21.33-q22.1 locus and one 18q21.33-q22.1 locus affected by a translocation.



SPEC BCL2 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Neck lymph node tissue section with translocation of the BCL2 gene as indicated by two non-rearranged orange/green fusion signals, one orange and one

separate green signal indicating the translocation.			ing the translocation.
Prod. No.	Product	Label	Tests* (Volume)
Z-2192-50	Zyto <i>Light</i> SPEC BCL2 Dual Color Break Apart Probe C€ IVD	•/•	5 (50 µl)
Z-2192-200	Zyto <i>Light</i> SPEC BCL2 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C E  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml;  Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

135



# Zyto Light® SPEC BCL2/CEN 18 Dual Color Probe



## **Background**

The ZytoLight ® SPEC BCL2/CEN 18 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the BCL2 gene. The BCL2 (B-cell CLL/lymphoma 2, a.k.a. PPP1R50) gene is located on chromosome 18q21.33 and encodes an antiapoptosis factor involved in normal B-cell development and differentiation. The expression of BCL2 usually decreases upon B-cell differentiation. However, increased BCL2 expression has been detected in lymphomas harboring the translocation t(14;18) (q32.3;q21.3). Moreover, overexpression of BCL2 can also be caused by amplification of the BCL2 gene as detected in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

DLBCL is the most common type of non-Hodgkin lymphoma characterized by an aggressive clinical course. On the basis of their gene expression profiles, ABC (activated B-cell-like) and GCB (germinal center B-cell-like) were identified as two molecular subtypes of DLBCL. BCL2 was found to be frequently amplified in the ABC subgroup of DLBCL but rarely in the GCB subgroup. BCL2 overexpression as a result of 18q21 amplification is associated with poor survival in the ABC subgroup. Hence, the identification of BCL2 gene copy number changes by Fluorescence in situ Hybridization may be of prognostic significance in non-Hodgkin lymphomas.


Alizadeh AA, et al. (2000) Nature 403: 503-11. Beà S, et al. (2009) Blood 113: 3059-69. Iqbal J, et al. (2006) J Clin Oncol 24: 961-8. Monni O, et al. (1999) Leuk Lymphoma 34: 45-52.

## **Probe Description**

The SPEC BCL2/CEN 18 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC BCL2 probe hybridizing to the human BCL2 gene in the chromosomal region 18q21.33 and an orange fluorochrome direct labeled CEN 18 probe specific for the alpha satellite centromeric region of chromosome 18 (D18Z1).




Ideogram of chromosome 18 indicating the hybridization locations



SPEC BCL2 Probe map (not to scale)

## Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the BCL2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC BCL2/CEN 18 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2174-50	Zyto <i>Light</i> SPEC BCL2/CEN 18 Dual Color Probe C € IVD	•/•	5 (50 µl)
Related Produ	cts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informat



## Zyto Light ® SPEC BCL2/IGH Dual Color Dual Fusion Probe



## **Background**

The ZytoLight ® SPEC BCL2/IGH Dual Color Dual Fusion Probe is designed to detect the translocation t(14;18)(q32.3;q21.3)affecting the BCL2 gene in the chromosomal region 18q21.33 and the IGH locus in 14q32.33.

Translocations involving the BCL2 (B-cell lymphoma 2) gene and the IGH (immunoglobulin heavy locus, a.k.a. IGH@) gene are considered to be cytogenetic hallmarks for follicular lymphoma (FL). FL represents one of the most common non-Hodgkin lymphoma (NHL).


About 75% of breakpoints on chromosome 18 are clustered in the major breakpoint region (MBR) and the minor cluster region (mcr), whereas the remaining breakpoints are scattered between these clusters, or at the 5' side (variant cluster region or vcr) of the BCL2 gene.


The translocation t(14;18)(q32.3;q21.3) has been identified in about 80% of FLs but is also observed in 20% to 30% of patients with diffuse large B-cell lymphoma (DLBCL). The rearrangement results in juxtaposition of the BCL2 gene at 18q21.33 next to the IgH (immunoglobulin heavy chain) locus at 14q32.33 and leads to overexpression of the anti-apoptotic protein BCL2. This represents most likely the initial step of malignant transformation, leading to suppression of apoptosis and progression to lymphoma.

Detection of t(14;18) by Fluorescence in situ Hybridization (FISH) can be used to confirm the diagnosis of FL if histology is inconclusive. Additionally, this method can be used to monitor the response to therapy and detect recurrent disease.


## **Probe Description**

The SPEC BCL2/IGH Dual Color Dual Fusion Probe is a mixture of an orange fluorochrome direct labeled BCL2 probe spanning the known BCL2 breakpoints, and a green fluorochrome direct labeled IGH probe spanning the known breakpoints of IGH.





Ideograms of chromosomes 18 (above) and 14 (below) indicating the hybridization locations.



SPEC BCL2 Probe map (not to scale)




SPEC IGH Probe map (not to scale).


Baró C, et al. (2011) Leuk Res 35: 256-9. Da Cunha Santos G, et al. [2011] Cancer Cytopathol 119: 254-62. Einerson RR, et al. [2005] Am J Clin Pathol 124: 421-9. Gu K, et al. [2008] Arch Pathol Lab Med 132: 1355-61. Nguyen-Khac F, et al. (2011) Am J Blood Res 1: 13-21 Weinberg OK, et al. (2007) J Mol Diagn 9: 530-7.

### Results

In a normal interphase nucleus, two orange and two green signals are expected. A reciprocal translocation involving two breakpoints splits the two signals and generates a fusion signal on each of the chromosomes involved. The chromosomal regions which are not translocated are indicated by the single orange and green signal, respectively.



SPEC BCL2/IGH Dual Color Dual Fusion Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



Bone marrow biopsy section with translocation affecting the BCL2/IGH loci as indicated by one separate orange signal, one separate green signal, and two orange/green fusion signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2114-50	Zyto <i>Light</i> SPEC BCL2/IGH Dual Color Dual Fusion Probe C € IVD	<b>/</b>	5 (50 µl)
Z-2114-200	Zyto Light SPEC BCL2/IGH Dual Color Dual Fusion Probe C € IVD	<b>o/o</b>	20 (200 µl)
Related Prod	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD Ind. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.



## Zyto Light ® SPEC MALT1 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC MALT1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 18q21.32 harboring the MALT1 gene. The MALT1 (mucosa associated lymphoid tissue lymphoma translocation gene 1, a.k.a. MLT) gene encodes a human paracaspase and is often rearranged in MALT lymphomas accounting for 5-10% of all B-cell non-Hodgkin lymphomas (NHL). The most common translocations affecting the MALT1 gene are t(11;18)(q22.2;q21.3) and t(14;18) (q32.3;q21.3) occurring in 50% and 15-20% of MALT lymphomas, respectively. These translocations lead to the expression of BIRC3-MALT1 (a.k.a. API2-MALT1) and IGH-MALT1 fusion proteins, resulting in constitutive activation of the NF-кВ signaling pathway which controls the expression of numerous anti-apoptotic and proliferation-promoting genes. The translocation t(11;18)(q22.2;q21.3)is mainly found in pulmonary and gastric lymphomas, whereas t(14;18) (q32.3;q21.3) occurs more frequently in non-gastrointestinal MALT lymphomas, e.g., of the skin and salivary glands. The presence of a t(11;18)(q22.2;q21.3) correlates with unresponsiveness to eradication of Helicobacter pylori in gastric MALT lymphomas. Hence, detection of

MALT1 translocations by Fluorescence in


situ Hybridization (FISH) may be a suppor-

tive tool to identify patients eligible for anti


H. pylori therapy.

## **Probe Description**

The SPEC MALT1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 18q21.31q21.32 band. The green fluorochrome direct labeled probe hybridizes proximal to the MALT1 gene at 18q21.31-q21.32, and the orange fluorochrome direct labeled probe hybridizes distal to the MALT1 gene region at 18q21.32.



Ideogram of chromosome 18 indicating the hybridization locations.



SPEC MALT1 Probe map (not to scale).

Afonina IS, et al. (2015) FEBS J 282: 3286-97.

Beans M, et al. (2014) PloS One 9: e103774. Dierlamm J, et al. (1999) Blood 93: 3601-9. Levine EG, et al. (1989) Blood 74: 1796-800.


Lucas PC, et al. (2001) J Biol Chem 276: 19012-9

Martinelli G, et al. (2005) J Clin Oncol 23: 1979-83.
Pereira MI & Medeiros JA (2014) World J Gastroenterol 20: 684-98.


Troppan K, et al. (2015) Gastroenterol Res Pract 2015: 102656

### **Results**

In an interphase nucleus lacking a translocation involving the 18q21.31-q21.32 band, two orange/green fusion signals are expected representing two normal (non-rearranged) 18q21.31-q21.32 loci. A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal 18q21.31-q21.32 locus and one 18q21.31-q21.32 locus affected by a translocation.



SPEC MALT1 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Lymphoma tissue section with translocation of the MALT1 gene as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

	· · ·		
Prod. No.	Product	Label	Tests* (Volume)
Z-2196-50	Zyto Light SPEC MALT1 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)
Z-2196-200	Zyto Light SPEC MALT1 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)
Related Prod	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C ( IVD Incl. Hear Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# Zyto Light ® SPEC AXL/19p13 Dual Color Probe



## **Background**

The ZytoLight ® SPEC AXL/19p13 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the AXL gene. The AXL (AXL receptor tyrosine kinase, a.k.a. ARK, Tyro7) gene is located on

chromosome 19q13.2 and encodes a receptor tyrosine kinase which is a member of the TAM (TYRO3/AXL/MERTK) family. AXL overexpression has been reported in several human cancers including colon, esophageal, thyroid, breast, lung, liver, glioblastoma, and acute leukemia. Binding of the ligand growth arrest-specific 6 (GAS6) to AXL activates the downstream MAPK and PI3K/Akt signaling pathways, thereby promoting proliferation and survival of normal and cancer cells. AXL expression was shown to be associated with migration and invasion resulting in tumor progression and metastasis in various cancer types including lung adenocarcinoma where AXL was found to be overexpressed in 48% of patient samples.


Overexpression of AXL tyrosine kinase correlates with an adverse prognosis in glioblastoma multiforme, pancreatic adenocarcinoma, and breast cancer. Inhibition of AXL was shown to reduce tumor growth in xenograft models indicating that AXL may be an important target for new therapeutic developments in AXL overexpressing cancers.

Hence, the identification of AXL gene copy number changes by Fluorescence in situ Hybridization and targeted AXL signaling inhibition may be of therapeutic significance in various types of tumors.


References
Gjerdrum C, et al. (2010) Proc Natl Acad Sci U S A 107: 1124-9.
Hutterer M, et al. (2008) Clin Cancer Res 14: 130-8.
Knubel KH, et al. (2014) Oncolarget 5: 1338-51.
Koorstra JB, et al. (2009) Cancer Biol Ther 8: 618-26.
Li Y, et al. (2009) Oncogene 28: 3442-55.
Shieh YS, et al. (2005) Neoplasia 7: 1058-64.
Song X, et al. (2011) Cancer 117: 734-43.
Verma A, et al. (2011) Mol Cancer Ther 10: 1763-73.

## **Probe Description**

The SPEC AXL/19p13 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC AXL probe hybridizing to the AXL gene in the chromosomal region 19q13.2 and an orange fluorochrome direct labeled SPEC 19p13 probe specific for 19p13.3. Since chromosomes 1, 5, and 19 share the same repetitive sequences, probes specific for 19p13.3 are commonly used for chromosome 19 copy number detection.



Ideogram of chromosome 19 indicating the hybridization locations.




SPEC AXL Probe map (not to scale).




SPEC 19p13 Probe map (not to scale).

## **Results**

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the AXL gene locus, multiple copies of the green signal or green signal clusters will be observed.



SPEC AXL/19p13 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals per nucleus.



Pulmonary adenocarcinoma tissue section with amplification of the AXL gene as indicated by multiple green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2154-200	Zyto <i>Light</i> SPEC AXL∕19p13 Dual Color Probe C € IVD	•/•	20 (200 µl)
Related Pro	ducts		
Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC BCL2L1/CEN 20 Dual Color Probe



## **Background**

The ZytoLight ® SPEC BCL2L1/CEN 20 Dual Color Probe is designed for the detection of BCL2L1 gene amplifications. The BCL2L1 (BCL2-like 1, a.k.a. BCLX) gene is located in the chromosomal region 20q11.21 and encodes for an antiapoptotic protein that belongs to the BCL2 family. These genes are involved in a wide variety of cellular activities including lymphocyte development and hematopoiesis. BCL2L1 amplifications have been reported in several human cancers including lung, ovarian breast, melanoma, and hematologic malignancies.

Overexpression of BCL2L1 reduces MYC-induced apoptosis in immortalized bronchial epithelial cells.


Furthermore, BCL2L1 amplifications are found in many tumor cell lines with resistance to chemotherapeutic agents. Targeting the BCL2 family proteins with small non-peptidic compounds, so called BH3-mimetics, is currently investigated in clinical trials.

Hence, the identification of BCL2L1 amplifications by Fluorescence in situ Hybridization and the inhibition of BCL2L1 signaling may be of therapeutic significance in various types of tumors.

References
Beroukhim R, et al. (2010) Nature 463: 899-905.
Booher RN, et al. (2014) PloS One 9: e108371.
Sochalska M, et al. (2015) FEBS J 282: 834-49. Yasui K, et al. (2004) Cancer Res 64: 1403-10.

## **Probe Description**

The SPEC BCL2L1/CEN 20 Dual Color Probe is a mixture of an orange fluorochrome direct labeled SPEC BCL2L1 probe hybridizing to the BCL2L1 gene in the chromosomal region 20q11.21 and a green fluorochrome direct labeled CEN 20 probe specific for the alpha satellite centromeric region of chromosome 20 (D20Z2).




Ideogram of chromosome 20 indicating the hybridization locations.




SPEC BCL2L1 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with amplification of the BCL2L1 gene locus, multiple copies of the orange signal or orange signal clusters will be observed.



SPEC BCL2L1/CEN 20 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.



SK-LU-1 cell line with interphase cells showing amplification of the BCL2L1 gene locus as indicated by orange signal clusters in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2171-200	Zyto <i>Light</i> SPEC BCL2L1/CEN 20 Dual Color Probe C € IVD	<b>●/●</b>	20 (200 µl)
Related Prod	ucts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C€ IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Light ® SPEC PTPRT/20q11 Dual Color Probe



## **Background**

The ZytoLight ® SPEC PTPRT/20q11 Dual Color Probe is designed to detect deletions of the long arm of chromosome 20. 20q deletions can occur in various myeloid disorders, e.g., myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPNs). In MDS, del(20q) as the sole cytogenetic abnormality is associated with a favorable prognosis, with better survival, and a lower risk for transformation to AML. Del(20a) occurring with additional cytogenetic aberrations predicts a poor prognosis. The breakpoints of the 20g deletion were identified to be heterogeneous in several studies. The minimal common deleted region (CDR) was defined to be flanked by the genes PTPRT (20q12) and EYA2


It has been suggested that one or more tumor suppressor genes could be located in the CDR, the deletion or inactivation of which may play a role in malignant growth. However, the target gene(s) remain unknown.

(20q13.12).


References
Bacher U, et al. (2014) Br J Haematol 164: 822-33.
Brezinová J, et al. (2005) Cancer Genet Cytogenet 160: 188-92.
Okada M, et al. (2012) Cancer Genet 205: 18-24.
Testa JR, et al. (1978) Blood 52: 868-77.

## **Probe Description**


The SPEC PTPRT/20q11 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC PTPRT probe hybridizing in the CDR at 20q12, an orange fluorochrome direct labeled SPEC 20q11 probe specific for the chromosomal region 20q11.21 harboring the DUSP15 gene. For an unambigous enumeration of chromosome 20, the SPEC 20q11 is found to be suitable.



Ideogram of chromosome 20 indicating the hybridization locations.




SPEC PTPRT Probe map (not to scale)



Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the 20q12 locus, one or no copy of the green signal will be observed.



SPEC PTPRT/20q11 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
Z-2213-50	Zyto <i>Light</i> SPEC PTPRT/20q11 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Related Produ	ucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C   IND Ind. Heat Pretreatment Solution Gitric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C € IVD  Ind. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

141



## Zyto Light ® SPEC ERG Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC ERG Dual Color Break Apart Probe is designed to detect aberrations involving the ERG gene at 21q22.2 frequently detected in prostate cancers.

ERG (ETS-related gene) rearrangements have been observed in 40-60% of prostate cancers identified via prostatespecific antigen (PSA) screening. The most common aberration affecting ERG is the interstitial deletion of about 3 Mb at the chromosomal region 21q22 found in 90% of the cases. This deletion leads to the fusion of the hormonally regulated promoter of the TMPRSS2 (transmembrane protease, serine 2) gene to the coding region of ERG, resulting in overexpression of the ERG transcription factor. However, about 10% of the ERG rearranged prostate cancer cases show alternative fusions, as e.g. SLC45A3-ERG or NDRG1-ERG.

Several studies detected associations of ERG rearrangements with histomorphologic features as well as characteristic copy number gains, and gene expression signatures, defining a distinct sub-class of prostate cancers with unfavorable prognosis. Hence, the evaluation of the ERG rearrangement status in tissue or urine samples by FISH might be of diagnostic and prognostic relevance.

EWSR1-ERG gene fusions present in about 10% of patients with Ewing sarcoma may result from complex genomic rearrangements and may therefore not be detected by FISH analysis or may result in a nonclassical translocation signal pattern.


References Esgueva R, et al. (2010) Mod Pathol 23: 539-46. Maire G, et al. (2008) Cancer Genet Cytogenet 181: 81-92. Nam RK, et al. (2007) Br J Cancer 97: 1690-5. Perner S, et al. (2006) Cancer Res 66: 8337-41. Pflueger D, et al. (2009) Neoplasia 11: 804-11. Tomlins SA, et al. (2005) Science 310: 644-8.

## **Probe Description**

The SPEC ERG Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the long arm of chromosome 21. The orange fluorochrome direct labeled probe hybridizes at 21q22.13-q22.2 proximal to the ERG gene breakpoint region, the green direct labeled probe hybridizes at 21q22.2 distal to the ERG gene breakpoint region.



Ideogram of chromosome 21 indicating the hybridization locations.




SPEC ERG Probe map (not to scale).

### Results


In an interphase nucleus of a normal cell lacking an aberration involving the 21q22.13-q22.2 band, two orange/ green fusion signalsare expected representing the two normal (non-rearranged) 21q22.13-q22.2 loci.

One 21q22.13-q22.2 locus affected by a 21q22.2 deletion resulting in the TMPRSS2-ERG fusion is indicated by the loss of one green signal.

A signal pattern consisting of one orange/ green fusion signal, a separate green, and a separate orange signal indicates an ERG translocation without involvement of TMPRSS2 (e.g. SLC45A3-ERG).



SPEC ERG Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



deletion of the chromosomal region 21q22.2 resulting in the TMPRSS2-ERG fusion as indicated by the loss of one green signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2138-200	Zyto <i>Light</i> SPEC ERG Dual Color Break Apart Probe C	•/•	20 (200 µl)
Related Produ	icts		
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C€ IVD		20
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAP1/DuraTect-Solution, 0.8 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Light ® SPEC ERG/TMPRSS2 TriCheck™ Probe



## **Background**

The ZytoLight® SPEC ERG/TMPRSS2 TriCheck™ Probe is designed to detect deletions between the ERG and the TMPRSS2 gene at 21q22 resulting in the TMPRSS2-ERG fusion. Furthermore, the triple color approach allows the detection of other translocations affecting either of these genes. ERG (ETS-related gene) rearrangements have been observed in 40-60% of prostate cancers identified via prostate-specific antigen (PSA) screening. The most common aberration affecting ERG is the interstitial deletion of about 3 Mb at the chromosomal region 21q22 found in 90% of the cases. This deletion leads to the fusion of the hormonally regulated promoter of the TMPRSS2 (transmembrane protease, serine 2) gene to the coding region of ERG, resulting in overexpression of the ERG transcription factor. The deleted fragment is sometimes observed as insertion on other chromosomes. However, about 10% of the ERG rearranged prostate cancer cases show alternative fusions, as e.g. SLC45A3-ERG. On the other hand non-ERG translocations fusing TMPRSS2 to other ETS family members, as e.g. TMPRSS2-ETV1, have been found in a few percent of these malignancies.

Several studies detected associations of ERG rearrangements with histomorphologic features as well as characteristic copy number gains and gene expression signatures defining a distinct sub-class of prostate cancers with unfavorable prognosis. Hence, the evaluation of the TMPRSS2-ERG rearrangement status in tissue or urine samples by Fluorescence in situ Hybridization might be of diagnostic and prognostic relevance.


References
Esgueva R, et al. (2010) Mod Pathol 23: 539-46.
Nam RK, et al. (2007) Br J Cancer 97: 1690-5.
Perner S, et al. (2006) Cancer Res 66: 8337-41. Tomlins SA, et al. (2005) Science 310: 644-8

## **Probe Description**

The SPEC ERG/TMPRSS2 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the chromosomal regions 21q22.13-q22.3. The orange fluorochrome direct labeled probe hybridizes at 21q22.13-q22.2 proximal to the ERG gene breakpoint region, the green fluorochrome direct labeled probe hybridizes at 21a22.2 distal to that region, and the blue fluorochrome direct labeled probe hybridizes at 21q22.3 distal to the TMPRSS2 gene region.



Ideogram of chromosome 21 indicating the hybridization locations.




SPEC ERG/TMPRSS2 TriCheck™ Probe map (not to scale).

### Results


In a normal interphase nucleus, two orange/green fusion signals and two blue signals in close proximity of the respective fusion signals are expected representing two normal (non-rearranged) 21q22.13q22.3 loci.

One 21q22 locus affected by a 21q22.2 deletion resulting in the TMPRSS2-ERG fusion is indicated by one separate orange signal co-localizing with one blue signal, and the loss of one green signal.

An ERG translocation without involvement of TMPRSS2 is indicated by a separated orange signal and a blue signal co-localizing with the separate green signal. A non-ERG translocation affecting TMPRSS2 is indicated by a separated blue signal not co-localizing with the ERG fusion signal.



SPEC ERG/TMPRSS2 TriCheck Probe hybridized to normal interphase cells as indicated by two orange/ green fusion signals and two blue signals in close proximity of the respective fusion signals.



Prostate cancer tissue section with one 21q22 locus affected by an interstitial deletion of the chromosomal region 21q22.2 resulting in the TMPRSS2-ERG fusion as indicated by one separate orange signal co-localizing with one blue signal, and the loss of one green signal.

F	Prod. No.	Product	Label	Tests* (Volume)	
7	Z-2135-200	Zyto <i>Light</i> SPEC ERG/TMPRSS2 TriCheck Probe C€ IVD	•/•/•	20 (200 µl)	
F	Related Products				
Z	7-2028-20	Zyto Light FISH-Tissue Implementation Kit C    IVD		20	
		Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

143



## Zyto Light ® SPEC SMARCB1/22q12 Dual Color Probe



## **Background**

The ZytoLight ® SPEC SMARCB1/22q12 Dual Color Probe is designed for the detection of deletions of the chromosomal region harboring the SMARCB1 gene. The SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, a.k.a. INI1, SNF5, or BAF47) gene is located on chromosome 22q11.23 and encodes a tumor suppressor.

Rhabdoid tumors are highly malignant neoplasms that typically arise in infancy and early childhood. They are classified as atypical teratoid/rhabdoid tumors (AT/ RT) when they occur in the CNS or as malignant rhabdoid tumors (MRT) when they are found in renal or extra-renal sites. The vast majority of AT/RTs and MRTs are characterized by loss of function of the SMARCB1 gene due to deletions or mutations. The molecular alterations are often bi-allelic resulting in complete loss of this tumor suppressor gene, and thus in cell cycle progression.

Patients with germline alterations of SMARCB1, including deletions, duplications, and mutations, were found to be predisposed to malignant rhabdoid tumors and schwannomatosis.

Moreover, deletions of the SMARCB1 gene were found to occur in patients with highly aggressive renal medullary carcinoma (RMC), epithelioid sarcoma, and poorly differentiated sarcoma.


The identification of SMARCB1 deletions by FISH may represent a powerful adjunctive diagnostic tool useful in the differential diagnosis of rhabdoid tumors. Moreover, prenatal testing should be performed in situations where alterations of SMARCB1 have been documented in the family.

## **Probe Description**


The SPEC SMARCB1/22q12 Dual Color Probe is a mixture of a green fluorochrome direct labeled SPEC SMARCB1 probe hybridizing to the human SMARCB1 gene in the chromosomal region 22q11.23 and an orange fluorochrome direct labeled SPEC 22q12 probe specific for the KRE-MEN1 (kringle containing transmembrane protein 1) gene region in 22q12.1-q12.2. Due to cross-hybridizations of chromosome 22 alpha satellites to other centromeric regions, probes specific for 22q12 are frequently used for chromosome 22 copy number detection.



Ideogram of chromosome 22 indicating the hybridization locations.




SPEC SMARCB1 Probe map (not to scale).



SPEC 22q12 Probe map (not to scale).

### Results

In a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletion of the SMARCB1 gene locus, a reduced number of green signals will be observed. Deletions affecting only parts of the SMARCB1 gene might result in a normal signal pattern with green signals of reduced size.



SPEC SMARCB1/22q12 Dual Color Probe hybridized to normal interphase cells as indicated by two orange and two green signals per nucleus.



SPEC SMARCB1/22q12 Dual Color Probe hybridized to epithelioid sarcoma tissue section with biallelic deletion of the SMARCB1 gene as indicated by missing green signals in the nuclei.

References Calderaro J, et al. (2012) Histopathology 61: 428-35. Eaton KW, et al. (2011) Pediatr Blood Cancer 56: 7-15. Mobley BC, et al. (2010) Acta Neuropathol 120: 745-53. Roberts CW & Biegel JA (2009) Cancer Biol Ther 8: 412-6. Sullivan LM, et al. (2013) Mod Pathol 26: 385-92.

Prod. No.	Product	Label	Tests* (Volume)
Z-2178-50	Zyto Light SPEC SMARCB1/22q12 Dual Color Probe C € IVD	•/•	5 (50 µl)
Related Produ	icts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



# Zyto Light® SPEC EWSR1 Dual Color Break Apart Probe



## **Background**

The ZytoLight ® SPEC EWSR1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 22q12.2 harboring the EWSR1 (Ewing sarcoma breakpoint region 1) gene (a.k.a. EWS).

Translocations involving the chromosomal region 22q12.2 are found in 90-95% of patients with Ewing sarcoma or peripheral primitive neuroectodermal tumors (PNET). Ewing sarcoma is the second most common, highly malignant bone tumor in children and young adults. The most frequent translocation involving the EWSR1 gene region is t(11;22)(q24.3;q12.2) juxtaposing the EWSR1 gene in 22q12.2 next to the FLI-1 (friend leukemia virus integration 1) locus in 11q24.3. FLI-1 is a member of the ETS family of transcription factors. Less frequently, EWSR1 can also be fused to ERG, a transcription factor closely related to FLI-1 but located in 21q22.2.

For prognosis and appropriate treatment it is important to differentiate Ewing sarcoma/PNET from classic neuroblastoma, Wilms tumor, and rhabdomyosarcoma. In combination with the histopathological diagnosis, detection of the EWSR1 rearrangements by FISH can be used to confirm the diagnosis of Ewing sarcoma/ PNET.


References
Bridge RS, et al. (2006) Mod Pathol 19: 1-8.
Delattre O, et al. (1992) Nature 359: 162-5.
Lee J, et al. (2005) Cancer Genet Cytogenet 159: 177-80.
Rekhi B, et al. (2012) Virchows Arch 461: 687-97.
Romeo S & Dei Tos AP (2010) Virchows Arch 456: 219-34.
Sandhera AA & Bridge IA (2000) Cancer Genet Cytogenet Sandberg AA & Bridge JA (2000) Cancer Genet Cytogenet 123: 1-26. Yang L, et al. (2012) Human Pathology 43: 1463-70. Zucman J, et al. (1993) EMBO J 12: 4481-7.

## **Probe Description**

The SPEC EWSR1 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 22q12.1-q12.2 band. The orange fluorochrome direct labeled probe hybridizes proximal and extends inward into intron 4 of the EWSR1 gene, the green fluorochrome direct labeled probe hybridizes distal to that gene.




Ideogram of chromosome 22 indicating the hybridization locations.




SPEC EWSR1 Probe map (not to scale).

## Results

In an interphase nucleus lacking a translocation involving the 22q12.1-q12.2 band two orange/green fusion signals are expected representing two normal (nonrearranged) 22q12.1-q12.2 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 22q12.1-q12.2 locus and one 22q12.1q12.2 locus affected by a 22q12.1-q12.2 translocation.



hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Ewing sarcoma tissue section with translocation affecting the 22q12.1-q12.2 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

	Prod. No.	Product	Label	Tests* (Volume)	
	Z-2096-50	Zyto <i>Light</i> SPEC EWSR1 Dual Color Break Apart Probe C	•/•	5 (50 µl)	
	Z-2096-200	Zyto <i>Light</i> SPEC EWSR1 Dual Color Break Apart Probe C	•/•	20 (200 µl)	
Related Products					
	Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD  Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5	
	Z-2028-20	Zyto <i>Light</i> FISH-Tissue Implementation Kit C € □VD		20	
		Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# Zyto Light ® SPEC EWSR1/FLI1 TriCheck™ Probe



## **Background**

The ZytoLight ® SPEC EWSR1/FLI1 TriCheck™ Probe is designed to detect translocations involving the chromosomal region 22q12.2 harboring the EWSR1 (Ewing sarcoma breakpoint region 1, a.k.a. EWS) gene and the chromosomal region 11q24.3 harboring the FLI1 (Fli-1 protooncogene, ETS transcription factor, a.k.a. EWSR2) gene.

Translocations involving the chromosomal region 22a12.2 are found in 90-95% of patients with Ewing sarcoma or peripheral primitive neuroectodermal tumors (PNET). Ewing sarcoma is the second most common, highly malignant bone tumor in children and young adults. The most frequent translocation involving the EWSR1 gene region is t(11;22)(q24.3;q12.2) juxtaposing the EWSR1 gene in 22q12.2 next to the FLI1 locus. FLI1 is a member of the ETS family of transcription factors. Less frequently, EWSR1 can also be fused to ERG, a transcription factor closely related to FLI1 but located in 21q22.2.


For prognosis and appropriate treatment it is important to differentiate Ewing sarcoma/PNET from classic neuroblastoma. Wilms tumor, and rhabdomyosarcoma. In combination with the histopathological diagnosis, detection of the EWSR1 rearrangements by FISH can be used to confirm the diagnosis of Ewing sarcoma/PNET.

References Bridge RS, et al. (2006) Mod Pathol 19: 1-8. Delattre O, et al. (1992) Nature 359: 162-5. Lee J, et al. (2005) Cancer Genet Cytogenet 159: 177-80. Romeo S & Dei Tos AP (2010) Virchows Arch 456: 219-34 Sandberg AA & Bridge JA (2000) Cancer Genet Cytogenet 123: 1-26. Zucman J, et al. (1993) EMBO J 12: 4481-7.


## **Probe Description**

The SPEC EWSR1/FLI1 TriCheck™ Probe is a mixture of three direct labeled probes hybridizing to the 22q12.1-q12.2 and 11q24.3 bands. The orange fluorochrome direct labeled probe hybridizes proximal to the EWSR1 breakpoint region at 22q12.1-q12.2 and the green fluorochrome direct labeled probe hybridizes distal to the EWSR1 breakpoint region at 22q12.2. The blue fluorochrome direct labeled probe hybridizes distal to the FLI1 gene at 11q24.3.






Ideograms of chromosomes 22 (above) and 11 (below) indicating the hybridization locations.



SPEC EWSR1 Probe map (not to scale).




SPEC FLI1 Probe map (not to scale).

## Results


In an interphase nucleus without FLI1-EWSR1 rearrangement, two green/orange fusion signals and two blue signals are expected.

A FLI1-EWSR1 fusion is indicated by one separate orange signal co-localizing with one blue signal and one separate green

An EWSR1 translocation without involvement of FLI1 is indicated by the split of one green/orange fusion signal without co-localization of the separated orange signal with one blue signal.



Ewing sarcoma tissue section with FLI1-EWSR1 fusion as indicated by orange/blue fusion signals.



Ewing sarcoma tissue section with a non-FU1 EWSR1 rearrangement as indicated by the lack of co-localization of the separated orange signal with one blue signal.

Prod. No.	Product	Label	Tests* (Volume)
Z-2183-50	ZytoLight SPEC EWSR1/FLI1 TriCheck Probe C    IVD	•/•/•	5 (50 µl)
Related Proc	lucts		
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C € IVD		5
	Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>n



# Zyto Light® SPEC PDGFB Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC PDGFB Dual Color Break Apart Probe is designed for the detection of specific translocations involving the chromosomal region 22q13.1 harboring the PDGFB (a.k.a. SIS) gene.

The PDGFB gene (platelet-derived growth factor beta polypeptide) belongs to the platelet-derived growth factor family and encodes a protein which acts as a receptor tyrosine kinase.

The most frequent translocation involving the PDGFB gene is t(17;22)(q21.3;q13.1) juxtaposing the PDGFB gene next to the COL1A1 gene in 17q22. Reciprocal translocations involving t(17;22)(q21.3;q13.1) are characteristic for dermatofibrosarcoma protuberans (DFSP) patients. DFSP is a highly recurrent, infiltrative skin tumor of intermediate malignancy.

The rearrangements are cytogenetically characterized by the presence of supernumerary ring chromosomes containing low-level amplified sequences from chromosomes 17q22-qter and 22q10-q13.1, or unbalanced derivatives of the t(17;22) (q21.3;q13.1) translocation.

The rearrangement results in a COL1A1-PDGFB fusion protein which is posttranscriptionally processed to a functional platelet-derived growth factor beta chain (PDGFB) protein.


The importance of accurately diagnosing DFSP lies in its intermediate malignant nature and the availability of a therapy with significant anti-neoplastic activity but relatively minor adverse effects for cases not amenable to surgical excision.

## **Probe Description**

The SPEC PDGFB Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the 22q13.1 band. The orange fluorochrome direct labeled probe hybridizes proximal to the breakpoint region of the PDGFB gene, and the green fluorochrome direct labeled probe hybridizes distal to the breakpoint region of the PDGFB gene.




Ideogram of chromosome 22 indicating the hybridization locations.




SPEC PDGFB Probe map (not to scale).

## Results

In an interphase nucleus lacking a translocation involving the 22q13.1 band two orange/green fusion signals are expected representing two normal (non-rearranged) 22q13.1 loci. A signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates one normal 22q13.1 locus and one 22q13.1 locus affected by a 22q13.1 translocation.



SPEC PDGFB Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.



Dermatofibrosarcoma protuberans tissue section with translocation affecting the 22q13.1 locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

References
Broom RJ, et al. (2012) Clin Genitourin Cancer 10: 202-6.
Labropoulos SV & Razis ED (2007) Biologics 4: 347-53.
Patel KU, et al. (2008) Human Pathol 39: 184-93.
Shimizu A, et al. (1999) Cancer Res 59: 3719-23.
Simon MP, et al. (1997) Nat Genet 15: 95-8.
Sirvent N, et al. (2003) Genes Chromosomes Cancer 37: 1-19.

Prod. No.	Product	Label	Tests* (Volume)
Z-2119-50	Zyto Light SPEC PDGFB Dual Color Break Apart Probe CE IVD	<b>●/●</b>	5 (50 µl)
Z-2119-200	Zyto Light SPEC PDGFB Dual Color Break Apart Probe CE IVD	<b>●/●</b>	20 (200 µl)
Related Prod			
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



# Zyto Light ® SPEC CRLF2 Dual Color Break Apart Probe



## **Background**

The ZytoLight® SPEC CRLF2 Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal regions Xp22.33 and Yp11.32 harboring the CRLF2 (cytokine receptor-like factor 2, a.k.a. CRL2, TSLPR) gene. The CRLF2 protein interacts with IL7R to form a receptor for TSLP, binding of which activates cell signaling through JAK/STAT pathways.


Approximately 7% of patients with B-cell precursor ALL (B-ALL) and more than 50% of B-ALL in children with Down syndrome harbor alterations involving the CRLF2 gene. These include the translocations t(X;14)(p22.33;q32.3) or t(Y;14)(p11.32;q32.3) which fuse the entire CRLF2 gene to the immunoglobulin heavy chain enhancer region (IGH-CRLF2). Another common alteration is an interstitial deletion involving the pseudoautosomal region (PAR1) of the sex chromosomes upstream of CRLF2, juxtaposing the first non-coding exon of P2RY8 to the entire coding region of CRLF2 (P2RY8-CRLF2). These rearrangements, which are often accompanied by JAK mutations, result in overexpression of CRLF2 and were shown to contribute to lymphoid transformation. Patients with CRLF2 rearrangements and JAK mutations have a poor event-free and overall survival.

Moreover, the detection of CRLF2 rearrangements by FISH may help in selecting B-ALL patients eligible for therapy with inhibitors of the JAK/STAT pathway.

Keterences
Harvey RC, et al. (2010) Blood 115: 5312-21.
Mullighan CG, et al. (2009) Nat Genet 41: 1243-6.
Roberts KG, et al. (2014) N Engl J Med 371: 1005-15.
Russell U, et al. (2009) Blood 114: 2688-98.
Tasian SK, et al. (2012) Blood 120: 833-42.

## **Probe Description**


The SPEC CRLF2 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the Xp22.33 and Yp11.32 band, respectively. The orange fluorochrome direct labeled probe hybridizes proximal to the CRLF2 gene at Xp22.33 and Yp11.32, the green fluorochrome direct labeled probe hybridizes distal to the CRLF2 gene at Xp22.33 and Yp11.32.




Ideogram of chromosome X indicating the hybridization locations.



Ideogram of chromosome Y indicating the hybridization locations.



SPEC CRLF2 Probe map (not to scale)



SPEC CRLF2 Probe map (not to scale)


## Results

In an interphase nucleus of a normal female cell lacking a translocation involving the Xp22.33 band, two orange/green fusion signals are expected representing normal (non-rearranged) Xp22.33 loci.

In an interphase nucleus of a normal male cell lacking a translocation involving the Xp22.33 or Yp11.32 band, two orange/ green fusion signals are expected representing normal (non-rearranged) Xp22.33 and Yp11.32 loci.

A signal pattern consisting of one orange/ green fusion signal, one orange signal, and a separate green signal indicates one normal Xp22.33 or Yp11.32 locus and one Xp22.33 or Yp11.32 locus affected by a translocation.

Loss of the orange signals or orange signals of reduced size are the result of deletions proximal to the CRLF2 breakpoint region.



Bone marrow smear with translocation affecting the CRLF2 gene locus as indicated by one non-rearranged orange/green fusion signal, one orange signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)	
Z-2201-50 ZytoLight SPEC CRLF2 Dual Color Break Apart Probe C € IVD		•/•	5 (50 µl)	
Related Products				
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Ind. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5	
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C    IVD  Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgQ <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20	

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informat



# Zyto Light® SPEC TFE3 Dual Color Break Apart Probe



## **Background**


The ZytoLight® SPEC TFE3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region Xp11.23 harboring the TFE3 (transcription factor binding to IGHM enhancer 3, a.k.a. TFEA) gene. Translocations involving the chromosomal region Xp11.2 are frequently detected in renal cell carcinomas (RCCs) which usually affect children and adolescents. The Xp11.2 translocation RCCs represent a predominant and aggressive subtype in the pediatric age group but can also occur in adults. Macroscopically, Xp11.2 translocation RCCs may mimic conventional clear cell RCCs and thus, differential diagnosis of Xp11.2 translocation RCCs is clinically important.

Additionally, the unbalanced chromosomal translocation of der(17)t(X;17)(p11.23;q25) is cytogenetically characteristic for alveolar soft part sarcoma (ASPS). ASPS is a rare high grade mesenchymal malignancy affecting mainly adolescents. This translocation fuses the TFE3 gene at Xp11.23 to the ASPSCR1 (alveolar soft part sarcoma chromosome region, candidate 1, a.k.a ASPL) gene on 17q25.3. Diagnosis of ASPS is often difficult due to histologic overlap with other tumors, particularly in small biopsies. Thus, FISH analysis can improve accuracy of ASPS diagnosis.


Argani P, et al. (2001) Am J Pathol 159: 179-92. Armah HB, et al. (2009) Diagn Pathol 4: 15. Dijkhuizen T, et al. (1995) Genes Chromosomes Cancer 14: 43-50. Ladanyi M, et al. (2011) Oncogene 20: 48-57. Llamas-Velasco M, et al. (2013) Histopathology 63: 122-9. Pflueger D, et al. (2013) Neoplasia 15: 1231-40. Miliams A, et al. (2011) Virchows Arch 458: 291-300. Wu A, et al. (2008) Histopathology 53: 533-44. Yan BC, et al. (2009) Arch Pathol Lab Med 133: 1026-32.

## **Probe Description**

The SPEC TFE3 Dual Color Break Apart Probe is a mixture of two direct labeled probes hybridizing to the Xp11.23 band. The orange fluorochrome direct labeled probe hybridizes distal to the TFE3 gene, the green fluorochrome direct labeled probe hybridizes proximal to that gene.




Ideogram of chromosome X indicating the hybridization locations.



SPEC TFE3 Probe map (not to scale).

## Results

In a female interphase nucleus lacking a translocation involving the Xp11.23 band two orange/green fusion signals are expected representing two normal (non-rearranged) Xp11.23 loci. In a normal male interphase nucleus one orange/green fusion signal is expected representing one normal (non-rearranged) Xp11.23 locus. One separate green and separate orange signal indicate one Xp11.23 locus affected by a translocation.



SPEC TFE3 Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)			
Z-2109-50	Zyto Light SPEC TFE3 Dual Color Break Apart Probe CE IVD	•/•	5 (50 µl)			
Z-2109-200	Zyto <i>Light</i> SPEC TFE3 Dual Color Break Apart Probe C€ IVD	•/•	20 (200 µl)			
Related Products						
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C    INCL Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5			
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C   IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml		20			

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



# **ZytoLight® Probes for Chromosome Enumeration**

## **Background**

The ZytoLight® Chromosome Enumeration Probes are designed for identification and enumeration of human chromosomes in interphase cells and as an adjunct to standard karyotyping in metaphases. These probes will produce sharp, bright signals specific for each individual chromosome.

## **Probe Description**


For most chromosomes, direct labeled ZytoLight® CEN™ Probes hybridizing to highly repetitive human satellite DNA sequences mainly located at the centromeric regions of chromosomes are applicable. As several chromosomes share the same repetitive sequences resulting in cross-hybridization signals, they cannot be differentiated by centromere specific probes. Instead, these chromosomes can be identified by direct labeled ZytoLight® SPEC™ Probes hybridizing in close proximity to the respective satellite DNA sequences or to other chromosome specific loci.

The ZytoLight ® SPEC 1p12 Probe is designed to hybridize in close proximity of centromere 1 at 1p12 harboring WARS2, and HAO2. Since chromosomes 1, 5, and 19 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.




SPEC 1p12 Probe map (not to scale).

The ZytoLight® SPEC 2q11 Probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.



SPEC 2q11 Probe map (not to scale)

The ZytoLight® SPEC 4p11 Probe is designed to hybridize in close proximity of centromere 4 at 4p11 harboring the ZAR1 (zygote arrest 1) gene. For an unambiguous enumeration of chromosome 4 the SPEC 4p11 is found to be more suitable.




SPEC 4p11 Probe map (not to scale).

The ZytoLight ® SPEC 13q12 Probe is designed to hybridize in close proximity of centromere 13 at 13q12.11. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.




SPEC 13q12 Probe map (not to scale).

The SPEC 18q21 Probe, included in the ZytoLight ® SPEC 18/CEN X/Y Triple Color Probe, is specific for NEDD4L (neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase) gene region in 18q21.31-q21.32.



SPEC 18q21 Probe map (not to scale).

The ZytoLight® SPEC 21q22 Probe hybridizes to the so-called Down Syndrome Critical Region on 21q22.13-q22.2 commonly duplicated in cases with partial trisomy 21. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.




SPEC 21q22 Probe map (not to scale).




## **Results**


In a normal interphase nucleus, two signals are expected using Chromosome Enumeration Probes specific for autosomes. Using chromosome Y specific probes will result in normal male cells in one signal and in normal female cells in no signal. Using chromosome X specific probes will result in normal male cells in one signal and in normal female cells in two signals per nucleus. Other signal patterns indicate numerical aberrations of the respective chromosome.



CEN X/Y Dual Color Probe on a metaphase spread.




CEN X/Yq12 Dual Color Probe on interphase cells.



SPEC 13/CEN 18/SPEC 21 Triple Color Probe on cytology specimen.

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.



SPEC 13/21 Dual Color Probe on interphase cells with trisomy of chromosome 21 (orange).



Prod. No.	Product	Alpha/Class. Sat.	Chr. Band	Label	Tests* (Volume)		
Z-2101-200	Zyto Light SPEC 1p12 Probe C   IVD	-	1p12	•	20 (200 µl)		
Z-2049-200	Zyto <i>Light</i> SPEC 2q11 Probe	-	2q11.2	•	20 (200 µl)		
Z-2001-200	Zyto <i>Light</i> CEN 3 Probe	D3Z1	3p11-q11.1	•	20 (200 µl)		
Z-2083-200	Zyto <i>Light</i> SPEC 4p11 Probe	-	4p11	•	20 (200 µl)		
Z-2002-200	Zyto <i>Light</i> CEN 6 Probe	D6Z1	6p11.1-q11.1	•	20 (200 µl)		
Z-2003-200	Zyto <i>Light</i> CEN 7 Probe	D7Z1	7q11.1	•	20 (200 µl)		
Z-2004-50/-20	0 Zyto <i>Light</i> CEN 8 Probe C	D8Z2	8p11.1-q11.1	•	5/20 (50/200 µl)		
Z-2067-200	Zyto <i>Light</i> CEN 9 Probe	III D9Z3	9q12	•	20 (200 µl)		
Z-2079-200	Zyto <i>Light</i> CEN 10 Probe	D10Z1	10p11.1-q11.1	•	20 (200 µl)		
Z-2005-200	Zyto <i>Light</i> CEN 11 Probe	D11Z1	11p11.1-q11	•	20 (200 µl)		
Z-2050-200	Zyto Light CEN 12 Probe C€ IVD	D12Z3	12p11.1-q11	•	20 (200 µl)		
Z-2085-200	Zyto Light SPEC 13q12 Probe C E IVD	-	13q12.11	•	20 (200 µl)		
Z-2095-50	Zyto Light SPEC 13/CEN 18/SPEC 21 Triple Color Probe C€ IVD	] D18Z1	13q12.11/18p11.1-q11.1/21q22.13-q22.2	•/•/•	5 (50 µl)		
Z-2095-200	Zyto Light SPEC 13/CEN 18/SPEC 21 Triple Color Probe C€ IVD	] D18Z1	13q12.11/18p11.1-q11.1/21q22.13-q22.2	•/•/•	20 (200 µl)		
Z-2164-200	Zyto <i>Light</i> SPEC 13/21 Dual Color Probe C € IVD	-	13q12.11/21q22.13-q22.2	•/•	20 (200 µl)		
Z-2006-200	Zyto Light CEN 17 Probe C€ IVD	D17Z1	17p11.1-q11.1	•	20 (200 µl)		
Z-2007-200	Zyto <i>Light</i> CEN 18 Probe	D18Z1	18p11.1-q11.1	•	20 (200 µl)		
Z-2163-200	Zyto <i>Light</i> SPEC 18/CEN X/Y Triple Color Probe C€ IVD	DXZ1/DYZ3	18q21.31-q21.32/Xp11.1-q11.1/Yp11.1-q11.1	<b>•</b> /•/•	20 (200 µl)		
Z-2086-200	Zyto <i>Light</i> SPEC 21q22 Probe C € IVD	-	21q22.13-q22.2	•	20 (200 µl)		
Z-2180-200	Zyto Light SPEC 21/CEN X/Yq12 Triple Color Probe C € IVD	DXZ1/III DYZ1	21q22.13-q22.2/Xp11.1-q11.1/Yq12	<b>•/•/•</b>	20 (200 µl)		
Z-2008-200	Zyto <i>Light</i> CEN X Probe	DXZ1	Xp11.1-q11.1	•	20 (200 µl)		
Z-2010-200	Zyto <i>Light</i> CEN Yq12 Probe	III DYZ1	Yq12	•	20 (200 µl)		
Z-2123-200	Zyto <i>Light</i> CEN Y (DYZ3) Probe C € IVD	DYZ3	Yp11.1-q11.1	•	20 (200 µl)		
Z-2016-200	Zyto <i>Light</i> CEN X/Yq12 Dual Color Probe C€ IVD	DXZ1/III DYZ1	Xp11.1-q11.1/Yq12	<b>/</b>	20 (200 µl)		
Z-2016-50	Zyto <i>Light</i> CEN X/Yq12 Dual Color Probe C€ IVD	DXZ1/III DYZ1	Xp11.1-q11.1/Yq12	<b>-/-</b>	5 (50 µl)		
Z-2120-200	Zyto <i>Light</i> CEN X/Y Dual Color Probe C € IVD	DXZ1/DYZ3	Xp11.1-q11.1/Yp11.1-q11.1	•/•	20 (200 µl)		
Related Prod	ucts						
Z-2104-10	Zyto Light Aneusomy Probe Set C € IVD Incl. Zyto Light CEN X/Yq12 Dual Color Probe, 0.05 ml; Zyto Light SPEC 13/CEN 18/SPEC 21 Triple	Color Probe, 0.05 ml			10		
Z-2104-40	Zyto Light Aneusomy Probe Set C € IVD Incl. Zyto Light CEN X/Yq12 Dual Color Probe, 0.2 ml; Zyto Light SPEC 13/CEN 18/SPEC 21 Triple C	olor Probe, 0.2 ml			40		
Z-2028-5	Incl. Lyto Light FISH-Tissue Implementation Kit C €     VD						
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C € IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 2:	ix Wash Buffer A, 100 ml; DAPI,	/DuraTect-Solution, 0.8 ml		20		
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C€ IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl₂, 50 ml; 10x PBS, 50			lution, 0.8 ml	20		

ZytoLight © FISH probes are direct labeled using the unique ZytoLight © Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Light® porcine X/Y Dual Color Probe

## **Background**

The ZytoLight® porcine X/Y Dual Color Probe is designed for the simultaneous identification and enumeration of porcine sex chromosomes X and Y in interphase

A possible application of this probe is the identification of host and donor cells in porcine homografts in case of sexmismatched organ transplants. Implanted and host cells can be clearly distinguished without distorting the tissue.

Additionally, the engraftment success of xenotransplants can be determined as this probe has been shown not to hybridize to human chromosomes.

National References Francisco (1997) J Pathol 183: 99-104.

Quilter CR, et al. (2002) Mamm Genome 13: 588-94.


Riera del Moral L, et al. (2015) J Surg Res 195: 325-33.

Rohrer G, et al. (1996) Genome Res 6: 371-91.

Zudova D, et al. (2003) Cytogenet Genome Res 102: 179-83.

## **Probe Description**

The porcine X/Y Dual Color Probe is a mixture of an orange fluochrome direct labeled probe specific for the porcine ZFX gene region in Xp2.1-p2.2 and a green fluochrome direct labeled probe specific for the porcine SRY gene region in Yp1.2-p1.3. The porcine X/Y Dual Color Probe does not cross-hybridize to human chromosomes.




Ideograms of Sus scrofa chromosomes X and Y indicating the hybridization locations.


## Results

In a normal porcine male interphase nucleus, one orange and one green signal are expected. In a normal porcine female interphase nucleus, two orange signals will be observed. Other signal patterns indicate numerical aberrations of sex chromosomes

In human nuclei no signals will be visible.



Porcine X/Y Dual Color Probe hybridized to normal male interphase cells of a pig as indicated by one orange (chromosome X) and one green (chromosome Y) signal per nucleus.



Porcine X/Y Dual Color Probe hybridized to normal female interphase cells of a pig as indicated by two orange (chromosome X) signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)				
Z-2094-200	Zyto <i>Light</i> porcine X/Y Dual Color Probe	<u> </u>	20 (200 µl)				
Related Products							
Z-2028-20	4-200 Zyto Light porcine X/Y Dual Color Probe  ed Products		20				
	Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml						

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informat

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct Label System II providing improved signal intensity. Advanced specificity of the single copy SPEC probes is obtained by the unique ZytoVision® Repeat Subtraction Technique.



# **Accessories**



## **ZytoLight** ® Implementation Kits

For the detection of ZytoLight ® Probes

Prod. No.	Product	Tests
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml	5
Z-2028-20	Zyto Light FISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml	20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C (IVD) Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl., 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8ml	20

## **ZytoLight** ® Pretreatment Reagents

-	_	
Prod. N	No.	Product
ES-0001	1-4	Pepsin Solution, 4 ml C E IVD
ES-0001	1-8	Pepsin Solution Set, 2x 4 ml C E IVD
ES-0001	1-50	Pepsin Solution, 50 ml CE IVD
ES-0001	1-1000	Pepsin Solution, 1000 ml C€ IVD
ES-0002	2-4	Cytology Pepsin Solution, 4 ml C € IVD
ES-0002	2-50	Cytology Pepsin Solution, 50 ml C ( IVD)
PT-0001	1-1000	Heat Pretreatment Solution Citric, 1000 ml C€ IVD
PT-0006		Formaldehyde Dilution Buffer Set CE IVD  Ind. 10x MgCl <sub>u</sub> , 50 ml; 10x PBS, 50 ml

## **ZytoLight® Wash Buffers & Ancillary Reagents**

Prod. No.	Product
E-4005-50	Fixogum, Rubber Cement, 50 g
E-4005-125	Fixogum, Rubber Cement, 125 g
MT-0007-0.8	DAPI/DuraTect-Solution, 150 ng DAPI/ml, 0.8 ml C E IVD
MT-0008-0.8	DAPI/DuraTect-Solution (ultra), 1360 ng DAPI/ml, 0.8 ml C    IVD
WB-0001-500	Wash Buffer SSC, 500 ml C € IVD
WB-0002-50	25x Wash Buffer A, 50 ml C€ IVD
WB-0003-50	20x SSC Solution, 50 ml
WB-0005-50	20x Wash Buffer TBS, 50 ml ← IVD
WB-0007-500	Cytology Stringency Wash Buffer SSC, 500 ml C € IVD
WB-0008-500	Cytology Wash Buffer SSC, 500 ml C € IVD



## FlexISH® Page Method Introduction - FlexISH® 156 Probes, sorted by Chromosome Index 157 sorted by Gene Index 158 sorted by Indication 158 **Product Data Sheets** 159 f. Accessories 161 ZytoVision FISH Reagents, Fluorochromes and Filter Recommendations 162 ff.



# Simply Adapt the Hybridization Time to your Needs!



## Introduction

FlexISH® products are designed for identification of chromosomal aberrations on various specimens by FISH. Using the FlexISH® products gives you the flexibility to choose between a 1-day (2 h hybridization) or a 2-day (overnight hybridization) protocol by adapting the hybridization time just according to your individual needs!


## Advantages of FlexISH®

- Hybridization time can be varied between 2 hours and overnight.
- With a hybridization temperature of 37°C the FlexISH® protocol is fully compatible with routine workflows in pathology laboratories.
- Short hybridization time does not negatively affect the performance, specimen quality or diagnostic result<sup>1</sup>.

## FlexISH® Kit - Convenient Solution

All FlexISH® probes can be combined with the FlexISH®-Tissue Implementation Kit to obtain reliable results already within 4.5 hours.

The FlexISH® protocol can also be incorporated into the routine workflow with overnight hybridization providing the highest flexibility.



References

1 Brockhoff G, et al. (2016) Histopathology 69: 635-46.



				onio maoxy noman			
		Ch	r. Band	Product Name	Product No.	Quantity	Page
				no probes available yet			
2		2p:	23	FlexISH ALK/ROS1 DistinguISH™ Probe C	Z-2203-50/-200	50 μl/200 μl	159
3-5				no probes available yet			
6		/ 6q <sup>2</sup>	22.1	FlexISH ALK/ROS1 DistinguISH™ Probe C€ IVD NEW	Z-2203-50/-200	50 μl/200 μl	159
7-16				no probes available yet			
17		170	q12	FlexISH ERBB2/CEN 17 Dual Color Probe C€ IVD NEW	Z-2166-50/-200	50 μl/200 μl	160
18-22				no probes available yet			
X, Y				no probes available yet			

The unique composition of the  $FlexISH^{\otimes}$  probes enables a flexible FISH protocol application giving the choice between a fast 2 hour hybridization or a standard overnight hybridization.





# **Gene Index**

HUGO Name	Synonym	Product Name	Product No.	Quantity	Page
ALK	CD246	F/ex/SH ALK/ROS1 DistinguISH™ Probe C € IVD NEW	Z-2203-50/-200	50 μl/200 μl	159
ERBB2	HER2, NEU	FlexISH ERBB2/CEN 17 Dual Color Probe C€ IVD NAW	Z-2166-50/-200	50 µl/200 µl	160
ROS1	MCF3, ROS	FlexISH ALK/ROS1 DistinguISH™ Probe C € IVD NEW	Z-2203-50/-200	50 μl/200 μl	159

# **Probes Sorted by Indication**

Indication	Product Name	Product No.	Quantity	Page
Solid Tumors Breast Cancer	FlexISH ERBB2/CEN 17 Dual Color Probe C € NOD NEW	Z-2166-50/-200	50 µl/200 µl	160
Lung Cancer	FlexISH ALK/ROS1 DistinguISH™ Probe C€ IVD NEW FlexISH ERBB2/CEN 17 Dual Color Probe C€ IVD NEW	Z-2203-50/-200 Z-2166-50/-200	50 µl/200 µl 50 µl/200 µl	159 160
Other Solid Tumors	FlexISH ERBB2/CEN 17 Dual Color Probe C € IVD NEW	Z-2166-50/-200	50 µl/200 µl	160





# FlexISH® ALK/ROS1 DistinguISH™ Probe



## **Background**

The FlexISH® ALK/ROS1 DistinguISH™ Probe is designed to detect rearrangements involving the chromosomal region 2p23.1-p23.2 and 6q22.1 harboring the ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246) and ROS1 (c-ros oncogene 1) gene, respectively. Using this probe, it is possible to simultaneously detect ALK and ROS1 rearrangements and, additionally, to discriminate between possible aberrations affecting these chromosomal regions.

Both, the ALK as well as the ROS1 gene, encode for transmembrane receptor tyrosine kinases. Rearrangements affecting the ALK or the ROS1 gene locus are frequently found in non-small cell lung cancer (NSCLC). The most frequent ALK rearrangement in NSCLC is the inversion [inv(2)(p21p23)] affecting the genes ALK and EML4, both located on chromosome 2. The ROS1 gene is evolutionary closely related to the ALK family which forms part of the scientific basis of using inhibitors of ALK as inhibitors of ROS1. ALK and ROS1 positive NSCLC patients benefit from a tyrosine kinase targeted therapy, like, e.g., crizotinib.


Birchmaier C, et al. (1987) Proc Natl Acad Sci 84: 9270-4. Bos M, et al. (2013) Lung Cancer 81: 142-3. Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80. Shaw AT, et al. (2014) N Engl J Med 371: 1963-71.




ALK Probe map (not to scale).

## **Probe Description**

The FlexISH® ALK/ROS1 DistinguISH™ Probe is a mixture of five direct labeled probes hybridizing to the 2p23.1-p23.2 and 6q22.1-q22.2 bands. The orange fluorochrome direct labeled probe fractions hybridize distal to the ALK and ROS1 breakpoint regions, the green direct labeled probe fractions hybridize proximal to the ALK and ROS1 breakpoint regions. The blue fluorochrome direct labeled probe hybridizes distal and proximal to the ROS1 breakpoint region.




Ideograms of chromosomes 2 (left) and 6 (right) indicating the hybridization locations.




ROS1 Probe map (not to scale).

## Results

In an interphase nucleus without ALK or ROS1 rearrangements, two ALK specific green/orange fusion signals and two ROS1 specific green/orange/blue fusion signals are expected. An ALK rearrangement is indicated by one separate orange signal and/or one separate green signal, both not co-localizing with blue signals. A ROS1 rearrangement is indicated by one separate green signal, and/or one separate orange signal both co-localizing with blue signals.



H3122 cell line which shows two green/orange/blue fusion signals and one orange/green fusion signal. An ALK rearrangement is indicated by one separate orange and one separate green signal, both not co-localizing with blue signals.



HCC78 cell line which shows two green/orange fusion signals and one green/orange/blue fusion signal. ROS1 rearrangement is indicated by one separate orange and one separate green signal, both co-localizing with blue signals.

Prod. No.	Product	Label	Tests* (Volume)
Z-2203-50	FlexISH ALK/ROS1 DistinguISH Probe C€ IVD	•/•/•	5 (50 µl)
Z-2203-200	FlexISH ALK/ROS1 DistinguISH Probe C€ IVD	•/•/•	20 (200 µl)
Related Proc	lucts		
Z-2182-5	FlexISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution (tric, 150 ml; Pepsin Solution, 1 ml; 5x FlexISH Wash Buffer, 150 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2182-20	FlexISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution (tric, 500 ml; Pepsin Solution, 4 ml; 5x FlexISH Wash Buffer, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>n





# FlexISH® ERBB2/CEN 17 Dual Color Probe



## **Background**

The FlexISH® ERBB2/CEN 17 Dual Color Probe is designed for the detection of ERBB2 gene amplification frequently observed in solid malignant neoplasms, e.g., breast cancer samples.

The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185-190 kDa transmembrane glycoprotein, p185, acting as a cellular growth factor receptor. The p185 protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including EGFR (ERBB1), ERBB3 (HER3), and ERBB4 (HER4). Amplification of the proto-oncogene ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease. Similar results have been obtained for a variety of other malignant neoplasms, e.g., ovarian cancer, stomach cancer, and carci-

## References

References
Baselga J, et al. (1999) Semin Oncol 26: 78-83.
Brockhoff G, et al. (2016) Histopathology 69: 635-46.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Coussens L, et al. (1985) Science 230: 1132-9.
Etil T, et al. (2012) Br J Cancer 106: 719-26.
Hwang CC, et al. (2011) Histopathology 59: 984-92.
Hynes NE & Stern DF (1994) Biochim Biophys Acta 1198: 165-84.
Machen CE, et al. (2011) Crit Pau-Conel Homethe 190: 390-32 Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92. Park JB, et al. (1989) Cancer Res 49: 6605-9. Popescu NC, et al. (1989) Genomics 4: 362-6. Sassen A, et al. (2008) Breast Cancer Res 10: R2. Slamon DJ, et al. (1987) Science 235: 177-82. Voutsas IF, et al. (2013) Int J Radiat Biol 89: 319-25. Wolff AC, et al. (2013) J Clin Oncol 31: 3997-4013.


nomas of the salivary gland.

## **Probe Description**

The ERBB2/CEN 17 Dual Color Probe is a mixture of a green fluorochrome direct labeled ERBB2 probe specific for the chromosomal region 17q12-q21.1 harboring the ERBB2 gene and an orange fluorochrome direct labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1).




Ideogram of chromosome 17 indicating the hybridization locations.




ERBB2 Probe map (not to scale).

## Results

In a normal interphase nucleus, two green and two orange signals are expected. In a cell with amplification of the ERBB2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



FlexISH ERBB2/CEN 17 Dual Color Probe hybridized for 2 hours on an endometrial carcinoma tissue section with ERBB2 (green) amplification.



FlexISH ERBB2/CEN 17 Dual Color Probe hybridized overnight on an endometrial carcinoma tissue section with ERBB2 (green) amplification.

Prod. No.	Product	Label	Tests* (Volume)
Z-2166-50	F/exISH ERBB2/CEN 17 Dual Color Probe C€ IVD	•/•	5 (50 µl)
Z-2166-200	F/exISH ERBB2/CEN 17 Dual Color Probe C€ IVD	•/•	20 (200 µl)
Related Pro	ducts		
Z-2182-5	FlexISH-Tissue Implementation Kit C    IND Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; 5x FlexISH Wash Buffer, 150 ml; DAPI/DuraTect-Solution, 0.2 ml		5
Z-2182-20	FlexISH-Tissue Implementation Kit C E IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; 5x FlexISH Wash Buffer, 500 ml; DAPI/DuraTect-Solution, 0.8 ml		20

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

160

night hybridization.





# **Accessories**



## **Implementation Kits**

For the detection of FlexISH® Probes

Prod. No.	Product	Tests
Z-2182-5	F/exISH-Tissue Implementation Kit C    Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; 5x F/exISH Wash Buffer, 150 ml; DAPI/DuraTect-Solution, 0.2 ml	5
Z-2182-20	F/exISH-Tissue Implementation Kit C    Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; 5x F/exISH Wash Buffer, 500 ml; DAPI/DuraTect-Solution, 0.8 ml	20
Z-2099-20	Zyto Light FISH-Cytology Implementation Kit C F IVD Incl. Cytology Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 50 ml; 10x MgCl <sub>2</sub> , 50 ml; 10x PBS, 50 ml; Cytology Stringency Wash Buffer SSC, 500 ml; Cytology Wash Buffer SSC, 500 ml; DAPI/DuraTect-Solution, 0.8 ml	20

The FlexISH®-Tissue Implementation Kit can be used for FFPE samples and the ZytoLight® FISH-Cytology Implementation Kit for cytology specimens in combination with any FlexISH® FISH probe.

## FlexISH® Pretreatment Reagents

Prod. No.	Product
ES-0001-4	Pepsin Solution, 4 ml CE IVD
ES-0001-8	Pepsin Solution Set, 2x 4 ml C € IVD
ES-0001-50	Pepsin Solution, 50 ml C € IVD
ES-0001-1000	Pepsin Solution, 1000 ml C€ IVD
ES-0002-4	Cytology Pepsin Solution, 4 ml C€ IVD
ES-0002-50	Cytology Pepsin Solution, 50 ml C € IVD
PT-0001-1000	Heat Pretreatment Solution Citric, 1000 ml C € IVD
	Formaldehyde Dilution Buffer Set C € IVD Ind. 10x MgCl <sub>x</sub> , 50 ml; 10x PBS, 50 ml


## FlexISH® Wash Buffers & Ancillary Reagents

Prod. No.	Product
E-4005-50	Fixogum, Rubber Cement, 50 g
E-4005-125	Fixogum, Rubber Cement, 125 g
MT-0007-0.8	DAPI/DuraTect-Solution, 150 ng DAPI/ml, 0.8 ml CE IVD
MT-0008-0.8	DAPI/DuraTect-Solution (ultra), 1360 ng DAPI/ml, 0.8 ml C ( IVD
WB-0007-500	Cytology Stringency Wash Buffer SSC, 500 ml C€ IVD
WB-0008-500	Cytology Wash Buffer SSC, 500 ml C € IVD
WB-0010-500	5x FlexISH Wash Buffer, 500 ml C€ IVD

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# **DAPI/DuraTect<sup>™</sup>-Solutions**



## **Product Description**

ZytoVision's DAPI/Antifade Mounting Solutions are ready-to-use mounting media that are applied directly to fluorescently labeled tissue or cell specimens on microscope slides. They contain the nuclear counterstain DAPI (4', 6-diamidino-2-phenylindole) which produces a blue fluorescence when bound to DNA.

ZytoVision's DAPI/Antifade Mounting Solutions are optimized to be used on tissue or cell specimens that have been hybridized with any available ZytoLight® or FlexISH® Probe. They are all particularly compatible with the ZytoVision fluorochromes ZyGreen<sup>TM</sup>, ZyOrange<sup>TM</sup>, ZyBlue<sup>TM</sup>, ZyGold<sup>TM</sup> and ZyRed<sup>TM</sup>.

ZytoVision's DAPI/Antifade Mounting Solutions prevent permanent loss of fluorescence and protect fluorescent dyes from photobleaching during fluorescence microscopy.

Prod. No.	Product	Concentration	Storage Temperature	Description
MT-0007-0.8	DAPI/DuraTect-Solution, 0.8 ml CE IVD	150 ng DAPI/ml	28℃ .	Best overall signal protection
				Superior signal stability of mounted tissue sections
				(≤3 months at 221°C)
MT-0008-0.8	DAPI/DuraTect-Solution (ultra), 0.8 ml C€ IVD	1360 ng DAPI/ml	28°C ·	Best overall signal protection
				Superior signal stability of mounted tissue sections
				(≤3 months at 221°C)
				Recommended when a more intense DAPI stain is desired



# **ZyBlack™ Quenching Solution**

# Without ZyBlack™ Quenching Solution

# With ZyBlack™ Quenching Solution

Kidney tissue section hybridized with the ZytoLight® SPEC PTEN/CEN 10 Dual Color Probe.

## **Product Description**

ZyBlack™ Quenching Solution is a readyto-use solution to reduce autofluorescence on both formaldehyde-fixed paraffin-embedded and frozen sections.

It can be easily incorporated into the FISH protocol by applying it after the proteolytic pretreatment.

One of the major concerns of Fluorescence in situ Hybridization (FISH)-based diagnostic assays is the interference by autofluorescence. Several types of tissue tend to emit intense autofluorescence, including brain, liver, kidney and myocardium, making it difficult to evaluate FISH results.

ZyBlack™ Quenching Solution reduces autofluorescence without adversely affecting tissue integrity or specific fluorescence signals.

Prod. No.	Product	Volume
BS-0002-8	ZyBlack Quenching Solution CE IVD	8 ml



# **ZytoVision Fluorochromes and Filter Recommendations**

## **ZytoVision Fluorochromes**

Two factors that mainly influence FISH analyses:

- Fluorochromes of the FISH probes
- · Appropriate filter sets

Fluorochrome	Excitation	Emission	Equivalent to
<ul> <li>ZyBlue<sup>™</sup></li> </ul>	418 nm	467 nm	DEAC
<ul> <li>ZyGreen<sup>™</sup></li> </ul>	503 nm	528 nm	FITC
ZyGold™	532 nm	553 nm	Rhodamine 6G
ZyOrange <sup>™</sup>	547 nm	572 nm	Rhodamine
ZyRed™	580 nm	599 nm	TexasRed ®

## **Recommended Filter Sets**

All filter sets are produced by well known manufacturers and have a superior-signal-to-noise ratio!

Prod. No	Product	Detected Fluorochrome
E-4030-1	DAPI Single Bandpass Filter Set v2	DAPI
E-4026-1	ZyBlue™ Single Bandpass Filter Set v2	•
E-4012-1	ZyGreen™ Single Bandpass Filter Set v2	•
E-4027-1	ZyGold™ Single Bandpass Filter Set v2	•
E-4013-1	ZyOrange™ Single Bandpass Filter Set v2	•
E-4017-1	ZyRed™ Single Bandpass Filter Set v2	•
E-4016-1	ZyGreen™/ZyOrange™ Dual Bandpass Filter Set v2	•/•
E-4010-1	DAPI/ZyGreen™/ZyOrange™ Triple Bandpass Filter Set	DAPI/•/•
E-4028-1	ZyBlue™/ZyGreen™/ZyOrange™ Triple Bandpass Filter Set	●/●/●

## Fluorescence Filter Holder

The filter sets need to be assembled in fluorescence filter holder specific for the respective microscope.

Prod. No	Product	Compatible for Microscopes e.g.*
E-4111-1	ZEISS Fluorescence Filter Holder "FL EC P&C"	Zeiss: Axio Imager, Axiostar plus, Axioskop 40
E-4113-1	ZEISS Fluorescence Filter Holder "FL"	Zeiss: Axioplan 2, Axio Scope 2, Axiophot 2
E-4121-1	OLYMPUS Fluorescence Filter Holder "U-MF 2"	Olympus: AX, AX70, BX41, BX50, BX51
E-4122-1	OLYMPUS Fluorescence Filter Holder "U-FF"	Olympus: BX43, BX53, BX63
E-4131-1	LEICA Fluorescence Filter Holder "DM K"	Leica: DM-2000, DM-3000, DM-5500
E-4141-1	NIKON Fluorescence Filter Holder "C-FL"	Nikon: Eclipse 50i, Eclipse 80i, TI Eclipse

<sup>\*</sup>If your model is not listed, please contact info@zytovision.com

## **Microscope Specifications**

In order to provide you with the best possible service, please provide us with the following details:

- Microscope manufacturer
- Type or model of microscope
- · Approx. age of microscope




These filter sets, optimized for ZytoLight  $^{\circ}$  and FlexISH  $^{\circ}$  FISH probes, will significantly increase brightness and quality of your FISH results!



ZytoDot® Products for CISH analysis	Page
Method Introduction - Zyto <i>Dot</i> ® - Zyto <i>Dot 2C</i> ®	166 167
Probes, sorted by Chromosome Index	168 ff.
sorted by Gene Index sorted by Indication	172 f. 174 ff.
Product Data Sheets	1 <i>77</i> ff.
Accessories	218 f.




# Reliable and Simple Detection of Genomic Alterations using **Light Microscopy!**



## Introduction

The ZytoDot® products are designed for the detection of aneuploidies and gene amplifications by Chromogenic in situ Hybridization (CISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears, and metaphase chromosome spreads.



## CISH: A reliable Alternative to FISH

High concordance between CISH and FISH ranging from 92-100% has been shown by numerous international studies for ERBB2 amplification.

## Advantages of CISH

- Quick and easy interpretation of results comparable to IHC
- Simultaneous observation of tissue morphology and CISH signals
- Storage of slides at room temperature -CISH signals are permanent
- No costly fluorescent microscope needed

## High Signal-to-Noise Ratio


The ZytoDot® probes are processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background. No further blocking of repetitive sequences is needed!

## **ZytoDot** ® Kits - Convenient Solutions

For making CISH analysis reliable and user-friendly, all ZytoDot® CISH probes can be combined with the ZytoDot® CISH Implementation Kit (C-3018-40) which includes all necessary pretreatment solutions, wash buffers, antibodies, chromogenic substrates, counterstaining solution, mounting solution and a detailed protocol to perform successful CISH experiments. Additionally, for some major targets, complete kits including probes and all necessary reagents are available.

The ZytoDot® system uses Digoxigenin-labeled probes ① which are, after blocking (2), detected using a Mouse-anti-Digoxigenin antibody (3). This antibody is detected by a polymerized HRP-Goat-anti-Mouse antibody (4). The enzymatic reaction of DAB (5) leads to the formation of strong permanent brown signals that can be visualized by light microscopy using a 40x objective.


## **Protocol Overview**



# ZytoDot ®**2** Products for CISH analysis



# Zyto Dot® 2C™ - 2-Color CISH for the Detection of Genomic Alterations



## Introduction


The ZytoDot® 2C™ products are designed for the simultaneous detection of two different genomic targets by Chromogenic in situ Hybridization (CISH) in formalinfixed, paraffin-embedded tissue sections, cell samples, and blood or bone marrow smears. This two color system is especially useful for the differentiation of aneuploidies from gene amplifications, and the detection of deletions and translocations.

## Advantages of ZytoDot® 2C™

- Simultaneous observation of tissue morphology and CISH signals at 40x using light microscopy
- Two targets detected simultaneously
- High contrasting distinct red and green signals
- Quick and easy interpretation of results comparable to IHC
- Standardized and complete kits
- No costly fluorescent microscope needed

## ZytoDot® 2C™ Kits -**Standardized Solutions**

For making CISH analysis reliable and user-friendly, complete ZytoDot® 2C™ kits are available for some major targets. These kits include a ZytoDot® 2C™ probe, all necessary pretreatment solutions, wash buffers, antibodies, chromogenic substrates, counterstaining and mounting solutions, and a detailed protocol. For other targets, any separately available ZytoDot® 2C™ probe can be combined with ZytoDot® 2C™ Implementation Kits resulting in target specific kit solutions.



The ZytoDot® 2C™ system uses DIGand DNP-labeled probe cocktails targeting different genomic sections (1) which are detected using a Mouse-anti-DIG/Rabbit-anti-DNP cocktail (2). These antibodies are detected by a unique cocktail of polymerized HRP-Goat-anti-Mouse/AP-Goat-anti-Rabbit antibodies (3). The enzymatic reaction of AP-Red (4) and HRP-Green (5) leads to the formation of strong permanent red respectively green signals that can be visualized by light microscopy using a 40x objective.

## **Protocol Overview**

























Apply Probe

Apply HRP-/ AP-Polymer Cocktail



		. 011103	onic mack, noman			
		Chr. Band	Product Name	Product No.	Quantity	Page
	/	1p36.3 1p12 1q25.3	Zyto Dot 2C SPEC 1p36/1q25 Probe C € IVD  Zyto Dot 2C SPEC 1p36/1q25 Probe C € IVD  Zyto Dot 2C SPEC 1p36/1q25 Probe C € IVD	C-3036-100/-400 C-3035-400 C-3036-100/-400	100 µl/400 µl 400 µl 100 µl/400 µl	177 216 f. 177
2	<u> </u>	2p24 2p23 2p21 2q11.2	Zyto Dot SPEC MYCN Probe C € IVD  Zyto Dot 2C SPEC ALK Break Apart Probe C € IVD  Zyto Dot 2C SPEC EML4 Break Apart Probe C € IVD  Zyto Dot SPEC 2q11 Probe C € IVD	C-3029-400 C-3055-100/-400 C-3059-400 C-3051-400	400 µl 100 µl/400 µl 400 µl 400 µl	179 180 181 216 f.
3		3p11.1-q11.1 3q27	Zyto Dot CEN 3 Probe C€ IVD  Zyto Dot 2C SPEC BCL6 Break Apart Probe C€ IVD NEW	C-3045-400 C-3074-100	400 μl 100 μl	216 f. 182
	/					
4-5			no probes available yet			
6	// (	6p11.1-q11 6q22.1 6q25.1	Zyto Dot CEN 6 Probe C€ IVD  Zyto Dot 2C SPEC ROS1 Break Apart Probe C€ IVD  Zyto Dot SPEC ESR1 Probe C€ IVD	C-3002-400 C-3063-100/-400 C-3024-400	400 µl 100 µl/400 µl 400 µl	216 f. 183 184
	/					

C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



	III OIIIO2	ome inaex, noman			
	Chr. Band	Product Name	Product No.	Quantity	Page
7	7p11.2 7q11.1 7q31.2	Zyto Dot SPEC EGFR Probe C € IVD  Zyto Dot 2C SPEC EGFR/CEN 7 Probe C € IVD  Zyto Dot CEN 7 Probe C € IVD  Zyto Dot 2C SPEC MET/CEN 7 Probe C € IVD	C-3007-400 C-3033-100/-400 C-3008-400 C-3057-400	400 µl 100 µl/400 µl 400 µl 400 µl	185 186 216 f. 187
8	8p11.2	Zyto Dot SPEC FGFR1 Probe C€ IVD  Zyto Dot 2C SPEC FGFR1/CEN 8 Probe C€ IVD	C-3023-400 C-3050-400	400 μl 400 μl	188 189
	8p11.1-q11.1	Zyto Dot CEN 8 Probe CE IVD	C-3016-400	400 μl	216 f.
	8q24.21	Zyto Dot SPEC MYC Probe C € IVD	C-3013-400	400 µl	190
	-	Zyto Dot 2C SPEC MYC Break Apart Probe C € IVD	C-3066-400	400 µl	191
9	9p21	Zyto Dot 2C SPEC CDKN2A/CEN 9 Probe C   IVD	C-3067-400	400 μΙ	192
10	10q11.2	ZytoDot 2C SPEC RET Break Apart Probe C € IVD	C-3064-100/-400	100 µl/400 µl	193
	10q23.3	ZytoDot 2C SPEC PTEN/CEN 10 Probe C€ IVD	C-3053-400	400 µl	194
	10q26.1	ZytoDot 2C SPEC FGFR2/CEN 10 Probe C € IVD	C-3056-400	400 µl	195
11	11q13.3	Zyto Dot SPEC CCND1 Probe C € IVD	C-3034-400	400 μΙ	196
		ZytoDot 2C SPEC CCND1 Break Apart Probe C€ NEW NEW	C-3075-100	100 µl	197
12	12p11.1-q11	Zyto Dot CEN 12 Probe C € IVD	C-3014-400	400 µl	216 f.
	12q13.3	ZytoDot 2C SPEC DDIT3 Break Apart Probe C€ IVD	C-3047-100	100 µl	198
	12q14	ZytoDot 2C SPEC CDK4/CEN 12 Probe C€ IVD	C-3062-400	400 µl	199
	12q15	Zyto Dot SPEC MDM2 Probe C € IVD	C-3012-400	400 µl	200
		Zyto Dot 2C SPEC MDM2/CEN 12 Probe C€ IVD	C-3049-100/-400	100 µl/400 µl	201



		omo maoxy noman			
	Chr. Band	Product Name	Product No.	Quantity	Page
13	13q12.1 13q14.1	Zyto Dot 2C SPEC FOXO1 Break Apart Probe C€ IVD	C-3052-400 C-3065-100	400 µl 100 µl	216 f. 202
14	14q32.3	Zyto Dot 2C SPEC IGH Break Apart Probe C € IVD NEW	C-3071-100	100 µl	203
15		no probes available yet			
16	16p11.2	Zyto Dot 2C SPEC FUS Break Apart Probe C€ IVD	C-3054-100	100 ји	204
17	17p11.1-q11.1 17q12 17q21.2	Zyto Dot CEN 17 Probe C € IVD  Zyto Dot SPEC ERBB2 Probe C € IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe C € IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe Kit C € IVD  Zyto Dot 2C SPEC ERBB2/D17S122 Probe C € IVD  Zyto Dot SPEC TOP2A Probe C € IVD  Zyto Dot 2C SPEC TOP2A/CEN 17 Probe C € IVD	C-3006-400 C-3001-100/-400 C-3003-10/-40 C-3032-100/-400 C-3022-10/-40 C-3068-100 C-3021-400 C-3040-400	400 μl 100 μl/400 μl 10 Tests/40 Tests 100 μl/400 μl 10 Tests/40 Tests 100 μl 400 μl	206
18	18q11.2 18q21.3	Zyto Dot 2C SPEC SS18 Break Apart Probe C € IVD NEW  Zyto Dot 2C SPEC BCL2 Break Apart Probe C € IVD NEW  Zyto Dot 2C SPEC MALT1 Break Apart Probe C € IVD NEW	C-3046-100 C-3073-100 C-3072-100	100 µl 100 µl 100 µl	210 212 211
19	19p13.3 19q13.3	Zyto Dot 2C SPEC 19q13/19p13 Probe C€ IVD  Zyto Dot 2C SPEC 19q13/19p13 Probe C€ IVD	C-3037-100/-400 C-3037-100/-400	100 µl/400 µl 100 µl/400 µl	178 178
20	— 20q12	Zyto Dot 2C SPEC TOP1/CEN 20 Probe C € IVD	C-3069-400	400 µl	213



	Chr. Band	Product Name	Product No.	Quantity	Page
21	21q22.1-q22.2 21q22.2	Zyto Dot SPEC 21q22 Probe C€ IVD  Zyto Dot 2C SPEC ERG Break Apart Probe C€ IVD	C-3026-400 C-3058-400	400 µl 400 µl	216 f. 214
22	22q12.2	ZytoDot 2C SPEC EWSR1 Break Apart Probe C € IVD	C-3043-100	100 µl	215
X	Xp11.1-q11.1	Zyto Dot CEN X Probe C € IVD  Zyto Dot 2C CEN X/Y Probe C € IVD	C-3025-400 C-3048-400	400 µl 400 µl	216 f. 216 f.
Y	Yp11.1-q11.1 Yq12	Zyto Dot 2C CEN X/Y Probe C € IVD  Zyto Dot CEN Yq12 Probe C € IVD	C-3048-400 C-3020-400	400 μl 400 μl	216 f. 216 f.



# **Gene Index**

HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
ALK		CD246	ZytoDot 2C SPEC ALK Break Apart Probe C€ IVD	C-3055-100/-400	100 µl/400 µl	180
BCL2		Bcl-2	ZytoDot 2C SPEC BCL2 Break Apart Probe C€ IVD NEW	C-3073-100	100 μΙ	212
BCL6		BCL5, BCL6A	ZytoDot 2C SPEC BCL6 Break Apart Probe C€ IVD NEW	C-3074-100	100 μΙ	182
CCND1		BCL1, U21B31	Zyto Dot SPEC CCND1 Probe C € IVD  Zyto Dot 2C SPEC CCND1 Break Apart Probe C € IVD NEW	C-3034-400 C-3075-100	400 µl 100 µl	196 197
CDK4		PSK-J3	Zyto Dot 2C SPEC CDK4/CEN 12 Probe C€ IVD	C-3062-400	400 μΙ	199
CDKN2A		p16, ARF, INK4	Zyto Dot 2C SPEC CDKN2A/CEN 9 Probe C€ IVD	C-3067-400	400 μΙ	192
DDIT3	СНОР	CHOP10, GADD153	Zyto <i>Dot</i> 2C SPEC DDIT3 Break Apart Probe C€ IVD	C-3047-100	100 μΙ	198
EGFR		HER1, ERBB1	Zyto Dot SPEC EGFR Probe C € IVD  Zyto Dot 2C SPEC EGFR/CEN 7 Probe C € IVD	C-3007-400 C-3033-100/-400	400 µl 100 µl/400 µl	185 186
EML4		ROPP120	ZytoDot 2C SPEC EML4 Break Apart Probe C € IVD	C-3059-400	400 μΙ	181
ERBB2	HER2	HER-2, NEU	Zyto Dot SPEC ERBB2 Probe C € IVD  Zyto Dot SPEC ERBB2 Probe Kit C € IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe C € IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe Kit C € IVD  Zyto Dot 2C SPEC ERBB2/D17S122 Probe C € IVD	C-3001-100/-400 C-3003-10/-40 C-3032-100/-400 C-3022-10/-40 C-3068-100	100 µl/400 µl 10 Tests/40 Tests 100 µl/400 µl 10 Tests/40 Tests 100 µl	206
ERG		erg-3, p55	ZytoDot 2C SPEC ERG Break Apart Probe C€ IVD	C-3058-400	400 μΙ	214
ESR1		Era, NR3A1	Zyto Dot SPEC ESR1 Probe C€ IVD	C-3024-400	400 μΙ	184
EWSR1		EWS	ZytoDot 2C SPEC EWSR1 Break Apart Probe C€ IVD	C-3043-100	100 μΙ	215
FGFR1		FLT2, BFGFR	Zyto Dot SPEC FGFR1 Probe C € IVD  Zyto Dot 2C SPEC FGFR1/CEN 8 Probe C € IVD	C-3023-400 C-3050-400	400 µl 400 µl	188 189
FGFR2		BEK, CD332	Zyto Dot 2C SPEC FGFR2/CEN 10 Probe C€ IVD	C-3056-400	400 μΙ	195
FOX01		FKHR, FKH1	ZytoDot 2C SPEC FOXO1 Break Apart Probe C€ IVD	C-3065-100	100 μΙ	202
FUS		FUS1	ZytoDot 2C SPEC FUS Break Apart Probe C€ IVD	C-3054-100	100 µl	204
IGH		IGH@	Zyto Dot 2C SPEC IGH Break Apart Probe C€ IVD NEW	C-3071-100	100 µl	203
MALT1		MLT	ZytoDot 2C SPEC MALT1 Break Apart Probe C€ IVD NEW	C-3072-100	100 µl	211
MDM2		HDM2	Zyto Dot SPEC MDM2 Probe C€ IVD  Zyto Dot 2C SPEC MDM2/CEN 12 Probe C€ IVD	C-3012-400 C-3049-100/-400	400 µl 100 µl/400 µl	200 201



# **Gene Index**

HUGO Name	Previous Product Name	Synonym	Product Name	Product No.	Quantity	Page
MET		HGFR, RCCP2	Zyto Dot 2C SPEC MET/CEN 7 Probe C € IVD	C-3057-400	400 μΙ	187
MYC	СМҮС	bHLHe39, c-Myc	Zyto Dot SPEC MYC Probe C	C-3013-400 C-3066-400	400 µl 400 µl	190 191
MYCN	NMYC	N-myc	Zyto Dot SPEC MYCN Probe C € IVD	C-3029-400	400 μΙ	179
PTEN		MMAC1, TEP1	Zyto Dot 2C SPEC PTEN/CEN 10 Probe C € IVD	C-3053-400	400 µl	194
RET		HSCR1, CDHF12	Zyto Dot 2C SPEC RET Break Apart Probe C€ IVD	C-3064-100/-400	100 µl/400 µl	193
ROS1		MCF3, ROS	Zyto Dot 2C SPEC ROS1 Break Apart Probe C€ IVD	C-3063-100/-400	100 µl/400 µl	183
SS18	SYT	TX22	Zyto Dot 2C SPEC SS18 Break Apart Probe C€ IVD	C-3046-100	100 μΙ	210
TOP1			Zyto Dot 2C SPEC TOP1/CEN 20 Probe C€ IVD	C-3069-400	400 μΙ	213
TOP2A		ТОР2	Zyto Dot SPEC TOP2A Probe C€ IVD Zyto Dot 2C SPEC TOP2A/CEN 17 Probe C€ IVD	C-3021-400 C-3040-400	400 µl 400 µl	208 209

The Gene Index list includes only those probes directed against DNA sequences assigned to known genes. It does not contain probes directed against other genomic sequences as e.g. repetitive satellite DNA sequences. For a complete overview of all ZytoDot® probes, please refer to the Chromosome Index.

For cross referencing of previous ZytoVision probe names and new HUGO gene names - please visit the HUGO gene nomenclature committee website at www.genenames.org.



# **Probes Sorted by Indication**

Indication	Product Name	Product No.	Quantity	Page
Solid Tumors Brain and Neural Tumors	Zyto Dot 2C SPEC 1p36/1q25 Probe C € IVD  Zyto Dot 2C SPEC 19q13/19p13 Probe C € IVD  Zyto Dot 2C SPEC CDKN2A/CEN 9 Probe C € IVD  Zyto Dot SPEC EGFR Probe C € IVD  Zyto Dot 2C SPEC EGFR/CEN 7 Probe C € IVD  Zyto Dot 2C SPEC MET/CEN 7 Probe C € IVD  Zyto Dot SPEC MYCN Probe C € IVD  Zyto Dot 2C SPEC PTEN/CEN 10 Probe C € IVD	C-3036-100/-400 C-3037-100/-400 C-3067-400 C-3007-400 C-3033-100/-400 C-3057-400 C-3029-400 C-3053-400	100 µl/400 µl 100 µl/400 µl 400 µl 400 µl 100 µl/400 µl 400 µl 400 µl	177 178 192 185 186 187 179
Breast Cancer	Zyto Dot SPEC CCND1 Probe C	C-3034-400 C-3007-400 C-3033-100/-400 C-3001-100/-400 C-3032-100/-400 C-3022-10/-40 C-3068-100 C-3024-400 C-3023-400 C-3050-400 C-3056-400 C-3013-400 C-3021-400 C-3040-400	400 µl 400 µl 100 µl/400 µl 100 µl/400 µl 10 Tests/40 Tests 100 µl/400 µl 10 Tests/40 Tests 100 µl 400 µl	206
Cervical Cancer	Zyto <i>Dot</i> SPEC MYC Probe C € IVD	C-3013-400	400 µl	190
Lung Cancer	Zyto Dot 2C SPEC ALK Break Apart Probe C€ IVD  Zyto Dot 2C SPEC EML4 Break Apart Probe C€ IVD  Zyto Dot 2C SPEC EGFR Probe C€ IVD  Zyto Dot SPEC ERBB2 Probe C€ IVD  Zyto Dot SPEC ERBB2 Probe Kit C€ IVD  Zyto Dot 2C SPEC ERBB2 Probe Kit C€ IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe C€ IVD  Zyto Dot 2C SPEC ERBB2/CEN 17 Probe Kit C€ IVD  Zyto Dot 2C SPEC ERBB2/D17S122 Probe C€ IVD  Zyto Dot 2C SPEC FGFR1 Probe C€ IVD  Zyto Dot 2C SPEC FGFR1/CEN 8 Probe C€ IVD  Zyto Dot 2C SPEC FGFR2/CEN 10 Probe C€ IVD  Zyto Dot 2C SPEC MET/CEN 7 Probe C€ IVD  Zyto Dot 2C SPEC RET Break Apart Probe C€ IVD  Zyto Dot 2C SPEC ROS1 Break Apart Probe C€ IVD	C-3055-100/-400 C-3059-400 C-3007-400 C-3033-100/-400 C-3001-100/-400 C-3003-10/-40 C-3032-100/-400 C-3068-100 C-3053-400 C-3050-400 C-3056-400 C-3057-400 C-3064-100/-400 C-3063-100/-400	100 µl/400 µl 400 µl 400 µl 100 µl/400 µl 100 pl/400 µl 10 Tests/40 Tests 100 µl/400 µl 400 µl 400 µl 400 µl 400 µl 100 µl/400 µl 100 µl/400 µl	206

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



# **Probes Sorted by Indication**

Indication	Product Name	Product No.	Quantity	Page
Other Solid Tumors	Zyto Dot 2C SPEC ALK Break Apart Probe C € IVD  Zyto Dot 2C SPEC CDKN2A/CEN 9 Probe C € IVD NEW  Zyto Dot SPEC EGFR Probe C € IVD  Zyto Dot 2C SPEC EGFR/CEN 7 Probe C € IVD  Zyto Dot CEN 8 Probe C € IVD  Zyto Dot 2C SPEC MET/CEN 7 Probe C € IVD  Zyto Dot 2C SPEC MYCN Probe C € IVD  Zyto Dot 2C SPEC TOP1/CEN 20 Probe C € IVD	C-3055-100/-400 C-3067-400 C-3007-400 C-3033-100/-400 C-3016-400 C-3057-400 C-3029-400 C-3069-400	100 µl/400 µl 400 µl 400 µl 100 µl/400 µl 400 µl 400 µl 400 µl	180 192 185 186 216 f. 187 179 213
Prostate Cancer	Zyto Dot 2C SPEC ERG Break Apart Probe C € IVD  Zyto Dot 2C SPEC PTEN/CEN 10 Probe C € IVD	C-3058-400 C-3053-400	400 µl 400 µl	214 194
Sarcomas	Zyto Dot 2C SPEC ALK Break Apart Probe C € IVD  Zyto Dot 2C SPEC CDK4/CEN 12 Probe C € IVD  Zyto Dot 2C SPEC DDIT3 Break Apart Probe C € IVD  Zyto Dot 2C SPEC EWSR1 Break Apart Probe C € IVD  Zyto Dot 2C SPEC FOX01 Break Apart Probe C € IVD  Zyto Dot 2C SPEC FUS Break Apart Probe C € IVD  Zyto Dot SPEC MDM2 Probe C € IVD  Zyto Dot 2C SPEC SS18 Break Apart Probe C € IVD  Zyto Dot 2C SPEC SS18 Break Apart Probe C € IVD	C-3055-100/-400 C-3062-400 C-3047-100 C-3043-100 C-3065-100 C-3054-100 C-3012-400 C-3049-100/-400 C-3046-100	100 µl/400 µl 400 µl 100 µl 100 µl 100 µl 100 µl 400 µl 100 µl/400 µl	180 199 198 215 202 204 200 201 210
<b>Hematology Specific Probes</b> Acute Lymphoblastic Leukemia (ALL)	Zyto Dot 2C SPEC CDKN2A/CEN 9 Probe C€ IVD	C-3067-400	400 µl	192
Acute Myelogenous Leukemia (AML)	ZytoDot CEN 8 Probe C € IVD	C-3016-400	400 µl	216 f.
Chronic Lymphocytic Leukemia (CLL)	Zyto Dot 2C SPEC BCL2 Break Apart Probe C€ IVD NEW  Zyto Dot SPEC CCND1 Probe C€ IVD  Zyto Dot 2C SPEC CCND1 Break Apart Probe C€ IVD NEW  Zyto Dot SPEC MYC Probe C€ IVD	C-3073-100 C-3034-400 C-3075-100 C-3013-400	100 µl 400 µl 100 µl 400 µl	212 196 197 190
Chronic Myelogenous Leukemia (CML)	ZytoDot CEN 8 Probe C € IVD	C-3016-400	400 µl	216 f.
Multiple Myeloma	Zyto Dot SPEC CCND1 Probe C € IVD  Zyto Dot 2C SPEC CCND1 Break Apart Probe C € IVD NEW  Zyto Dot 2C SPEC IGH Break Apart Probe C € IVD NEW	C-3034-400 C-3075-100 C-3071-100	400 µl 100 µl 100 µl	196 197 203
Myelodysplastic Syndrome (MDS)	Zyto Dot CEN 8 Probe C€ IVD	C-3016-400	400 µl	216 f.
Non-Hodgkin Lymphoma, other	Zyto Dot 2C SPEC ALK Break Apart Probe C€ IVD NEW Zyto Dot 2C SPEC BCL6 Break Apart Probe C€ IVD NEW Zyto Dot 2C SPEC BCL6 Break Apart Probe C€ IVD NEW Zyto Dot SPEC CCND1 Probe C€ IVD Zyto Dot 2C SPEC CCND1 Break Apart Probe C€ IVD NEW Zyto Dot 2C SPEC IGH Break Apart Probe C€ IVD NEW Zyto Dot 2C SPEC MALT1 Break Apart Probe C€ IVD NEW Zyto Dot 2C SPEC MYC Break Apart Probe C€ IVD NEW	C-3055-100/-400 C-3073-100 C-3074-100 C-3034-400 C-3075-100 C-3071-100 C-3072-100 C-3066-400	100 µl/400 µl 100 µl 100 µl 400 µl 100 µl 100 µl 100 µl	180 212 182 196 197 203 211

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.





# **Probes Sorted by Indication**

Indication	Product Name	Product No.	Quantity	Page
Genetics Sex Mismatched Bone-Marrow Transplantant Management	Zyto Dot CEN X Probe C € IVD  Zyto Dot CEN Yq12 Probe C € IVD  Zyto Dot 2C CEN X/Y Probe C € IVD	C-3025-400 C-3020-400 C-3048-400	400 µl 400 µl 400 µl	216 f. 216 f. 216 f.
Prenatal, Postnatal, and Preimplantation Genetics	Zyto Dot SPEC 21q22 Probe C € IVD  Zyto Dot CEN X Probe C € IVD  Zyto Dot CEN Yq12 Probe C € IVD  Zyto Dot 2C CEN X/Y Probe C € IVD	C-3026-400 C-3025-400 C-3020-400 C-3048-400	400 µl 400 µl 400 µl 400 µl	216 f. 216 f. 216 f. 216 f.

# ZytoDot ®2 Products for CISH analysis



# Zyto Dot ® 2C SPEC 1p36/1q25 Probe



## **Background**

The Zyto Dot ® 2C SPEC 1p36/1q25 Probe is designed for the detection of 1p

Deletions affecting the short arm of chromosome 1 (1p) are frequently found in human gliomas and neuroblastomas, but also in breast, lung, endometrial, ovarian, and colorectal carcinomas. Loss of 1p is a strong prognostic factor in patients with neuroblastoma. Since loss of 1p reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable, more aggressive therapy may be considered in these patients.


Deletions affecting the long arm of chromosome 19 (19g) are frequently found in human malignant gliomas as well as in neuroblastomas and epithelial ovarian

Several studies showed correlation of combined allelic losses at 1p36 and 19q13 with oligodendroglioma histology and association with both chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Hence, determination of 1p and 19q status may aid therapeutic decisions and predict outcome in patients with anaplastic oligodendrogliomas.


References
Barbashina V, et al. (2005) Clin Cancer Res 11: 1119-28.
Cairncross JG, et al. (1998) J Natl Cancer Inst 90: 1473-9.
Capper D, et al. (2010) Acta Neuropathol 121: 241-52.
Caron H, et al. (1996) N Engl J Med 334: 225-30.
Elsir T, et al. (2011) Br J Cancer 11: 1747-54.
Hoeller S, et al. (2012) Hum Pathol 43: 405-12.
Lass U, et al. (2013) Brain Pathol 23: 311-8.
Ragnarsson G, et al. (1999) Br J Cancer 79: 1468-74.
Rosenberg JE, et al. (1999) Oncogene 13: 2483-5.
Smith JS, et al. (1999) Oncogene 18: 4144-52.
Smith JS, et al. (2000) Genes Chromosomes Cancer 29: 16-25.
White PS, et al. (2005) Oncoaene 24: 2684-94. White PS, et al. (2005) Oncogene 24: 2684-94. Woelfel C, et al. (2011) Cancer Genet 204: 671-6

## **Probe Description**

The Zyto Dot ® 2C SPEC 1p36/1g25 Probe is a mixture of a Dinitrophenyl-labeled 1p36 probe specific for the smallest region of consistent deletion (SRD) of chromosome 1 defined in neuroblastoma at 1p36.31 and a Digoxigenin-labeled 1q25 probe specific for 1q25.3.




Ideogram of chromosome 1 indicating the hybridization locations.



## Results

In a normal interphase nucleus, using the ZytoDot® 2C SPEC 1p36/1q25 Probe in combination with ZytoDot® 2C CISH Implementation Kit, two red (1p) and two green (1q) signals are expected. In a cell with deletions affecting the 1p36 locus, one or no copy of the red signal will be observed.



SPEC 1p36/1q25 Probe hybridized to glioma tissue section with 1p36 deletion as indicated by one red signal in each nucleus.

Image kindly provided by Prof. W. Müller, University Leipzig, Germany.

Prod. No.	Product	Label	Tests* (Volume)
C-3036-100	Zyto Dot 2C SPEC 1p36/1q25 Probe C € IVD	DNP / Digoxigenin	10 (100 µl)
C-3036-400	Zyto <i>Dot</i> 2C SPEC 1p36/1q25 Probe C€ IVD	DNP /Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C   IVD  Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit C    IVD  Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Muclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40
WB-0009-500	Clear-it™ Stringency Buffer C € IVD		500 ml

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more inf<u>ormation</u>

# ZytoDot ®2 Products for CISH analysis



# Zyto Dot ® 2C SPEC 19q13/19p13 Probe



## **Background**

The ZytoDot® 2C SPEC 19q13/19p13 Probe is designed for the detection of 19a

Deletions affecting the short arm of chromosome 1 (1p) are frequently found in human gliomas and neuroblastomas, but also in breast, lung, endometrial, ovarian, and colorectal carcinomas. Loss of 1p is a strong prognostic factor in patients with neuroblastoma. Since loss of 1p reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable, more aggressive therapy may be considered in these patients.

Deletions affecting the long arm of chromosome 19 (19q) are frequently found in human malignant gliomas as well as in neuroblastomas and epithelial ovarian cancers.


Several studies showed correlation of combined allelic losses at 1p36 and 19q13 with oligodendroglioma histology and association with both chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Hence, determination of 1p and 19q status may aid therapeutic decisions and predict outcome in patients with anaplastic oligodendrogliomas.

## References


Barbashina V, et al. (2005) Clin Cancer Res 11: 1119-28. Cairncross JG, et al. (1998) J Natl Cancer Inst 90: 1473-9 Capper D, et al. (2010) Acta Neuropathol 121: 241-52. Capper D, et al. (2010) Acta Neuropathol 121: 241-52. Caron H, et al. (1996) N. Engl J Med 334: 225-30. Elsir T, et al. (2011) Br J Cancer 11: 1747-54. Hoeller S, et al. (2012) Hum Pathol 43: 405-12. Lass U, et al. (2013) Brain Pathol 23: 311-8. Ragnarsson G, et al. (1999) Br J Cancer 79: 1468-74. Rosenberg JE, et al. (1996) Oncogene 13: 2483-5. Smith JS, et al. (1999) Oncogene 18: 4144-52. Smith JS, et al. (2000) Genes Chromosomes Cancer 29: 16-25. White PS, et al. (2005) Oncogene 24: 2684-94. Woelfel C, et al. (2011) Cancer Genet 204: 671-6.

## **Probe Description**


The ZytoDot® 2C SPEC 19q13/19p13 Probe is a mixture of a Dinitrophenyl-labeled 19q13 probe specific for the region of common deletion in gliomas at 19q13.32q13.33 and a Digoxigenin-labeled 19p13 probe specific for 19p13.3.



Ideogram of chromosome 19 indicating the hybridization locations.



SPEC 19p13 Probe map (not to scale).



SPEC 19q13 Probe map (not to scale).

## **Results**

Using the ZytoDot® 2C SPEC 19q13/ 19p13 Probe in combination with the ZytoDot® 2C CISH Implementation Kit, two red (19q) and two green (19p) signals are expected in a normal interphase nucleus. In a cell with deletions affecting the 19q13 locus, one or no copy of the red signal will be observed.



SPEC 19q13/19p13 Dual Color Probe hybridized to glioma tissue section with 19q13 deletion as indicated by one red signal in each nucleus.

Image kindly provided by Prof. W. Müller, University Leipzig, Germany

Prod. No.	Product	Label	Tests* (Volume)
C-3037-100	ZytoDot 2C SPEC 19q13/19p13 Probe C € IVD	DNP /Digoxigenin	10 (100 µl)
C-3037-400	Zyto Dot 2C SPEC 19q13/19p13 Probe C € IVD	DNP /Digoxigenin	(ابر 400) 40
Related Produ			
C-3044-10	Zyto Dot 2C CISH Implementation Kit C    IVD  Ind. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit CE IVD Ind. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40
WB-0009-500	Clear-it™ Stringency Buffer C € IVD		500 ml

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# **Zyto***Dot* ® **SPEC MYCN Probe**

## Previously: Zyto Dot SPEC NMYC Probe



## **Background**

The Zyto Dot ® SPEC MYCN Probe is designed for the detection of MYCN amplification which represents the most powerful unfavorable prognostic factor for neuroblastoma. Less frequently amplifications are found in retinoblastoma, small cell lung cancer, astrocytoma and other tumors derived from the neuroectoderm.

The MYCN (v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived, a.k.a. NMYC) gene is located in the chromosomal region 2p24.3 and encodes a 62-64 kDa transcription factor normally expressed in the developing nervous system and other selected tissues. The MYCN oncogene is amplified in about 25% of primary neuroblastomas and 90% of tumor-derived cell lines. Additional copies are rarely located at the normal locus but are detected as double minute chromosomes or homogeneously staining regions.


Amplification of the MYCN gene is strongly associated with rapid tumor progression, advanced stages of the disease, and poor prognosis. Hence, amplification status is increasingly being used for stratification of patients to different treatment protocols.

## References


Kaneko M, et al. (1998) Med Pediatr Oncol 31: 1-7. Lee WH, et al. (1984) Nature 309: 458-60. Maris JM, et al. (2007) Lancet 369: 2106-20 Slamon DJ, et al. (1986) Science 232: 768-72 Suita S, et al. (2007) J Pediatr Surg 42: 489-93. Thorner PS, et al. (2006) Am J Surg Pathol 30: 635-42.

## **Probe Description**

The ZytoDot® SPEC MYCN Probe is a Digoxigenin-labeled probe specific for the MYCN gene at 2p24.3, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 2 indicating the hybridization locations.



SPEC MYCN Probe map (not to scale).

## **Results**

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the MYCN gene locus or aneuploidy of chromosome 2 will show multiple dots or large signal clusters.



Normal nuclei each with two MYCN signals

Prod. No.	Product	Label	Tests* (Volume)				
C-3029-400	ZytoDot SPEC MYCN Probe C€ IVD	Digoxigenin	40 (400 µl)				
Related Produ	cts						
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40				
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-D1G, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml						

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



# Zyto Dot ® 2C SPEC ALK Break Apart Probe



## **Background**

The ZytoDot® 2C SPEC ALK Break Apart Probe is designed to detect rearrangements involving the chromosomal region 2p23.2 harboring the ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246)


ALK encodes a transmembrane receptor tyrosine kinase. This gene exerts characteristic oncogenic activities through fusion to several gene partners or mutations both in hematopoietic and non-hematopoietic solid tumors.

Translocations affecting the ALK gene locus are frequently found in anaplastic large cell lymphoma (ALCL), an aggressive non-Hodgkin lymphoma arising from Tcells. The most frequent translocation t(2;5) results in a fusion with the NPM1 (nucleophosmin a.k.a. nucleolar phosphoprotein B23, numatrin) gene located on chromosome 5q35. This rearrangement results in a NPM1/ALK fusion protein, which is constitutively activated through autophosphorylation, and that in turn mediates malignant cell transformation by activating downstream effectors like e.g. STAT3. Additionally, inversions affecting the ALK gene located on the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts.

ALK kinase targeted therapies may represent a very effective therapeutic strategy in NSCLC patients carrying EML4-ALK rearrangements.

## **Probe Description**

The ZytoDot® 2C SPEC ALK Break Apart Probe is a mixture of a Digoxigeninlabeled probe and a Dinitrophenyl-labeled probe hybridizing to the 2p23.2 band. The Digoxigenin-labeled probe hybridizes proximal to the ALK gene at 2p23.2, the Dinitrophenyl-labeled probe hybridizes distal to the ALK gene at 2p23.2.




Ideogram of chromosome 2 indicating the hybridization locations.



SPEC ALK Probe map (not to scale).

## **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 2p23.2 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 2p23.2 loci. A signal pattern consisting of one red/ green fusion signal, one red signal, and a separate green signal indicates one normal 2p23.2 locus and one 2p23.2 locus affected by a translocation or inversion. EML4-ALK inversion with deletion of 5'-ALK sequences is indicated by one or multiple isolated red signals.



Lung carcinoma tissue section with translocation affecting the 2p23.2 locus as indicated by one red/green fusion (non-rearranged) signal, one red signal, and one separate green signal.

References
Inamura K, et al. (2009) Mod Pathol 22: 508-15.
Koivunen JP, et al. (2008) Clin Cancer Res 14: 4275-83.
Martelli MP, et al. (2009) Am J Pathol 174: 661-70.
Palmer RH, et al. (2009) Biochem J 420: 345-61.
Penner S, et al. (2008) Neoplosia 10: 298-302.
Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.
Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80. Schildhaus HU, et al. (2013) Mod Pathol 26: 1468-77. von Laffert M, et al. (2014) J Thorac Oncol 9: 1464-9. Wagner F, et al. (2014) J Clin Pathol 67: 403-7. Zhang Q, et al. (2007) Nat Med 11:1341-8.

Prod. No.	Product	Label	Tests* (Volume)
C-3055-100	Zyto <i>Dot</i> 2C SPEC ALK Break Apart Probe C	Digoxigenin/DNP	10 (100 µl)
C-3055-400	Zyto <i>Dot</i> 2C SPEC ALK Break Apart Probe C	Digoxigenin/DNP	40 (400 µl)
Related Products			
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC EML4 Break Apart Probe



#### Background

The ZytoDot® 2C SPEC EML4 Break Apart Probe is designed to detect rearrangements involving the chromosomal region 2p21 harboring the EML4 (echinoderm microtubule-associated protein-like 4, a.k.a. ROPP120) gene.


Inversions in the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. A few reports also identified these fusion transcripts in breast, gastric, and colorectal cancers. EML4 belongs to the family of echinoderm microtubule-associated protein-like proteins. The EML4-ALK fusion transcripts comprise variably truncated N-terminal portions of the EML4 gene and the intracellular signaling domain of the receptor tyrosine kinase ALK (anaplastic lymphoma receptor tyrosine kinase, a.k.a. CD246). It was found that EML4 mediates ligandindependent dimerization of ALK, resulting in constitutive kinase activity. EML4-ALK was demonstrated to possess transforming activity in vitro and in vivo.

The EML4-ALK fusion transcript is found in about 5% of NSCLC, predominantly adenocarcinomas, and is considered to be mutually exclusive to EGFR or KRAS mutations. The detection of the inversion by in situ Hybridization might represent a valuable tool to identify a subpopulation of NSCLC likely to respond to ALK kinase targeting therapies.


References
Choi YL, et al. (2008) Cancer Res 69: 4971-6.
Inamura K, et al. (2009) Mod Pathol 22: 508-15.
Lin E, et al. (2009) Mol Cancer Res 7: 1466-76.
Perner S, et al. (2008) Neoplasia 10: 298-302.
Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.
Shaw AT, et al. (2009) J Clin Oncol 27: 4247-53. Soda M, et al. (2007) Nature 448: 561-6. Schildhaus HU, et al. (2013) Mod Pathol 26: 1468-77.

#### **Probe Description**

The Zyto Dot ® 2C SPEC EML4 Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 2p21 band. The DNPlabeled probe hybridizes proximal to the EML4 gene breakpoint region at 2p21, the DIG-labeled probe hybridizes distal to the EML4 gene breakpoint region.




Ideogram of chromosome 2 indicating the hybridization locations.



SPEC EML4 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 2p21 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 2p21 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 2p21 locus and one 2p21 locus affected by a translocation or inversion.



SPEC EML4 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals pert nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3059-400	Zyto <i>Dot</i> 2C SPEC EML4 Break Apart Probe CE IVD	Digoxigenin/DNP	40 (400 µl)
C-3059-400 Zyto Dot 2C SPEC EML4 Break Apart Probe C € IVD Digoxigenin/DNP 40 (400 µl)  Related Products			
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informatic



## Zyto Dot ® 2C SPEC BCL6 Break Apart Probe



### **Background**


The ZytoDot® 2C SPEC BCL6 Break Apart Probe is designed for the detection of translocations involving the chromosomal region 3q27.3 harboring the BCL6 (B-cell CLL/lymphoma 6, a.k.a. ZNF51, LAZ3)

The BCL6 protein acts as a transcriptional repressor that is involved in the regulation of lymphoid development and function. Chromosomal rearrangements of the BCL6 gene region were found to occur in different types of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The most common BCL6 translocation t(3;14)(q27;q32.3) results in the IGH-BCL6 gene fusion. In addition, more than 20 partner loci have been identified including immunoglobulin (Ig) genes but also a number of non-lg genes. As a result of these translocations, the rearranged BCL6 gene comes under the control of the promoter of the partner gene leading to deregulated expression of BCL6. In DLBCL, the most common histologic subtype of NHL, BCL6 translocations represent one of the most frequent cytogenetic abnormality, occurring in 20% to 40% of the cases. Several studies reported a correlation of BCL6 translocation with an inferior overall survival. Moreover, DLBCL which are positive for both BCL6 and MYC rearrangements have been shown to have an extremely poor prognosis. Hence, the detection of BCL6 rearrangements by CISH may help in predicting the clinical outcome in patients with NHL.


References
Akyurek N, et al. (2012) Cancer 118: 4173-83.
Cady FM, et al. (2008) J Clin Oncol 26: 4814-9.
Ohno H (2004) Histol Histopathol 19: 637-50.
Ohno H (2006) J Clin Exp Hematop 46: 43-53.

#### **Probe Description**

The ZytoDot® 2C SPEC BCL6 Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 3q27.3-q28 band. The DNP-labeled probe hybridizes distal to the BCL6 gene at 3q27.3-q28, the DIG-labeled probe hybridizes proximal to the BLC6 gene at 3q27.3.




Ideogram of chromosome 3 indicating the hybridization locations.



SPEC BCL6 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 3q27.3-q28 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 3q27.3-q28 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 3q27.3-q28 locus and one 3q27.3-q28 locus affected by a translocation.



SPEC BCL6 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3074-100	ZytoDot 2C SPEC BCL6 Break Apart Probe CE IVD	Digoxigenin/DNP	10 (100 µl)
Related Prod	ucts		
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution A, 0.1 ml; AP-Red Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



## Zyto Dot ® 2C SPEC ROS1 Break Apart Probe



### **Background**

The ZytoDot ® 2C SPEC ROS1 Break Apart Probe is designed to detect translocations involving the chromosomal region 6q22.1 harboring the c-ros oncogene 1 (ROS1, a.k.a. MCF3) gene.


The ROS1 gene is located on 6q22.1 and encodes a receptor tyrosine kinase. Translocations affecting ROS1 have been detected in glioblastoma, cholangiocarcinoma, and non-small cell lung cancer (NSCLC).

In NSCLC several ROS1 translocation partners have been detected all of which result in the fusion of variably truncated forms of e.g. TPM3, SDC4, SLC34A2, CD74, EZR, or LRIG3 to the kinase domain of ROS1. GOPC has also been found to be fused to ROS1 in NSCLC. GOPC-ROS1 fusions result from interstitial deletion of approx. 240 kb on 6q22.1. ROS1 rearrangements have been exclusively detected in adenocarcinoma of the lung and are thought to define a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK rearranged NSCLC


First evidence suggests that administration of ROS1 kinase inhibitors may represent a very effective therapeutic strategy in NSCLC patients harboring activating ROS1 rearrangements. Accordingly, detection of ROS1 rearrangements using Chromogenic *in situ* Hybridization might be a helpful tool for the identification of patients likely to respond to ROS1 kinase targeting therapies.

### **Probe Description**

The ZytoDot <sup>®</sup> 2C SPEC ROS1 Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 6q22.1 band. The DNP-labeled probe hybridizes distal to the ROS1 gene breakpoint region at 6q22.1, the DIG-labeled probe hybridizes proximal to the ROS1 gene breakpoint region.



Ideogram of chromosome 6 indicating the hybridization locations.




SPEC ROS1 Probe map (not to scale).


#### Results

In an interphase nucleus of a normal cell lacking an aberration involving the 6q22.1 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 6q22.1 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 6q22.1 locus and one 6q22.1 locus affected by a translocation.

Isolated green signals are the result of deletions distal to the ROS1 breakpoint region or are due to unbalanced translocations affecting this chromosomal region.



SPEC ROS1 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Lung cancer tissue section with rearrangement of the ROS1 gene as indicated by isolated green signals.

Prod. No.	Product	Label	Tests* (Volume)
C-3063-100	Zyto <i>Dot</i> 2C SPEC ROS1 Break Apart Probe C E IVD	Digoxigenin/DNP	40 (400 µl)
C-3063-400	Zyto <i>Dot</i> 2C SPEC ROS1 Break Apart Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	lucts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C    Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit C    IVD  Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40

References Bergethon K, et al. (2012) J Clin Oncol 30: 863-70. Bos M, et al. (2013) Lung Cancer 81: 142-3. Rikova K, et al. (2007) Cell 131: 1190-203. Rimkunas VM, et al. (2012) Clin Cancer Res 18: 4449-57. Suehara Y, et al. (2012) Clin Cancer Res 18: 6599-608. Takeuchi K, et al. (2012) Nat Med 18: 378-81.

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® SPEC ESR1 Probe



### **Background**

The ZytoDot® SPEC ESR1 Probe is designed for the detection of ESR1 gene amplification frequently observed in breast cancer.


The ESR1 (estrogen receptor 1) gene is located in the chromosomal region 6q25.1 and encodes estrogen receptor alpha (ER). ER expression is one of the most important known factors in the development of breast cancer, and assessing its status by immunohistochemistry is important for determining the use of anti-estrogen receptor therapies.

ESR1 gene amplification has been found frequently in ER-positive breast tumors. Additionally, it has been recently shown for breast cancer patients receiving adjuvant tamoxifen monotherapy that survival is significantly longer in cases of ESR1 gene amplification as determined by FISH compared to immunohistochemically ER-positive cases without gene amplification. Additionally, it has been shown that response to tamoxifen is dependent on the absolute ESR1 copy number. Thus, determination of ESR1 amplification may identify a subgroup of breast cancer patients particularly likely to respond to anti-estrogen therapy.


References
Holst F, et al. (2007) Nature Genet 39: 655-60.
Lacroix M (2006) Endocr Relat Cancer 13: 1033-67.
Marchio C, et al. (2008) J Pathol 215: 398-410.
Nembrot M, et al. (1990) Biochem Biophys Res Comm 166: 601-7.
Nessling M, et al. (2005) Cancer Res 65: 439-47.

#### **Probe Description**

The ZytoDot®SPEC ESR1 Probe is a Digoxigenin-labeled probe specific for the ESR1 gene region at 6q25.1, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 6 indicating the hybridization locations.




SPEC ESR1 Probe map (not to scale).

#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the ESR1 gene locus or aneusomy of chromosome 6 will show multiple dots or large signal clusters.



Normal nuclei each with two ESR1 signals



Breast carcinoma tissue section with ESR1 amplification.

Prod. No.	Product	Label	Tests* (Volume)
C-3024-400	ZytoDot SPEC ESR1 Probe C€ IVD	Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-D1G, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® SPEC EGFR Probe



### **Background**

The Zyto Dot ® SPEC EGFR Probe is designed for the detection of EGFR gene amplification frequently observed in solid neoplasms including non-small-cell lung cancer (NSCLC) and glioblastoma. The EGFR gene (a.k.a. ERBB1 and HER1) is located in the chromosomal region 7p11.2 and encodes a transmembrane glycoprotein acting as a cellular growth factor receptor.

Overexpression of EGFR has been shown in a number of tumor entities and is associated with poor prognosis. EGFR copy number identified by in situ Hybridization is thought to be a molecular predictor in neoplasms.

References
Balla P, et al. (2011) Histopathology 59: 376-89.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Ettl T, et al. (2012) Hum Pathol 43: 921-31.
Gont A, et al. (2013) Oncotarget 4: 1266-79.
Isola J & Tanner M (2004) Methods Mol Med 97: 133-44.
Kondo I & Shimizu N (1983) Cytogenet Cell Genet 35: 9-14.
Laurent-Puig P, et al. (2009) J Clin Oncol 27: 5924-30.
Marquez A, et al. (2004) Discan Med Pethol 13: 9. Laurent-Pug P, et al. (2004) Diagn Mol Pathol 13: 1-8.

Miyazawa H, et al. (2004) Diagn Mol Pathol 13: 1-8.

Miyazawa H, et al. (2008) Cancer Sci 99: 595-600.

Oikawa M, et al. (2013) J Oral Pathol Med 42: 424-34.


Thomas F, et al. (2007) Clin Cancer Res 13: 7086-92.

Tsukamoto T, et al. (1991) Int J Dev Biol 35: 25-32.


Walker F, et al. (2009) Hum Pathol 40: 1517-27. Yoo SB, et al. (2010) Lung Cancer 67: 301-5. Zaczek A, et al. (2005) Histol Histopathol 20: 1005-15.

#### **Probe Description**

The Zyto Dot ® SPEC EGFR Probe is a Digoxigenin-labeled probe specific for the EGFR gene at 7p11.2, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC EGFR Probe map (not to scale).

#### **Results**

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the EGFR gene locus or aneuploidy of chromosome 7 will show multiple dots or large signal clusters.



Normal nuclei each with two EGFR signals



Cancer cells with multiple EGFR signals in sputum sample from a NSCLC patient.

Prod. No.	Product	Label	Tests* (Volume)		
C-3007-400	Zyto Dot SPEC EGFR Probe CE IVD	Digoxigenin	40 (400 µl)		
Related Products					
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit CE IVD		40		
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml				

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.



# Zyto Dot ® 2C SPEC EGFR/CEN 7 Probe



### **Background**

The ZytoDot® 2C SPEC EGFR/CEN 7 Probe is designed for the simultaneous detection of EGFR and centromere 7 in formalin-fixed, paraffin-embedded tissue sections and cell samples.


The EGFR gene (a.k.a. ERBB1 and HER1) is located in the chromosomal region 7p11.2 and encodes a transmembrane glycoprotein acting as a cellular growth factor receptor.

Overexpression of EGFR has been shown in a number of tumor entities and is associated with poor prognosis. EGFR copy number identified by in situ Hybridization is thought to be a molecular predictor in neoplasms.


References
Balla P, et al. (2011) Histopathology 59: 376-89.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Ettl T, et al. (2012) Hum Pathol 43: 921-31.
Isola J & Tanner M (2004) Methods Mol Med 97: 133-44. Sould be Shimizu N (1983) Cytogenet Cell Genet 35: 9-14. Kondo I & Shimizu N (1983) Cytogenet Cell Genet 35: 9-14. Marquez A, et al. (2004) Diagn Mol Pathol 13: 1-8. Tsukamoto T, et al. (1991) Int J Dev Biol 35: 25-32. Zaczek A, et al. (2005) Histol Histopathol 20: 1005-15.

#### **Probe Description**

The ZytoDot® 2C SPEC EGFR/CEN 7 Probe is a mixture of a Digoxigenin-labeled probe specific for the EGFR gene at 7p11.2 and a Dinitrophenyl-labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1).




Ideogram of chromosome 7 indicating the hybridization locations.




SPEC EGFR Probe map (not to scale).

#### Results

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two green and two red signals are expected. In a cell with amplification of the EGFR gene locus, multiple copies of the green signal or green signal clusters will be observed.



Normal nuclei each with two EGFR (green) and two centromere 7 (red) signals.



Trisomy of chromosome 7 as indicated by three EGFR (green) and three CEN 7 (red) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3033-100	ZytoDot 2C SPEC EGFR/CEN 7 Probe C€ IVD	Digoxigenin/DNP	10 (100 µl)
C-3033-400	Zyto Dot 2C SPEC EGFR/CEN 7 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	icts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C   IVD  Ind. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit C   IVD Ind. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® 2C SPEC MET/CEN 7 Probe



### **Background**


The ZytoDot® 2C SPEC MET/CEN 7 Probe is designed for the detection of MET gene amplifications found in a variety of human tumors.

The MET gene (a. k. a. c-Met) is located in the chromosomal region 7q31.2 and encodes a transmembrane tyrosine kinase receptor for the hepathocyte growth factor (HGF). HGF and MET play an important role in angiogenesis and tumor growth. Activation or upregulation of MET was found in a number of carcinomas including lung, breast, colorectal, prostate, and gastric carcinomas as well as in gliomas, melanomas and some sarcomas. MET overexpression is known as a negative prognostic indicator in patients with various carcinomas, multiple myeloma, or glioma. Therefore, several inhibitors of the HGF/MET signaling pathway are being studied and developed as potent therapies to inhibit angiogenesis and tumor growth. Recently, it was shown that MET amplification leads to resistance to gefitinib or erlotinib in lung cancer by driving ERBB3dependent activation of the PI3K pathway.

References Cooper CS, et al. (1984) Nature 311: 29-32. Engelman JA, et al. (2007) Science 316: 1039-43. Garcia S, et al. (2007) Int J Oncol 31: 49-58. Hara T, et al. (1998) Lab Invest 78: 1143-53.

#### **Probe Description**

The Zyto Dot ® 2C SPEC MET/CEN 7 Probe is a mixture of a Dinitrophenyl-labeled CEN 7 probe specific for the alpha satellite centromeric region of chromosome 7 (D7Z1) and a Digoxigenin-labeled probe specific for the chromosomal region 7q31.2 harboring the MET gene.



Ideogram of chromosome 7 indicating the hybridization locations.



SPEC MET Probe map (not to scale).

#### Results

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two red (CEN 7) and two green (MET) signals are expected. In a cell with amplification of the MET gene locus, multiple copies of the green signal or green signal clusters will be observed.



Lung cancer tissue section with multiple copies of chromosome 7 (red) and extra MET signals (green) in the nuclei.

	Prod. No.	Product	Label	Tests* (Volume)
	C-3057-400	Zyto Dot 2C SPEC MET/CEN 7 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Products				
	C-3044-40	Zyto Dot 2C CISH Implementation Kit C € IVD		40
		Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## Zyto Dot ® SPEC FGFR1 Probe



## **Background**

The Zyto Dot ® SPEC FGFR1 Probe is designed for the detection of FGFR1 gene amplification frequently observed in malignant tumors e.g. breast and prostate cancer and oral squamous cell carcinoma (OSCC).


The FGFR1 (fibroblast growth factor receptor 1) gene is located in the chromosomal region 8p11.23-p11.22 and encodes a transmembrane receptor tyrosine kinase. Amplification of the FGFR1 gene, observed in approximately 10% of all breast cancer samples, has revealed to be an independent prognostic factor for overall survival. FGFR1 is believed to emerge as a potential therapeutic target for lobular breast carcinomas.

In prostate cancer, FGFR1 gene amplification seems to be an important step during the transmission to hormone resistance. In OSCC, FGFR1 gene amplification, observed in nearly 20% of all cases, is indicated to contribute to oral carcinogenesis at an early stage of development.


References
Brunello E, et al. (2012) J Exp Clin Cancer Res 31: 103.
Edwards J, et al. (2003) Clin Cancer Res 9: 5271-81.
Elbauomy Elsheikh S, et al. (2007) Breast Cancer Res 9: R23.
Freier K, et al. (2007) Oral Oncology 43: 60-6.
Lacroix-Triki M, et al. (2010) J Pathol 222: 282-98.
Lee PL, et al. (1989) Science 245: 57-60.
Pair Filha IS. et al. (2006) Clin Cancer Res 12: 6652-62. Turner N, et al. (2010) Cancer Res 70: 2085-94 Wetterskog D, et al. (2012) J Pathol 226: 84-96.

### **Probe Description**

The ZytoDot®SPEC FGFR1 Probe is a Digoxigenin-labeled probe specific for the FGFR1 gene at 8p11.23-p11.22, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 8 indicating the hybridization locations.




SPEC FGFR1 Probe map (not to scale).

#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the FGFR1 gene locus or polysomy of chromosome 8 will show multiple dots or large signal clusters.



Normal nuclei each with two FGFR1 signals



Nuclei with strong FGFR1 amplification.

Prod. No.	Product	Label	Tests* (Volume)
C-3023-400	Zyto Dot SPEC FGFR1 Probe C€ IVD	Digoxigenin	40 (400 µl)
Related Produ	ucts		
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC FGFR1/CEN 8 Probe



### **Background**

The Zyto Dot ® 2C SPEC FGFR1/CEN 8 Probe is designed for the detection of FGFR1 gene amplification frequently observed in malignant tumors e.g. breast and prostate cancer and oral squamous cell carcinoma (OSCC).


The FGFR1 (fibroblast growth factor receptor 1) gene is located in the chromosomal region 8p11.23-p11.22 and encodes a transmembrane receptor tyrosine kinase. Amplification of the FGFR1 gene, observed in approximately 10% of all breast cancer samples, has revealed to be an independent prognostic factor for overall survival. FGFR1 is believed to emerge as a potential therapeutic target for lobular breast carcinomas.

In prostate cancer, FGFR1 gene amplification seems to be an important step during the transmission to hormone resistance. In OSCC, FGFR1 gene amplification, observed in nearly 20% of all cases, is indicated to contribute to oral carcinogenesis at an early stage of development.


References Edwards J, et al. (2003) Clin Cancer Res 9: 5271-81. Elbauomy Elsheikh S, et al. (2007) Breast Cancer Res 9: R23. Freier K, et al. (2007) Oral Oncology 43: 60-6. Lee PL, et al. (1989) Science 245: 57-60. Lear I., et al. (17) Sciente 243, 37-30. Lacroix-Triki M, et al. (2010) J Pathol 222: 282-98. Swoboda A, et al. (2011) Genes Chromosomes Cancer 50: 680-8. Turner N, et al. (2010) Cancer Res 70: 2085-94. Wetterskog D, et al. (2012) J Pathol 226: 84-96

### **Probe Description**

The ZytoDot® 2C SPEC FGFR1/CEN 8 Probe is a mixture of a Digoxigenin-labeled probe specific for the FGFR1 gene at 8p11.23-p11.22 and a Dinitrophenyl-labeled CEN 8 probe specific for the alpha satellite centromeric region of chromosome 8 (D8Z2).




Ideogram of chromosome 8 indicating the hybridization locations.



SPEC FGFR1 Probe map (not to scale)

#### Results

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two green (FGFR1) and two red (CEN 8) signals are expected. In a cell with an amplification of the FGFR1 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Breast carcinoma tissue section with FGFR1 amplification as indicated by large green clusters.

Prod. No.	Product	Label	Tests* (Volume)		
C-3050-400	Zyto Dot 2C SPEC FGFR1/CEN 8 Probe C    IVD	Digoxigenin/DNP	40 (400 µl)		
Related Products					
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40		
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml				

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## **Zyto Dot** ® **SPEC MYC Probe**

## Previously: Zyto Dot SPEC CMYC Probe



## **Background**

The ZytoDot® SPEC MYC Probe is designed for the detection of MYC gene amplification frequently observed in malignant tumors e.g. breast and endometrial


The proto-oncogene MYC (a.k.a. CMYC) is located in the chromosomal region 8q24.21 and encodes a nuclear transcription factor displaying high-affinity, site specific DNA-binding capacity when complexed with its cellular partners. Thus, the MYC protein is involved in proliferation, growth, differentiation, and apoptosis. Amplification of the chromosomal MYC gene region has been detected in many types of malignant neoplasms e.g. breast, lung, head, colon, kidney, neck, ovary, bladder, and endometrial cancers. It was shown that MYC amplification occurs in advanced, widespread tumors or in aggressive, primary tumors. In non-small cell lung cancer (NSCLC) and breast cancer, for example, MYC amplification was strongly associated with lymph node status. Accordingly, the MYC gene can be considered as a powerful prognostic marker.

Additionally, malignant cutaneous angiosarcomas but not benign and atypical vascular lesions occurring after radiotherapy of breast cancer are characterized by amplification of the MYC gene. The presence of MYC amplification is thus of considerable diagnostic importance for the distinction of malignant from atypical postradiation vascular neoplasms of the skin.


References
Alves Rde C, et al. (2014) J Cancer Res Clin Oncol 140: 2021-5.
Buth AJ, et al. (2005) Endocr Relat Cancer 12: 47-59.
Dalla-Favera R, et al. (1982) Proc Natl Acad Sci USA 79: 6497-501.
Deming St., et al. (2000) Br J Cancer 83: 1688-95. Denimg 3t, et al. (2004) An Tourier of 3th 1843-53. Kubokura H, et al. (2001) Ann Thorac Cardiovasc Surg 7: 197-203. Mentzel T, et al. (2012) Mod Pathol 25: 75-95. Rummukainen JK, et al. (2001) Lab Invest 81: 1445-51. Schraml P, et al. (1999) Clin Cancer Res 5: 1966-75. Yokota J, et al. (1986) Science 231: 261-5.

### **Probe Description**

The Zyto Dot ® SPEC MYC Probe is a Digoxigenin-labeled probe specific for the MYC gene region at 8q24.21, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 8 indicating the hybridization locations.



SPEC MYC Probe map (not to scale)

#### **Results**

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the MYC gene locus or polysomy of chromosome 8 will show multiple dots or large signal clusters.



Tetrasomy of chromosome 8 as indicated by four MYC signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3013-400	Zyto Dot SPEC MYC Probe C€ IVD	Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC MYC Break Apart Probe




### **Background**

The Zyto Dot ® 2C SPEC MYC Break Apart Probe is designed to detect translocations involving the chromosomal region 8q24.21 harboring the MYC gene. The MYC proto-oncogene (v-myc avian myelocytomatosis viral oncogene homolog, a.k.a. CMYC) encodes a transcription factor essential for cell growth and proliferation and is broadly implicated in tumorigenesis. Translocations involving the MYC gene are considered to be cytogenetic hallmarks for Burkitt Lymphoma but are also found in other types of lymphomas. The most frequent translocation involving the MYC gene region is t(8;14) (q24.21;q32.3) juxtaposing the MYC gene in 8q24.21 next to the IgH (immunoglobulin heavy chain) locus in 14q32.33. Further translocations affecting the MYC gene are t(8;22)(q24.21;q11.2) and t(2;8)(p11.2;q24.21), both of which involve one of the two immunoglobulin light chain loci. All three translocations bring the MYC gene under the control of a regulatory element from one of the immunoglobulin loci resulting in constitutive overexpression of MYC.

References Boerma EG, et al. (2009) Leukemia 23: 225-34 Dalla-Favera R, et al. (1982) PNAS 79: 6497-501. Haralambieva E, et al. (2004) Genes Chromosomes Cancer 40: 10-8. Veronese ML, et al. (1995) Blood 85: 2132-8. Walker BA, et al. (2014) Blood Cancer J 4: e191.

### **Probe Description**

The Zyto Dot ® 2C SPEC MYC Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the 8q24.21 band. The DNPlabeled probe hybridizes proximal to the MYC gene breakpoint region at 8q24.21, the DIG-labeled probe hybridizes distal to the MYC gene breakpoint region.




Ideogram of chromosome 8 indicating the hybridization locations




SPEC MYC Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 8q24.21 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 8q24.21 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 8q24.21 locus and one 8q24.21 locus affected by a translocation. Alternative break points particularly observed in variant MYC translocations t(8;22) and t(2;8) might result in different signal patterns.



SPEC MYC Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Non-Hodgkin lymphoma tissue section with translocation affecting the 8q24.21 locus as indicated by one red/green fusion (non-rearranged) signal, one red signal, and one separate green signal.

Prod. No.	Product	Label	Tests* (Volume)
C-3066-400	ZytoDot 2C SPEC MYC Break Apart Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	ucts		
C-3044-40	Zyto Dot 2C CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



# Zyto Dot ® 2C SPEC CDKN2A/CEN 9 Probe



### **Background**


The Zyto Dot ® 2C SPEC CDKN2A/CEN 9 Probe is designed for the detection of CDKN2A deletions frequently observed in most tumor cell lines as well as in primary human malignancies.

The CDKN2A gene, often referred to as p16 or INK4a/ARF, is located in the chromosomal region 9p21.3. Using alternative first exons and an alternative reading frame, the gene encodes for two distinct tumor suppressor proteins p16INK4a and p14ARF, both involved in cell cycle regulation. CDKN2A has been identified as a major susceptibility gene for melanoma. The tumor suppressor gene CDKN2A is inactivated by homozygous deletions with high frequency in a variety of human primary tumors e.g. bladder and renal cell carcinoma, prostate and ovarian adenocarcinoma, non-small cell lung cancer, sarcoma, glioma, mesothelioma, and melanoma. Furthermore, deletion of the CDKN2A gene is found in up to 80% of T-cell acute lymphoblastic leukemia cases and is associated with poor prognosis and relapse of the disease.

References Arif Q & Husain AN (2015) Arch Pathol Lab Med 139: 978-80. Cowon JM et al. (1988) J Natl Cancer Inst 80: 1159-64. Holley T, et al. (2012) PLoS One 7: e50586. Hussussian CJ, et al. (1994) Nat Genet 8: 15-21. Kamb A, et al. (1994) Science 264: 436-40. Nobori T, et al. (1994) Nature 368: 753-6. Nobori 1, et al. (1994) Nature 308: 753-6. Quelle DE, et al. (1995) Cell 83: 993-1000. Rocco JW & Sidransky D (2001) Exp Cell Res 264: 42-55. Schopmeyer K, et al. (1999) Neoplasia 1: 128-37. Schwarz S, et al. (2008) Cytometry A 73: 305-11. Sharpless NE (2005) Mutat Res 576: 22-38.

#### **Probe Description**

The Zyto Dot ® 2C SPEC CDKN2A/CEN 9 Probe is a mixture of a Digoxigenin-labeled probe specific for the CDKN2A gene at 9p21.3 and a Dinitrophenyl-labeled CEN 9 probe specific for the classical satellite III region of chromosome 9 (D9Z3) at 9q12.




Ideogram of chromosome 9 indicating the hybridization locations.



SPEC CDKN2A Probe map (not to scale)

#### **Results**

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two green (CDKN2A) and two red (CEN 9) signals are expected. In a cell with deletion of the CDKN2A gene locus, a reduced number of green signals will be observed. Deletions affecting only parts of the CDKN2A gene might result in a normal signal pattern with green signals of reduced size.



SPEC CDKN2A/CEN 9 Probe hybridized to normal interphase cells as indicated by two red and two green signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3067-400	ZytoDot 2C SPEC CDKN2A/CEN 9 Probe C € IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	cts		
C-3044-40	Zyto Dot 2C CISH Implementation Kit C   IVD  Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC RET Break Apart Probe



### **Background**

The Zyto Dot ® 2C SPEC RET Break Apart Probe is designed to detect translocations involving the chromosomal region 10q11.21 harboring the RET (rearranged during transfection proto-oncogene) gene. RET encodes a tyrosine kinase (TK) receptor.

Translocations involving RET were first described in papillary thyroid carcinoma (PTC) where somatic rearrangements result in the fusion of its TK catalytic domain with an N-terminal dimerization domain encoded by various fusion partner genes.

More recently, recurrent inversions [inv (10)(p11.2q11.2)] fusing the coiled-coil domains of the kinesin family member 5B (KIF5B) gene to the RET kinase domain have been detected in lung adenocarcinoma. The resulting KIF5B-RET fusion protein can form homodimers through the coiled-coil domains of KIF5B, causing an aberrant activation of the TK of RET, a mechanism known from KIF5B-ALK fusions which is also found in lung adenocarcinoma.


Since in vitro studies showed transforming activity of KIF5B-RET which could be suppressed by a TK inhibitor, it was assumed that the chimeric oncogene might be a promising molecular target for the treatment of lung cancer.

The same holds true for the BCR-RET and FGFR1OP-RET fusion genes in chronic myelomonocytic leukemia (CMML) generated by two balanced translocations t(10;22) (q11.2;q11.2) and t(6;10)(q27;q11.2), respectively.


References
Ballerini P, et al. (2012) Leukemia 26: 2384-9.
Gautschi O, et al. (2013) J Thorac Oncol 8: e43-4.
Ju YS, et al. (2012) Genome Res 22: 436-45.
Kohno T, et al. (2012) Nat Med 18: 375-7.
Nikiforov YE (2002) Endocr Pathol 13: 3-16.
Takahashi M, et al. (1985) Cell 42: 581-8.
Takeuchi K, et al. (2012) Nat Med 18: 378-81.

### **Probe Description**

The Zyto Dot ® 2C SPEC RET Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 10q11.21 band. The DNP-labeled probe hybridizes proximal to the RET gene breakpoint region at 10q11.21, the DIG-labeled probe hybridizes distal to the RET gene breakpoint region.




Ideogram of chromosome 10 indicating the hybridization locations.



SPEC RET Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 10q11.21 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 10q11.21 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 10q11.21 locus and one 10a11.21 locus affected by a translocation or inversion.



SPEC RET Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3064-100	Zyto <i>Dot</i> 2C SPEC RET Break Apart Probe C€ IVD	Digoxigenin/DNP	10 (100 µl)
C-3064-400	Zyto <i>Dot</i> 2C SPEC RET Break Apart Probe C E IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	ucts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C € IVD Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit CE IVD  Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



## Zyto Dot ® 2C SPEC PTEN/CEN 10 Probe



### **Background**

The ZytoDot® 2C SPEC PTEN/CEN 10 Probe is designed for the detection of PTEN deletions frequently observed in many tumor types, including renal, melanoma, endometrial, breast, prostate, lung, bladder, and thyroid cancer but also in hematological neoplasms.


The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome ten), often referred to as MMAC1 (mutated in multiple advanced cancers 1), is located on 10q23.31 and encodes a 47 kDa dual-specificity phosphatase that has both lipid and protein phosphatase activity. Its inactivation results in constitutive activation of the PI3K/AKT pathway and in subsequent increase in protein synthesis, cell cycle progression, migration, and survival.

Deletions affecting the long arm of chromosome 10 have been detected in 30 to 50% of early and advanced stage sporadic melanomas and about 40 to 70% of prostate cancers. In both tumor entities loss of PTEN has been associated with poor clinical outcome. Currently, several drugs targeting the PI3K/AKT pathway for the therapy of solid tumors have entered clinical trials.


References
Dahia PLM, et al. (1999) Hum Mol Genet 8: 185-93. Dahia PLM, et al. (1999) Hum Mol Genet 8: 185-93. Healy E, et al. (1998) Oncogene 16: 2213-8. Li J, et al. (1997) Science 275: 1943-7. Swoboda A, et al. (2011) Genes Chromosomes Cancer 50: 680-8. Weng LP, et al. (2001) Hum Mol Genet 10: 599-604. Yoshimoto M, et al. (2006) Cancer Genet Cytogenet 169: 128-37. Yoshimoto M, et al. (2007) Br J Cancer 97: 678-85.

### **Probe Description**

The Zyto Dot ® 2C SPEC PTEN/CEN 10 Probe is a mixture of a Dinitrophenyl-labeled CEN 10 probe specific for the alpha satellite centromeric region of chromosome 10 (D10Z1) and a Digoxigenin-labeled probe specific for the chromosomal region 10q23.2-q23.31 harboring the PTEN gene.




Ideogram of chromosome 10 indicating the hybridization locations.



SPEC PTEN Probe map (not to scale).

#### **Results**

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two red (CEN 10) and two green (PTEN) signals are expected. In a cell with a deletion of the PTEN gene locus a reduced number of green signals will be observed. Deletions affecting only parts of the PTEN gene might result in normal signal pattern with green signals of reduced size.



Prostate cancer tissue section with deletion of the PTEN gene as indicated by one green signal.

Prod. No.	Product	Label	Tests* (Volume)
C-3053-400	ZytoDot 2C SPEC PTEN/CEN 10 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	ucts		
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

# ZytoDot Products for CISH analysis



## Zyto Dot ® 2C SPEC FGFR2/CEN 10 Probe



## **Background**

The Zyto Dot <sup>®</sup> 2C SPEC FGFR2/CEN 10 Probe is designed for the detection of FGFR2 gene amplifications frequently observed in breast cancer as well as in gastric cancer.

The FGFR2 (fibroblast growth factor gene 2, a.k.a. BEK) gene is located on chromosome 10q26.13 and encodes splice variants of the receptor tyrosine kinases FGFR2b and FGFR2c.

Amplification of the FGFR2 gene leads to overexpression of the FGFR2 protein and subsequently to signal activation. Additionally, during the amplification process the C-terminal deletion of FGFR2 can occur due to exclusion of the last exon from the FGFR2 amplicon. Both, overexpression and deletion of the last exon result in FGFR2 signaling activation based on constitutive phosphorylation of the FRS2 adaptor molecule.


The process of ligand independent FGFR2 signaling leads to a more severe malignant phenotype of these tumors. Moreover, high FGFR2 expression is correlated with poor overall survival (OS) and poor disease-free survival (DFS) rates in breast cancer patients. Consequently, FGFR2 gene amplification detected by Chromogenic in situ Hybridization might be used as a prognostic marker in breast cancer.

#### References


References
Azuma K, et al. (2011) Biochem Biophys Res Commun 407: 219-24.
Katoh M (2010) Expert Rev Anticancer Ther 10: 1375-9.
Katoh Y & Katoh M (2009) Int J Mol Med 23: 307-11.
Moffa AB, et al. (2004) Mol Zancer Res 2: 643-52.
Sun S, et al. (2012) J Surg Oncol 105: 773-9

#### **Probe Description**

The Zyto Dot ® 2C SPEC FGFR2/CEN 10 Probe is a mixture of a Dinitrophenyl-labeled CEN 10 probe specific for the alpha satellite centromeric region of chromosome 10 (D10Z1) and a Digoxigenin-labeled probe specific for the chromosomal region 10q26.12-q26.13 harboring the FGFR2 gene.




Ideogram of chromosome 10 indicating the hybridization locations.



SPEC FGFR2 Probe map (not to scale).

#### **Results**

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two red (CEN 10) and two green (FGFR2) signals are expected. Nuclei with amplification of the FGFR2 gene locus at 10q26.12-q26.13 or polysomy of chromosome 10 will show multiple copies of the green signal or large green signal clusters.



Breast carcinoma tissue section with FGFR2 (green) amplification.

Prod. No.	Product	Label	Tests* (Volume)
C-3056-400	Zyto Dot 2C SPEC FGFR2/CEN 10 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	octs		
C-3044-40	Zyto Dot 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; Huse Blue Solution B, 15 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® SPEC CCND1 Probe



### **Background**


The ZytoDot® SPEC CCND1 Probe is designed for the detection of CCND1 gene amplifications frequently observed in breast cancer and other human tumors. The cyclin D1 gene (a.k.a. CCND1 or PRAD1) is located in the chromosomal region 11q13.3 and encodes a regulatory subunit of cyclin-dependent kinases that promote progression through the cell cycle.

The proto-oncogene CCND1 is amplified in a number of solid tumors including approx. 20% of all human breast cancer cases and about 30% of squamous cell carcinomas of the esophagus and the head and neck region. Amplification of chromosomal material from 11q13.3 harboring the CCND1 gene is discussed as prognostic marker in terms of metastasis, tumor recurrence, and survival for several tumor entities. In gastrointestinal stromal tumors (GIST), CCND1 amplification was found in 16% of high-risk tumors and was absent in low- or intermediate-risk tumors indicating the prognostic relevance of this genetic alteration in GIST.


NEW TRANSPORT RES 64: 8534-40. AI-Kuraya K, et al. (2004) Cancer Res 64: 8534-40. Courjal F, et al. (1997) Cancer Res 57: 4360-7. Duprez R, et al. (2012) J Pathol 226: 427-41. Motokura T, et al. (1991) Nature 350: 512-5. Notousira 1, et al. (1771) Nature 300: 312-3. Ormandy CJ, et al. (2003) Breast Cancer Res Treat 78: 323-35. Schuuring E (1995) Gene 159: 83-96. Tornillo L, et al. (2005) Lab Invest 85: 921-31. Xiong Y, et al. (1991) Cell 65: 691-9.

#### **Probe Description**

The ZytoDot® SPEC CCND1 Probe is a Digoxigenin-labeled probe specific for the CCND1 gene region at 11q13.3, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 11 indicating the hybridization locations.



#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the CCND1 gene locus or polysomy of chromosome 11 will show multiple dots or large signal clusters.



Normal nuclei each with two CCND1 signals

Prod. No.	Product	Label	Tests* (Volume)
C-3034-400	Zyto Dot SPEC CCND1 Probe C € IVD	Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3018-40	Zyto Dot CISH Implementation Kit CE IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blacking Solution, 4 ml; Mouse-anti-D16, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

# ZytoDot Products for CISH analysis



# **Zyto Dot** ® **2C SPEC CCND1 Break Apart Probe**



### **Background**

The ZytoDot® 2C SPEC CCND1 Break Apart Probe is designed to detect translocations involving the chromosomal region 11q13.3 harboring the CCND1 gene. The CCND1 gene (cyclin D1, a.k.a. PRAD1) encodes a regulatory subunit of cyclin-dependent kinases.

Translocations involving the chromosomal region t(11;14)(q13.3;q32.3) are considered to be characteristic for mantle cell lymphomas (MCL) but have also been identified in other lymphoproliferative disorders (LPDs), such as B-prolymphocytic leukemia, and, less frequently, in plasma cell myelomas, B-cell chronic lymphocytic leukemia, and in splenic lymphomas with villous lymphocytes (SLVL).

The t(11;14) rearrangement often leads to overexpression of the CCND1 protein. Determination of translocations involving the chromosomal region 11q13.3 can also help to distinguish MCL from other chronic lymphoproliferative disorders. Since the course of MCL is aggressive, and its response to chemotherapy is poor, differential diagnosis is clinically important.


Additionally, it was also shown that a renal oncocytoma (RO) specific breakpoint is located in band 11q13.3, involving the CCND1 locus. The histologic features of RO may overlap with those of chromophobe renal cell carcinoma (ChRCC). CISH can be used as a diagnostic tool for differentiation of RO from ChRCC.

#### References


Reterences
Bentz JS, et al. (2004) Cancer 102: 124-31.
Bosch F, et al. (1997) Cancer 82: 567-75.
Sinke RJ, et al. (1997) Cancer Genet Cytogenet 96: 95-101.
Sukov WR, et al. (2007) Hum Pathol 40: 1296-303.
Tarsitano M, et al. (2009) Cancer Genet Cytogenet 195: 164-7.
Isujimoto Y, et al. (1984) Science 224: 1403-6.
Vaandrager JW, et al. (1996) Blood 4: 1177-82.

### **Probe Description**

The ZytoDot ® 2C SPEC CCND1 Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the 11q13.3 band. The DNP-labeled probe hybridizes distal to the CCND1 gene breakpoint region at 11q13.3, the DIG-labeled probe hybridizes proximal to the CCND1 gene breakpoint region.



Ideogram of chromosome 11 indicating the hybridization locations.




SPEC CCND1 Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 11q13.3 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 11q13.3 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 11q13.3 locus and one 11q13.3 locus affected by a translocation.



SPEC CCND1 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Mantle cell lymphoma tissue section with translocation affecting the 11q13.3 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
C-3075-100	Zyto <i>Dot</i> 2C SPEC CCND1 Break Apart Probe CE IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	ucts		
C-3044-10	ZytoDot 2C CISH Implementation Kit C € IVD Ind. Heal Pretreatment Solution EDIA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix,1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® 2C SPEC DDIT3 Break Apart Probe

Previously: Zyto Dot 2C SPEC CHOP Break Apart Probe




#### **Background**

The Zyto Dot ® 2C SPEC DDIT3 Break Apart Probe is designed to detect translocations involving the chromosomal region 12q13.3 harboring the DDIT3 (C/EBPhomologous protein) gene (a.k.a. CHOP, GADD153) in formalin-fixed, paraffinembedded tissue sections or cell samples. The DDIT3 gene encodes for a stressinduced dominant-negative inhibitor of the transcription factors C/EBP and LAP. DDIT3 is consistently rearranged in myxoid liposarcomas (MLS). The most frequent translocation involving the DDIT3 gene region is t(12;16)(q13.3;p11.2) and occurs in about 90% of patients with MLS. The rearrangement results in a fusion gene comprising the 5'part of the FUS (fused in sarcoma) gene, located in 16p11.2, and the complete coding region of the DDIT3 gene. The FUS-DDIT3 fusion protein acts as an abnormal transcription factor and development of myxoid liposarcomas is thus regarded as a consequence of deregulated FUS-DDIT3 target genes. Differential diagnosis of liposarcomas and accurate classification, the latter being especially important with regard to appropriate treatment and prognosis, are often problematic. Therefore, detection of DDIT3 rearrangements via ISH analysis is a valuable tool to confirm the histopathological diagnosis of myxoid liposacrcoma.


References Áman P, et al. (1992) Genes Chromosomes Cancer 5: 278-85. Aman r, et al. (1972) Genes Carromosomes Cancer 3: 276-63 Andersson M, et al. (2010) BMC Cancer 10: 249-58. Germano G, et al. (2010) Cancer Res 70: 2235-44. Meis-Kindblom JM, et al. (2001) Virchows Arch 439: 141-51. Panagopoulos I, et al. (1994) Cancer Res 54: 6500-3. Ron D & Habener JF (1992) Genes Dev 6: 439-53.

#### **Probe Description**

The Zyto Dot ® 2C SPEC DDIT3 Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 12q13.3-q14.1 band. The DNP-labeled probe hybridizes proximal to the DDIT3 gene and the DIG-labeled probe hybridizes distal to that gene.




Ideogram of chromosome 12 indicating the hybridization locations.




SPEC DDIT3 Probe map (not to scale).

#### Results

In an interphase nucleus of a normal cell lacking a translocation involving the 12q13.3-q14.1 band, using the Zyto-Dot ® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 12q13.3-q14.1 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 12q13.3-q14.1 locus and one 12a13.3-a14.1 locus affected by a translocation or inversion.



SPEC DDIT3 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Myxoid liposarcoma tissue section with translocation affecting the 12q13.3-q14.1 locus as indicated by one nonrearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
C-3047-100	ZytoDot 2C SPEC DDIT3 Break Apart Probe C€ IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	cts		
C-3044-10	ZytoDot 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		
WB-0009-500	Clear-it™ Stringency Buffer C€ IVD		500 ml

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Dot ® 2C SPEC CDK4/CEN 12 Probe



### **Background**


The ZytoDot® 2C SPEC CDK4/CEN 12 Probe is designed for the detection of CDK4 gene amplifications. The cyclin-dependent kinase 4 (CDK4) gene is located in the chromosomal region 12q14.1, ~10 Mb centromeric to the murine double minute (MDM2) gene and is frequently coamplified with MDM2 in different malignancies.

In a complex with cyclin D1 (CCND1), the CDK4 encoded serine/threonine kinase phosphorylates the retinoblastoma protein 1 (RB1) which in turn leads to the release of the EF2 transcription factor and subsequently to an upregulation of genes which are required for progression through the S-, G2-, and M-phases of the cell cycle. Due to amplification of the respective chromosomal region, CDK4 is overexpressed in many human tumors such as soft tissue sarcomas, osteosarcomas (OS), and gliomas. In glioblastomas, the lack of amplification of several genes like CDK4 was recognized to be associated with a longer survival time. In OS, coamplification of MDM2 and CDK4, located in two discontinuous regions, occurs frequently in parosteal OS and less often in classical high-grade OS.


Although MDM2/CDK4 coamplification is not restricted to atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLPS) and dedifferentiated liposarcomas (DDLPS), its detection is a strong criterion for distinguishing these tumor types from other undifferentiated sarcomas and even from carcinomas and lymphomas. Moreover, CDK4 amplification is a poor prognostic factor in WDLPS and DDLPS.

### **Probe Description**

The ZytoDot® 2C SPEC CDK4/CEN 12 Probe is a mixture of a Digoxigenin-labeled probe specific for the chromosomal region 12q13.3-q14.1 harboring the CDK4 gene and a Dinitrophenyl-labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3).




Ideogram of chromosome 12 indicating the hybridization locations.



SPEC CDK4 Probe map (not to scale).

#### **Results**

In a normal interphase nucleus, using the Zyto Dot © 2C CISH Implementation Kit, two green (CDK4) and two red (CEN 12) signals are expected. In a cell with amplification of the CDK4 gene locus or polysomy of chromosome 12, multiple copies of the green signal or green signal clusters will be observed.



Liposarcoma tissue section with CDK4 amplification as indicated by large green clusters.

#### References

Binh MB, et al. (2005) Am J Surg Pathol 29: 1340-7. Fischer U, et al. (2010) Int J Cancer 126: 2594-602. Lee SE, et al. (2014) Histol Histopathol 29: 127-38. Lopes MA, et al. (2001) Oral Oncol 37: 566-71. Mejia-Guerrero S, et al. (2010) Genes Chromosomes Cancer 49: 518-25. Sirvent A, et al. (2007) Am J Surg Pathol 31: 1476-89. Wunder JS, et al. (1999) Oncogene 18: 783-8.

Prod. No.	Product	Label	Tests* (Volume)
C-3062-400	Zyto Dot 2C SPEC CDK4/CEN 12 Probe CE IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	ucts		
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® SPEC MDM2 Probe



### **Background**


The Zyto Dot ® SPEC MDM2 Probe is designed for the detection of MDM2 gene amplifications found in more than 10% of human tumors.

The MDM2 (murine double minute 2) gene is located in the chromosomal region 12q15 and encodes for an E3 ubiquitin ligase which acts as a major negative regulator of the tumor suppressor p53. Due to the amplification of the respective chromosomal region, MDM2 is overexpressed in many human tumors such as soft tissue sarcomas, osteosarcomas, gliomas, NSCLC, gastric and breast carcinomas. Well-differentiated liposarcomas (WDLPS), the most common soft tissue tumors in adults, are characterized by the amplification of 12q-derived chromosomal material, harboring the MDM2 oncogene while lipomas show balanced translocations involving 12q13-15. Accordingly, detection of the 12q14-15 amplification is regarded as a valuable tool for the differential diagnosis between welldifferentiated liposarcomas and lipomas. Furthermore, detection of the MDM2 amplification might have prognostic relevance in gastrointestinal stromal tumors (GIST), the most common primary mesenchymal tumor of the gastrointestinal tract.


Kerterences Korcheva VB, et al. (2011) Appl Immunhistochem Mol Morphol 19: 119-25. Larousserie F, et al. (2013) Eur J Radiol 82: 2149-53. Luan SL, et al. (2010) J Pathol 222: 166-79. Momand J, et al. (1992) Cell 69: 1237-45. Oliner JD, et al. (1992) Nature 358: 80-3. Pedeutour F, et al. (1994) Genes Chromosomes Cancer 10: 85-94. Pedeutour F, et al. (2004) Bull Cancer 91: 317-23. Poaty H, et al. (2012) PLoS One 7: e29426. Toledo F & Wahl GM (2006) Nat Rev Cancer 6: 909-23. Tornillo L, et al. (2005) Lab Invest 85: 921-31. Vassilev LT (2007) Trends Mol Med 13: 23-31

#### **Probe Description**

The ZytoDot® SPEC MDM2 Probe is a Digoxigenin-labeled probe specific for the MDM2 gene region at 12q15, processed by the the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 12 indicating the hybridization locations.



SPEC MDM2 Probe map (not to scale).

#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the MDM2 gene locus or polysomy of chromosome 12 will show multiple dots or large signal clusters.



Normal nuclei each with two MDM2 signals.

Prod. No.	Product	Label	Tests* (Volume)
C-3012-400	Zyto Dot SPEC MDM2 Probe C € IVD	Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC MDM2/CEN 12 Probe



#### **Background**


The ZytoDot® 2C SPEC MDM2/CEN 12 Probe is designed for the simultaneous detection of MDM2 and centromere 12 in formalin-fixed, paraffin-embedded tissue sections or cell samples.

The MDM2 (mouse double minute 2) gene is located in the chromosomal region 12q15 and encodes for an E3 ubiquitin ligase which acts as a major negative regulator of the tumor suppressor


MDM2 gene amplifications are found in more than 10% of human tumors. Due to the amplification of the respective chromosomal region, MDM2 is overexpressed in many human tumors such as soft tissue sarcomas, osteosarcomas, gliomas, NSCLC, gastric and breast carcinomas. Well-differentiated liposarcomas (WDLPS), the most common soft tissue tumors in adults, are characterized by the amplification of 12g-derived chromosomal material, harboring the MDM2 oncogene while lipomas show balanced translocations involving 12q13-15. Accordingly, detection of the 12q14-15 amplification is regarded as a valuable tool for the differential diagnosis between well-differentiated liposarcomas and lipomas. Furthermore, detection of the MDM2 amplification might have prognostic relevance in gastrointestinal stromal tumors (GIST), the most common primary mesenchymal tumor of the gastrointestinal tract.

#### **Probe Description**

The ZytoDot® 2C SPEC MDM2/CEN 12 Probe is a mixture of a Digoxigenin-labeled probe specific for MDM2 gene at 12q15 and a Dinitrophenyl-labeled CEN 12 probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3).




Ideogram of chromosome 12 indicating the hybridization locations.



SPEC MDM2 Probe map (not to scale).

#### Results

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two red and two green signals are expected. In a cell with amplification of the MDM2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Liposarcoma tissue section with MDM2 amplification as indicated by large green clusters.

References
Flanagan A, et al. (2010) Skeletal Radiol 39: 213-24.
Kashima T, et al. (2012) Mod Pathol 25: 1384-96.
Korcheva VB, et al. (2012) Appl Immunhistochem Mol Morphol 19: 119-25.
Larousserie F, et al. (2013) Eur J Radiol 82: 2149-53.
Luan SL, et al. (2010) J Pathol 222: 166-79.
Momand J, et al. (1992) Cell 69: 1237-45.
Oliner JD, et al. (1992) Nature 358: 80-3.
Pedeutour F, et al. (2004) Bull Cancer 91: 317-23.
Pedeutour F, et al. (2004) Bull Cancer 91: 317-23. Federitor F, et al. (2004) Burn Carlett 91: 317-25. Poaty H, et al. (2012) PLoS One 7: e29426. Toledo F & Wahl GM (2006) Nat Rev Cancer 6: 909-23. Tornillo L, et al. (2005) Lab Invest 85: 921-31. Vassilev LT (2007) Trends Mol Med 13: 23-31.

Prod. No.	Product	Label	Tests* (Volume)
C-3049-100	Zyto Dot 2C SPEC MDM2/CEN 12 Probe C€ IVD	Digoxigenin/DNP	10 (100 µl)
C-3049-400	Zyto Dot 2C SPEC MDM2/CEN 12 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	ucts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit CE IVD  Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10
C-3044-40	Zyto Dot 2C CISH Implementation Kit C E IVD Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		40

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



## Zyto Dot ® 2C SPEC FOXO1 Break Apart Probe



### **Background**

The ZytoDot® 2C SPEC FOXO1 Break Apart Probe is designed for the detection of specific translocations involving the chromosomal region 13q14.11 harboring the FOXO1 (forkhead box O1, a.k.a. FKHR) gene characteristic for alveolar rhabdomyosarcoma.

Among solid tumors of the childhood, rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma. RMS are classified in two main categories: embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). The alveolar histology is associated with a poorer prognosis. ARMS is characterized by two tumor-specific reciprocal translocations t(2;13)(q36;q14.1) and t(1;13)(p36.1;q14.1) detectable in more than 80% of all ARMS. These translocations fuse the FOXO1 locus on 13q14.11 to either PAX3 on chromosome 2 or to PAX7 on chromosome 1. The resulting fusion transcripts encode for the chimeric proteins PAX3-FOXO1 and PAX7-FOXO1 that combine transcriptional domains from the corresponding wild-type proteins and thereby acquire oncogenic activity. The translocations and their fusion genes represent highly specific genetic markers useful in the diagnosis of ARMS.


References
Dal Cin P, et al. (1991) Cancer Genet Cytogenet 55: 191-5.
Douglass EC, et al. (1991) Genes Chromosomes Cancer 3: 480-2.
Gunawan B, et al. (1999) Pathol Oncol Res 5: 211-3.
Seidal T, et al. (1982) Acta Pathol Microbiol Immunol Scand A 90: 345-54.
Sorensen PH, et al. (2002) J Clin Oncol 20: 2672-9.

#### **Probe Description**

The ZytoDot ® 2C SPEC FOXO1 Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 13q14.11 band. The DNP-labeled probe hybridizes distal to the FOXO1 gene breakpoint region at 13q14.11, the DIG-labeled probe hybridizes proximal to the FOXO1 gene breakpoint region.




Ideogram of chromosome 13 indicating the hybridization locations.



SPEC FOXO1 Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 13q14.11 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 13q14.11 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 13q14.11 locus and one 13a14.11 locus affected by a translocation.



SPEC FOXO1 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)	
C-3065-100	ZytoDot 2C SPEC FOXO1 Break Apart Probe C E IVD	Digoxigenin/DNP	10 (100 µl)	
Related Prod	ucts			
C-3044-10	Zyto Dot 2C CISH Implementation Kit C€ IVD		10	
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml			

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>

# ZytoDot \*2 Products for CISH analysis



## Zyto Dot ® 2C SPEC IGH Break Apart Probe



## **Background**

The ZytoDot® 2C SPEC IGH Break Apart Probe is designed to detect translocations involving the chromosomal region 14q32.33 harboring the IGH gene.

Rearrangements involving the IGH (immunoglobulin heavy locus, a.k.a. IGH@) gene are considered to be cytogenetic hallmarks for non-Hodgkin lymphoma (NHL). NHLs represent 50% of all hematological malignancies. IGH gene rearrangements have been identified in about 50% of NHLs and are associated with specific subtypes of NHLs.

Translocation t(11;14)(q13.3;q32.3) can be found in about in 95% of mantle cell lymphoma (MCL), t(14;18)(q32.3;q21.3) in 80% of follicular lymphoma (FL), t(3;14) (q27;q32.3) in diffuse large B-cell lymphoma (DLBCL), and t(8;14)(q24.21;q32.3) in Burkitt's lymphoma. In all of these translocations an oncogene located near the breakpoint of the translocation partner is activated by juxtaposing to IGH regulatory sequences.


Rearrangements involving 14q32.33 have unique biological characteristics and correlate with clinical, morphological, and immunophenotypic features. CISH is a helpful tool for the diagnosis, selecting treatment, and giving prognostic information.

#### References


Bernicot I, et al. (2007) Cytogenet Genome Res 118: 345-52.
Hehne S, et al. (2012) Pathol Res Pract 208: 510-7.
Kazuhiro N, et al. (1997) Bload 90: 526-34.
Lu S, et al. (2004) Cancer Genet and Cytogenet 152: 141-5.
Nishida K, et al. (1989) Cancer Res 49: 1275-81.
Quintero-Rivera F, et al. (2009) Cancer Genet and Cytogenet 190: 33-9.

#### **Probe Description**

The ZytoDot ® 2C SPEC IGH Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the 14q32.33 band. The DNP-labeled probe hybridizes proximal and the DIG-labeled probe hybridizes distal to the constant regions of the IGH locus at 14q32.33.



Ideogram of chromosome 14 indicating the hybridization locations.



SPEC IGH Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 14q32.33 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 14q32.33 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 14q32.33 locus and one 14q32.33 locus affected by a translocation.



SPEC IGH Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3071-100	Zyto <i>Dot</i> 2C SPEC IGH Break Apart Probe C   IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	ucts		
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/ONP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® 2C SPEC FUS Break Apart Probe



### **Background**

The ZytoDot® 2C SPEC FUS Break Apart Probe is designed to detect translocations involving the chromosomal region 16p11.2 harboring the FUS (FUsed in Sarcoma) gene (a.k.a. TLS, FUS/TLS, hnRNP P2).

The FUS gene encodes an RNA-binding protein, the C-terminal end of which is involved in protein and RNA binding and which appears to be involved in transcriptional activation with its N-terminal end. It shares distinct characteristics with EWS and TAF15 which together with FUS are frequently referred to as the FET family of proteins.


FUS gene rearrangements have been shown to be involved in both solid tumors and leukemias fusing the N-terminal end of FUS to various fusion partners. The most frequent translocation involving the FUS gene region is t(12;16)(q13.3;p11.2). Occurring in over 90% of myxoid liposarcomas, the FUS-DDIT3 fusion protein is regarded as being consequential for the development of myxoid liposarcomas by acting as an abnormal transcription factor and thus deregulating FUS-DDIT3 target genes.

Differential diagnosis of liposarcomas and accurate classification, the latter being especially important with regard to appropriate treatment and prognosis, are often problematic. Therefore, detection of FUS rearrangements via in situ Hybridization analysis is a valuable tool to confirm the histopathological diagnosis of myxoid liposarcoma.


References
Andersson M, et al. (2010) BMC Cancer 10: 249-58 Antonesco C, et al. (2010) BMC Cancer 10: 247-36. Antonesco C, et al. (2000) J Mol Diagn 2: 132-8. Germano G, et al. (2010) Cancer Res 70: 2235-44. Kuroda M, et al. (1995) Am J Pathol 147: 1221-7. Meis-Kindblom JM, et al. (2001) Virchows Arch 439: 141-51. Panagopoulos I, et al. (1994) Cancer Res 54: 6500-3. Panagopoulos I, et al. (1997) Oncogene 15: 1357-62.

#### **Probe Description**

The ZytoDot® 2C SPEC FUS Break Apart Probe is a mixture of a Digoxigeninlabeled and a Dinitrophenyl-labeled probe hybridizing to the 16p11.2 band. The DNP-labeled probe hybridizes proximal to the FUS gene, the DIG-labeled probe hybridizes distal to that gene.




Ideogram of chromosome 16 indicating the hybridization locations.



SPEC FUS Probe map (not to scale).

#### Results

In an interphase nucleus lacking a translocation involving the 16p11.2 band, using the ZytoDot® 2C CISH Implementation Kit two red/green fusion signals are expected representing two normal (non-rearranged) 16p11.2 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 16p11.2 locus and one 16p11.2 locus affected by a 16p11.2 translocation.



Myxoid liposarcoma tissue section with translocation affecting the 16p11.2 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

• • • •	· · · · ·			
Prod. No.	Product	Label	Tests* (Volume)	
C-3054-100	Zyto <i>Dot</i> 2C SPEC FUS Break Apart Probe C   IVD	Digoxigenin/DNP	10 (100 µl)	
Related Produ	icts			
C-3044-10	Zyto Dot 2C CISH Implementation Kit C    IVD  Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix,1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10	
WB-0009-500	Clear-it™ Stringency Buffer C€ IVD		500 ml	

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more informati



## Zyto Dot ® SPEC ERBB2 Probe

## Previously: Zyto Dot SPEC HER2 Probe



#### **Background**

The ZytoDot® SPEC ERBB2 Probe is designed for the detection of ERBB2 gene amplification, frequently observed in solid malignant neoplasms, in formalin-fixed, paraffin-embedded tissue sections or cell samples.

The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes the cellular growth factor receptor p185.


Amplification of the proto-oncogene ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease. Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland.

References


Ataseven B, et al. (2012) Breast Care 7: 465-70.
Bhargava R, et al. (2005) Am J Clin Pathol 123: 237-43.
Boissière-Michot F, et al. (2013) Pathol Oncol Res 19: 41-53.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2016) Science 230: 1132-9.
Cruz-Reyes C & Gamboo-Dominguez A (2013) Int J Surg Pathol 21: 240-6.
Di Palma S, et al. (2008) J Clin Pathol 61: 757-60.
Ettl T, et al. (2012) Hum Pathol 43: 921-31.
Fasching P, et al. (2011) BMC Cancer 11: 486.
Haas M, et al. (2011) Wirchows Arch 458: 403-11.
Hauser-Kronberger C & Dandachi N (2004) J Mol Histol 35: 647-53.
Hwang CC, et al. (2011) Histopathology 59: 984-92.
Kounelis S, et al. (2005) Anticancer Res 25: 939-46.
Kuijpers CCHJ, et al. (2013) PLoS One 19: 3078-87.
Lehmann-Che L, et al. (2011) Br J Cancer 104: 1739-46.
Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92.
Mori N, et al. (2013) J Huazhong Univ Sci Technolog Med Sci 33: 379-84.
Oliveira-Costa JP, et al. (2011) Diagn Pathol 6: 73.
Shim BY, et al. (2009) Asia Pac J Clin Oncol 5: 232-41.
Tsukamoto T, et al. (1991) Int J Dev Biol 35: 25-32.

#### **Probe Description**

The ZytoDot®SPEC ERBB2 Probe is a Digoxigenin-labeled probe specific for the ERBB2 gene at 17q12, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2 Probe map (not to scale).

#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the ERBB2 gene locus or polysomy of chromosome 17 will show multiple dots or large signal clusters.



Normal nuclei each with two ERBB2 signals



Breast carcinoma tissue section with ERBB2 amplification.

Prod. No.	Product	Label	Tests* (Volume)
C-3001-100	ZytoDot SPEC ERBB2 Probe C€ IVD	Digoxigenin	10 (100 µl)
C-3001-400	ZytoDot SPEC ERBB2 Probe C€ IVD	Digoxigenin	40 (400 µl)
C-3003-10	Zyto Dot SPEC ERBB2 Probe Kit C    IVD  Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Probe, 0.1 ml; Wash Buffer SSC, 150 ml; PBS/Tween, good for 1000 ml; Blocking Solution, 1 ml; Mouse-anti-DIG, 1 ml; Anti-Mouse-HRP-Polymer, 1 ml; DAB Solution A, 0.1 ml; DAB Solution B, 2 ml; Mayer's Hematoxylin Solution, 4 ml; Mounting Solution (alcoholic), 1 ml; Control Slides, 1 pcs.	Digoxigenin	10
C-3003-40	ZytoDot SPEC ERBB2 Probe Kit C€ IVD	Digoxigenin	40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Probe, 0.4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-D1G, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml; Control Slides, 2 pcs.		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

# ZytoDot Products for CISH analysis



## Zyto Dot ® 2C SPEC ERBB2/CEN 17 Probe

Previously: Zyto Dot 2C SPEC HER2/CEN 17 Probe



#### **Background**

The ZytoDot® 2C SPEC ERBB2/CEN 17 Probe is designed for the simultaneous detection of ERBB2 and centromere 17 in formalin-fixed, paraffin-embedded tissue sections or cell samples.


The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes the cellular growth factor receptor p185. Amplification of the proto-oncogene ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease. Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland.

#### References


Bhargava R, et al. (2005) Am J Clin Pathol 123: 237-43.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Brunner K, et al. (2010) Anal Quant Cytol Histol 32: 78-89.
Carbone A, et al. (2008) J Mol Diagn 10: 527-36.
Caussens I, et al. (1985) Science 230: 1132-9.
Ettl T, et al. (2012) Hum Pathol 43: 921-31.
Fasching P, et al. (2011) BMC Cancer 11: 486.
Haas M, et al. (2011) BMC Cancer 11: 486.
Haas M, et al. (2011) Wirchows Arch 458: 403-11.
Hauser-Kronberger C & Dandachi N (2004) J Mol Histol 35: 647-53.
Hopman AHN, et al. (1997) Histochem Cell Biol 108: 291-8.
Hwang CC, et al. (2011) Histopathology 59: 984-92.
Kounelis S, et al. (2005) Anticancer Res 25: 939-46.
Lehmann-Che L, et al. (2011) Br J Cancer 104: 1739-46.
Mayr D, et al. (2009) Histopathology 55: 716-23.
Mosch B, et al. (2007) J Neuroscience 27: 6859-67.
Moelans CB, et al. (2011) I Grit Rev Oncol Hematol 80: 380-92.
Niex A, et al. (2013) J Huazhong Univ Sci Technolog Med Sci 33: 379-84.
Oliveira-Costa JP, et al. (2011) Diagn Pathol 6: 73.
Santos PB, et al. (2012) Diagn Pathol 7: 104.
Schiavon BN, et al. (2012) Diagn Pathol 7: 104.
Schiavon BN, et al. (2012) Histo Histopathology 7: 1353-9.
Speel EJ, et al. (1994) J Histochem Cytochem 42: 1299-307.
Vasconcellos FA, et al. (2013) UHOD 3: 156-62.

#### **Probe Description**

The ZytoDot® 2C SPEC ERBB2/CEN 17 Probe is a mixture of a Digoxigenin-labeled probe specific for the ERBB2 gene at 17q12 and a Dinitrophenyl-labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1).




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC ERBB2 Probe map (not to scale).

#### **Results**

Using the ZytoDot® 2C SPEC ERBB2/CEN 17 Probe Kit, two green (ERBB2) and two red (CEN 17) signals are expected in a normal interphase nucleus. In a cell with amplification of the ERBB2 gene locus, multiple copies of the green signal or green signal clusters will be observed.



Breast cancer tissue section with ERBB2 amplification as indicated by multiple green signals in each nucleus.



Gastric carcinoma tissue section with strong ERBB2 amplification as indicated by large green clusters.

Prod. No.	Product	Label	Tests* (Volume)
C-3032-100	Zyto Dot 2C SPEC ERBB2/CEN 17 Probe C € IVD	Digoxigenin/DNP	10 (100 µl)
C-3032-400	Zyto Dot 2C SPEC ERBB2/CEN 17 Probe C € IVD	Digoxigenin/DNP	40 (400 µl)
C-3022-10	Zyto Dot 2C SPEC ERBB2/CEN 17 Probe Kit C € IVD  Ind. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Probe, 0.1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml; Control Slides, 1 pcs.	Digoxigenin/DNP	10
C-3022-40	Zyto Dot 2C SPEC ERBB2/CEN 17 Probe Kit C € IVD Ind. Heat Pretreatment Solution EDTA, 500 ml; Pepsis Solution, 4ml; Probe, 0.4 ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (lackoholic), 4 ml; Control Sides, 2 pcs.	Digoxigenin/DNP	40

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

# ZytoDot ® 2 CProducts for CISH analysis



## Zyto Dot ® 2C SPEC ERBB2/D17S122 Probe



### **Background**

The ZytoDot® 2C SPEC ERBB2/D17S122 Probe is designed for the detection of ERBB2 gene amplification frequently observed in solid malignant neoplasms e.g. breast cancer samples.

The ERBB2 gene (a.k.a. HER2 and NEU) is located in the chromosomal region 17q12 and encodes a 185-190 kDa transmembrane glycoprotein, p185, acting as a cellular growth factor receptor. The p185 protein belongs to the EGFR (epidermal growth factor receptor) subgroup of the RTK (receptor tyrosine kinase) superfamily also including ERBB1 (HER1), ERBB3 (HER3), and ERBB4 (HER4). Amplification of the proto-oncogene ERBB2, observed in approximately 20% of all breast cancer samples, has been correlated with a poor prognosis of the disease.


Similar results have been obtained for a variety of other malignant neoplasms e.g. ovarian cancer, stomach cancer, and carcinomas of the salivary gland. Chromogenic in situ Hybridization targeting the alpha satellite centromeric regions of chromosome 17 may be misleading in some cases due to possible gains or losses of this region. For these cases, judged as equivocal according to the ASCO guidelines, reflex testing is recommended using the SPEC ERBB2/D17S122 Probe.

#### Reference


References
Baselga J, et al. (1999) Semin Oncol 26: 78-83.
Coussens I, et al. (1985) Science 230: 1132-9.
Hwang CC, et al. (2011) Histopathology 59: 984-92.
Hynes NE & Stern DF (1994) Biochim Biophys Acta 1198: 165-84.
Moelans CB, et al. (2011) Crit Rev Oncol Hematol 80: 380-92.
Park JB, et al. (1989) Cancer Res 49: 6605-9.
Popescu NC, et al. (1987) Science 235: 177-82.
Voutsas IF, et al. (2013) Int J Radiat Biol 89: 319-25.
Wolff AC, et al. (2013) J Clin Oncol 31: 3997-4013.

#### **Probe Description**

The ZytoDot® 2C SPEC ERBB2/D17S122 Probe is a mixture of a Digoxigenin-labeled probe specific for the chromosomal region 17q12 harboring the ERBB2 gene and a Dinitrophenyl-labeled SPEC D17S122 probe specific for the chromosomal region 17p12. The SPEC D17S122 probe is designed to be used for chromosome 17 copy number detection.




Ideogram of chromosome 17 indicating the hybridization locations.



#### **Results**

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit, two green (ERBB2) and two red (D17S122) signals are expected. In a cell with amplification of the ERBB2 gene locus or polysomy of chromosome 17, multiple copies of the green signal or green signal clusters will be observed.



Breast carcinoma tissue section with amplification of the ERBB2 gene as indicated by multiple green signals in relation to red (D17S122) signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3068-100	Zyto Dot 2C SPEC ERBB2/D17S122 Probe C€ IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	icts		
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Dot ® SPEC TOP2A Probe



#### **Background**

The ZytoDot® SPEC TOP2A Probe is designed for the detection of TOP2A deletions and gene amplifications in formalin-fixed, paraffin-embedded tissue sections or cell samples.


The TOP2A (topoisomerase II alpha) gene is located in the chromosomal region 17q21.2 and encodes for a 170 kDa DNA topoisomerase which controls and alters the topologic state of DNA during replication, transcription, and chromosome segregation.

TOP2A gene copy number changes are frequently observed in the majority of ERBB2 amplified primary breast tumors as well as in other human malignancies without simultaneous ERBB2 amplification e.g. acute lymphoblastic leukemias, gastric and bladder carcinomas. Recent data suggests that amplification and deletion of the TOP2A gene locus may account for relative chemosensitivity or resistance to TOP2A inhibitor therapy, respectively. Thus, determination of the TOP2A status may predict benefit from adjuvant anthracyclines in ERBB2 positive breast cancer.


Noterences
Arriola E, et al. (2007) Breast Cancer Res Treat 106: 181-9.
Ataseven B, et al. (2012) Breast Care 7: 465-70.
Järvinen TA & Liu ET (2006) Curr Cancer Drug Targets 6: 579-602.
Järvinen TA, et al. (2000) Am J Pathol 156: 839-47.
Tanner M, et al. (2000) J Clin Oncol 24: 2428-36. Tamer W, et al. (1984) Science 226: 242630. Tsai:Pflugfelder M, et al. (1988) Proc Nat Acad Sci 85: 7177-81. Wang JC (1996) Annu Rev Biochem 65: 635-92.

#### **Probe Description**

The Zyto Dot ® SPEC TOP2A Probe is a Digoxigenin-labeled probe specific for the TOP2A gene at 17q21.2, processed by the unique ZytoVision® Repeat Subtraction Technique resulting in advanced specificity and less background.




Ideogram of chromosome 17 indicating the hybridization locations.




SPEC TOP2A Probe map (not to scale).

#### Results

In normal cells, two distinct dot-shaped signals per nucleus will be observed. Nuclei with amplification of the TOP2A gene locus or polysomy of chromosome 17 will show multiple dots or large signal clusters. Deletion of the TOP2A gene results in one or no signal per nucleus.



Normal nuclei each with two TOP2A signals



Breast carcinoma tissue section with TOP2A amplification.

Prod. No.	Product	Label	Tests* (Volume)
C-3021-400	ZytoDot SPEC TOP2A Probe C € IVD	Digoxigenin	40 (400 µl)
Related Prod	ucts		
C-3018-40	Zyto <i>Dot</i> CISH Implementation Kit C€ IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-D16, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Dot ® 2C SPEC TOP2A/CEN 17 Probe



### **Background**

The ZytoDot® 2C SPEC TOP2A/CEN 17 Probe is designed for the detection of TOP2A deletions and gene amplifications in formalin-fixed, paraffin-embedded tissue sections or cell samples.

The TOP2A (topoisomerase II alpha) gene is located in the chromosomal region 17q21.2 and encodes for a 170 kDa DNA topoisomerase which controls and alters the topologic state of DNA during replication, transcription, and chromosome segregation.

TOP2A gene copy number changes are frequently observed in the majority of ERBB2 amplified primary breast tumors as well as in other human malignancies without simultaneous ERBB2 amplification e.g. acute lymphoblastic leukemias, gastric and bladder carcinomas. Recent data suggests that amplification and deletion of the TOP2A gene locus may account for relative chemosensitivity or resistance to TOP2A inhibitor therapy, respectively. Thus, determination of the TOP2A status may predict benefit from adjuvant anthracyclines in ERBB2 positive breast cancer.


Retreences
Arriola E, et al. (2007) Breast Cancer Res Treat 106: 181-9.
Brunello E, et al. (2012) Histopathology 60: 482-8.
Järvinen TA & Liu ET (2006) Curr Cancer Drug Targets 6: 579-602.
Järvinen TA, et al. (2000) Am J Pathol 156: 839-47.
Razis E, et al. (2011) Breast Cancer Res Treat 128: 447-56. Tanner M, et al. (2006) J Clin Oncol 24: 2428-36. Tanner M, et al. (1984) Science 226: 466-8. Taci-Pflugfelder M, et al. (1988) Proc Nat Acad Sci 85: 7177-81. Wang JC (1996) Annu Rev Biochem 65: 635-92.

#### **Probe Description**

The ZytoDot® 2C SPEC TOP2A/CEN 17 Probe is a mixture of a Digoxigenin-labeled probe specific for the TOP2A gene at 17q21.2 and a Dinitrophenyl-labeled CEN 17 probe specific for the alpha satellite centromeric region of chromosome 17 (D17Z1).




Ideogram of chromosome 17 indicating the hybridization locations.



SPEC TOP2A Probe map (not to scale).

#### Results

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit two green and two red signals are expected. In a cell with amplification of the TOP2A gene locus, multiple copies of the green signal or green signal clusters will be observed.



Breast carcinoma tissue section with TOP2A amplification as indicated by multiple green signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3040-400	ZytoDot 2C SPEC TOP2A/CEN 17 Probe C € IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	ucts		
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>



## Zyto Dot ® 2C SPEC SS18 Break Apart Probe

Previously: Zyto Dot 2C SPEC SYT Break Apart Probe



### **Background**


The Zyto Dot ® 2C SPEC SS18 Break Apart Probe is designed to detect translocations involving the chromosomal region 18q11.2 harboring the SS18 (synovial sarcoma translocation, chromosome 18) gene (a.k.a. SYT).

Translocations involving the region 18a11.2 are found in over 90% of synovial sarcoma. Among soft tissue sarcomas, synovial sarcoma is one of the most common and classically occurs in the extremities of young adults with greater prevalence in males even though, the occurrence of synovial sarcoma has also been described in a wide variety of anatomical locations and in all ages. The most frequent translocation involving the SS18 gene region is t(X;18) (p11.23;q11.2) juxtaposing the SS18 gene in 18q11.2 either next to the SSX1 (synovial sarcoma, translocated to X chromosome) or the SSX2 gene, or very rarely to the SSX4 locus located in Xp11.23. Complex translocations involving other chromosomes are observed in less than 10% of synovial sarcomas. In combination with histopathological diagnosis, detection of SS18 rearrangements via in situ Hybridization (ISH) analysis is a valuable tool to confirm the diagnosis of synovial sarcoma.


References
Amary MF, et al. (2007) Mod Pathol 20: 482-96.
Clark J, et al. (1994) Nat Genet 7: 502-8.
Kawai A, et al. (1998) N Engl J Med 338: 153-60.
Surace C, et al. (2004) Lab Invest 84: 1185-92. Torres L, et al. (2008) Cancer Genet Cytogenet 187: 45-9.

#### **Probe Description**

The Zyto Dot ® 2C SPEC SS18 Break Apart Probe is a mixture of a Digoxigeninlabeled probe and a Dinitrophenyl-labeled probe hybridizing to the 18q11.2 band. The DNP-labeled probe hybridizes distal to the SS18 gene and the DIG-labeled probe hybridizes proximal to that gene.




Ideogram of chromosome 18 indicating the hybridization locations.




SPEC SS18 Probe map (not to scale).

#### **Results**

In an interphase nucleus lacking a translocation involving the 18q11.2 band, using the ZytoDot® 2C CISH Implementation Kit two red/green fusion signals are expected representing two normal (non-rearranged) 18q11.2 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 18q11.2 locus and one 18q11.2 locus affected by an 18q11.2 translocation.



SPEC SS18 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Synovial sarcoma tissue section with translocation affecting the 18q11.2 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
C-3046-100	Zyto Dot 2C SPEC SS18 Break Apart Probe C    IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	icts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C E IVD  Incl. Heat Pretreatment Solution EDIA, 150 mt, Pepsin Solution, 1 mt; Wash Buffer SSC, 150 mt, 20x Wash Buffer TBS, 50 mt, Anti-DIG/DNP-Mix, 1 mt; HRP/AP-Polymer-Mix, 1 mt; AP-Red Solution A, 0.1 mt; AP-Red Solution B, 4 mt, HRP-Green Solution A, 0.2 mt, HRP-Green Solution B, 4 mt, Nuclear Blue Solution, 4 mt; Mounting Solution (alcoholic), 1 mt		10

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

# ZytoDot \*2 Products for CISH analysis



## Zyto Dot ® 2C SPEC MALT1 Break Apart Probe



### **Background**

The ZytoDot® 2C SPEC MALT1 Break Apart Probe is designed to detect translocations involving the chromosomal region 18q21.32 harboring the MALT1 gene. The MALT1 (mucosa associated lymphoid tissue lymphoma translocation gene 1, a.k.a. MLT) gene encodes a human paracaspase and is often rearranged in MALT lymphomas accounting for 5-10% of all B-cell non-Hodgkin lymphomas (NHL). The most common translocations affecting the MALT1 gene are t(11;18)(q22.2;q21.3) and t(14;18)(q32.3;q21.3) occurring in 50% and 15-20% of MALT lymphomas, respectively.

These translocations lead to the expression of BIRC3-MALT1 (a.k.a. API2-MALT1) and IGH-MALT1 fusion proteins, resulting in constitutive activation of the NF- $\kappa$ B signaling pathway which controls the expression of numerous anti-apoptotic and proliferation-promoting genes.


The translocation t(11;18)(q22.2;q21.3) is mainly found in pulmonary and gastric lymphomas, whereas t(14;18) (q32.3;q21.3) occurs more frequently in non-gastrointestinal MALT lymphomas, e.g., of the skin and salivary glands. The presence of a t(11;18)(q22.2;q21.3) correlates with unresponsiveness to eradication of *Helicobacter pylori* in gastric MALT lymphomas. Hence, detection of MALT1 translocations by CISH may be a supportive tool to identify patients eligible for an anti-*H. pylori* therapy.

#### References

Afonina IS, et al. (2015) FEBS J 282: 3286-97.
Beans M, et al. (2014) PLoS One 9: e103774.
Dierlamm J, et al. (1999) Blood 93: 3601-9.
Levine EG, et al. (1989) Blood 74: 1796-800.
Lucas PC, et al. (2001) J Biol Chem 276: 19012-9.
Martinelli G, et al. (2005) J Clin Oncol 23: 1979-83.
Pereira MI & Medeiros JA (2014) World J Gastroenterol 20: 684-98.
Troppan K, et al. (2015) Gastroenterol Res Pract 2015: 102656.

### **Probe Description**

The ZytoDot ® 2C SPEC MALT1 Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the 18q21.31-q21.32 band. The DNP-labeled probe hybridizes distal to the MALT1 gene at 18q21.32, the DIG-labeled probe hybridizes proximal to the MALT1 gene at 18q21.31-q21.32.




Ideogram of chromosome 18 indicating the hybridization locations.



SPEC MALT1 Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 18q21.31-q21.32 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 18q21.31-q21.32 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 18q21.31-q21.32 locus and one 18q21.31-q21.32 locus affected by a translocation.



SPEC MALT1 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3072-100	Zyto <i>Dot</i> 2C SPEC MALT1 Break Apart Probe C   IVD	Digoxigenin/DNP	10 (100 µl)
Related Prod	ucts		
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; Muchaer Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

# ZytoDot Products for CISH analysis



## Zyto Dot ® 2C SPEC BCL2 Break Apart Probe



#### **Background**

The ZytoDot ® 2C SPEC BCL2 Break Apart Probe is designed to detect translocations involving the chromosomal region 18q21.33 harboring the BCL2 gene. The BCL2 (B-cell CLL/lymphoma 2, a.k.a. PPP1R50) gene encodes a mitochondrial membrane protein that regulates apoptosis and is expressed in B-cells.

Translocations involving the BCL2 gene are commonly identified in B-cell lymphomas. In particular, the translocation t(14;18)(q32.3;q21.3) has been identified in about 80% of follicular lymphoma (FL), in 20% to 30% of diffuse large B-cell lymphoma (DLBCL), and rarely in B-cell chronic lymphocytic leukemia (B-CLL). In FL this translocation is considered to be a cytogenetic hallmark. As a result of this rearrangement, the BCL2 gene is juxtaposed to the IGH (Immunglobulin heavy chain) locus at 14q32.33 which leads to overexpression of the anti-apoptotic protein BCL2, and finally to progression to lymphoma.

Alternative BCL2 translocations to immunoglobulin light chain genes as well as non-IG translocation events have been reported.

In DLBCL, BCL2 gene overexpression has been implicated in conferring resistance to chemotherapy and has been associated with poor prognosis.

Hence, detection of BCL2 translocations by CISH may be of diagnostic and prognostic relevance.

#### References


Da Cunha Santos G, et al. (2011) Cancer Cytopathol 119: 254-62. Dyer MJ, et al. (1994) Blood 83: 3682-8. Gu K, et al. (2008) Arch Pathol Lab Med 132: 1355-61. Hockenbery D, et al. (1990) Nature 348: 334-6. Impera L, et al. (2008) Oncogene 27: 6187-90. López-Guillermo A, et al. (1999) Blood 93: 3081-7. Nelson BP, et al. (2007) Am J Clin Pathol 128: 323-32. Tibiletti MG, et al. (2009) Hum Pathol 40: 645-52. Tomita N, et al. (2009) Ham John 20: 34: 935-43. Weinberg OK, et al. (2007) J Mol Diagn 9: 530-7.

### **Probe Description**

The ZytoDot® 2C SPEC BCL2 Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the 18q21.33 band. The DNP-labeled probe hybridizes distal to the BCL2 gene at 18q21.33, the DIG-labeled probe hybridizes proximal to the BLC2 gene at 18q21.33.




Ideogram of chromosome 18 indicating the hybridization locations.



SPEC BCL2 Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking a translocation involving the 18q21.33 band, using the ZytoDot® 2C CISH Implementation Kit, two red/green fusion signals are expected representing two normal (non-rearranged) 18q21.33 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 18q21.33 locus and one 18q21.33 locus affected by a translocation.



SPEC BCL2 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3073-100	Zyto <i>Dot</i> 2C SPEC BCL2 Break Apart Probe CE IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	ucts		
C-3044-10	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		10
	Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/ONP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution B, 4 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

# ZytoDot ®2 Products for CISH analysis



## Zyto Dot ® 2C SPEC TOP1/CEN 20 Probe



### **Background**

The Zyto Dot ® 2C SPEC TOP1/CEN 20 Probe is designed for the detection of TOP1 gene amplifications.

The TOP1 (topoisomerase (DNA) I) gene is located in the chromosomal region 20q12 and encodes a DNA topoisomerase 1, a nuclear enzyme that is required in replication and which is responsible for unwinding DNA and preventing lethal strand breaks.

The TOP1 locus appears to undergo frequent copy number alterations which are either focal in nature, e.g., amplicondriven, or may involve larger chromosomal regions, such as 20q.

TOP1 copy number gain has been reported in several tumor entities, as e.g. breast cancer, melanoma, gastric cancer, and in colorectal cancer. In stage III colorectal cancer patients, TOP1 copy number increase seems to be associated with longer overall survival.

For metastatic colorectal cancer (mCRC), irinotecan is included in the treatment regimens. The active metabolite is SN-38, which is cytotoxic and destabilizes the TOP1-DNA covalent complex leading to cancer cell death. Studies evaluating the efficacy of this topoisomerase I inhibtor in metastatic breast cancer are currently ongoing.

Thus, detection of TOP1 gene status by Chromogenic in situ Hybridization might be of predictive value.


References Kümler I, et al. (2015) BMC Cancer 15: 78. McLeod HL & Keith KN (1996) Br J Cancer 74: 508-12. Panczyk M (2014) World J Gastroenterol 20: 9775-827. Rømer MU, et al. (2012) Mol Oncol 7: 101-11. Sønderstrup IM, et al. (2015) Mol Oncol 9: 1207-17. Stenvang J, et al. (2013) Front Oncol 3: 313.

#### **Probe Description**

The Zyto Dot ® 2C SPEC TOP1/CEN 20 Probe is a mixture of a Digoxigenin-labeled probe specific for the chromosomal region 20q12 harboring the TOP1 gene and a Dinitrophenyl-labeled CEN 20 probe specific for the alpha satellite centromeric region of chromosome 20 (D20Z2).




Ideogram of chromosome 20 indicating the hybridization locations.



SPEC TOP1 Probe map (not to scale).

#### **Results**

In a normal interphase nucleus, using the ZytoDot® 2C CISH Implementation Kit, two green (TOP1) and two red (CEN 20) signals are expected. In a cell with amplification or gain of the TOP1 gene locus, polysomy of chromosome 20, or gain of the chromosomal arm 20q, multiple copies of the green signal or green signal clusters will be observed.



Breast carcinoma tissue section with amplification of the TOP1 gene as indicated by multiple green signals in each nucleus.

Prod. No.	Product	Label	Tests* (Volume)
C-3069-400	Zyto Dot 2C SPEC TOP1/CEN 20 Probe C€ IVD	Digoxigenin/DNP	40 (400 µl)
Related Produ	ucts		
C-3044-40	Zyto <i>Dot</i> 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information

# ZytoDot ®2 Products for CISH analysis



## Zyto Dot ® 2C SPEC ERG Break Apart Probe



### **Background**

The Zyto Dot ® 2C SPEC ERG Break Apart Probe is designed to detect aberrations involving the ERG gene at 21q22.2 frequently found in prostate cancers. ERG (ETS-related gene) rearrangements have been observed in 40-60% of prostate cancers identified via prostatespecific antigen (PSA) screening. The most common aberration affecting ERG is the interstitial deletion of about 3 Mb at the chromosomal region 21a22 found in 90% of the cases. This deletion leads to the fusion of the hormonally regulated promoter of the TMPRSS2 (transmembrane protease, serine 2) gene to the coding region of ERG, resulting in overexpression of the ERG transcription factor. However, about 10% of the ERG rearranged prostate cancer cases show alternative fusions, as e.g. SLC45A3-ERG or NDRG1-ERG.

Several studies detected associations of ERG rearrangements with histomorphologic features as well as characteristic copy number gains, and gene expression signatures, defining a distinct sub-class of prostate cancers with unfavorable prognosis. Hence, the evaluation of the ERG rearrangement status in tissue or urine samples by CISH might be of diagnostic and prognostic relevance.

EWSR1-ERG gene fusions present in about 10% of patients with Ewing sarcoma may result from complex genomic rearrangements and may therefore not be detected by CISH analysis or may result in a nonclassical translocation signal pattern.

Meterences Esgueva R, et al. (2010) Mod Pathol 23: 539-46.

Maire G, et al. (2008) Cancer Genet Cytogenet 181: 81-92.

Nam RK, et al. (2007) Br J Cancer 97: 1690-5.

Perner S, et al. (2006) Cancer Res 66: 8337-41.


Pflueger D, et al. (2009) Neoplasia 11: 804-11. Tomlins SA, et al. (2005) Science 310: 644-8

#### **Probe Description**

The Zyto Dot ® 2C SPEC ERG Break Apart Probe is a mixture of a Digoxigenin-labeled and a Dinitrophenyl-labeled probe hybridizing to the long arm of chromosome 21. The DNP- labeled probe hybridizes proximal to the ERG gene breakpoint region at 21q22.13-q22.2, the DIG-labeled probe hybridizes distal to the ERG gene breakpoint region at 21q22.2.



Ideogram of chromosome 21 indicating the hybridization locations.




SPEC ERG Probe map (not to scale).

#### **Results**

In an interphase nucleus of a normal cell lacking an aberration involving the 21q22.13-q22.2 band, using the ZytoDot® 2C CISH Implementation Kit, two red/ green fusion signals are expected representing the two normal (non-rearranged) 21q22.13-q22.2 loci.

A 21q22.13-q22.2 locus affected by a 21q22.2 deletion resulting in the TMPRSS2-ERG fusion is indicated by the loss of one green signal.

A signal pattern consisting of one red/ green fusion signal, a separate green, and a separate red signal indicates an ERG translocation without involvement of TMPRSS2 (e.g. SLC45A3-ERG).



Prostate cancer tissue section with translocation affecting the 21q22.13-q22.2 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
C-3058-400	Zyto Dot 2C SPEC ERG Break Apart Probe CE IVD	Digoxigenin/DNP	40 (400 µl)
Related Prod	ucts		
C-3044-40	Zyto Dot 2C CISH Implementation Kit C € IVD		40
	Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A. 0.4 ml; AP-Red Solution B. 15 ml; Nuclear Blue Solution. 20 ml; Mounting Solution (alcoholic). 4 ml		

<sup>\*</sup> Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatio</u>.

# ZytoDot ®2 Products for CISH analysis



# Zyto Dot ® 2C SPEC EWSR1 Break Apart Probe



### **Background**

The Zyto Dot ® 2C SPEC EWSR1 Break Apart Probe is designed to detect translocations involving the chromosomal region 22q12.2 harboring the EWSR1 (Ewing sarcoma breakpoint region 1) gene (a.k.a. EWS).

Translocations involving the chromosomal region 22q12.2 are found in 90-95% of patients with Ewing sarcoma or peripheral primitive neuroectodermal tumors (PNET). Ewing sarcoma is the second most common, highly malignant bone tumor in children and young adults. The most frequent translocation involving the EWSR1 gene region is t(11;22)(q24.3;q12.2) juxtaposing the EWSR1 gene in 22q12.2 next to the FLI-1 (friend leukemia virus integration 1) locus in 11q24.3. FLI-1 is a member of the ETS family of transcription factors. Less frequently, EWSR1 can also be fused to ERG, a transcription factor closely related to FLI-1 but located in 21q22.2.

For prognosis and appropriate treatment it is important to differentiate Ewing sarcoma/PNET from classic neuroblastoma, Wilms tumor, and rhabdomyosarcoma. In combination with the histopathological diagnosis, detection of EWSR1 rearrangements by using in situ Hybridization can be used to confirm the diagnosis of Ewing sarcoma/PNET.

References Bridge RS, et al. (2006) Mod Pathol 19: 1-8. Bridge KS, et al. (2006) Mod Pathol 19: 1-8.

Delattre O, et al. (1992) Nature 359: 162-5.

Lee J, et al. (2005) Cancer Genet Cytogenet 159: 177-80.

Romeo S & Dei Tos AP (2010) Virchows Arch 456: 219-34.

Sandberg AA & Bridge JA (2000) Cancer Genet Cytogenet 123: 1-26.


Zucman J, et al. (1993) EMBO J 12: 4481-7.

### **Probe Description**

The ZytoDot® 2C SPEC EWSR1 Break Apart Probe is a mixture of a Digoxigeninlabeled probe and a Dinitrophenyl-labeled probe hybridizing to the 22q12.1-q12.2 band. The DNP-labeled probe hybridizes proximal and extends inward intron 4 of the EWSR1 gene, the DIG-labeled probe hybridizes distal to that gene.




Ideogram of chromosome 22 indicating the hybridization locations.




SPEC EWSR1 Probe map (not to scale).

#### **Results**

In an interphase nucleus lacking a translocation involving the 22q12.1-q12.2 band, using the ZytoDot® 2C CISH Implementation Kit two red/green fusion signals are expected representing two normal (non-rearranged) 22q12.1-q12.2 loci. A signal pattern consisting of one red/green fusion signal, one red signal, and a separate green signal indicates one normal 22q12.1-q12.2 locus and one 22q12.1q12.2 locus affected by a 22q12.1-q12.2 translocation.



SPEC EWSR1 Break Apart Probe hybridized to normal interphase cells as indicated by two red/green fusion signals per nucleus.



Ewing sarcoma tissue section with translocation affecting the 22q12.1-q12.2 locus as indicated by one non-rearranged red/green fusion signal, one red signal, and one separate green signal indicating the translocation.

Prod. No.	Product	Label	Tests* (Volume)
C-3043-100	Zyto <i>Dot</i> 2C SPEC EWSR1 Break Apart Probe C E IVD	Digoxigenin/DNP	10 (100 µl)
Related Produ	ucts		
C-3044-10	Zyto Dot 2C CISH Implementation Kit C € IVD  Incl. Hearl Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; HRP-Green Solution A, 0.2 ml; HRP-Green Solution A, 0.7 ml; Nuclear Blue Solution, 4 ml; Mounting Solution (alcoholic), 1 ml		10

<sup>\*</sup> Using 10 µl probe solution per test. C E IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more info<u>rmatic</u>



# **Zyto***Dot* ® **Probes for Chromosome Enumeration**




### **Background**

The ZytoDot® Chromosome Enumeration Probes are designed for identification and enumeration of human chromosomes in interphase cells and as an adjunct to standard karyotyping in metaphases. These probes will produce sharp, bright signals specific for each individual chromosome.

## **Probe Description**

For most chromosomes, direct labeled ZytoDot® CEN™ Probes hybridizing to highly repetitive human satellite DNA sequences mainly located at the centromeric regions of chromosomes are applicable. As several chromosomes share the same repetitive sequences resulting in cross-hybridization signals, they cannot be differentiated by centromere specific probes. Instead these chromosomes can be identified by direct labeled ZytoDot® SPEC™ Probes hybridizing in close proximity to the respective satellite DNA sequences or to other chromosome specific loci.

The ZytoDot ® SPEC 1p12 Probe is designed to hybridize in close proximity of centromere 1 at 1p12 harboring the WARS2 gene. Since chromosomes 1, 5, and 19 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.




SPEC 1p12 Probe map (not to scale).

The ZytoDot ® SPEC 2q11 Probe is specific for the AFF3 (AF4/FMR2 family, member 3) gene region in 2q11.2. Due to cross-hybridizations of chromosome 2 alpha satellites to other centromeric regions, probes specific for 2q11 are frequently used for chromosome 2 copy number detection.




SPEC 2q11 Probe map (not to scale).

The ZytoDot® SPEC 13q12 Probe is designed to hybridize in close proximity of centromere 13 at 13q12.11. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.



SPEC 13q12 Probe map (not to scale).

The Zyto Dot ® SPEC 21q22 Probe hybridizes to the so-called Down Syndrome Critical Region on 21q22.13-q22.2 commonly duplicated in cases with partial trisomy 21. Since chromosomes 13 and 21 share the same repetitive sequences, they cannot be differentiated by probes detecting centromere specific repeats.




SPEC 21q22 Probe map (not to scale).


#### **Results**

In a normal interphase nucleus, two signals are expected using Chromosome Enumeration Probes specific for autosomes. Using chromosome Y specific probes will result in normal male cells in one signal and in normal female cells in no signal. Using chromosome X specific probes will result in normal male cells in one signal and in normal female cells in one signal and in normal female cells in two signals per nucleus. Other signal patterns indicate numerical aberrations of the respective chromosome.






Normal nuclei each with two CEN 12 signals.



CEN X/Y Probe hybridized on normal male interphase cells as indicated by one red (chromosome X) and one green (chromosome Y) signal per nucleus.



CEN X/Y Probe hybridized on normal female interphase cells as indicated by two red (chromosome X) signals per nucleus.

		Tests* (Volume)
1p12	Digoxigenin	40 (400 µl)
2q11.2	Digoxigenin	40 (400 µl)
3p11-q11.1	Digoxigenin	40 (400 µl)
6p11.1-q11.1	Digoxigenin	40 (400 µl)
7q11.1	Digoxigenin	40 (400 µl)
8p11.1-q11.1	Digoxigenin	40 (400 µl)
12p11.1-q11	Digoxigenin	40 (400 µl)
13q12.11	Digoxigenin	40 (400 µl)
17p11.1-q11.1	Digoxigenin	40 (400 µl)
21q22.13-q22.2	Digoxigenin	40 (400 µl)
Xp11.1-q11.1	Digoxigenin	40 (400 µl)
Yq12	Digoxigenin	40 (400 µl)
.1-q11.1/Yp11.1-q11.1	DNP/Digoxigenin	40 (400 µl)
		40
4 ml; Mouse-anti-DIG, 4 ml; c), 4 ml		
		40
ix, 4 ml; HRP/AP-Polymer-Mix, 4 ml;		
c	2q11.2 3p11-q11.1 6p11.1-q11.1 7q11.1 8p11.1-q11.1 12p11.1-q11 13q12.11 17p11.1-q11.1 21q22.13-q22.2 Xp11.1-q11.1 Yq12 .1-q11.1/Yp11.1-q11.1	2q11.2 Digoxigenin 3p11-q11.1 Digoxigenin 6p11.1-q11.1 Digoxigenin 7q11.1 Digoxigenin 8p11.1-q11.1 Digoxigenin 12p11.1-q11 Digoxigenin 13q12.11 Digoxigenin 17p11.1-q11.1 Digoxigenin 21q22.13-q22.2 Digoxigenin Xp11.1-q11.1 Digoxigenin Yq12 Digoxigenin Yq12 Digoxigenin 1-q11.1/Yp11.1-q11.1 DNP/Digoxigenin 0.1-q11.1/Yp11.1-q11.1 DNP/Digoxigenin

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.





## **ZytoDot® Kits**

For the detection of Digoxigenin-labeled ZytoDot® Probes

Prod. No.	Product	Tests
C-3005-10	Zyto Dot CISH Polymer Detection Kit CE IVD Incl. Blocking Solution, 1 ml; Mouse-anti-DIG, 1 ml; Anti-Mouse-HRP-Polymer, 1 ml; DAB Solution A, 0.1 ml; DAB Solution B, 2 ml; Mayer's Hematoxylin Solution, 4 ml; Mounting Solution (alcoholic), 1 ml	10
C-3005-40	Zyto Dot CISH Polymer Detection Kit CE IVD Incl. Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alkoholic), 4 ml	40
C-3018-10	Zyto Dot CISH Implementation Kit C E IVD  Ind. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; PBS/Tween, good for 1000 ml; Blocking Solution, 1 ml; Mouse-anti-DIG, 1 ml; Anti-Mouse-HRP-Polymer, 1 ml; DAB Solution B, 2 ml; Mayer's Hematoxylin Solution, 4 ml; Mounting Solution (akoholic), 1 ml	10
C-3018-40	Zyto Dot CISH Implementation Kit C E IVD Incl. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 500 ml; PBS/Tween, good for 2000 ml; Blocking Solution, 4 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Moyer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

## **ZytoDot® 2C Kits**

For the detection of Digoxigenin/Dinitrophenyl-labeled ZytoDot® 2C Probes

		MANDS ON !
Prod. No.	Product	Tests
C-3028-40	Zyto Dot 2C CISH Polymer Detection Kit C TVD  Incl. 20x Wash Buffer 1BS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40
C-3044-10	Zyto Dot 2C CISH Implementation Kit CE IVD  Incl. Heat Pretreatment Solution EDTA, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 150 ml; 20x Wash Buffer TBS, 50 ml; Anti-DIG/DNP-Mix, 1 ml; HRP/AP-Polymer-Mix, 1 ml; AP-Red Solution A, 0.1 ml; AP-Red Solution B, 4 ml; Muclear Blue Solution B, 4 ml; Muclear Blue Solution (alcoholic), 1 ml	10
C-3044-40	ZytoDot 2C CISH Implementation Kit CE IVD Ind. Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4ml; Wash Buffer SSC, 500 ml; 20x Wash Buffer TBS, 2x 50 ml; Anti-DIG/DNP-Mix, 4 ml; HRP/AP-Polymer-Mix, 4 ml; AP-Red Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

## **ZytoDot® Pretreatment Reagents**

Prod. No.	Product
C-3004-40	Zyto Dot Pretreatment Kit C   IVD Incl. Pepsin Solution, 4 ml; Heat Pretreatment Solution EDTA, 500 ml
ES-0001-4	Pepsin Solution, 4 ml CE IVD
ES-0001-8	Pepsin Solution Set, 2x 4 ml C € IVD
ES-0001-50	Pepsin Solution, 50 ml C € IVD
ES-0001-1000	Pepsin Solution, 1000 ml C€ IVD
PT-0002-500	Heat Pretreatment Solution EDTA, 500 ml C € IVD

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.





## **ZytoDot® Wash Buffers & Ancillary Reagents**


Prod. No.         Product           AB-0001-4         Mouse-anti-IDIG, a on IC ∈ IVD           AB-0001-30         Mouse-anti-IDIG, so on IC ∈ IVD           AB-0002-4         Anti-Mouse-HRP-Polymer, 4 mi C ∈ IVD           AB-0013-4         HRP/AP-Polymer-Mix, 4 mi C ∈ IVD           BS-0001-4         Blocking Solution, 4 mi C ∈ IVD           C-3011-40         Zyto Dot Wash Buffer Sct ∈ € IVD           Ind. Wesh Buffer Sct, 500 mi, PSV, News, goad for 2000 mi           C-3015-100         Das Solution Sct ∈ € IVD           Ind. AB Solution Sct ∈ IVD         Ind. AB Solution Sct ∈ IVD           Ind. AB Solution A, 0 and, PSV Red Solution S, 15 mil good for 15 mil AP-Red Solution         Zyto Dot AP-Red Solution A, 0 and AP-Red Solution S, 0 and (PSV)           C-3038-100         Zyto Dot AP-Red Solution A, 0 and AP-Red Solution B, 15 mil good for 15 mil AP-Red Solution           C-3039-100         Zyto Dot HRP-Green Solution A, 0 and AP-Red Solution B, 0 and AP-Red So	_	, , ,
AB-0001-30 Mouse-anti-DIG, so m (	Prod. No.	Product
AB-0002-4 Anti-Mouse-HRP-Polymer, 4 ml C	AB-0001-4	Mouse-anti-DIG, 4 ml C € IVD
AB-0013-4 HRP/AP-Polymer-Mix, 4 ml C € □VD  BS-0001-4 Blocking Solution, 4 ml C € □VD  C-3011-40 Zyto Dat Wash Buffer Set C € □VD  Incl. Mas Solution Set C € □VD  Incl. Mas Solution A, 0.3 ml; Dats Solution B, 10 ml; good for 10 ml DAB Solution  C-3038-100 Zyto Dat AP-Red Solution A, 0.4 ml; Park Pard Solution B, 15 ml; good for 15 ml AP-Red Solution  C-3039-100 Zyto Dat HRP-Green Solution Set C € □VD  Incl. MRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; good for 15 ml HRP-Green Solution  CS-0001-20 Mayer's Hematoxylin Solution, 20 ml C € □VD  E-4005-10 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € □VD  WB-0001-500 Wash Buffer SSC, 500 ml C € □VD  WB-0001-500 Wash Buffer SSC, 500 ml C € □VD  WB-0004-1000 PBS/Tween, good for 1000 ml C € □VD  WB-0004-1000 PBS/Tween, good for 1000 ml C € □VD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € □VD	AB-0001-30	Mouse-anti-DIG, 30 ml C€ IVD
AB-0014-4 Anti-DIG/DNP-Mix, 4 ml C € IVD  BS-0001-4 Blocking Solution, 4 ml C € IVD  Incl. Worth Buffer Set C € IVD  Incl. Worth Buffer Set, 500 ml; PSS/Tween, good for 2000 ml  C-3015-100 DAB Solution Set C € IVD  Incl. AP-Red Solution Set C € IVD  Incl. MP-Red Solution Set C € IVD  Incl. MP-Red Solution Set C € IVD  Incl. MP-Green Solution Set C € IVD  Incl. MR-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; good for 15 ml AP-Red Solution  CS-0001-20 Mayer's Hematoxylin Solution, 20 ml C € IVD  E-4005-50 Fixogum, Rubber Cement, 50 g  E-4007-2 ERBB2 Control Slide Set, 2 pc. C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0005-50 20x Wash Buffer IBS, 50 ml C € IVD	AB-0002-4	Anti-Mouse-HRP-Polymer, 4 ml C € IVD
BS-0001-4   Blocking Solution, 4 ml C	AB-0013-4	HRP/AP-Polymer-Mix, 4 ml C E IVD
C-3011-40	AB-0014-4	Anti-DIG/DNP-Mix, 4 ml C€ IVD
Incl. Wash Buffer SSC, 500 mt; PBS/Tween, good for 2000 mt	BS-0001-4	Blocking Solution, 4 ml C € IVD
Incl. DAB Solution A, 0.3 mt; DAB Solution B, 10 mt; good for 10 mt DAB Solution  C-3038-100 Zyto Dat AP-Red Solution Set C € IVD Incl. AP-Red Solution A, 0.4 mt; AP-Red Solution B, 15 mt; good for 15 mt AP-Red Solution  C-3039-100 Zyto Dat HRP-Green Solution Set C € IVD Incl. HRP-Green Solution A, 0.8 mt; HRP-Green Solution B, 15 mt; good for 15 mt HRP-Green Solution  CS-0001-20 Mayer's Hematoxylin Solution, 20 mt C € IVD  CS-0002-20 Nuclear Blue Solution, 20 mt C € IVD  E-4005-50 Fixogum, Rubber Cement, 50 g  E-4005-125 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € IVD  E-4009-2 EGFR Control Slide Set, 2 pcs. C € IVD  WB-0001-500 Wash Buffer SSC, 500 mt C € IVD  WB-0004-1000 PBS/Tween, good for 1000 mt C € IVD  WB-0005-50 20x Wash Buffer TBS, 50 mt C € IVD	C-3011-40	<i>,</i>
Incl. AP-Red Solution A, 0.4 ml; AP-Red Solution B, 15 ml; good for 15 ml AP-Red Solution  Zyto Dot HRP-Green Solution Set C € □VD  Incl. HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; good for 15 ml HRP-Green Solution  CS-0001-20 Mayer's Hematoxylin Solution, 20 ml C € □VD  CS-0002-20 Nuclear Blue Solution, 20 ml C € □VD  E-4005-50 Fixogum, Rubber Cement, 50 g  E-4005-125 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € □VD  E-4009-2 EGFR Control Slide Set, 2 pcs. C € □VD  WB-0001-500 Wash Buffer SSC, 500 ml C € □VD  WB-0001-500 Vash Buffer TBS, 50 ml C € □VD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € □VD	C-3015-100	
CS-0001-20 Mayer's Hematoxylin Solution, 20 ml C € IVD  CS-0002-20 Nuclear Blue Solution, 20 ml C € IVD  E-4005-50 Fixogum, Rubber Cement, 50 g  E-4005-125 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € IVD	C-3038-100	
CS-0002-20       Nuclear Blue Solution, 20 ml C € IVD         E-4005-50       Fixogum, Rubber Cement, 50 g         E-4005-125       Fixogum, Rubber Cement, 125 g         E-4007-2       ERBB2 Control Slide Set, 2 pcs. C € IVD         E-4009-2       EGFR Control Slide Set, 2 pcs. C € IVD         WB-0001-500       Wash Buffer SSC, 500 ml C € IVD         WB-0004-1000       PBS/Tween, good for 1000 ml C € IVD         WB-0005-50       20x Wash Buffer TBS, 50 ml C € IVD	C-3039-100	·
E-4005-50 Fixogum, Rubber Cement, 50 g  E-4005-125 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € IVD  E-4009-2 EGFR Control Slide Set, 2 pcs. C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € IVD	CS-0001-20	Mayer's Hematoxylin Solution, 20 ml C € IVD
E-4005-125 Fixogum, Rubber Cement, 125 g  E-4007-2 ERBB2 Control Slide Set, 2 pcs. C ∈ IVD  E-4009-2 EGFR Control Slide Set, 2 pcs. C ∈ IVD  WB-0001-500 Wash Buffer SSC, 500 ml C ∈ IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C ∈ IVD  WB-0005-50 20x Wash Buffer TBS, 50 ml C ∈ IVD	CS-0002-20	Nuclear Blue Solution, 20 ml C € IVD
E-4007-2 ERBB2 Control Slide Set, 2 pcs. C € IVD  E-4009-2 EGFR Control Slide Set, 2 pcs. C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € IVD	E-4005-50	Fixogum, Rubber Cement, 50 g
E-4009-2 EGFR Control Slide Set, 2 pcs. C € IVD  WB-0001-500 Wash Buffer SSC, 500 ml C € IVD  WB-0004-1000 PBS/Tween, good for 1000 ml C € IVD  WB-0005-50 20x Wash Buffer TBS, 50 ml C € IVD	E-4005-125	Fixogum, Rubber Cement, 125 g
WB-0001-500       Wash Buffer SSC, 500 ml C € IVD         WB-0004-1000       PBS/Tween, good for 1000 ml C € IVD         WB-0005-50       20x Wash Buffer TBS, 50 ml C € IVD	E-4007-2	ERBB2 Control Slide Set, 2 pcs. C € IVD
WB-0004-1000       PBS/Tween, good for 1000 ml C ∈ IVD         WB-0005-50       20x Wash Buffer TBS, 50 ml C ∈ IVD	E-4009-2	EGFR Control Slide Set, 2 pcs. C € IVD
WB-0005-50 20x Wash Buffer TBS, 50 ml C€ IVD	WB-0001-500	Wash Buffer SSC, 500 ml C€ IVD
·	WB-0004-1000	PBS/Tween, good for 1000 ml C
WB-0009-500 Clear-it™ Stringency Buffer, 500 ml C € IVD	WB-0005-50	20x Wash Buffer TBS, 50 ml C€ IVD
	WB-0009-500	Clear-it™ Stringency Buffer, 500 ml C € IVD



ZytoFast® Products for CISH analysis	
Troducts for Clarr undrysis	Page
AA .I . I	001
Method Introduction - ZytoFast®	221
- ZytoFast® PLUS	222
Probes, sorted by Virus Index	223
sorted by mRNA Index	223
sorted by Indication	224
Product Data Sheets	225 ff.
Accessories	233 f.
7 10000001100	200 1.



## Achieving Chromogenic in situ Hybridization Results in just 4 Hours!



### Introduction

The ZytoFast ® products are designed for outstandingly fast detection and discrimination of human pathogen viruses, e.g. HPV, EBV, CMV, and the determination of lymphocyte clonality by detecting Ig- $\kappa$  and Ig- $\lambda$  light chain RNA by Chromogenic *in situ* Hybridization (CISH) in formalin-fixed, paraffin-embedded tissue sections and cell samples.

### ZytoFast®: Outstandingly fast CISH

Optimized protocols and faster tissue penetration due to short oligonucleotide probes of the ZytoFast® system, make the ZytoFast® CISH procedure outstandingly fast.


Single color results can be achieved within just 4 hours, hands-on time is about 2 hours!

## **High Sensitivity and Specificity**

All ZytoFast® probes are tagged using the unique ZytoFast® HighTag System providing improved signal intensity! High specificity without risk of cross-hybridizations is obtained due to optimized oligonucleotide probes.

### **Advantages of CISH**

- Simultaneous observation of tissue morphology and CISH signals
- No risk of false positives due to mispriming or contamination as with PCR
- Easy method comparable to IHC
- No costly equipment needed
- Ability to test archival specimens
- High sensitivity and specificity




The ZytoFast® system uses oligonucleotide probes tagged with Biotin or Digoxigenin ① which are detected using enzyme-conjugated antibodies or streptavidin targeting the tags ②. The enzymatic reaction of chromogenic substrates ③, e.g. BCIP/NBT or AEC, leads to the formation of strong color precipitates that can be visualized by light microscopy.

### **Protocol Overview**





## **ZytoFast** ® PLUS for Increased Sensitivity!



### Introduction


The ZytoFast® PLUS products are designed for outstandingly fast and sensitive detection and discrimination of human pathogen viruses, e.g. HPV, EBV, CMV, and the determination of lymphocyte clonality by detecting Ig- $\kappa$  and Ig- $\lambda$  light chain RNA by Chromogenic in situ Hybridization (CISH) in formalin-fixed, paraffin-embedded tissue sections and cell samples. The signal intensity of ZytoFast® probes is increased even more when using the ZytoFast® PLUS Implementation Kits.

## ZytoFast® PLUS - Outstandingly fast and sensitive CISH

Depending on the time required for dewaxing and pretreatment of tissue sections, ZytoFast® PLUS protocols can be performed within approx. 4 hours! Thus, due to optimized protocols, the ZytoFast® PLUS method takes only slightly more time compared to ZytoFast® protocols while being much more sensitive!

## ZytoFast® PLUS - Flexibility that meets your Needs

Several ZytoFast® PLUS CISH Implementation Kits using different enzyme/substrate combinations can be combined with any separately available Digoxigenin-labeled Zyto Fast® probe to meet your preferences concerning the detection chemistry, counterstaining, and embedding. Each ZytoFast® PLUS CISH Implementation Kit includes a detailed protocol, all necessary reagents as well as positive and negative control probes for versatile use in DNA as well as RNA in situ hybridizations.



The ZytoFast® PLUS system uses Digoxigenin-labeled probes (1) which are detected using primary antibodies 2). These antibodies are detected by polymerized enzymeconjugated secondary antibodies 3. The enzymatic reaction of chromogenic substrates (4), e.g. NBT/BCIP or DAB, leads to the formation of strong color precipitates that can be visualized by light microscopy.

### **Protocol Overview**



& Hybridize



## **Virus Index**

Virus Index	Product Name	Label	Product No.	Quantity	Page
HPV	Zyto Fast HPV type 6/11 Probe  Zyto Fast HPV type 6/11 Probe C € IVD  Zyto Fast HPV type 16/18 Probe C € IVD  Zyto Fast HPV type 16/18 Probe C € IVD  Zyto Fast HPV type 31/33 Probe  Zyto Fast HPV type 31/33 Probe C € IVD  Zyto Fast HPV High-Risk (HR) Types Probe C € IVD  (specific for HPV type 16/18/31/33/35/39/45/51/52/56/58/59/66/68/82)  Zyto Fast HPV Screening Probe C € IVD  (specific for HPV type 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/82)	Biotin Digoxigenin Biotin Digoxigenin Biotin Digoxigenin Digoxigenin Digoxigenin	T-1032-400 T-1055-400 T-1035-400 T-1056-400 T-1038-400 T-1057-400 T-1140-400	400 μl 400 μl 400 μl 400 μl 400 μl 400 μl 400 μl	225 f. 225 f. 225 f. 225 f. 225 f. 225 f. 225 f. 225 f.
EBV	Zyto <i>Fast</i> EBV Probe Zyto <i>Fast</i> EBV Probe C€ IVD	Biotin	T-1014-400	400 μl	227 f.
(a.k.a. HHV-4)		Digoxigenin	T-1114-400	400 μl	227 f.
CMV	Zyto <i>Fast</i> CMV Probe	Biotin	T-1013-400	400 μl	229 f.
(a.k.a. HHV-5)	Zyto <i>Fast</i> CMV Probe	Digoxigenin	T-1113-400	400 μl	229 f.

## **mRNA** Index

mRNA Index	Product Name	Label	Product No.	Quantity	Page
lg-kappa	Zyto <i>Fast</i> human lg-kappa Probe  Zyto <i>Fast</i> human lg-kappa Probe C	Biotin Digoxigenin Digoxigenin/Biotin Digoxigenin/Biotin Digoxigenin/Biotin	T-1015-400 T-1115-400 T-1017-400 T-1005-40 T-1105-40	400 µl 400 µl 400 µl 40 Tests 40 Tests	231 f. 231 f. 231 f. 231 f. 231 f.
Ig-lambda	Zyto <i>Fast</i> human lg-lambda Probe  Zyto <i>Fast</i> human lg-lambda Probe C €	Biotin Digoxigenin Digoxigenin/Biotin Digoxigenin/Biotin Digoxigenin/Biotin	T-1016-400 T-1116-400 T-1017-400 T-1005-40 T-1105-40	400 µl 400 µl 400 µl 40 Tests 40 Tests	231 f. 231 f. 231 f. 231 f. 231 f.

# ZytoFast Products for CISH analysis



# **Probes Sorted by Indication**

Indication	Product Name	Label	Product No.	Quantity	Page
Solid Tumors					
Cervical Cancer	ZytoFast HPV type 6/11 Probe	Biotin	T-1032-400	400 µl	225 f.
	Zyto Fast HPV type 6/11 Probe C€ IVD	Digoxigenin	T-1055-400	400 µl	225 f.
	Zyto Fast HPV type 16/18 Probe	Biotin	T-1035-400	400 µl	225 f.
	Zyto Fast HPV type 16/18 Probe C€ IVD	Digoxigenin	T-1056-400	400 µl	225 f.
	Zyto Fast HPV type 31/33 Probe	Biotin	T-1038-400	400 µl	225 f.
	Zyto Fast HPV type 31/33 Probe C€ IVD	Digoxigenin	T-1057-400	400 µl	225 f.
	Zyto Fast HPV High-Risk (HR) Types Probe C € IVD	Digoxigenin	T-1140-400	400 µl	225 f.
	(specific for HPV type 16/18/31/33/35/39/45/51/52/56/58/59/66/68/82)				
	Zyto Fast HPV Screening Probe C € IVD	Digoxigenin	T-1144-400	400 µl	225 f.
	(specific for HPV type 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/82)				
Hematology					
Lymphoma	Zyto Fast EBV Probe	Biotin	T-1014-400	400 µl	227 f.
	Zyto Fast EBV Probe C € IVD	Digoxigenin	T-1114-400	ابر 400	227 f.
	Zyto <i>Fast</i> human Ig-kappa Probe	Biotin	T-1015-400	ابر 400	231 f.
	Zyto Fast human Ig-kappa Probe C€ IVD	Digoxigenin	T-1115-400	ابر 400	231 f.
	Zyto Fast human Ig-lambda Probe	Biotin	T-1016-400	ابر 400	231 f.
	Zyto Fast human Ig-lambda Probe C€ IVD	Digoxigenin	T-1116-400	400 µl	231 f.
	Zyto <i>Fast</i> human Ig-kappa∕Ig-lambda Probe C€ IVD	Digoxigenin/Biotin	T-1017-400	400 µl	231 f.
	Zyto <i>Fast</i> human Ig-kappa∕Ig-lambda CISH Kit C€ IVD	Digoxigenin/Biotin	T-1005-40	40 Tests	231 f.
	Zyto <i>Fast</i> human lg-kappa/lg-lambda Permanent CISH Kit C € IVD	Digoxigenin/Biotin	T-1105-40	40 Tests	231 f.



## **ZytoFast** ® HPV-CISH System



### **Background**

The ZytoFast® HPV-CISH System is designed for the detection and discrimination of human papilloma virus (HPV) DNA in paraffin-embedded tissue sections or cell samples.

At least 50 percent of sexually active men and women acquire some form of genital HPV infection at some point in their lives. Most of the approx. 30 identified genital HPV types, predominantly types 6 and 11, are called "low-risk" types, and may cause mild Pap test abnormalities or genital warts.


Until now, approximately 10-15 HPV types are associated with lesions that can progress to cancer. Among those are the HPV types 16/18/31/33/35/39/45/ 51/52/56/58/59/66/68/82.

These cancer-associated HPV types are designated as high-risk HPV (hr-HPV) types. The infection with the HPV hr-types can lead to development of cancer of the cervix, vulva, vagina, anus, or penis. The majority of malignant cervical carcinomas (approx. 70%) occur as a result of infections with HPV types 16 or 18.

References
Cothran MM & White JP (2002) Health Care Women Int 23: 306-19.
Cubie HA & Norval M (1988) J Virol Methods 20: 239-49.
Faulkner-Jones BE, et al. (1993) J Virol Methods 41: 277-96.
Francis IM, et al. (2013) Sultan Qaboos Univ Med J 13: 527-33.
Grundmeier N, et al. (2011) Dermatology 223: 293-300.
Kaspersen MD, et al. (2011) PLoS One 6: e18095.
Mirasoli M, et al. (2009) Anal Bioanal Chem 394: 981-7.
Montag M, et al. (2011) Arch Gynecol Obstet 284: 999-1005.
Poljak M & Kocjan BJ (2010) Expert Rev Anti Infect Ther 8: 1139-62.
Reinholz M, et al. (2013) Arch Dermatol Res 305: 723-32.
Walboomers JMM, et al. (1999) J Pathol 189: 12-9.

### **Probe Description**


ZytoFast ® HPV specific probes are directed against DNA sequences which encode the HPV proteins E6, E7 and/or L1. The probes consist of HPV-type-specific oligonucleotides, Biotin or Digoxigenin labeled by using the unique ZytoFast® HighTag System providing improved signal intensity. In addition to the detection of HPV at the DNA level, HPV probes will also allow detection of E6, E7, and/or L1 RNAs, which are expressed during some stages of infection.




Schematic representation of the HPV genome with E and L'open reading frames. Genomic regions targeted by ZytoFast® HPV specific oligonucleotides are indicated in blue.

### Results

A positive reactivity for HPV DNA in epithelial cells is indicated by a distinctly stained nucleus. Due to the detection of HPV DNA as well as E6, E7, and/or L1 RNAs, depending on the infection stage, cytoplasmic staining might be observed additionally. Depending on the detection chemistry that is used, colored precipitates, which can be clearly distinguished from the background, will be dark violetblue when using NBT/BCIP as substrate, dark brown when using DAB, or strong red when using Permanent Red.



HPV infected cervix tissue hybridized with the ZytoFast® HPV type 6/11 Probe, detected with the ZytoFast® PLUS CISH Implementation Kit AP-Permanent Red.



HPV infected cervix tissue hybridized with the ZytoFast® HPV High-Risk (HR) Types Probe, detected with the ZytoFast® PLUS CISH Implementation Kit HRP-DAB.



## **ZytoFast® HPV Probes**

## Biotin-labeled

Prod. No.	Product	Tests* (Volume)
T-1032-400	Zyto <i>Fast</i> HPV type 6/11 Probe	40 (400 µl)
T-1035-400	ZytoFast HPV type 16/18 Probe	40 (400 µl)
T-1038-400	ZytoFast HPV type 31/33 Probe	40 (400 µl)
Related Pro	ducts	
T-1070-40	Zyto Fast CISH Implementation Kit AP-NBT/BCIP Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; AP-Streptavidin, 4 ml; NBT/BCIP Solution, 4 ml	40

## **ZytoFast® HPV-Probes**

## Digoxigenin-labeled

Product	Tests* (Volume)
	lesis (volulie)
Zyto Fast HPV type 6/11 Probe C E IVD	40 (400 µl)
Zyto Fast HPV type 16/18 Probe C€ IVD	40 (400 µl)
Zyto Fast HPV type 31/33 Probe C € IVD	40 (400 µl)
Zyto Fast HPV High-Risk (HR) Types Probe (specific for HPV type 16/18/31/33/35/39/45/51/52/56/58/59/66/68/82) C € IVD	40 (400 µl)
Zyto Fast HPV Screening Probe (specific for HPV type 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/82) C € IVD	40 (400 µl)
ucts	
Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP C€ IVD	40
Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDIA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; NBT/BCIP Solution, 4 ml; Nuclear Red Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	
Zyto Fast PLUS CISH Implementation Kit HRP-DAB C € IVD	40
Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Mouse-anti-D1G, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	
Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C € IVD	40
Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Reat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	
	Zyto Fast HPV type 16/18 Probe C € IVD  Zyto Fast HPV type 31/33 Probe C € IVD  Zyto Fast HPV High-Risk (HR) Types Probe (specific for HPV type 16/18/31/33/35/39/45/51/52/56/58/59/66/68/82) C € IVD  Zyto Fast HPV Screening Probe (specific for HPV type 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/82) C € IVD  Iucts  Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP C € IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; PNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; NBT/BCIP Solution, 4 ml; Nuclear Red Solution, 20 ml; Mounting Solution (alcoholic), 4 ml  Zyto Fast PLUS CISH Implementation Kit HRP-DAB C € IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml  Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C € IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution, 20 ml; Mounting Solution (alcoholic), 4 ml  Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C € IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; RNA (-) Control Probe

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## Zyto Fast ® EBV-CISH System



### **Background**

The ZytoFast® EBV-CISH System is designed for the detection of Epstein-Barr virus (EBV) RNA in paraffin-embedded tissue sections or cell samples.


EBV (a.k.a. human herpesvirus-4, HHV-4) is a member of the gamma-herpesvirus group and one of the most common viruses in humans.

Transmission of EBV requires close, intimate contact with a person excreting the virus in its saliva. EBV has two major target tissues in vivo, B lymphocytes and squamous pharyngeal epithelium. Infection of B lymphocytes with EBV results in persistant latent infection, immortalization of the cells, and perpetual proliferation. EBV, the first virus to be identified as an oncovirus, is the etiological agent of infectious mononucleosis and has been implicated in the pathogenesis of an increasing number of human malignancies such as Burkitt's lymphoma, nasopharyngeal carcinoma, and polyclonal lymphomas in immunocompromised individuals. CISH-based diagnosis of EBV infection has the advantage over other methods in that it permits unequivocal localization of EBV genomes in cells and thereby obviates the risk of false positive results due to laboratory or clinical contamination.

References
Agaimy A & Wünsch PH (2006) Pathol Res Pract 202: 541-8. Fuchs S, et al. (2012) J Immunol 88: 1523-33.
Gaiser T, et al. (2012) Diagn Pathol 7: 38.
Greifenegger N, et al. (1998) J Virol 72: 9323-8.
Khan G, et al. (1992) J Clin Pathol 45: 616-20.
Kim DN, et al. (2013) J Gen Virol 94: 497-506.
Murphy JK, et al. (1990) J Clin Pathol 43: 220-3. Rosa MD, et al. (1981) Mol Cell Biol 1: 785-96 Sides MD, et al. (2013) Virol J 10: 152. Thorley-Lawson DA (2001) Nat Rev Immunol 1: 75-82.

### **Probe Description**


The ZytoFast® EBV Probe is directed against EBER-1 and EBER-2 RNA sequences that were found to be transcribed in every latently infected cell. Due to the large number (up to 107) of copies per cell, these RNAs are the most abundant transcripts in latently EBV-infected cells. The probe consists of EBV-specific oligonucleotides, Biotin or Digoxigenin labeled by using the unique ZytoFast® High Tag System providing improved signal intensity.




Schematic representation of the EBV genome with the EBER-1 and EBER-2 encoding region indicated in blue. U1-U5 indicate unique nucleotide sequences, hatched boxes represent terminal and internal repeats.

### Results

A positive reactivity for Epstein-Barr-Virus (EBV) EBER RNA in the target cells is indicated by a distinctly stained nucleus. Depending on the detection chemistry that is used, colored precipitates, which can be clearly distinguished from the background, will be dark violet-blue when using NBT/ BCIP as substrate, dark brown when using DAB, or strong red when using Permanent Red.



CISH analysis of paraffin-embedded tonsil tissue using the ZytoFast® EBV Probe, detected with ZytoFast® CISH Implementation Kit AP-NBT/BCIP.



EBV infected tonsil tissue hybridized with ZytoFast® EBV Probe, detected with ZytoFast® PLUS CISH Implementation Kit HRP-DAB.



## **ZytoFast** ® **EBV-CISH** Probes

## Biotin-labeled

Prod. No.	Product	Tests* (Volume)
T-1014-400	Zyto Fast EBV Probe	40 (400 µl)
Related Proc	lucts	
T-1070-40	ZytoFast CISH Implementation Kit AP-NBT/BCIP Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; Pass rRNA (+) Control Probe, 0.1 ml; Passin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; AP-Streptavidin, 4 ml; NBT/BCIP Solution, 4 ml	40

## **ZytoFast** ® EBV-CISH Probes

## Digoxigenin-labeled

Prod. No.	Product	Tests* (Volume)
T-1114-400	Zyto Fast EBV Probe C€ IVD	40 (400 µl)
Related Prod	lucts	
T-1061-40	Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP CE IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml	40
T-1063-40	Zyto Fast PLUS CISH Implementation Kit HRP-DAB CE IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; Nuclear Blue Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40
T-1151-40	Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C [VD] Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; Anti-Rabbit-AP-Polymer, 4 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.



## **ZytoFast** ® CMV-CISH System

### **Background**

The ZytoFast ® CMV-CISH System is designed for the detection of cytomegalovirus (CMV) DNA in paraffin-embedded tissue sections or cell samples. CMV (a.k.a. human herpesvirus-5, HHV-5) is a member of the beta-herpesvirus group and may be found in 40-100% of people. CMV can be transmitted sexually as well as via breast milk, transplanted organs, and rarely from blood transfusions.

Following primary CMV infection in the normal host, the virus remains in a latent state and can be found in multiple body sites as it is, unlike other herpesviruses, not restricted to certain body areas. Among immunosuppressed patients, such as recipients of solid organ or haematopoietic stem cell allografts, CMV infections are common causes of morbidity and mortality.

In histology, the hallmark of CMV infection is the finding of intranuclear inclusions consistent with the virus. CISH-based diagnosis of CMV infection has the advantage over other methods in that it permits unequivocal localization of CMV genomes in cells and thereby obviates the risk of false positive results due to laboratory or clinical contamination.

Cobbs CS (2002) Cancer Res 62: 3347-50. Chen HP, et al. (2012) J Clin Virol 54: 240-4. Greenaway PJ & Wilkinson GWG (1987) Virus Res 7: 17-31. Spector SA (1990) Semin Hematol 27 (2 Suppl 1): 11-6; 28-9. Wu TC, et al. (1992) Am J Pathol 141: 1247-54.

### **Probe Description**


The ZytoFast® CMV Probe is directed against the sequence of the \$2.7 gene, the most abundantly transcribed early CMV gene. The probe consists of CMVspecific oligonucleotides, Biotin or Digoxigenin labeled by using the unique ZytoFast ® HighTag System providing improved signal intensity. In addition to the detection of CMV at the DNA level, the CMV Probe will also allow detection of the β2.7 RNA, which is expressed during all stages of infection.



Schematic representation of the CMV genome with the β2.7 encoding region indicated in blue. UL and US indicate unique nucleotide sequences, hatched boxes represent terminal and internal repeats.

### **Results**

Due to the detection of CMV DNA as well as of the abundantly transcribed β2.7 RNA, a positive reactivity for cytomegalovirus (CMV) in the target cells is indicated by a cytoplasmic and/or nuclear staining pattern. Depending on the detection chemistry that is used, colored precipitates, which can be clearly distinguished from the background, will be dark violet-blue when using NBT/BCIP as substrate, dark brown when using DAB, or strong red when using Permanent Red.



CISH analysis of paraffin-embedded adrenal gland tissue using the ZytoFast® CMV Probe, detected with ZytoFast® PLUS CISH Implementation Kit AP-NBT/BCIP.



## **ZytoFast** ® CMV-CISH Probes

## Biotin-labeled

Prod. No.	Product	Tests* (Volume)
T-1013-400	Zyto Fast CMV Probe	40 (400 µl)
Related Pro	ducts	
T-1070-40	Zyto <i>Fast</i> CISH Implementation Kit AP-NBT/BCIP	40
	Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28s rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; AP-Streetavidin. 4 ml; NBT/BCIP Solution. 4 ml	

## **ZytoFast** ® CMV-CISH Probes

## Digoxigenin-labeled

Prod. No.	Product	Tests* (Volume)
T-1113-400	Zyto Fast CMV Probe	40 (400 µl)
Related Proc	lucts	
T-1061-40	Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP CE IVD  Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; Past rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; NBT/BCIP Solution, 4ml; Nuclear Red Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40
T-1063-40	Zyto Fast PLUS CISH Implementation Kit HRP-DAB C E IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; D	40
T-1151-40	Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C   IVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 285 rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

# Products for CISH analysis

# Molecular diagnostics simplified

# Zyto Fast ® Ig-kappa/Ig-lambda-CISH System



### **Background**

The ZytoFast® Ig-kappa/Ig-lambda-CISH System is designed for the detection of Ig-kappa ( $\kappa$ ) and/or Ig-lambda ( $\lambda$ ) light chain mRNA in paraffin-embedded tissue sections or cell samples.

B-cells (a.k.a. B lymphocytes) develop from lymphoid stem cells in the bone marrow. Each clone of B-cells expresses a unique antibody molecule, composed of 2 identical heavy and 2 identical light chains, the latter either of  $\kappa$  or  $\lambda$  type. Determination of kappa-to-lambda ratio is useful to distinguish between neoplastic and reactive lymphoid proliferations. Polyclonal expression of  $\kappa$  or  $\lambda$  light chains is considered to reflect a reactive hyperplasia in contrast to the monoclonal expression in malignant lymphoma, the most common hematologic malignancy encountered in the Western world. Whereas detection of Ig- $\kappa$  and Ig- $\lambda$ by immunohistochemistry often results in excessive background staining, in situ Hybridization has the advantage of a virtually background-free signal, allowing a safe and simple analysis of the clonality of a given lymphocyte population.


Keterences Erber WN, et al. (1993) Pathology 25: 63-7. Ke L, et al. (2011) Int J Clin Exp Pathol 4: 190-6. McElroy MK, et al. (2011) Hum Pathol 42: 1813-8. McNicol AM & Farquharson MA (1997) J Pathol 182: 250-61. Pringle JH, et al. (1990) J Pathol 162: 197-207.

### **Probe Description**


ZytoFast® human Ig-kappa Probe is directed against mRNA sequences encoding ĸ light chain constant regions of human immunoglobulins.

The ZytoFast® human Ig-lambda Probe is directed against mRNA sequences encoding  $\lambda$  light chain constant regions of human immunoglobulins.


The ZytoFast® human Ig-kappa/Ig-lambda Probe is a probe mixture consisting of a Digoxigenin labeled Ig-k mRNA specific probe and a Biotin labeled Ig-λ mRNA specific probe. All probes are tagged by using the unique ZytoFast® HighTag System providing improved signal intensity.



Basic immunoglobulin structure indicating the heavy chains (black),  $\lambda$  (blue) and  $\kappa$  (red) lights chains. The light chain constant regions (C) whose encoding mRNA sequences are targeted by ZytoFast® lg-lambda and lg-kappa probes are indicated in dark blue and red respectively, the variable regions (V) in light blue and red.



CISH analysis of a paraffin-embedded tonsil tissue using the ZytoFast® human lg-kappa/lg-lambda Permanent CISH Kit.



Tonsil tissue with B-cells expressing Ig-kappa hybridized with ZytoFast® human Ig-kappa Probe, detected with ZytoFast® PLUS CISH Implementation Kit AP-Permanent Red.

### Results


A positive reactivity in the target cells is indicated by cytoplasmic staining. Depending on the detection chemistry that is used, colored precipitates, which can be clearly distinguished from the background, will be dark violet-blue when using NBT/ BCIP as substrate, strong red when using AEC, dark brown when using DAB, green when using HRP-Green, or strong red when using Permanent Red.

Using the ZytoFast® human Ig-kappa Probe, B-cells expressing antibodies with κ light chains will result in cytoplasmic staining whereas Ig-λ expressing B-cells are not stained.


Using the ZytoFast® human Ig-lambda Probe, B-cells expressing antibodies with λ light chains will result in cytoplasmic staining whereas Ig-κ expressing B-cells are not stained.

Using the ZytoFast® human Ig-kappa/ Ig-lambda CISH Kit, B-cells expressing antibodies with  $\kappa$  light chains will result in a red cytoplasmic staining and simultaneously  $Ig-\lambda$  expressing B-cells will result in a dark violet-blue cytoplasmic staining.

Using the ZytoFast® human Ig-kappa/ la-lambda Permanent CISH Kit, B-cells expressing antibodies with  $\kappa$  light chains will result in a green cytoplasmic staining and simultaneously Ig-λ expressing B-cells will result in permanent red cytoplasmic staining.



Tonsil tissue with B-cells expressing Ig-kappa hybridized with ZytoFast® human Ig-kappa Probe, detected with ZytoFast® PLUS CISH Implementation Kit HRP-DAB.



CISH analysis of a paraffin-embedded bone marrow biopsy specimen using the ZytoFast® human Ig-kappa/Ig-lambda ČISH Kit.



# **Zyto***Fast* <sup>®</sup> **Ig-kappa/Ig-lambda Probes** Biotin-labeled

Prod. No.	Product	Tests* (Volume)
T-1015-400	Zyto <i>Fast</i> human lg-kappa Probe	40 (400 µl)
T-1016-400	Zyto <i>Fast</i> human lg-lambda Probe	40 (400 μl)
Related Pro	lucts	
T-1070-40	ZytoFast CISH Implementation Kit AP-NBT/BCIP	40
	Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; AP-Streptavidin, 4 ml; NBT/BCIP Solution, 4 ml	

# **ZytoFast** <sup>®</sup> **Ig-kappa/Ig-lambda Probes** Digoxigenin-labeled


Prod. No.	Product	Tests* (Volume)
T-1115-400	Zyto <i>Fast</i> human lg-kappa Probe C€ IVD	40 (400 µl)
T-1116-400	Zyto <i>Fast</i> human lg-lambda Probe C€ IVD	40 (400 µl)
Related Pro	ducts	
T-1061-40	Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP C IVD  Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; NBT/BCIP Solution, 4ml; Nuclear Red Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40
T-1063-40	Zyto Fast PLUS CISH Implementation Kit HRP-DAB C TVD  Ind. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 285 rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Mouse-anti-DIG, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 mll	40
T-1151-40	Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C E IVD Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 285 rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer 185, 4x50 ml; Robbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

# **ZytoFast** ® **Ig-kappa/Ig-lambda Probes** Biotin/Digoxigenin-labeled

Prod. No.	Product	Tests* (Volume)
T-1017-400	Zyto <i>Fast</i> human lg-kappa/lg-lambda Probe CE IVD	40 (400 µl)
Related Proc	lucts	
T-1005-40	Zyto Fast human lg-kappa/lg-lambda CISH Kit C TVD  Ind. lg-kappa/lg-lambda Probe (Digozigenin/Biotin labeled), 0.4 ml; 285 rRNA (+) Control Probe (Biotin labeled), 0.1 ml; RNA (-) Control Probe (Biotin labeled), 0.1 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; HRP-anti-Digoxigenin, 4 ml; AP-Streptovidin, 4 ml; AEC Solution, 4 ml; NBT/BCIP Solution, 4 ml	40
T-1105-40	Zyto Fast human Ig-kappa/Ig-lambda Permanent CISH Kit C E IVD Ind. Ig-kappa/Ig-lambda Probe (Digoxigenin/Biotin labeled), 0.4 ml; 285 rRNA (+) Control Probe (Biotin labeled), 0.1 ml; RNA (-) Control Probe (Biotin labeled), 0.1 ml; Pepsin Solution, 4 ml; 20x Wosh Buffer TBS, 2x S0 ml; HRP-anti-Digoxigenin, 4 mr, AP-Streptovidin, 4 ml; HRP-Green-Solution A, 0.8 ml; HRP-Green-Solution B, 15 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	40

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information





## **ZytoFast ® PLUS Implementation Kits**

For the detection of Digoxigenin-labeled ZytoFast® Probes

Prod. No.	Product	Tests
T-1061-40	Zyto Fast PLUS CISH Implementation Kit AP-NBT/BCIP C € IVD	40
	Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 285 rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Rabbit-anti-D1G, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; NBT/BCIP Solution, 4ml; Nuclear Red Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	
T-1063-40	Zyto Fast PLUS CISH Implementation Kit HRP-DAB C € IVD	40
	Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Heat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x 50 ml; Mouse-anti-D1G, 4 ml; Anti-Mouse-HRP-Polymer, 4 ml; DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; Nuclear Blue Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	
T-1151-40	Zyto Fast PLUS CISH Implementation Kit AP-Permanent Red C€ IVD	40
	Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Reat Pretreatment Solution EDTA, 500 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 4x50 ml; Rabbit-anti-DIG, 4 ml; Anti-Rabbit-AP-Polymer, 4 ml; Permanent Red Solution A, 0.25 ml; Permanent Red Solution B, 15 ml; Mayer's Hematoxylin Solution, 20 ml; Mounting Solution (alcoholic), 4 ml	

## **ZytoFast** ® Implementation Kits

For the detection of Biotin-labeled ZytoFast® Probes

Prod. No.	Product	Tests
T-1070-40	Zyto Fast CISH Implementation Kit AP-NBT/BCIP	40
	Incl. DNA (+) Control Probe, 0.1 ml; DNA (-) Control Probe, 0.1 ml; 28S rRNA (+) Control Probe, 0.1 ml; RNA (-) Control Probe, 0.1 ml; Pepsin Solution, 4 ml; 20x Wash Buffer TBS, 2x 50 ml; AP-Streptavidin, 4 ml; NBT/BCIP, 4 ml	



## **ZytoFast**® Pretreatment Reagents

_	
Prod. No.	Product
ES-0001-4	Pepsin Solution, 4 ml C€ IVD
ES-0001-8	Pepsin Solution Set, 2x 4 ml C E IVD
ES-0001-50	Pepsin Solution, 50 ml C € IVD
ES-0001-1000	Pepsin Solution, 1000 ml C € IVD
PT-0002-500	Heat Pretreatment Solution EDTA, 500 ml C E IVD

## **ZytoFast® Wash Buffers & Ancillary Reagents**

Prod. No.	Product
AB-0001-4	Mouse-anti-DIG, 4 ml C€ IVD
AB-0001-30	Mouse-anti-DIG, 30 ml C € IVD
AB-0002-4	Anti-Mouse-HRP-Polymer, 4 ml C E IVD
AB-0008-4	HRP-anti-Digoxigenin, 4 ml CE IVD
AB-0009-4	AP-Streptavidin, 4 ml C € IVD
AB-0011-4	Rabbit-anti-DIG, 4 ml C € IVD
AB-0012-4	Anti-Rabbit-AP-Polymer, 4 ml CE IVD
C-3015-100	DAB Solution Set CE IVD Incl. DAB Solution A, 0.3 ml; DAB Solution B, 10 ml; good for 10 ml DAB Solution
C-3039-100	Zyto Dot HRP-Green Solution Set C € IVD Incl. HRP-Green Solution A, 0.8 ml; HRP-Green Solution B, 15 ml; good for 15 ml HRP-Green Solution
CS-0001-20	Mayer's Hematoxylin Solution, 20 ml C € IVD
CS-0002-20	Nuclear Blue Solution, 20 ml C € IVD
CS-0003-20	Nuclear Red Solution, 20 ml CE IVD
E-4005-50	Fixogum, Rubber Cement, 50 g
E-4005-125	Fixogum, Rubber Cement, 125 g
SB-0004-4	NBT/BCIP Solution, 4 ml C € IVD
SB-0005-4	AEC Solution, 4 ml C € IVD
T-1006-40	Zyto Fast AP-Streptavidin Detection Kit, Incl. NBT/BCIP, 4 ml; AP-Streptovidin, 4ml
WB-0005-50	20x Wash Buffer TBS, 50 ml C€ IVD
WB-0006-0.5	2x Oligo Buffer RNA, 0.5 ml; good for 1 ml customer made labeled oligonucleotides

# **ZytoFast** ® **Control Probes** Biotin-labeled

Prod.	. No.	Product	Tests* (Volume)
T-1022	2-100	ZytoFast DNA (+) Control Probe	10 (100 µl)
T-1023	3-100	ZytoFast DNA () Control Probe	10 (100 µl)
T-1020	0-100	ZytoFast 28S rRNA (+) Control Probe C€ IVD	10 (100 µl)
T-1019	9-100	ZytoFast RNA (−) Control Probe C € IVD	10 (100 µl)

# **ZytoFast** ® **Control Probes** Digoxigenin-labeled

Prod. No.	Product	Tests* (Volume)
T-1053-400	ZytoFast DNA (+) Control Probe C E IVD	40 (400 µl)
T-1054-400	ZytoFast DNA (—) Control Probe C E IVD	40 (400 µl)
T-1120-400	ZytoFast 28S rRNA (+) Control Probe C€ IVD	40 (400 µl)
T-1119-400	ZytoFast RNA (—) Control Probe C E IVD	40 (400 Jul)

<sup>\*</sup> Using 10 µl probe solution per test. C € IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information



sionArray® Arrays for DNA analysis	Page
Method Introduction - VisionArray®	236
Product Data Sheets	237 f.
Accessories	239 f.



## Vision Array ® Chip - Fast and Reliable Detection of DNA Sequences!



### Introduction

The VisionArray® products are designed for the qualitative detection of specific DNA sequences by DNA/DNA hybridization on immobilised catcher molecules which are arranged on a glass chip. All capture sequences and positive controls are set up on the VisionArray® Chip as duplicates.

## Advantages of VisionArray®


- · High sensitivity and specificity
- Quick & easy 1 hour protocol
- Automated evaluation using the VisionArray® Analyzer Software simple visualization & quick analysis in just a few minutes

### Sample Collection

For the detection of DNA sequences with the VisionArray® system, the following raw material can be used for DNA extraction:

- Formalin-fixed, paraffin-embedded (FFPE) tissue or cell samples
- Liquid based cytology specimens (e.g. ThinPrep®)
- Cervical swab/brush specimen

## Step 1: Amplification and Labeling in a PCR



The DNA is extracted from e.g. FFPE samples and is used as a template for PCR. Biotinylated primers are used to amplify and label different sections of the target sequences. The human HLA-DQA1 gene is also amplified and serves as a PCR positive control and as a genomic control.

## Step 2: Hybridization on the Glass Chip









After amplification, the biotinylated sequences hybridize to complementary DNA capture sequences on the glass chip.

## **Step 3: Detection and Visualization**



Specifically bound and biotinylated sequences are visualized by secondary marking with a streptavidin-peroxidase conjugate and a staining with tetramethylbenzidine. After color development, evaluation is performed using the VisionArray® Analyzer Software.



## Vision Array ® HPV Chip 1.0



### Introduction

The VisionArray® HPV Chip 1.0 is intended to be used for the qualitative detection and genotyping of PCR amplificates of 41 clinically relevant Human Papilloma Virus (HPV) genotypes that have been produced with the help of the VisionArray® HPV Primer Kit and the VisionArray® Detection Kit.


HPV has been conclusively identified as the major risk factor for cervical cancer. It is the third most common cancer in women worldwide, with an estimated number of 530,000 new cases and 280,000 deaths each year. Over the last years the relevance of HPV in the history of oropharyngeal cancers has become more and more important which is indicated by a dramatically risen number of cancers of the oral cavity and pharynx linked to HPV.


At present, there are more than 150 different HPV-types described. Depending on their risk to induce cancer, they are divided into Low Risk (LR), Probably High Risk, and High Risk (HR) types.

### **Chip Description**

**Probably High Risk** 

The VisionArray® HPV Chip 1.0 is designed to detect 41 clinically relevant HPV genotypes. All capture sequences and the positive control are set up on the chip as duplicates and the guide dots as triplicates. The signals are visible on the chip as dark blue areas. The automated evaluation of the results is performed by the VisionArray® Analyzer Software.





### References

Colombo N, et al. (2012) Ann Oncol 23 Suppl 7: vii27-32. Crow JM, et al. (2012) Nature 488: S2-S3. IARC (2012) Biological Agents. IARC Monogr Eval Carcinog Risks Hum, 100B: 1-441. Poljak M, et al. (2016) J Clin Virol 76 Suppl 1: S3-S13.

Prod. No.	Product	Tests
VA-0001-10	VisionArray HPV Chip 1.0 Ind. 10 pieces C€ IVD	10
VA-0001-50	VisionArray HPV Chip 1.0 Incl. 5x 10 pieces C € IVD	50
VS-0001-50	VisionArray HPV Set C   Ind. VisionArray HPV Chip 1.0 (5x 10 pieces); VisionArray HPV Primer Kit; VisionArray Detection Kit	50
Related Produ	icts	
VP-0001-50	VisionArray HPV Primer Kit C € IVD Ind. HPV Primer Mix; dNTP/dUTP Solution	50
VK-0003-50	VisionArray Detection Kit C € IVD Ind. Hybridization Solution, 1 ml; Detection Solution, 5 ml; Blue Spot Solution, 5 ml; 100x Wash Buffer, 250 ml	50

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

Guide Dots (GD)/ Positive Control (+)



## Vision Array ® HPV High Risk Chip 1.0



### Introduction


The VisionArray® HPV High Risk Chip 1.0 is intended to be used for the qualitative detection and genotyping of PCR amplificates of 24 clinically relevant Human Papilloma Virus (HPV) genotypes that have been produced with the help of the Vision Array HPV Primer Kit and the VisionArray Detection Kit.


HPV has been conclusively identified as the major risk factor for cervical cancer. It is the third most common cancer in women worldwide, with an estimated number of 530,000 new cases and 280,000 deaths each year. Over the last years the relevance of HPV in the history of oropharyngeal cancers has become more and more important which is indicated by a dramatically risen number of cancers of the oral cavity and pharynx linked to HPV.

At present, there are more than 150 different HPV-types described. Several HPV-types were classified as High Risk and Probably High Risk types based on their association with cervical cancer.

### **Chip Description**

The VisionArray® HPV High Risk Chip 1.0 is designed to detect 24 clinically relevant HPV genotypes. All capture sequences and the positive control are set up on the chip as duplicates and the guide dots as triplicates. The signals are visible on the chip as dark blue areas. The automated evaluation of the results is performed by the VisionArray® Analyzer Software.





References
Colombo N, et al. (2012) Ann Oncol 23 Suppl 7: vii27-32. Crow JM, et al. [2012] Nature 488: S2-S3.

IARC (2012) Biological Agents. IARC Monogr Eval Carcinog Risks Hum, 100B: 1-441.

Poljak M, et al. (2016) J Clin Virol 76 Suppl 1: S3-S13.

Probably	Hinh	Dick
IIUDUDIY	HIIUH	I/15V

High Risk

Prod. No.	Product	Tests
VA-0002-10	VisionArray HPV High Risk Chip 1.0 Incl. 10 pieces C€ IVD	10
VA-0002-50	VisionArray HPV High Risk Chip 1.0 Incl. 5x 10 pieces CE IVD	50
VS-0002-50	VisionArray HPV High Risk Set CE IVD Incl. VisionArray HPV High Risk Chip 1.0 (5x 10 pieces); VisionArray HPV Primer Kit; VisionArray Detection Kit	50
Related Produ	ıcts	
VP-0001-50	VisionArray HPV Primer Kit C € IVD Incl. HPV Primer Mix; dNTP/dUTP Solution	50
VK-0003-50	VisionArray Detection Kit C € IVD Incl. Hybridization Solution, 1 ml; Detection Solution, 5 ml; Blue Spot Solution, 5 ml; 100x Wash Buffer, 250 ml	50

CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

Guide Dots (GD) / Positive Control (+)





**VisionArray** ® **Detection Kit**For hybridization and detection of PCR products on Vision*Array* ® Chips

Prod. No.	Product	Tests
VK-0003-50	Vision <i>Array</i> Detection Kit C€ IVD	50
	Incl. Hybridization Solution, 1 ml; Detection Solution, 5 ml; Blue Spot Solution, 5 ml; 100x Wash Buffer, 250 ml	

# **VisionArray** ® **PCR Reagents**For amplification and biotinylation of target sequences

Prod. No.	Product	Tests
VP-0001-50	Vision <i>Array</i> HPV Primer Kit C€ IVD	50
	Incl. HPV Primer Mix; dNTP/dUTP Solution	





## VisionArray® Analysis Package

For visualization and quick analysis of the VisionArray® Chips data


Prod. No. Product

E-4060-1 Vision Array Analysis Package C € IVD

Ind. Scanner 8100; Slide Holder; Hand Scanner; PC with preinstalled Vision Array Analyzer Software; USB-Hub; External Hard Drive; Computer Mouse

## VisionArray® Analyzer Software

- Simple visualization and quick analysis of the VisionArray® Chip data
- Analysis of a chip and the report of the results can be achieved in just a few minutes
- Program navigation is easy and intuitive for the user
- Scans are stored including all sample and chip data in an integrated database on the enclosed external hard drive



## General Information



## **Product Use**

All products manufactured and/or distributed by ZytoVision GmbH should be used in accordance with the labeled intended use of the given product. Products labeled as CE/IVD are *in vitro* diagnostic medical devices according to the European Directive 98/79/EC. Products labeled as "For research use only" should be used for research applications, not for use in diagnostic procedures.

## **Trademarks**

ZytoDot®, ZytoFast®, ZytoLight®, FlexISH® and ZytoVision® are registered trademarks of ZytoVision GmbH. CEN™, SPEC™, ZyBlack™, ZyBlue™, ZyGold™, ZyGreen™, ZyOrange™, ZyRed™, ZytoDot® 2C™, TriCheck™, Clear-it™, DuraTect™ and DistinguISH™ are trademarks of ZytoVision GmbH. TexasRed® is a registered trademark of Molecular Probes, Inc., Eugene, OR. VisionArray® is a registered trademark of 42 life sciences GmbH & Co. KG, Bremerhaven, Germany.

## **CE Marking & ISO Certificates**

All probes in this catalog are manufactured by ZytoVision GmbH, Bremerhaven, Germany. ZytoLight® probes are direct labeled using the unique ZytoLight® Direct Label System II (ZytoVision GmbH) providing improved signal intensity. Advanced specificity of single copy ZytoLight®, FlexISH®, and ZytoDot® probes is obtained by the unique ZytoVision® Repeat Subtraction Technique (ZytoVision GmbH). ZytoFast® probes are tagged using the unique ZytoFast® HighTag System (ZytoVision) providing improved signal intensity.

Product development and manufacturing of all products by ZytoVision GmbH is carried out according to ISO 9001:2008 and ISO 13485:2003 regulations, for which ZytoVision GmbH holds certificates. These certificates were issued and are annually monitored by mdc medical device certification GmbH, Germany. mdc was, as one of the first German entities, notified in 1994 by the German Ministry of Health to the European Commission for conformity assessment procedures under the European Directive 98/79/EC for *in vitro* diagnostic devices. Current certificates can be downloaded at www.zytovision.com.



Prod. No.	Product	Page	Prod. No.	Product	Page
AB-0001-4	Mouse-anti-DIG	219, 234	C-3049-100/-400	ZytoDot 2C SPEC MDM2/CEN 12 Probe	201
AB-0001-30	Mouse-anti-DIG	219, 234	C-3050-400	ZytoDot 2C SPEC FGFR1/CEN 8 Probe	189
AB-0002-4	Anti-Mouse-HRP-Polymer	219, 234	C-3051-400	ZytoDot SPEC 2q11 Probe	216 f.
AB-0008-4	HRP-anti-Digoxigenin	234	C-3052-400	ZytoDot SPEC 13q12 Probe	216 f.
AB-0009-4	AP-Streptavidin	234	C-3053-400	ZytoDot 2C SPEC PTEN/CEN 10 Probe	194
AB-0011-4	Rabbit-anti-DIG	234	C-3054-100	ZytoDot 2C SPEC FUS Break Apart Probe	204
AB-0012-4	Anti-Rabbit-AP-Polymer NEW	234	C-3055-100/-400	ZytoDot 2C SPEC ALK Break Apart Probe	180
AB-0013-4	HRP/AP-Polymer-Mix	219	C-3056-400	ZytoDot 2C SPEC FGFR2/CEN 10 Probe	195
AB-0014-4	Anti-DIG/DNP-Mix	219	C-3057-400	ZytoDot 2C SPEC MET/CEN 7 Probe	187
BS-0001-4	Blocking Solution	219	C-3058-400	ZytoDot 2C SPEC ERG Break Apart Probe	214
BS-0002-8	ZyBlack™ Quenching Solution NEW	163	C-3059-400	ZytoDot 2C SPEC EML4 Break Apart Probe	181
C-3001-100/-400	ZytoDot SPEC ERBB2 Probe	205	C-3062-400	ZytoDot 2C SPEC CDK4/CEN 12 Probe	199
C-3002-400	ZytoDot CEN 6 Probe	216 f.	C-3063-100/-400	ZytoDot 2C SPEC ROS1 Break Apart Probe	183
C-3003-10/-40	ZytoDot SPEC ERBB2 Probe Kit	205	C-3064-100/-400	ZytoDot 2C SPEC RET Break Apart Probe	193
C-3004-40	ZytoDot Pretreatment Kit	218	C-3065-100	ZytoDot 2C SPEC FOXO1 Break Apart Probe	202
C-3005-10/-40	ZytoDot CISH Polymer Detection Kit	218	C-3066-400	ZytoDot 2C SPEC MYC Break Apart Probe	191
C-3006-400	ZytoDot CEN 17 Probe	216 f.	C-3067-400	ZytoDot 2C SPEC CDKN2A/CEN 9 Probe	192
C-3007-400	ZytoDot SPEC EGFR Probe	185	C-3068-100	ZytoDot 2C SPEC ERBB2/D17S122 Probe	207
C-3008-400	ZytoDot CEN 7 Probe	216 f.	C-3069-400	ZytoDot 2C SPEC TOP1/CEN 20 Probe	213
C-3011-40	ZytoDot Wash Buffer Set	219	C-3071-100	ZytoDot 2C SPEC IGH Break Apart Probe NIEVA	203
C-3012-400	ZytoDot SPEC MDM2 Probe	200	C-3072-100	ZytoDot 2C SPEC MALT1 Break Apart Probe NAV	211
C-3013-400	ZytoDot SPEC MYC Probe	190	C-3073-100	ZytoDot 2C SPEC BCL2 Break Apart Probe NEW	212
C-3014-400	ZytoDot CEN 12 Probe	216 f.	C-3074-100	ZytoDot 2C SPEC BCL6 Break Apart Probe NIEW	182
C-3015-100	DAB Solution Set	219, 234	C-3075-100	ZytoDot 2C SPEC CCND1 Break Apart Probe NAVI	197
C-3016-400	ZytoDot CEN 8 Probe	216 f.	CS-0001-20	Mayer's Hematoxylin Solution ITEM	219, 234
C-3018-10/-40	ZytoDot CISH Implementation Kit	218	CS-0002-20	Nuclear Blue Solution	219, 234
C-3020-400	ZytoDot CEN Yq12 Probe	216 f.	CS-0003-20	Nuclear Red Solution	234
C-3021-400	ZytoDot SPEC TOP2A Probe	208	E-4005-125	Fixogum Rubber Cement	154, 161, 21
C-3022-10/-40	ZytoDot 2C SPEC ERBB2/CEN 17 Probe Kit	206	E-4005-50	Fixogum Rubber Cement	154, 161, 21
C-3023-400	ZytoDot SPEC FGFR1 Probe	188	E-4007-2	ERBB2 Control Slide Set	219
2-3024-400	ZytoDot SPEC ESR1 Probe	184	E-4009-2	EGFR Control Slide Set	219
C-3025-400	ZytoDot CEN X Probe	216 f.	E-4010-1	DAPI/ZyGreen™/ZyOrange™ Triple Bandpass Filter Set	164
C-3026-400	ZytoDot SPEC 21q22 Probe	216 f.	E-4012-1	ZyGreen™ Single Bandpass Filter Set v2	164
C-3028-40	ZytoDot 2C CISH Polymer Detection Kit	218	E-4013-1	ZyOrange™ Single Bandpass Filter Set v2	164
C-3029-400	ZytoDot SPEC MYCN Probe	179	E-4016-1	ZyGreen™/ZyOrange™ Dual Bandpass Filter Set v2	164
C-3032-100/-400	ZytoDot 2C SPEC ERBB2/CEN 17 Probe	206	E-4017-1	ZyRed™ Single Bandpass Filter Set v2	164
C-3033-100/-400	ZytoDot 2C SPEC EGFR/CEN 7 Probe	186	E-4026-1	ZyBlue™ Single Bandpass Filter Set v2	164
C-3034-400	ZytoDot SPEC CCND1 Probe	196	E-4027-1	ZyGold™ Single Bandpass Filter Set v2	164
C-3035-400	ZytoDot SPEC 1p12 Probe	216 f.	E-4028-1	ZyBlue™/ZyGreen™/ZyOrange™ Triple Bandpass Filter Set	164
C-3036-100/-400	ZytoDot 2C SPEC 1p36/1q25 Probe	177	E-4030-1	DAPI Single Bandpass Filter Set v2	164
C-3037-100/-400	ZytoDot 2C SPEC 19q13/19p13 Probe	178	E-4060-1	VisionArray Analysis Package NEW	240
C-3038-100	ZytoDot AP-Red Solution Set	219	E-4111-1	ZEISS-Fluorescence Filter Holder "FL EC P&C"	164
C-3039-100	ZytoDot HRP-Green Solution Set	219, 234	E-4113-1	ZEISS-Fluorescence Filter Holder "FL"	164
C-3040-400	ZytoDot 2C SPEC TOP2A/CEN 17 Probe	209	E-4121-1	OLYMPUS-Fluorescence Filter Holder "U-MF 2"	164
C-3043-100	ZytoDot 2C SPEC EWSR1 Break Apart Probe	215	E-4122-1	OLYMPUS-Fluorescence Filter Holder "U-FF"	164
C-3043-100 C-3044-10/-40	ZytoDot 2C CISH Implementation Kit	218	E-4131-1	LEICA-Fluorescence Filter Holder "DM K"	164
C-3044-10/-40	ZytoDot CEN 3 Probe	216 f.	E-4141-1	NIKON-Fluorescence Filter Holder "C-FL"	164
C-3045-400	ZytoDot 2C SPEC SS18 Break Apart Probe	2101.	ES-0001-4	Pepsin Solution	154, 161, 21
C-3046-100 C-3047-100	ZytoDot 2C SPEC DDIT3 Break Apart Probe	198	ES-0001-4 ES-0001-8	Pepsin Solution Set	154, 161, 21
C-3047-100 C-3048-400	ZytoDot 2C CEN X/Y Probe	216 f.	ES-0001-50	Pepsin Solution	154, 161, 21



Prod. No.	Product	Page	Prod. No.	Product	Page
ES-0001-1000	Pepsin Solution	154, 161, 218, 234	WB-0003-50	20x SSC Solution	154
ES-0002-4	Cytology Pepsin Solution	154, 161	WB-0004-1000	PBS/Tween	219
ES-0002-50	Cytology Pepsin Solution	154, 161	WB-0005-50	20x Wash Buffer TBS	154, 219, 23
MT-0007-0.8	DAPI/DuraTect™-Solution	154, 161, 162	WB-0006-0.5	2x Oligo Buffer RNA	234
MT-0008-0.8	, DAPI/DuraTect™-Solution (ultra)	154, 161, 162	WB-0007-500	Cytology Stringency Wash Buffer SSC	154, 161
PT-0001-1000	Heat Pretreatment Solution Citric	154, 161	WB-0008-500	Cytology Wash Buffer SSC	154, 161
PT-0002-500	Heat Pretreatment Solution EDTA	218, 234	WB-0009-500	. Clear-it™ Stringency Buffer	219
PT-0006-100	Formaldehyde Dilution Buffer Set	154, 161	WB-0010-500	5x FlexISH Wash Buffer NEW	161
SB-0004-4	NBT/BCIP Solution	234	Z-2001-200	ZytoLight CEN 3 Probe	150 ff.
SB-0005-4	AEC Solution	234	Z-2002-200	ZytoLight CEN 6 Probe	150 ff.
T-1005-40	ZytoFast human lg-kappa/lg-lambda CISH Kit	231 f.	Z-2003-200	ZytoLight CEN 7 Probe	150 ff.
T-1006-40	ZytoFast AP-Streptavidin Detection Kit	234	Z-2004-50/-200	ZytoLight CEN 8 Probe	150 ff.
T-1013-400	ZytoFast CMV Probe	229 f.	Z-2005-200	ZytoLight CEN 11 Probe	150 ff.
T-1014-400	ZytoFast EBV Probe	227 f.	Z-2006-200	ZytoLight CEN 17 Probe	150 ff.
T-1015-400	ZytoFast human Ig-kappa Probe	231 f.	Z-2007-200	ZytoLight CEN 18 Probe	150 ff.
T-1016-400	ZytoFast human Ig-lambda Probe	231 f.	Z-2007-200 Z-2008-200	ZytoLight CEN X Probe	150 ff.
T-1017-400	ZytoFast human Ig-kappa/Ig-lambda Probe	231 f.	Z-2010-200	ZytoLight CEN Yq12 Probe	150 ff.
T-1019-100	ZytoFast RNA (-) Control Probe	234	Z-2013-50/-200	ZytoLight SPEC MDM2/CEN 12 Dual Color Probe	108
T-1020-100	ZytoFast 28S rRNA (+) Control Probe	234	Z-2014-50/-200	ZytoLight SPEC MAML2 Dual Color Break Apart Probe	96
T-1022-100	ZytoFast DNA (+) Control Probe	234	Z-2014-30/-200 Z-2015-50/-200	ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe	126
T-1023-100	ZytoFast DNA (-) Control Probe	234	Z-2015-50/-200 Z-2016-50/-200	ZytoLight CEN X/Yq12 Dual Color Probe	150 ff.
T-1032-400	ZytoFast HPV type 6/11 Probe	234 225 f.	Z-2018-50/-200 Z-2018-50/-200	ZytoLight SPEC FOXO1/PAX3 Dual Color Single Fusion Probe	110
		225 f.	Z-2010-30/-200 Z-2019-50/-200		112
T-1035-400	ZytoFast HPV type 16/18 Probe	225 f.		ZytoLight SPEC FOXO1/PAX7 Dual Color Single Fusion Probe	126
T-1038-400	ZytoFast HPV type 31/33 Probe		7-2020-5/-20	ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe Kit	154
T-1053-400	ZytoFast DNA (+) Control Probe	234	7-2028-5/-20	ZytoLight FISH-Tissue Implementation Kit	
T-1054-400	ZytoFast DNA (-) Control Probe	234	7-2033-50/-200	ZytoLight SPEC EGFR/CEN 7 Dual Color Probe	65
T-1055-400	ZytoFast HPV type 6/11 Probe	225 f.	Z-2049-200	ZytoLight SPEC 2q11 Probe	150 ff.
T-1056-400	ZytoFast HPV type 16/18 Probe	225 f.	Z-2050-200	ZytoLight CEN 12 Probe	150 ff.
T-1057-400	ZytoFast HPV type 31/33 Probe	225 f.	Z-2056-200	ZytoLight SPEC ERBB3/CEN 12 Dual Color Probe	105
T-1061-40	ZytoFast PLUS CISH Implementation Kit AP-NBT/BCIP	233	Z-2057-200	ZytoLight SPEC ERBB4/2q11 Dual Color Probe	37
T-1063-40	ZytoFast PLUS CISH Implementation Kit HRP-DAB	233	Z-2062-200	ZytoLight SPEC FHIT/CEN 3 Dual Color Probe	41
T-1070-40	ZytoFast CISH Implementation Kit AP-NBT/BCIP	233	Z-2063-50/-200	ZytoLight SPEC CDKN2A/CEN 9 Dual Color Probe	79
T-1105-40	ZytoFast human lg-kappa/lg-lambda Permanent CISH Kit	231 f.	Z-2067-200	ZytoLight CEN 9 Probe	150 ff.
T-1113-400	ZytoFast CMV Probe	229 f.	Z-2069-50/-200	ZytoLight SPEC ESR1/CEN 6 Dual Color Probe	62
T-1114-400	ZytoFast EBV Probe	227 f.	Z-2071-50/-200	ZytoLight SPEC CCND1/CEN 11 Dual Color Probe	93
T-1115-400	ZytoFast human lg-kappa Probe	231 f.	Z-2072-50/-200	ZytoLight SPEC FGFR1/CEN 8 Dual Color Probe	72
T-1116-400	ZytoFast human Ig·lambda Probe	231 f.	Z-2074-50/-200	ZytoLight SPEC MYCN/2q11 Dual Color Probe	31
T-1119-400	ZytoFast RNA (-) Control Probe	234	Z-2075-50/-200	ZytoLight SPEC 1p36/1q25 Dual Color Probe	25
T-1120-400	ZytoFast 28S rRNA (+) Control Probe	234	Z-2076-50/-200	ZytoLight SPEC 19q13/19p13 Dual Color Probe	26
T-1140-400	ZytoFast HPV High-Risk (HR) Types Probe	225 f.	Z-2077-50/-200	ZytoLight CEN 17/SPEC ERBB2 Dual Color Probe	127
T-1144-400	ZytoFast HPV Screening Probe	225 f.	Z-2078-50/-200	ZytoLight SPEC PTEN/CEN 10 Dual Color Probe	87
T-1151-40	ZytoFast PLUS CISH Implementation Kit AP-Permanent Red	233	Z-2079-200	ZytoLight CEN 10 Probe	150 ff.
VA-0001-10/-50	VisionArray HPV Chip 1.0 New	237	Z-2080-200	ZytoLight SPEC MDM4/1p12 Dual Color Probe	30
VA-0002-10/-50	VisionArray HPV High Risk Chip 1.0 NEW	238	Z-2081-50/-200	ZytoLight SPEC CDKN2A/CEN 3/7/17 Quadruple Color Probe	80
VK-0003-50	VisionArray Detection Kit Nav	239	Z-2082-200	ZytoLight SPEC FGFR3/4p11 Dual Color Probe	49
VP-0001-50	VisionArray HPV Primer Kit NEW	239	Z-2083-200	ZytoLight SPEC 4p11 Probe	150 ff.
VS-0001-50	VisionArray HPV Set New	237	Z-2084-200	ZytoLight SPEC VHL/CEN 3 Dual Color Probe	38
VS-0002-50	VisionArray HPV High Risk Set NAW	238	Z-2085-200	ZytoLight SPEC 13q12 Probe	150 ff.
WB-0001-500	Wash Buffer SSC	154, 219	Z-2086-200	ZytoLight SPEC 21q22 Probe	150 ff.
WB-0002-50	25x Wash Buffer A	154	Z-2087-200	ZytoLight SPEC MET/CEN 7 Dual Color Probe	66



Prod. No.	Product	Page	Prod. No.	Product	Page
Z-2090-50/-200	ZytoLight SPEC MYC Dual Color Break Apart Probe	74	Z-2145-50	ZytoLight SPEC NR4A3 Dual Color Break Apart Probe	82
Z-2091-50	ZytoLight SPEC TERT/5q31 Dual Color Probe	51	Z-2146-50/-200	ZytoLight SPEC BIRC3/MALT1 Dual Color Dual Fusion Probe	97
Z-2092-50/-200	ZytoLight SPEC MYC/CEN 8 Dual Color Probe	75	Z-2148-50/-200	ZytoLight SPEC RET Dual Color Break Apart Probe	86
Z-2093-50/-200	ZytoLight SPEC ERBB2/TOP2A/CEN 17 Triple Color Probe	129	Z-2151-50	ZytoLight SPEC USP6 Dual Color Break Apart Probe	124
Z-2094-200	ZytoLight porcine X/Y Dual Color Probe	153	Z-2152-50/-200	ZytoLight SPEC RREB1/MYB/CEN 6 Triple Color Probe	57
Z-2095-50/-200	ZytoLight SPEC 13/CEN 18/SPEC 21 Triple Color Probe	150 ff.	Z-2153-50/-200	ZytoLight SPEC TP53/CEN 17 Dual Color Probe	123
Z-2096-50/-200	ZytoLight SPEC EWSR1 Dual Color Break Apart Probe	145	Z-2154-200	ZytoLight SPEC AXL/19p13 Dual Color Probe	139
Z-2097-50/-200	ZytoLight SPEC SS18 Dual Color Break Apart Probe	133	Z-2155-200	ZytoLight SPEC MERTK/2q11 Dual Color Probe	36
Z-2098-200	ZytoLight SPEC TYMS/CEN 18 Dual Color Probe	132	Z-2156-200	ZytoLight SPEC GAS6/13q12 Dual Color Probe	114
Z-2099-20	ZytoLight FISH-Cytology Implementation Kit	154, 161	Z-2157-50	ZytoLight SPEC ETV6/RUNX1 Dual Color Dual Fusion Probe	103
Z-2100-50/-200	ZytoLight SPEC DDIT3 Dual Color Break Apart Probe	106	Z-2158-200	ZytoLight SPEC FGF3,4,19/CEN 11 Dual Color Probe	95
Z-2101-200	ZytoLight SPEC 1p12 Probe	150 ff.	Z-2159-50/-200	ZytoLight SPEC TP53/ATM Dual Color Probe	98
Z-2102-200	ZytoLight SPEC VHL/1p12/CEN 7/17 Quadruple Color Probe	39	Z-2160-50/-200	ZytoLight SPEC D13S319/13q34/CEN 12 Triple Color Probe	99
Z-2103-50/-200	ZytoLight SPEC CDK4/CEN 12 Dual Color Probe	107	Z-2161-200	ZytoLight SPEC ALK/2q11 Dual Color Probe	34
Z-2104-10/-40	ZytoLight Aneusomy Probe Set	150 ff.	Z-2162-200	ZytoLight SPEC ROS1/CEN 6 Dual Color Probe	60
Z-2105-50/-200	ZytoLight SPEC MYC/IGH Dual Color Dual Fusion Probe	77	Z-2163-200	ZytoLight SPEC 18/CEN X/Y Triple Color Probe	150 ff.
Z-2107-50/-200	ZytoLight SPEC EGR1/5p15 Dual Color Probe	52	Z-2164-200	ZytoLight SPEC 13/21 Dual Color Probe	150 ff.
Z-2108-50/-200	ZytoLight SPEC CCND1 Dual Color Break Apart Probe	92	Z-2165-50/-200	ZytoLight SPEC RB1/13q12 Dual Color Probe	113
Z-2109-50/-200	ZytoLight SPEC TFE3 Dual Color Break Apart Probe	149	Z-2166-50/-200	FlexISH ERBB2/CEN 17 Dual Color Probe NEW	160
Z-2110-50/-200	ZytoLight SPEC IGH Dual Color Break Apart Probe	116	Z-2167-200	ZytoLight SPEC NTRK1 Dual Color Break Apart Probe	28
Z-2111-50/-200	ZytoLight SPEC BCR/ABL1 Dual Color Dual Fusion Probe	84	Z-2168-50/-200	ZytoLight SPEC FGFR1 Dual Color Break Apart Probe	71
Z-2111-50/ 200 Z-2112-50	ZytoLight SPEC RUNX1/RUNX1T1 Dual Color Dual Fusion Probe	73	Z-2169-200	ZytoLight SPEC FGFR2 Dual Color Break Apart Probe	88
Z-2112-50/-200	ZytoLight SPEC PML/RARA Dual Color Dual Fusion Probe	118	Z-2170-50/-200	ZytoLight SPEC FGFR3 Dual Color Break Apart Probe	47
Z-2114-50/-200	ZytoLight SPEC BCL2/IGH Dual Color Dual Fusion Probe	137	Z-2171-200	ZytoLight SPEC BCL2L1/CEN 20 Dual Color Probe	140
Z-2114-30/-200 Z-2115-200	ZytoLight SPEC KRAS/CEN 12 Dual Color Probe	104	Z-2172-200	ZytoLight SPEC BCL2L2/14q32 Dual Color Probe	115
Z-2116-50/-200	ZytoLight SPEC COL1A1/PDGFB Dual Color Dual Fusion Probe	131	Z-2173-200	ZytoLight SPEC MCL1/1p12 Dual Color Probe	27
Z-2110-30/-200 Z-2117-50/-200	ZytoLight SPEC ALK/EML4 TriCheck™ Probe	32	Z-2173-200 Z-2174-50	ZytoLight SPEC BCL2/CEN 18 Dual Color Probe	136
Z-2117-50/-200 Z-2118-200	ZytoLight SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple Color Probe	40	Z-2174-50 Z-2175-50	ZytoLight SPEC YWHAE Dual Color Break Apart Probe	125
	ZytoLight SPEC PDGFB Dual Color Break Apart Probe	147			
Z-2119-50/-200	ZytoLight CEN X/Y Dual Color Probe		Z-2176-50/-200	ZytoLight SPEC ETV6 Dual Color Break Apart Probe	102
Z-2120-200		150 ff.	Z-2177-50/-200	ZytoLight SPEC BCL6 Dual Color Break Apart Probe	46
Z-2121-200	ZytoLight SPEC COL1A1 Dual Color Break Apart Probe	130 89	Z-2178-50	ZytoLight SPEC SMARCB1/22q12 Dual Color Probe	144
7-2122-200	ZytoLight SPEC FGFR2/CEN 10 Dual Color Probe		Z-2179-50/-200	ZytoLight SPEC CD274,PDCD1LG2/CEN 9 Dual Color Probe	78
Z-2123-200	ZytoLight CEN Y (DYZ3) Probe	150 ff.	Z-2180-200	ZytoLight SPEC 21/CEN X/Yq12 Triple Color Probe	150 ff.
7-2124-50/-200	ZytoLight SPEC ALK Dual Color Break Apart Probe	33	Z-2181-200	ZytoLight SPEC NRG1 Dual Color Break Apart Probe	70
7-2125-50/-200	ZytoLight SPEC CCND1/IGH Dual Color Dual Fusion Probe	94	Z-2182-5/-20	FlexISH-Tissue Implementation Kit MAN	161
7-2127-200	ZytoLight SPEC SOX2/CEN 3 Dual Color Probe	45	Z-2183-50	ZytoLight SPEC EWSR1/FLI1 TriCheck™ Probe NEW	146
Z-2130-50	ZytoLight SPEC FUS Dual Color Break Apart Probe	120	Z-2184-50	ZytoLight SPEC SS18/SSX1 TriCheck™ Probe NEW	134
Z-2131-50	ZytoLight SPEC KIF5B Dual Color Break Apart Probe	85	Z-2185-50	ZytoLight SPEC FOXO1/PAX3 TriCheck™ Probe Maw	111
Z-2132-50	ZytoLight SPEC JAZF1 Dual Color Break Apart Probe	64	Z-2186-200	ZytoLight SPEC FGFR3 Break Apart/FGFR2/FGFR1 Quadruple Color Probe NAW	48
Z-2133-50	ZytoLight SPEC TFG Dual Color Break Apart Probe	42	Z-2189-200	ZytoLight SPEC BRAF Dual Color Break Apart Probe	67
Z-2135-200	ZytoLight SPEC ERG/TMPRSS2 TriCheck™ Probe	143	Z-2190-50	ZytoLight SPEC ERBB2/D17S122 Dual Color Probe	128
7-2136-50	ZytoLight SPEC EML4 Dual Color Break Apart Probe	35	Z-2191-200	ZytoLight SPEC BRAF/CEN 7 Dual Color Probe	68
Z-2137-50	ZytoLight SPEC CARS Dual Color Break Apart Probe	90	Z-2192-50/-200	ZytoLight SPEC BCL2 Dual Color Break Apart Probe	135
Z-2138-200 	ZytoLight SPEC ERG Dual Color Break Apart Probe	142	Z-2193-50	ZytoLight SPEC KMT2A Dual Color Break Apart Probe	101
Z-2139-50	ZytoLight SPEC FOXO1 Dual Color Break Apart Probe	109	Z-2194-200	ZytoLight SPEC NRG1/CD74 TriCheck™ Probe	69
Z-2140-200	ZytoLight SPEC PIK3CA/CEN 3 Dual Color Probe	44	Z-2195-200	ZytoLight SPEC VEGFA/CEN 6 Dual Color Probe	58
Z-2141-200	ZytoLight SPEC ETV1/CEN 7 Dual Color Probe	63	Z-2196-50/-200	ZytoLight SPEC MALT1 Dual Color Break Apart Probe	138
Z-2142-50	ZytoLight SPEC WT1 Dual Color Break Apart Probe	91	Z-2197-50	ZytoLight SPEC PDGFRB Dual Color Break Apart Probe	55
Z-2143-200	ZytoLight SPEC MYB Dual Color Break Apart Probe	61	Z-2198-50	ZytoLight SPEC TP53/17q22 Dual Color Probe	122
Z-2144-50/-200	ZytoLight SPEC ROS1 Dual Color Break Apart Probe	59	Z-2199-50	ZytoLight SPEC ABL1 Dual Color Break Apart Probe	83



Prod. No.	Product	Page
Z-2200-50	ZytoLight SPEC ABL2 Dual Color Break Apart Probe	29
Z-2201-50	ZytoLight SPEC CRLF2 Dual Color Break Apart Probe	148
Z-2202-50	ZytoLight SPEC CSF1R Dual Color Break Apart Probe	54
Z-2203-50/-200	FlexISH ALK/ROS1 DistinguISH™ Probe NEW	159
7-2204-200	ZytoLight SPEC MYC/CDKN2A/ERBB2/ZNF217 Quadruple Color Probe NEW	76
7-2205-200	ZytoLight SPEC NTRK2 Dual Color Break Apart Probe NEW	81
7-2206-200	ZytoLight SPEC NTRK3 Dual Color Break Apart Probe NEW	119
7-2207-50	ZytoLight SPEC CBFB Dual Color Break Apart Probe NEVA	121
7-2208-200	ZytoLight SPEC NUTM1 Dual Color Break Apart Probe NAW	117
7-2209-50	ZytoLight SPEC PDGFRA/FIP1L1 TriCheck™ Probe NIEW	50
7-2210-50	ZytoLight SPEC IRF4,DUSP22 Dual Color Break Apart Probe NEW	56
7-2211-50	ZytoLight SPEC EGR1/D5S23,D5S721 Dual Color Probe NEW	53
7-2212-50	ZytoLight SPEC WWTR1 Dual Color Break Apart Probe NAV	43
7-2213-50	ZytoLight SPEC PTPRT/20q11 Dual Color Probe NAW	141
7-2216-50	ZytoLight SPEC 11q gain/loss Triple Color Probe CUSY	100



Molecular diagnostics simplified

ZytoVision GmbH · Fischkai 1 27572 Bremerhaven · Germany Phone: +49 (0)471/4832-300 Fax: +49 (0)471/4832-509 info@zytovision.com

Your local distributor